<SEC-DOCUMENT>0001628280-16-012510.txt : 20160309
<SEC-HEADER>0001628280-16-012510.hdr.sgml : 20160309
<ACCEPTANCE-DATETIME>20160309172754
ACCESSION NUMBER:		0001628280-16-012510
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160309
DATE AS OF CHANGE:		20160309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Accelerate Diagnostics, Inc
		CENTRAL INDEX KEY:			0000727207
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				841072256
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31822
		FILM NUMBER:		161495504

	BUSINESS ADDRESS:	
		STREET 1:		3950 S. COUNTRY CLUB ROAD #470
		STREET 2:		BUILDING 3-307
		CITY:			TUCSON
		STATE:			AZ
		ZIP:			85714
		BUSINESS PHONE:		303-863-8088

	MAIL ADDRESS:	
		STREET 1:		3950 S. COUNTRY CLUB ROAD #470
		STREET 2:		BUILDING 3-307
		CITY:			TUCSON
		STATE:			AZ
		ZIP:			85714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCELR8 TECHNOLOGY CORP
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYDRO SEEK INC
		DATE OF NAME CHANGE:	19880802
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>axdx-123115x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>10-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sFDC614144B588D6A6FA2EFC22A9802DA"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#254;</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Commission file number: 001-31822</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">84-1072256</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(State&#160;or&#160;other&#160;jurisdiction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(I.R.S.&#160;Employer Identification&#160;No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">of&#160;incorporation&#160;or&#160;organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3950 South Country Club, Suite 470</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Tucson, Arizona</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">85714</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Address&#160;of&#160;principal&#160;executive&#160;offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Zip&#160;Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Registrant&#8217;s telephone number, including area code:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(520) 365-3100</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Common Stock, $0.001 par value per share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The NASDAQ Stock Market LLC</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(NASDAQ Capital Market)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act: None</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#32;Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;No</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#32;Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;No</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;No</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). </font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;No</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167; 229.405) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="52%"></td><td width="5%"></td><td width="43%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-accelerated file</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#9744; (Do not check if a smaller reporting company)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="sFDC614144B588D6A6FA2EFC22A9802DA"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font><font style="font-family:Arial;font-size:10pt;">&#32;&#160;No</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The aggregate market value of the shares of the registrant&#8217;s common stock held by non-affiliates on June 30, </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">, the last day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately </font><font style="font-family:Arial;font-size:10pt;">$483.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;based on the closing price quoted on the NASDAQ Stock Market.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There were </font><font style="font-family:Arial;font-size:10pt;">51,199,017</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock of the registrant outstanding as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;8, 2016</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portions of the definitive proxy statement relating to the registrant&#8217;s </font><font style="font-family:Arial;font-size:10pt;">2016</font><font style="font-family:Arial;font-size:10pt;">&#32;Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="s0CA14B50B1CC604C7B47EFC22AD1D7CB"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;padding-bottom:8px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="88%"></td><td width="12%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA2A0B29A2BD6918DA9D9EFC22B1FC430"><font style="font-family:Arial;font-size:11pt;">Introductory Note</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA2A0B29A2BD6918DA9D9EFC22B1FC430">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA9BB7D39655B2F989863EFC22B3F386A"><font style="font-family:Arial;font-size:11pt;">Forward-Looking Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA9BB7D39655B2F989863EFC22B3F386A">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sF1428F95842E6041327EEFC22B7100C7"><font style="font-family:Arial;font-size:11pt;">Industry and other data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sF1428F95842E6041327EEFC22B7100C7">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6E59C57BAE9D6EA20AD0EFC22B927131"><font style="font-family:Arial;font-size:11pt;">PART I</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6E59C57BAE9D6EA20AD0EFC22B927131">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sEDA3784C1F49BA7BE019EFC22BDA5EDA"><font style="font-family:Arial;font-size:11pt;">Item 1.&#160; Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sEDA3784C1F49BA7BE019EFC22BDA5EDA">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sDC7DFD3FCFA9650C2CC2EFC22C20557F"><font style="font-family:Arial;font-size:11pt;">Item 1A.&#160; Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sDC7DFD3FCFA9650C2CC2EFC22C20557F">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s3F3D8E358729BBE44BD8EFC22C61F4F0"><font style="font-family:Arial;font-size:11pt;">Item 1B.&#160; Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s3F3D8E358729BBE44BD8EFC22C61F4F0">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sE895422E039217F04517EFC22C641F36"><font style="font-family:Arial;font-size:11pt;">Item 2.&#160; Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sE895422E039217F04517EFC22C641F36">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s083DBF23C737EB5FAEF5EFC22C6BA68E"><font style="font-family:Arial;font-size:11pt;">Item 3.&#160; Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s083DBF23C737EB5FAEF5EFC22C6BA68E">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s509029C9DC5030CBD180EFC22C8CED54"><font style="font-family:Arial;font-size:11pt;">Item 4.&#160; Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s509029C9DC5030CBD180EFC22C8CED54">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s3AF3F3F7E930AF2E0B3CEFC22CBE0BD5"><font style="font-family:Arial;font-size:11pt;">PART II</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s3AF3F3F7E930AF2E0B3CEFC22CBE0BD5">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s16FEEF9CD24CA6A9DA0FEFC21EABEE2E"><font style="font-family:Arial;font-size:11pt;">Item 5.&#160; Market for Registrant&#8217;s Common Equity, Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s16FEEF9CD24CA6A9DA0FEFC21EABEE2E"><font style="font-family:Arial;font-size:11pt;">and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s16FEEF9CD24CA6A9DA0FEFC21EABEE2E">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA0AD8BE774EDF12085EAEFC22D18451A"><font style="font-family:Arial;font-size:11pt;">Item 6.&#160; Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA0AD8BE774EDF12085EAEFC22D18451A">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6995AEA30E1F2A62C1ECEFC21F0001E2"><font style="font-family:Arial;font-size:11pt;">Item 7.&#160; Management&#8217;s Discussion and Analysis of Financial Condition and Results of</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6995AEA30E1F2A62C1ECEFC21F0001E2"><font style="font-family:Arial;font-size:11pt;">Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6995AEA30E1F2A62C1ECEFC21F0001E2">46</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s9A195FF86B2E47684956EFC22E0D01BA"><font style="font-family:Arial;font-size:11pt;">Item 7A.&#160; Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s9A195FF86B2E47684956EFC22E0D01BA">47</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sADF0230EDA79D45FA531EFC22E2DFBCC"><font style="font-family:Arial;font-size:11pt;">Item 8.&#160; Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sADF0230EDA79D45FA531EFC22E2DFBCC">47</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sEEA5231A35C16CC04A05EFC2330F980E"><font style="font-family:Arial;font-size:11pt;">Item 9.&#160; Changes in and Disagreements With Accountants on Accounting and Financial</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sEEA5231A35C16CC04A05EFC2330F980E"><font style="font-family:Arial;font-size:11pt;">Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sEEA5231A35C16CC04A05EFC2330F980E">75</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sEEA5231A35C16CC04A05EFC2330F980E"><font style="font-family:Arial;font-size:11pt;">Item 9A.&#160; Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s63E422093B69E3493E43EFC2335868E6">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s17C90709FBADA0D66B96EFC233672511"><font style="font-family:Arial;font-size:11pt;">Item 9B.&#160; Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s17C90709FBADA0D66B96EFC233672511">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s9E711CCD62727F19E477EFC2339420CE"><font style="font-family:Arial;font-size:11pt;">PART&#160;III</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s9E711CCD62727F19E477EFC2339420CE">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA2BDFE79886EDB0E12FBEFC233B70D31"><font style="font-family:Arial;font-size:11pt;">Item 10.&#160; Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sA2BDFE79886EDB0E12FBEFC233B70D31">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sD910CB7413C01082783AEFC233E9B73A"><font style="font-family:Arial;font-size:11pt;">Item 11.&#160; Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sD910CB7413C01082783AEFC233E9B73A">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sCB34CCB76114D28290F9EFC234095CC5"><font style="font-family:Arial;font-size:11pt;">Item 12.&#160; Security Ownership of Certain Beneficial Owners and Management and Related</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sCB34CCB76114D28290F9EFC234095CC5"><font style="font-family:Arial;font-size:11pt;">Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sCB34CCB76114D28290F9EFC234095CC5">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6EA541107FC7FF3AF59CEFC2343B83D0"><font style="font-family:Arial;font-size:11pt;">Item 13.&#160; Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s6EA541107FC7FF3AF59CEFC2343B83D0">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s044BBA6FC521ECD193D8EFC2345CDB8F"><font style="font-family:Arial;font-size:11pt;">Item 14.&#160; Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s044BBA6FC521ECD193D8EFC2345CDB8F">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sE3FB3F14C39DE43ED91FEFC2348E667F"><font style="font-family:Arial;font-size:11pt;">Item 15.&#160; Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sE3FB3F14C39DE43ED91FEFC2348E667F">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sE296C9131D2086A3C2ADEFC234B19BC1"><font style="font-family:Arial;font-size:11pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#sE296C9131D2086A3C2ADEFC234B19BC1">79</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s1150B826FD85B173363CEFC234E31EBA"><font style="font-family:Arial;font-size:11pt;">EXHIBIT INDEX</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#s1150B826FD85B173363CEFC234E31EBA">79</a></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="sA2A0B29A2BD6918DA9D9EFC22B1FC430"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Introductory Note</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Except as otherwise indicated by the context, references in this Annual Report on Form 10K (this "Form 10K") to the "Company," "Accelerate," "we," "us," or "our" are references to the combined business of Accelerate Diagnostics, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sA9BB7D39655B2F989863EFC22B3F386A"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Company, intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements, which can be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; or variations thereon or comparable terminology, include the plans and objectives of management for future operations, including plans and objectives relating to the products and future economic performance of the Company. In addition, all statements other than statements of historical facts that address activities, events, or developments the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties. These forward-looking statements are based on assumptions that the Company will retain key management personnel, the Company will be successful in the development of the Accelerate ID/AST system, the Company will obtain sufficient capital to complete the development and required clinical trials of the Accelerate ID/AST system, the Company will be able to protect its intellectual property, the Company&#8217;s ability to respond to technological change, that the Company will accurately anticipate market demand for the Company&#8217;s products and that there will be no material adverse change in the Company&#8217;s operations or business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following discussion should be read in conjunction with the Company&#8217;s audited financial statements and related notes included elsewhere herein. The Company&#8217;s future operating results may be affected by various trends and factors which are beyond the Company's control. These include, among other factors, general public perception of issues and solutions, and other uncertain business conditions that may affect the Company&#8217;s business. The Company cautions the reader that a number of important factors discussed herein, and in other reports, filed with the Securities and Exchange Commission including but not limited to the risks in the section entitled &#8220;Risk Factors&#8221; in this Form 10-K, could affect the Company&#8217;s actual results and cause actual results to differ materially from those discussed in forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sF1428F95842E6041327EEFC22B7100C7"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Industry and other data</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We obtained the industry, statistical and market data from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified statistical, market and industry data from third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="s6E59C57BAE9D6EA20AD0EFC22B927131"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sEDA3784C1F49BA7BE019EFC22BDA5EDA"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 1.  Business</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention calls one of the most serious healthcare threats of our time, antibiotic resistance. A significant contributing factor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results. The delay of these results is often due to the reliance by microbiology laboratories on traditional culture-based tests that often take two to three days to complete. Our technology platform is built to address these challenges by delivering significantly faster and accurate testing of infectious pathogens in various patient sample types.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since 2004, we have focused our efforts on the development of an innovative rapid diagnostic platform, the Accelerate ID/AST System&#8482;, which we refer to as the ID/AST System or Accelerate ID/AST System, intended for the rapid diagnosis of infectious pathogens.  Our goal is to reduce the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to hours rather than the two to three days now required to deliver identification and susceptibility results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The ID/AST System utilizes genotypic technology to identify, or ID, infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing, or AST, which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.  The ID/AST blood culture assay kit, which we refer to as the Blood Culture Assay Kit, is being investigated for its ability to provide ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.  The Blood Culture Assay Kit consists of a highly multiplexed panel of more than 150 individual assays which have the potential to support clinicians in prescribing optimal antibiotic therapy for patients in this critical condition.  The final number of assays included in the Blood Culture Assay Kit will depend on the results of our clinical trial to support marketing authorization from the FDA and FDA review of each individual assay for marketing clearance.  This panel is designed to cover over 80% of the routine and significant pathogens causing blood stream infections and over 90% of the antibiotics useful in treating those pathogens.  On June 30, 2015, we declared our conformity to the European In Vitro Diagnostic Directive 98/79 EC and applied a CE Mark to the Accelerate ID/AST System and the Blood Culture Assay Kit for in vitro diagnostic use. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We anticipate commercializing the Accelerate ID/AST System in the United States, subject to the successful completion of the U.S. registration trial and submission to and clearance by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) of our de novo 510(k) for the ID/AST System, which could occur as early as the third quarter of 2016, see Risk Factors for FDA review time line risk.  See &#8220;Products&#8221; below for a description of the results from our recent multicenter pilot study and more information regarding our upcoming trial to support marketing authorization from the FDA.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">History</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We were incorporated in 1982 in Colorado under the name Sage Resources Corp., and through a series of subsequent transactions, we became Accelerate Diagnostics, Inc., a Delaware corporation, in December 2012.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">From 2001 to 2012, we focused primarily upon furthering the research and development of the OpTest portfolio of technologies (&#8220;OpTest&#8221;) that we acquired from DDx, Inc. in 2001 and the development of revenue producing products related to that technology.  The purchase of OpTest provided us with a proprietary surface chemistry formulation, which led to our OptiChem&#174; and other surface chemistry products, and quantitative bio-analytical measurement instruments.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2012, our Board of Directors and management team established a new strategic direction for the Company, which was (1) to focus on the internal development, manufacture, and commercialization of the ID/AST System and (2) to discontinue efforts to develop and actively market OptiChem and our other surface chemistry products.  Our Board of Directors and management team decided to pursue this new strategic direction based on the belief that we could internally develop and commercialize the ID/AST System, formerly called the BacCel System.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since the adoption of the new strategic direction in 2012, we have made significant investments in research and development personnel, facilities, equipment, and consumables to support the internal development of the ID/AST System.  The Company has also invested in the hiring of regulatory, manufacturing, quality, sales, and marketing personnel experienced in the manufacture and commercialization of medical devices.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The new strategic direction has also required the Company to raise additional capital.  In March 2013, the Company obtained additional capital through the exercise of warrants issued to Abeja Ventures, LLC in the aggregate amount of </font><font style="font-family:Arial;font-size:10pt;">$20.1 million</font><font style="font-family:Arial;font-size:10pt;">.  In August 2013, the Company completed a rights offering that raised gross proceeds of $20.0 million; in April 2014, the Company completed a rights offering that raised gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$45.0 million</font><font style="font-family:Arial;font-size:10pt;">; and in December 2015, the Company completed a publicly marketed offering that raised additional gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$109.3 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Clinical Need</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Antibiotic resistance has a significant healthcare impact, costing the U.S. healthcare system an estimated $55 billion per year.  This estimate includes $20 billion in direct costs and $35 billion in indirect costs, such as lost productivity and sick days.  Increasing infection rates and misuse of antibiotics results in serious treatment complications.  Recent studies have shown that the number of hospital-acquired infections in the United States ranges from 214,700 to 1.4 million per year, contributing to an estimated 75,000 deaths per year.  Moreover, inappropriate antibiotic use is widespread.  Of the 33 million patients admitted to U.S. hospitals each year, 56% (19 million) are put on empiric antibiotic therapy, of which more than half (9 million) are on inappropriate or unnecessary antibiotics.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AST is designed to address these challenges.  According to a recent company survey of 43 critical care physicians, 95% stated that AST is the most valuable lab test when selecting optimal antibiotic therapy.  Studies have shown that even a modest decrease in the time it takes to deliver an AST result correlates to reduced length and cost of hospital stay per patient.  One such study showed that a five hour reduction in the time to receive an AST result delivered a two-day reduction in length of stay and a reduction in patient treatment costs of $1,750 per patient.  Based on our conversations with potential customers and review of internal time studies, we estimate that the Blood Culture Assay Kit will reduce the time to receive an AST result from the time a sample is taken from a patient by a total of 29 hours on average for the Blood Culture Assay Kit.  Based on our analysis, we estimate that the ID/AST System is capable of delivering results in approximately 19 hours from the time a blood sample is taken from a patient, while current solutions take a total of approximately 48 hours to deliver results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Market Opportunity</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recent reports have indicated estimated growth in the hospital-acquired disease testing market, which we believe is a subset of the microbiology market in which we operate, at a combined average growth rate of 19.3% over seven years, from $2.2 billion in 2012 to an estimated $7.5 billion by 2019.  We believe this growth is driven by the entrance of new technologies coupled with higher volumes due to enhanced screening, immune-compromised patients and increasing challenges with multidrug-resistant organisms.  Across North America, Europe and Asia Pacific geographies, we estimate there are 14.1 million high-acuity tests completed annually across various sample types including blood, respiratory, skin and soft tissue, and urine.  We estimate there are 5 million high-acuity tests annually for blood culture samples globally, including over 4 million in North America, Europe and various countries in the Asia Pacific region.  Based on this estimated test volume, and an estimated current market price per test of approximately $180, we estimate the total available market of automated microbiological testing to be approximately $2.5 billion annually in North America, Europe and various countries in the Asia Pacific region, of which approximately $725 million is attributed to high-acuity tests for blood culture samples.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, based on information compiled from various competitor annual reports and other publicly available information, as well as our own estimates, we believe there are nearly 20,000 global instrument placements possible, consisting of approximately 10,000 bioMerieux Vitek 2 installations, 6,000 Danaher Microscan installations and 4,000 instruments from other companies.  Based on this estimated total instrument placement volume, and an estimated average price of an instrument sold for use in the microbiology lab today of approximately $100,000, we estimate the total available global instrument market for the ID/AST System to be approximately $2.0 billion.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain recent government initiatives are complementary to the ID/AST System.  Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) programs to decrease hospital-acquired infections directly impact hospital budgets via reimbursement cuts, incentivizing providers to enhance infection-management protocols.  These programs include the Medicare Hospital-Acquired Condition Reduction Program and the Hospital Readmissions Reduction Program.  </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Similarly, on March 27, 2015, the White House released the National Action Plan for Combating Antibiotic-Resistant Bacteria, which directly and indirectly promotes rapid susceptibility testing.  The plan identifies several milestones to accomplish this goal, such as calling on the National Institutes of Health to fund new projects and provide prizes aimed at the development of rapid diagnostic tests that characterize antibiotic susceptibility and improve antibiotic stewardship; mandated implementation of antibiotic stewardship programs by all hospitals participating in Medicare and Medicaid, to go into effect within three years; and FDA and CMS&#8217;s evaluation of new regulatory pathways to promote development and adoption of innovative infectious disease diagnostics.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Products</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Accelerate ID/AST System is the Company&#8217;s first </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;">&#32;diagnostic system and is intended for the identification and antibiotic susceptibility testing of pathogens most commonly associated with serious infections, including Gram-positive and Gram-negative organisms such as Staphylococcus organisms as well as yeasts.  The Accelerate ID/AST System uses long-accepted bacteriological testing principles, but applies the Company&#8217;s proprietary technology to adapt them to analyze live patient bacteria.  The Accelerate ID/AST System uses automated digital microscopy to simultaneously detect and identify multiple pathogens directly from a single patient sample and then, following such identification, perform susceptibility tests based on the identification results.  This technology eliminates the need for time-consuming traditional bacterial culturing, thus eliminating the major source of delay with current testing methods.  The identification result is provided in approximately seventy to ninety-five minutes of presenting the patient sample to the system, and the susceptibility result is provided approximately three to six hours after the presentation of the identification result.  In the case of our first test kit for positive blood culture samples a blood culture screening step is required which takes on average twelve hours to complete before the sample is introduced to the ID/AST System.  This combined turnaround time is a significant improvement over the days currently required to obtain these results using conventional testing methods.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The ID/AST System features walk-away automation and consists of a fixed instrument and proprietary single-use test kit.  The instrument consists of module(s) connected to a single analysis computer, which allows hospitals to acquire various numbers of modules to address their particular test volume.  In order to run a patient sample on the Accelerate ID/AST System the technician would pipette the patient sample into our system, insert the test kit, and initiate the run.  In the case of our initial test a positive blood culture sample is introduced to the system through pipetting directly from the blood culture bottle into our test kit. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Accelerate ID/AST System is the result of over a decade of technology development and several years of instrument design/engineering.  Initially prototype systems featured off-the-shelf pipetting robots, high-speed cameras, microscopes/illumination, and computers.  The now final instrument is comprised of custom-engineered functional components, including a pipette robot for fluidic manipulation, an optical system with both dark-field and fluorescent illumination, and an imaging system.  These components, among others, are used in the four processes that follow, each of which is a crucial component in delivering the rapid ID and AST results.  </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These processes include:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Automated specimen preparation.  </font><font style="font-family:Arial;font-size:10pt;">The initial step in the process is the automated purification of samples through an on-board and proprietary process to separate live organisms from sample debris.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Live-cell immobilization.  </font><font style="font-family:Arial;font-size:10pt;">Following preparation, the purified sample is moved to the imaging cassette where pathogens are immobilized onto the cassette surface such that they can be imaged and analyzed in a stationary position during the identification and antibiotic susceptibility testing.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Identification testing via fluorescent in situ hybridization (FISH).  </font><font style="font-family:Arial;font-size:10pt;">The now immobilized cells are tested with our proprietary FISH probes to enable identification.  Because the genetic sequences of bacteria are distinctive, the binding of fluorescently labeled probes indicates the presence of a specific target sequence of RNA associated with a single or group of bacterial species or yeasts.  When the probe finds a targeted sequence, it binds to it&#8212;generating a fluorescent signal&#8212;which is visible by the imaging system on the ID/AST System.  Positive fluorescent signals from more than one target probe indicate polymicrobial samples and a universal bacterial stain discriminates target from non-target bacteria/fungi.  The identification result is presented on the ID/AST System&#8217;s graphic user interface in approximately seventy to ninety-five minutes from the introduction of the sample into the ID/AST System.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Susceptibility testing via live-cell optical analysis.  </font><font style="font-family:Arial;font-size:10pt;">With the identification of the pathogen known, the </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:72px;padding-bottom:0px;text-align:justify;"><font style="font-family:Arial;font-size:10pt;">system&#8217;s software determines the antibiotic panel to be used for susceptibility testing.  These antibiotics, growth media, and additional patient sample are introduced to additional channels on the optical cassette.  Finally, our proprietary imaging platform and algorithms determine the minimum inhibitory concentration (MIC) of the bacteria through the observation of which antibiotics arrested live cell growth and lead to cell death and which antibiotics were ineffective in ceasing live cell growth.  The susceptibility test result is presented approximately three to six hours after the conclusion of the identification test.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Accelerate ID/AST System in its various iterations has been the subject of over 35 papers and scientific posters.  Further, our internal laboratories have conducted thousands of tests on the various prototype systems and the final instrument.  Published study abstracts and links to full papers are available on our website at http://acceleratediagnostics.com/our-science/publications/.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 2, 2015, we announced positive findings from a multicenter pilot study to evaluate external performance of our ID/AST System and Blood Culture Assay Kit.  Based on the results of the pilot study, we also announced the initiation of a larger trial intended to support 510(k) clearance by the FDA.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The pilot study included ten external sites and the analysis of 146 fresh de-identified positive blood culture samples from patients and 127 samples seeded with challenging bacterial or fungal isolates.  Enrollment for the pilot study followed a protocol similar to our larger upcoming trial to support marketing authorization from the FDA, which is planned to expand to 11 external clinical sites.  Our upcoming trial is expected to consist of approximately 2,800 samples (600 fresh patient blood samples and 2,200 seeded samples).  The FDA has established a threshold for the ID component of the Blood Culture Assay Kit of 95% or greater sensitivity and specificity.  For the AST component, we are seeking to match the predicate method&#8217;s categorical and essential agreement at a rate of 89.9%.  Contingent upon successful completion of the larger trial, we plan to submit a 510(k) notification seeking premarket clearance for the Accelerate ID/AST System and Blood Culture Assay Kit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company will be seeking a single initial FDA submission for the integrated Accelerate ID/AST System and positive blood culture test kit and will seek additional FDA submissions should they be required to remove restrictions following the initial submission.  This approach is similar to that taken by molecular diagnostic companies since early 2013 for their multiplexed identification tests. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and development </font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company plans to continue making significant investments in the research and development of new applications for existing technologies and in the research and development of new complementary technologies.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">With the development of the Accelerate ID/AST System and positive blood culture test kit substantially complete, the Company will focus on the development of additional test kits to address opportunities in sample types including but not limited to respiratory, skin and soft tissue, and urine.  Similar to the positive blood culture kit, the objective is to develop test kits which work seamlessly on the Accelerate ID/AST System and deliver substantial benefits to the microbiology laboratory and to physicians in the treatment of serious infections.  Proof of concept research has already been completed on some of these sample types aided in part by DMRDP grant which aims to apply the Accelerate ID/AST System to respiratory and skin and soft tissue samples.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We anticipate seeking separate regulatory approval for each additional test kit. If and when we determine that we will pursue regulatory approvals for those applications, we would likely include the identification of the most prevalent infectious pathogens found in each specimen type and the applicable antimicrobial agents for treatment.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our research activity is also focused on shortening the time required to distinguish between positive and negative whole blood and potentially urine samples prior to using the ID/AST System.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's research and development expense for years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;is included in the consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We rely on a combination of patent, copyright, trademark and trade secret laws, employee and third-party non-disclosure agreements, license agreements, and other intellectual property protection methods to protect our proprietary rights.  We intend to continue developing intellectual property, and we intend to aggressively protect our </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">position in key technologies.  Our patented technology covers key components of the ID/AST System and is, thus, very important to the Company.&#160; Our patents are focused on several key technologies, including our automated process for sample preparation, automated immobilization process, and methods for imaging and analysis of individual pathogen cells.  The Company&#8217;s first patent on the ID/AST System technology, U.S. Patent No. 7,341,841 titled "Rapid Microbial Detection and Antimicrobial Susceptibility Testing" was issued on March 11, 2008.  The patent specification covers methods used to derive identification and antibiotic susceptibility from tests on individual immobilized bacterial cells.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, we had 19 issued patents worldwide, including 12 patents issued in the United States and seven issued outside the United States.&#160; One of our patents expires in 2017, and the remaining 18 will expire on various dates in 2022 through 2033.&#160; Additionally, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, we had 21 patent applications pending worldwide, including 15 U.S. applications and six applications outside the United States.  The Company believes that its patent suite would make it difficult for any other company to conduct rapid antibiotic susceptibility testing of individual pathogens.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Sales, Marketing, and Distribution</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The target customer for our products is hospital microbiology laboratories that perform identification and antibiotic susceptibility testing.&#160; Globally, the vast majority of hospitals with an intensive care unit have such a laboratory.  In general, we plan to build our own sales force to market the ID/AST System directly to our targeted customers.&#160; However, in select geographies, we plan to use third-party distributors to market the product.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our commercial strategy is to focus initially on high volume and influential accounts in key geographies with a direct sales force in North America and in select European countries.  Early marketing efforts include the planned initiation of market studies at multiple sites across the United States and European Union.  In support of these efforts, we anticipate establishing a sales force based in the European Union and the United States.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Competition</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To the best of our knowledge, no other company has a single product with capabilities matching those of the ID/AST System.  The leading companies with automated microbiological testing products include Becton, Dickinson and Company (&#8220;BD&#8221;), bioMerieux, Danaher Corporation (&#8220;Danaher&#8221;), Bruker Corporation, Nanosphere, T2 Biosystems, Abbott and Thermo Fisher Scientific&#8217;s subsidiary TREK Diagnostics Systems, Inc. (&#8220;TREK&#8221;).  These companies provide products for the broad-based culturing and analysis of a wide variety of bacteria.  However, only BD, bioMerieux, Danaher and TREK market products that perform AST, and we believe that none of our competitor&#8217;s products are able to provide AST results as quickly as the ID/AST System.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our competitors&#8217; AST products require purified bacterial strains or &#8220;isolates&#8221; for analysis, which require at least overnight culturing of a sample to produce enough organisms to test.  We believe these standard culturing methods, including enrichment growth and colony isolation, cannot achieve the speed that the ID/AST System is expected to provide.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Industry Developments</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The clinical microbiology industry is subject to rapid technological changes, and new products are frequently introduced for rapid bacterial identification using genes or other molecular markers (&#8220;molecular diagnostics&#8221;).  Numerous acquisitions, licenses, and distribution arrangements have been announced over the last few years for such products.  However, we do not believe that any of these technologies offers the advantages offered by the ID/AST System.  For example, gene detection can be highly sensitive and specific for the identification of pathogens, but very few antibiotic resistance mechanisms are simple enough to allow accurate guidance for drug selection.  Even in those rare instances that have a direct relationship between a gene and effective resistance, such as particular </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Methicillin-Resistant Staphylococcus Aureus</font><font style="font-family:Arial;font-size:10pt;">&#32;(MRSA) strains, leading literature has reported novel mutations that escape detection by recently commercialized tests.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fundamental biological limitations arise from the complexity of the majority of drug resistance expression mechanisms.  This complexity precludes direct interpretation of molecular marker presence or absence and extrapolating to prescription guidance.  Many new diagnostic technologies also require prior isolation of cultured colonies in order to assure accuracy.  The time required to obtain such isolates, with a minimum of overnight turnaround, prevents these technologies from serving as rapid diagnostics for treatment decision support.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Another new technology receiving wide attention is mass spectrometry, and particularly the matrix-assisted </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">laser desorption ionization time of flight version (&#8220;MALDI-TOF&#8221;), such as the Biotyper&#174; system from Bruker Corporation, which has not yet received FDA clearance.  Bruker Corporation has agreements with a number of companies for distribution, including BD, TREK, and Siemens.  bioMerieux has a similar system for distribution with Shimadzu Corporation.  These systems build an empiric database from protein spectra acquired from many thousands of purified bacterial and fungal strains.  They require a pure strain isolate for analysis and enrichment culturing to produce enough material to analyze.  Some research papers on these systems report attempts to directly analyze isolate or blood culture smears, but results are not as reliable as those from samples prepared using a cleanup process to produce crude protein extracts.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">MALDI-TOF systems have a major advantage over other molecular methods in identifying a very broad range of organisms.  Cost of ownership is also substantially below that of older molecular methods.  But the requirement for extensive organism enrichment and purification, as well as the inability to quantify live organisms or distinguish samples derived from viable organisms, substantially limits this technology from time-critical decision support.  In this respect, the ID/AST System provides a substantial advantage for more rapid test results.  Finally, as with the older molecular methods, MALDI-TOF systems cannot identify major drug resistance expression and faces the same fundamental biological barriers as gene detection.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Government Regulation</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our products under development and our operations are subject to significant government regulation.  In the United States, our products are regulated as medical devices by the FDA and other federal, state, and local regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">FDA Regulation of Medical Devices</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The FDA and other U.S. and foreign governmental agencies regulate, with respect to medical devices:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">design, development, manufacturing, and storage;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">testing, content, and language of instructions for use and storage;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">labeling;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">pre-clinical testing and clinical trials;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">product safety;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">advertising, promotion, marketing, sales, and distribution;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">pre-market clearance and approval;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">record-keeping procedures;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">advertising and promotion;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">recalls and corrective field actions;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">post-market reporting, including reporting of deaths, serious injuries, and malfunctions that, if they were to recur, could lead to death or serious injury;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">post-market studies and surveillance; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">product import and export.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the United States, numerous laws and regulations govern all the processes by which medical devices are brought to market and marketed.  These include the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;) and the FDA's implementing regulations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">FDA Pre-market Clearance and Approval Requirements</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each medical device we seek to commercially distribute in the United States must first receive 510(k) clearance, approval of a reclassification petition or de novo classification request, or pre-market approval from the FDA, unless specifically exempted by the FDA.  The FDA classifies all medical devices into one of three classes.  Devices deemed to pose the lowest risk are categorized as either Class&#160;I or II, which generally requires the manufacturer to submit to the FDA a 510(k) pre-market notification submission requesting clearance of the device for commercial distribution in the United States.  Some low risk devices are exempted from this requirement.  Devices deemed by the FDA to pose the greatest risk, such as life sustaining, life-supporting, or implantable devices, or devices deemed not substantially equivalent to a previously 510(k)-cleared device are categorized as Class&#160;III.  These devices generally require submission and approval of a pre-market approval application, or PMA.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">510(k) Clearance Process</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To obtain 510(k) clearance, we must submit a pre-market notification to the FDA demonstrating that the proposed device is substantially equivalent to a device that has previously obtained 510(k) clearance, a device that has been classified into Class&#160;I or II, or a device that was legally marketed before May&#160;28, 1976 and that is not yet subject to an FDA order requiring pre-market approval.  In rare cases, Class&#160;III devices may be cleared through the 510(k) process.  The FDA has committed to review most 510(k) decisions within 90 days, but the review clock may be stopped due to requests for additional information.  A decision may take significantly longer, and clearance is never assured.  Although many 510(k) pre-market notifications are cleared without clinical data, in some cases, the FDA requires significant clinical data to support substantial equivalence.  In reviewing a pre-market notification submission, the FDA may request additional information, including clinical data, which may significantly prolong the review process.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or, in some cases, approval of a PMA.  The FDA requires each manufacturer to make this determination initially, but the FDA may review any such decision and may disagree with a manufacturer's determination.  If the FDA disagrees with a manufacturer's determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA is obtained.  Under these circumstances, the FDA may also subject a manufacturer to enforcement action and sanctions, including those described below.  In addition, the FDA is currently evaluating the 510(k) process and may make substantial changes to regulatory requirements, including changes that could affect which devices are eligible for 510(k) clearance, the FDA&#8217;s ability to rescind 510(k) clearances, and additional requirements that may significantly impact the 510(k) review process.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">&#160;Pre-market Approval Process</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A PMA generally must be submitted if the medical device is in Class&#160;III or cannot be cleared through the 510(k) process.  A PMA must be supported by extensive technical, preclinical, clinical, manufacturing, and labeling data to demonstrate to the FDA's satisfaction the safety and effectiveness of the device.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After a PMA is submitted and filed, the FDA begins an in-depth review of the submitted information.  During this review, the FDA may request additional information or clarification of information already provided.  Also during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device.  In addition, the FDA will conduct a pre-approval inspection of the manufacturing facility to ensure compliance with Quality System Regulation (&#8220;QSR&#8221;), which imposes elaborate development, testing, control, documentation and other quality assurance requirements on the design and manufacturing process.  The FDA has committed to review most PMAs within 180 days where an advisory panel is not required and within 320 days where an advisory panel is required, but the review clock may be stopped due to requests for additional information.  A decision may take significantly longer, and approval is never assured.  The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device including restrictions on labeling, promotion, sale, and distribution and collection of safety data.  Failure to comply with the conditions of approval can result in enforcement action and sanctions, including those described below.  New PMAs or PMA supplements are required for significant modifications to the manufacturing process, labeling of the product, or design of a device that is approved through the PMA process.  PMA supplements often require submission of the same type of information as an original PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel.&#160;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">De novo Classification Process</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medical device types that the FDA has not previously classified as Class&#160;I, II, or III are automatically classified into Class&#160;III regardless of the level of risk they pose.  The Food and Drug Administration Modernization Act of 1997 established a new route to market for low-to-moderate risk medical devices that are automatically placed into Class&#160;III due to the absence of a predicate device, called the "Request for Evaluation of Automatic Class&#160;III Designation," or the de novo classification procedure.  This procedure allows a manufacturer whose novel device is automatically classified into Class&#160;III to request down-classification of its medical device into Class&#160;I or Class&#160;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA.  Prior to the enactment of the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;) in July 2012, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) pre-market notification and received a determination from the FDA that the device was not substantially equivalent.  FDASIA streamlined the de novo classification pathway by permitting manufacturers to also request de novo classification directly without first submitting a 510(k) pre-market notification to the FDA and receiving a not substantially equivalent determination.  Under FDASIA, the FDA is required to classify the device within 120&#160;days following receipt of such a direct de novo request.  If the manufacturer seeks classification into Class&#160;II, the manufacturer should include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device.  In addition, the FDA may reject a de novo request if the FDA identifies a legally marketed predicate device that would be appropriate for a 510(k), determines that the device is not low-to-moderate risk, or determines that general controls would be inadequate to control the risks and special controls cannot be developed.  We plan to utilize the de novo classification process to obtain marketing authorization for the ID/AST System, which we believe will be placed within Class II.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trials</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clinical trial data is typically required to support a PMA and is sometimes required for a 510(k) pre-market notification.  Initiation of a clinical trial generally requires submission of an application for an Investigational Device Exemption (an &#8220;IDE&#8221;) to the FDA.  The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the investigational protocol is scientifically sound.  The IDE application must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a non-significant risk device and eligible for abbreviated IDE requirements.  Clinical trials for a significant risk device may begin once the IDE application is approved by the FDA as well as the appropriate institutional review boards at the clinical trial sites and the informed consent of the patients participating in the clinical trial is obtained.  After a trial begins, the FDA may place it on hold or terminate if it concludes that the clinical subjects are exposed to unacceptable risks.  Any trials we conduct must be conducted in accordance with FDA regulations as well as other federal regulations and state laws concerning human subject protection and privacy.  Moreover, the results of a clinical trial may not be sufficient to obtain clearance or approval of the product.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clinical trial sponsors may also be subject to the Medicare Secondary Payer laws, which prohibit Medicare from making a payment if payment has been made or can reasonably be expected to be made by other plans, such as liability insurance plans (including self-insurance).  Section 111 of the Medicare, Medicaid, and SCHIP Extension Act of 2007 (&#8220;MMSEA&#8221;) established mandatory reporting requirements with respect to Medicare beneficiaries who receive settlements, judgments, awards, or other payment from liability insurance (including self-insurance) plans.  When payments are made by sponsors of clinical trials for complications or injuries arising out of the trials, such payments are considered to be payments by liability insurance (including self-insurance) and must be reported.  Section III of the MMSEA includes authority for CMS to impose civil monetary penalties against liability insurance (including self-insurance) plans that are determined to be non-compliant with the applicable reporting requirements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Pervasive and Continuing Regulation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After a medical device is placed on the market, numerous FDA regulatory requirements apply, including the following:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the QSR, which imposes elaborate development, testing, control, documentation, and other quality assurance requirements on the design and manufacturing process;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">establishment registration, which requires establishments involved in the production and distribution of medical devices, intended for commercial distribution in the United States, to register with the FDA;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">medical device listing, which requires manufacturers to list the devices they have in commercial distribution </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:72px;padding-bottom:0px;text-align:justify;"><font style="font-family:Arial;font-size:10pt;">with the FDA;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">labeling regulations and various statutory provisions, which prohibit false or misleading labeling, as well as the promotion of products for unapproved or "off-label" uses, and impose other restrictions on labeling; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">post-market reporting requirements, which require that manufacturers report to the FDA deaths, serious injuries, and malfunctions that, if they were to recur, could lead to death or serious injury, recalls, and corrective field actions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In certain cases, advertising is also subject to scrutiny by the Federal Trade Commission.  The FDA and other agencies actively enforce these and other applicable laws and regulations.  Failure to comply with applicable requirements may result in enforcement action by the FDA and/or the U.S. Department of Justice, which may include one or more of the following administrative or judicial sanctions:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">untitled letters or warning letters;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">fines, injunctions, and civil penalties;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">mandatory recall or seizure of our products;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">administrative detention or banning of our products;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">operating restrictions, partial suspension, or total shutdown of production;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">import holds;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">refusing to approve pending 510(k) notifications or PMAs;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">revocation of 510(k) clearance or pre-market approvals previously granted; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">criminal prosecution and penalties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">International Regulation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sales of medical devices outside the United States are subject to foreign government regulations, which vary substantially from country to country.  In order to market our products in other countries, we must obtain regulatory approvals and comply with extensive safety and quality regulations in other countries.  The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ significantly.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the European Economic Area, or EEA, which comprises the 28&#160;Member States of the EU plus Liechtenstein, Norway and Iceland, in vitro medical devices are required to conform with the essential requirements of the EU Directive on in vitro diagnostic medical devices (Directive 98/79/EC, as amended).  To demonstrate compliance with the essential requirements, the manufacturer must undergo a conformity assessment procedure.  The conformity assessment varies according to the type of medical device and its classification.  For low-risk devices, the conformity assessment can be carried out internally, but for higher risk devices (self-test devices and those included in List A and B of Annex&#160;II of Directive 98/79/EC) it requires the intervention of an accredited EEA Notified Body.  If successful, the conformity assessment concludes with the drawing up by the manufacturer of an EC Declaration of Conformity entitling the manufacturer to affix the CE mark to its products and to sell them throughout the EEA. The EC Declaration of Conformity was received by the Company in 2015.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Other Healthcare Laws</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon commercialization of the ID/AST System, our business activities, including the activities of any third-party distributors that we retain, will likely be subject to additional healthcare laws and regulations and related enforcement by the federal government as well as the governments of states and foreign jurisdictions where we conduct our business.  These laws and regulations include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, and physician payment transparency laws and regulations.  Violations of these laws </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">or regulations can result in criminal or civil sanctions, including substantial fines and, in some cases, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid.  The following discussion describes certain federal and state healthcare laws and regulations that may impact our operations and the operations of our customers, but is not intended to be an exhaustive discussion of all potentially applicable federal and state health laws and regulations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal Anti-Kickback Statute prohibits any person from knowingly and willfully offering, soliciting, receiving, or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in exchange for or to induce either the referral of an individual for an item or service, or the purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs.  A person need not have actual knowledge of the Anti-Kickback Statute or specific intent in order to commit a violation, and several courts have interpreted the intent requirement of the Anti-Kickback Statute to mean that if any one purpose of an arrangement is to induce referrals or purchases of federal healthcare program business, the Anti-Kickback Statute has been violated.  In addition to criminal fines and penalties set forth under the Anti-Kickback Statute, violations of the Anti-Kickback Statute can result in exclusion or debarment from participation in the federal healthcare programs, as well as substantial penalties under the Civil Monetary Penalties Statute, which imposes penalties against any person or entity that is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.  A violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, which, as discussed below, imposes liability on any person or entity that knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program.  Several states also have anti-kickback laws which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal False Claims Act imposes liability on any person or entity that knowingly presents or causes to be presented a false or fraudulent claim for payment to, or approval by, the U.S. government.  Liability under the False Claims Act can give rise to treble damages and civil penalties of up to $11,000 per claim.  In addition to actions initiated by the government itself, the qui tam provisions of the False Claims Act authorize private individuals to bring False Claims Act actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in a percentage of the recovery.  In recent years, the government and qui tam relators have initiated suits resulting in multi-million and multi-billion dollar settlements under the False Claims Act in addition to criminal convictions under applicable criminal statutes.  Given the significant size of actual and potential settlements, it is expected that the government and qui tam relators will continue to devote substantial resources and use the False Claims Act to investigate and prosecute healthcare companies&#8217; compliance with applicable fraud and abuse laws.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program, including private third-party payors or to obtain&#8212;by means of false or fraudulent pretenses, representations, or promises&#8212;any of the money or property owned by or under the custody or control of any healthcare benefit program; and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.  The Affordable Care Act amended certain sections of the HIPAA criminal statutes such that a person need not have actual knowledge of the applicable statute or specific intent in order to have committed a healthcare fraud violation.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As stated above, many states and foreign countries have adopted similar fraud and abuse laws that may be broader in scope and may apply regardless of payor.  Violations of any of these laws can lead to additional risk such as risk of plaintiff class actions, state attorney general actions, and investigation by agencies such as the Department of Justice (&#8220;DOJ&#8221;) or the Federal Trade Commission (&#8220;FTC&#8221;).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Physician Payment Sunshine Act, implemented by Section&#160;6002 of the Affordable Care Act, imposes transparency requirements on certain manufacturers, referred to as &#8220;applicable manufacturers,&#8221; of drugs, devices, biological, or medical supplies for which payment is available under Medicare, Medicaid, the Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;), or a waiver of a plan offered under CHIP.  Applicable manufacturers must track and report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) certain payments or "transfers of value" provided to U.S. licensed physicians and teaching hospitals during the preceding calendar year, as well as certain ownership and investment interests held by U.S. licensed physicians and their immediate family members.  CMS releases the reported data on a public website on an annual basis.  Failure to report as required under the Physician Payment Sunshine Act could </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">subject applicable manufacturers to significant financial penalties, while tracking and reporting the required payments and transfers of value may result in considerable administrative expense.  Several states currently have similar laws, and more states may enact similar legislation, some of which may be broader in scope.  For example, certain states require the implementation of compliance programs, compliance with industry ethics codes, implementation of gift bans, and spending limits, and/or reporting of gifts, compensation, and other remuneration to healthcare professionals.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.  HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their respective implementing regulations, including the final omnibus rule published by the Department of Health and Human Services Office for Civil Rights (&#8220;OCR&#8221;) in January&#160;2013, restrict the use and disclosure of patient-identifiable health information, mandate the adoption of standards relating to the privacy and security of patient-identifiable health information, and require us to report certain security breaches to healthcare provider customers with respect to such information where we are acting as a HIPAA business associate, as that term is defined, to that customer.  In addition to HIPAA criminal penalties, HITECH created four new tiers of civil and monetary penalties and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA privacy and security laws and seek attorneys' fees and costs associated with pursuing federal civil actions.  In addition, state laws govern the privacy and security of health information in certain circumstances and impose reporting requirements for data breaches, many of which differ from each other and HIPAA in significant ways and may not have the same effect, thus complicating compliance efforts.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The use of certain diagnostic products by our potential customers is affected by the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) and related federal and state regulations that provide for regulation of laboratory testing.  CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality assurance, quality control, and inspections.  Current or future CLIA requirements or the promulgation of additional regulations affecting laboratory testing may prevent some laboratories, hospitals, providers, or other customers with laboratories from using some or all of our diagnostic products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Healthcare Reform</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the United States and several foreign jurisdictions, there have been, and we expect there may continue to be, a number of legislative and regulatory changes to the healthcare system seeking to reduce healthcare costs that could affect our future results of operations as we begin to commercialize our products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the United States, the Affordable Care Act (&#8220;ACA&#8221;), enacted in March 2010, made changes that are expected to have a continued and significant impact on the medical device industry and clinical laboratories, including the way healthcare is delivered and financed by governmental and private insurers.  For example, the legislation provided for reductions in the Medicare clinical laboratory fee schedule and, since 2013, has required that certain medical device manufacturers pay an excise tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices.  We will be subject to this tax once we begin selling the ID/AST System.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, frequently in recent years, other legislative, regulatory, and political changes aimed at regulating healthcare delivery in general and clinical laboratories in particular have been proposed and adopted in the United States.  Payment and reimbursement for the laboratory industry and hospital and other healthcare provider services have been under significant pressure.  Most recently, in January 2015, the Department of Health and Human Services (&#8220;HHS&#8221;) announced a plan to shift the Medicare program and the healthcare system at large toward paying providers based on quality, rather than the quantity of care provided to patients, and the President&#8217;s budget for fiscal year 2016 proposed reductions in Medicare spending.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reimbursement</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We do not believe that hospitals will specifically seek reimbursement from the government or private insurance companies for their purchase of the ID/AST System or the positive blood culture test kits.  Instead, we believe that hospitals will recoup such costs by obtaining reimbursement from the government or private insurance companies for in-bed occupancies, which traditionally includes all testing required for admitted patients.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospitals, clinical laboratories, and other healthcare provider customers that may purchase our products, if approved, generally bill various third-party payors to cover all or a portion of the costs and fees associated with diagnostic tests, including the cost of the purchase of our products.  We currently expect that all of our diagnostic tests </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">will be performed in a hospital inpatient setting, where governmental payors, such as Medicare, generally reimburse hospitals a single bundled payment that is based on the patient&#8217;s diagnosis under a classification system known as the Medicare severity diagnosis-related groups (&#8220;MS-DRGs&#8221;) classification for all items and services provided to the patient during a single hospitalization, regardless of whether our diagnostic tests are performed during such hospitalization.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Operations</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2013, we relocated our headquarters from Denver, Colorado to Tucson, Arizona, where we currently lease approximately </font><font style="font-family:Arial;font-size:10pt;">52,497</font><font style="font-family:Arial;font-size:10pt;">&#32;square feet of office, manufacturing and laboratory space.  Further information regarding our Tucson facility is included in </font><font style="font-family:Arial;font-size:10pt;">Item 2.  Properties</font><font style="font-family:Arial;font-size:10pt;">&#32;included elsewhere in this report, and details regarding our lease arrangement are included in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 14, Commitments</font><font style="font-family:Arial;font-size:10pt;">&#32;to the audited consolidated financial statements included elsewhere in this report.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We plan to assemble the ID/AST System instrument and consumable test kits in our facilities in Tucson, Arizona.  The ID/AST System requires certain components that are custom-fabricated to our specifications.  Such components include injection-molded plastic components, die-cut laminates, and machined mechanical components.  We own the necessary production tooling and believe that we will be able to qualify secondary sources as needed to support future demand for the ID/AST System.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Raw Materials</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We purchase many different types of raw materials, including plastics, glass, metals, electronic and mechanical sub-assemblies and various biological and chemical products.  We seek to ensure continuity of raw material supply by securing multiple options for sourcing.  However, our components are custom-made by only a few outside suppliers.  In certain instances, we have a sole source supply for key product components of the ID/AST System.  We have entered into supply agreements with most of our suppliers to help ensure component availability and flexible purchasing terms with respect to the purchase of such components.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Employees</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have 113 employees as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.  We have not entered into any collective bargaining agreements and consider our labor practices and employee relations to be good.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Available Information</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We regularly file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any other filings required by the SEC.  We make these reports available free of charge in the investor relations section of our corporate website (http://ir.axdx.com/) as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC.  References to our corporate website address in this report are intended to be inactive textual references only, and none of the information contained on our website is part of this report or incorporated in this report by reference.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The public may inspect and copy materials we file with the SEC at the SEC&#8217;s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.  You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  You may also access these materials, and other information regarding issuers like us that file information electronically with the SEC, from the SEC&#8217;s internet website at http://www.sec.gov/.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sDC7DFD3FCFA9650C2CC2EFC22C20557F"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A.  Risk Factors</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investing in our securities involves a high degree of risk.  You should carefully consider the risks described below, in addition to the other information included or incorporated by reference in this Annual Report on Form 10-K, including our financial statements and the related notes.  If any of the following risks materializes, our business, financial condition, results of operations or growth prospects could be materially adversely affected, and the value of an investment in our common stock may decline significantly.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Strategy</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Our future profitability and continued existence is dependent in large part upon the successful final development and commercialization of the Accelerate ID/AST System and further development and commercialization of complimentary products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our principal business strategy involves the successful final development and commercialization of the Accelerate ID/AST System, associated test kits and the future development and commercialization of complimentary products.  On June 30, 2015, we declared our conformity to the European </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">In Vitro</font><font style="font-family:Arial;font-size:10pt;">&#32;Diagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay Kit for </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;">&#32;diagnostic use.  We have dedicated a significant amount of resources to finalize the development of and prepare to market and sell the ID/AST System, and we plan to continue our investment in finalizing the development and commercialization of the ID/AST System in the United States and other jurisdictions in which we intend to pursue marketing authorization.  There can be no assurance that we will successfully finalize the development of and commercialize the ID/AST System, associated Blood Culture Assay Kit, or further develop and commercialize complimentary products.  We may be required to expend significantly more resources than planned in this process, and as a result we may have to cease investing in the ID/AST System or developing other products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we are not successful in the final development and commercialization of the ID/AST System, such failure could lead to impairment of certain of our intellectual property and may result in our ceasing operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further, if we are not successful in conveying to hospitals that the ID/AST System provides equivalent or superior diagnostic information in a shorter period of time compared to existing technologies, or that the ID/AST System improves patient outcomes or decreases healthcare costs, we may experience reluctance from hospitals to order our product.  If we fail to successfully commercialize the ID/AST System, we may never receive a return on the significant investments in product development, sales and marketing, regulatory compliance, manufacturing and quality assurance we have made and further investments we intend to make, and may fail to generate revenue and gain economies of scale from such investments.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Our product candidates have not obtained marketing authorization from the FDA, and they may never obtain such marketing authorization or other regulatory clearance.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our success depends on our ability to obtain marketing authorization from the FDA or regulatory clearance of the ID/AST System and other product candidates in our pipeline.  If our attempts to obtain marketing authorization or other regulatory clearance are unsuccessful, we may be unable to generate sufficient revenue to sustain and grow our business.  Our future product candidates may not be sufficiently sensitive or specific to obtain, or may prove to have other characteristics that preclude our obtaining, marketing authorization from the FDA or regulatory clearance.  The process of obtaining regulatory clearance is expensive and time-consuming and can vary substantially based upon, among other things, the type, complexity and novelty of our product candidates.  Changes in regulatory policy, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the clearance of, or receipt of marketing authorization from the FDA for, a product candidate or rejection of a regulatory application altogether.  The FDA has substantial discretion in the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:Arial;font-size:10pt;">&#32;review and clearance processes and may refuse to accept any application or may decide that our data are insufficient for clearance and require additional pre-clinical, clinical or other studies.  In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing authorization from the FDA or regulatory clearance of a product candidate.  Furthermore, the FDA may not provide clearance for all of the individual assays of our Blood Culture Assay Kit.  Any marketing authorization from the FDA or regulatory clearance we ultimately obtain may be limited or subject to restrictions or post-market commitments that render the product candidate not commercially viable.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals.  These goals may include the commencement or completion of clinical trials and the submission of regulatory filings.  From time to time, we may publicly announce the expected timing of some of these goals.  For example, we state that, contingent upon successful completion of the larger trial, we plan to submit a 510(k) notification seeking premarket clearance for the Accelerate ID/AST System and Blood Culture Assay Kit, and that we anticipate commercializing the Accelerate ID/AST System in the United States, subject to the successful completion of the U.S. registration trial and submission and clearance by the FDA of our </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:Arial;font-size:10pt;">&#32;510(k) for the ID/AST System and Blood Culture Assay Kit, which could occur as early as the third quarter of 2016.  All of these goals </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">are, and will be, based on a variety of assumptions.  The actual timing of these goals can vary significantly compared to our estimates, in some cases for reasons beyond our control.  We may experience numerous unforeseen events that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including the uncertainties and risks set forth in these risk factors.  If we do not meet our goals as publicly announced, the commercialization of our product candidates may be delayed and, as a result, our stock price may decline.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Although we announced positive findings from our recently completed pilot study, there is no guarantee that our larger trial to support marketing authorization from the FDA will have similar results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 2, 2015, we announced positive findings from a multicenter pilot study to evaluate external performance of our ID/AST System and Blood Culture Assay Kit.  Based on the results of the pilot study, we also announced the initiation of a larger trial intended to support 510(k) clearance by the FDA.  There is no guarantee that the larger upcoming trial to support marketing authorization from the FDA will achieve similar results.  If the larger trial does not achieve the results required to support marketing authorization from the FDA, we may be required to further develop our ID/AST System and Blood Culture Assay Kit and the commercialization of our technology would be delayed or may never be achieved, and, as a result, our stock price may decline.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may not be able to enhance the capabilities of our current and new products to keep pace with our industry&#8217;s rapidly changing technology and customer requirements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards.  Our future success will depend significantly on our ability to enhance our current products and develop or acquire and market new products that keep pace with technological developments and evolving industry standards as well as respond to changes in customer needs.  New technologies, techniques or products could emerge that might offer better combinations of price and performance than the products and systems that we plan to sell.  It is critical to our success that we anticipate changes in technology and customer requirements and physician, hospital and healthcare provider practices and successfully introduce new, enhanced and competitive technologies to meet our prospective customers&#8217; needs on a timely and cost-effective basis.  At the same time, however, we must carefully manage our introduction of new products.  If potential customers believe that such products will offer enhanced features or be sold for a more attractive price, they may delay purchases until such products are available.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We are developing additional uses for the ID/AST System.  Any failure or delay in launching new applications may compromise our ability to achieve our growth objectives.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are developing additional uses for the ID/AST System, including the ability to test on additional specimen types (</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Arial;font-size:10pt;">, respiratory samples, skin and soft tissue and urine).  We may have problems applying our technologies to additional specimen types, and our new applications may not be as effective in detection as our initial applications.  We may also encounter difficulties obtaining regulatory approval for additional uses of the ID/AST System.  Any failure or delay in launching new applications may compromise our ability to achieve our growth objectives.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There can be no assurance that we will be successful in developing or acquiring product enhancements or new products to address changing technologies and customer requirements adequately, that we can introduce such products on a timely basis or that any such products or enhancements will be successful in the marketplace.  If we are unable to successfully develop or acquire new products or if the market does not accept our products, or if we experience difficulties or delays in the final development and commercialization of our products, including the ID/AST System, we may be unable to attract additional customers for our products or license our products to other strategic partners.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">The failure of the ID/AST System or any future diagnostic products to perform as expected could significantly impair our reputation and the public image of our products, and we may be subject to legal claims arising from any defects or errors.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our success will depend on the market&#8217;s confidence that our technologies can provide reliable, high-quality diagnostic results.  We believe that our customers are likely to be particularly sensitive to any defects or errors in the ID/AST System.  If we experience disruptions or other performance problems with the ID/AST System or any future diagnostic product, we could face warranty and liability claims against us or our reputation could suffer as a result of such failures.  We cannot assure you that our product liability insurance would adequately protect our assets from the financial impact of defending a product liability claim.  Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future.  </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, the FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health.  A recall, material liability claim or other occurrence that harms our reputation or decreases market acceptance of our products could cause us to incur significant costs, divert the attention of our key personnel or cause other significant customer relations problems.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We have limited revenues from our products and no assurance of future revenues.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have received limited revenue from sales based on products using our OptiChem technology, and we are in the process of discontinuing our efforts to develop and actively market OptiChem and our other surface chemistry products.  During the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, we experienced losses from operations.  Our future revenues are dependent on the successful final development and commercialization of the ID/AST System, and there can be no assurance that we will be successful.  If we are unsuccessful in generating revenues from such product, we will likely continue to experience losses from operations and negative cash flow as we have in the past.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We are a development-stage company that has incurred significant losses in recent years, and we expect to incur losses in the future.  We cannot be certain that we will achieve or sustain profitability.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have incurred significant costs in connection with the development and commercialization of our technology, and there is no assurance that we will achieve sufficient revenues to offset anticipated operating costs.  We have incurred significant losses in recent years and expect to incur losses in the future.  We expect that our losses will continue for at least the next several years as we will be required to invest significant additional funds toward development and commercialization of our technology.  We also expect that our selling, general and administrative expenses will continue to increase due to the additional costs associated with establishing a dedicated sales force and other marketing efforts for the ID/AST System.  Our ability to achieve or sustain profitability depends on numerous factors, many of which are beyond our control, including our ability to achieve marketing authorization from the FDA or regulatory clearance for the Accelerate ID/AST System, the market acceptance of our product, future product development and our market penetration and margins.  If we are unsuccessful in completing the development of the ID/AST System and generating revenues from ID/AST System sales, we will likely continue to experience losses from operations and negative cash flow.  Although we anticipate deriving revenues from the sale of our products, no assurance can be given that these products can be sold on a net profit basis.  If we achieve profitability, we cannot give any assurance that we will be able to sustain or increase profitability on a quarterly or annual basis in the future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We have no experience in marketing and selling the ID/AST System.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have no experience marketing and selling the ID/AST System.  In anticipation of the receipt of marketing authorization from the FDA for the ID/AST System, we have begun to build our own sales force to market the ID/AST System directly to our target customers, and we plan to continue to build this sales force.  In select geographies outside of the United States and Europe, we may also use third-party distributors to market our product.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our future sales will depend in large part on our ability to successfully establish an effective sales force.  Because we have no experience in marketing and selling the ID/AST System, our ability to forecast demand, the infrastructure required to support such demand and the sales cycle of our potential customers is unproven.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Moreover, we may use third-party distribution partners for certain geographic areas outside of the United States and Europe, and there is no guarantee that we will be able to enter into such arrangements on favorable terms.  Distributors may not commit the necessary resources to market and sell the ID/AST System effectively or may choose to favor marketing the products of our competitors.  If distributors do not perform adequately, or if we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize our full potential for sales and growth in these areas.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">If treatment guidelines for bacterial infections change, or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for our product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If treatment guidelines for bacterial infections change, or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA or other regulatory clearance for our product candidates.  If treatment guidelines change so that different treatments become desirable, the ID/AST System may no longer provide the information sought by physicians, and we could be required to seek marketing authorization from the FDA or other regulatory clearance for a revised product.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may not be able to correctly estimate or control our future operating expenses, which could lead to cash shortfalls.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, many of which may be outside of our control.  These factors include, but are not limited to:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the time and resources required to finalize the development of, and conduct clinical studies and obtain marketing authorization from the FDA or other regulatory clearances for, the ID/AST System;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the expenses we incur for research and development required to maintain and improve our technology, including the final development of the ID/AST System;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the expenses we incur in connection with the development, marketing authorization and regulatory clearance of the use of the ID/AST System to test on additional specimen types;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs of preparing, filing, prosecuting, defending and enforcing patent claims and other patent related costs, including litigation costs and the results of such litigation;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the expenses we incur in connection with commercialization activities, including product marketing, sales and distribution expenses;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs incurred to build manufacturing capabilities;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the expenses to implement our sales strategy;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs to attract and retain personnel with the skills required for effective operations; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs associated with being a public company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our budgeted expense levels are based in part on our expectations concerning future revenues from sales of the ID/AST System, as well as our assessment of the future investments needed to expand our commercial organization and support research and development activities in connection with the ID/AST System.  We may be unable to reduce our expenditures in a timely manner to compensate for any unexpected events or a shortfall in revenue.  Accordingly, a shortfall in demand for our products or other unexpected events could have an immediate and material impact on our cash levels.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Breaches of our information technology systems could have a material adverse effect on our operations and potentially result in liability, depending on the type of breach and information compromised.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We rely on information technology systems to process, transmit and store electronic information, which may include protected health information, in our day-to-day operations.  In addition, our research and development operations are highly dependent on our information technology and storage.  Our information technology systems have been subjected to computer viruses or other malicious codes and phishing attacks, and we expect to be subject to similar viruses and codes in the future.  These attacks could result in our intellectual property, unsecured protected health information, and other confidential information being lost or stolen, including the disclosure of our trade secrets, disruption of our operations, loss of valuable research and development data, the need to notify individuals whose information was disclosed, increased costs for security measures or remediation costs and diversion of management attention and other negative consequences.  While we will continue to implement protective measures to reduce the risk of and detect future cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly.  There can be no assurance that our protective measures will prevent future attacks that could have a significant impact on our business.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We are dependent on our key employees.  If we are unable to recruit, train and retain qualified personnel, we may not achieve our goals.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because of the complex and technical nature of our products and the dynamic market in which we compete, our future success depends on our ability to recruit, train and retain key personnel, including our senior management, research and development, science and engineering, manufacturing and sales and marketing personnel.  In particular, </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we are highly dependent on the management and business expertise of Lawrence Mehren, our President and Chief Executive Officer.  We do not maintain key person life insurance for Mr. Mehren or any of our employees.  Our industry is very competitive for qualified personnel.  To the extent that the services of Mr. Mehren would be unavailable to us, we may be unable to employ another qualified person with the appropriate background and expertise to replace Mr. Mehren on terms suitable to us.  Our growth depends, in particular, on attracting, retaining and motivating highly trained sales personnel with the necessary scientific background and ability to understand our systems and pathogens at a technical level.  In addition, we may need additional employees at our manufacturing facilities to meet demand for our products as we scale up our sales and marketing operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">We face competition from industry participants who may have greater reso</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">u</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">rces than we do.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The industry in which we compete is subject to rapid technological changes, and we face and expect to continue to face competition for our products.  We may also face competition from non-medical device companies.  Many of our competitors and potential competitors may have substantially greater research and development, financial, manufacturing, customer support, sales and marketing resources, larger customer bases, longer operating histories, greater name recognition and more established relationships in the industry than we do.  In addition, some of our competitors may, individually or together with companies affiliated with them, have greater human and scientific resources than we do.  Our competitors could develop technologies and methods that are more effective than our current and proposed technologies, including but not limited to the ID/AST System.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot assure you that we will effectively compete or that we will be successful in the face of increasing competition from new products and technologies introduced by existing or new competitors.  In addition, we cannot assure you that our future competitors do not have or will not develop products or technologies that enable them to produce competitive products with greater capabilities or at lower costs than our products.  Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We expect to generate a portion of our future revenue internationally and are subject to various risks relating to our international activities which could adversely affect our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Assuming we receive the applicable regulatory approvals, we plan to market and sell the ID/AST System in Europe and other countries outside of the United States in the future.  In order to market our products in the European Union and many other foreign jurisdictions, we, or our distributors or partners, must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical studies and commercial sales and distribution of our products.  The approval procedure varies among countries and can involve additional testing.  In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country.  We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all, which could harm our ability to expand into markets outside the United States.  In addition, engaging in international business involves a number of other difficulties and risks, including:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">required compliance with existing and changing foreign healthcare and other regulatory requirements and laws, such as those relating to patient privacy or handling of bio-hazardous waste;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act, data privacy requirements, labor laws and anti-competition regulations; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">export and import restrictions; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">various reimbursement and insurance regimes; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">laws and business practices favoring local companies; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">political and economic instability;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers; </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">foreign exchange controls; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">fluctuations due to changes in foreign currency exchange rates;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties and costs of staffing and managing foreign operations; and </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties protecting or procuring intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Our employees, independent contractors, principal investigators, consultants, commercial partners, vendors and other agents may engage in misconduct or other improper activities, including non-compliance with legal standards and requirements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, consultants, commercial partners, vendors and other agents.  Misconduct by these parties could include intentional, reckless or negligent failures to: (i) comply with the laws and regulations of the FDA, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), the Department of Health and Human Services (&#8220;HHS&#8221;) Office of Inspector General, Office for Civil Rights and other similar foreign regulatory bodies; (ii) provide true, complete and accurate information to the FDA and other similar regulatory bodies; (iii) comply with manufacturing requirements of the FDA and other similar regulatory bodies and manufacturing standards we have established; (iv) comply with healthcare fraud and abuse laws and regulations in the United States and similar foreign fraudulent misconduct laws; or (v) report financial information or data accurately, or disclose unauthorized activities to us.  These laws may impact, among other things, our activities with principal investigators and research subjects, as well as our sales, marketing and education programs.  In particular, the promotion, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, unauthorized use of protected health information and data breaches, and other abusive practices.  These laws may restrict or prohibit a wide range of activities related to pricing, discounting, marketing and promotion, patient support, royalty, consulting, research and other business arrangements, as well as the improper use of patient information obtained in the course of clinical studies.  We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.  If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, corporate integrity agreements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.  Any of these actions or investigations could result in substantial costs to us, including legal fees, and divert the attention of management from operating our business.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may be unable to successfully manage our growth.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect to expand our operations following marketing authorization from the FDA and regulatory clearance and the commercial launch of the ID/AST System.  We intend to develop a targeted sales force in connection with our commercialization efforts.  Our growth has placed and will continue to place a significant strain on our management, operating and financial systems and our sales, marketing and administrative resources.  As a result of our growth, operating costs may escalate faster than planned, and some of our internal systems and processes, including those relating to manufacturing our products, may need to be enhanced, updated or replaced. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also plan to introduce additional test kits for use on the Accelerate ID/AST System to enable its use with other sample types (</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Arial;font-size:10pt;">, respiratory samples, skin, soft tissue and urine), and plan to invest in the development of additional instruments, tests and other microbiology solutions.  If we cannot effectively manage our expanding operations, manufacturing capacity and costs, including scaling to meet increased demand, we may not be able to continue to grow or we may grow at a slower pace than expected.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may in the future be subject to shareholder lawsuits, including purported class actions, which is expensive and could divert the attention of management away from our business.  In addition, any adverse result of such litigation could negatively impact our financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the past, companies such as Accelerate that have experienced volatility in the market price of their stock have been subject to an increased incidence of securities class action litigation and other shareholder lawsuits.  We may in the future be the target of this type of litigation.  Shareholder lawsuits against us, our officers or directors could result in substantial costs and divert the attention of management away from operating our business and other concerns, which could harm our business. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Current macroeconomic conditions and the uncertain economic outlook may remain challenging for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Global economic conditions may remain challenging and uncertain for the foreseeable future.  These conditions not only limit our access to capital but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities, and they could cause U.S. and foreign hospitals and other customers to slow spending on our products, which would delay and lengthen sales cycles.  Some of our customers rely on government research grants to fund technology purchases.  If negative trends in the economy affect the government&#8217;s allocation of funds to research, there may be less grant funding available for certain of our customers to purchase technologies from us.  Certain of our customers may face challenges gaining timely access to sufficient credit or may otherwise be faced with budget constraints, which could result in decreased purchases of our products or in an impairment of their ability to make timely payments to us.  If our customers do not make timely payments to us, we may be required to assume greater credit risk relating to those customers and increase our allowance for doubtful accounts, and our days sales outstanding would be negatively impacted.  Although we maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments, we may not continue to experience the same loss rates that we have in the past.  Additionally, challenging macroeconomic conditions and market turbulence may also impact our suppliers, causing them to be unable to supply in a timely manner sufficient quantities of customized components, thereby impairing our ability to manufacture on schedule and at commercially reasonable costs.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Compliance with public company corporate governance and reporting is complex and expensive.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are subject to laws and regulations affecting our domestic and international operations in a number of areas.  Many laws and regulations, notably those adopted in connection with the Sarbanes-Oxley Act of 2002 by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act and The NASDAQ Stock Market, impose obligations on public companies, such as ours, which have increased the scope, complexity and cost of corporate governance, reporting and disclosure practices.  Compliance with these laws, regulations and similar requirements may be onerous, requires substantial management time and oversight and requires us to incur significant additional accounting, legal and compliance costs.  Any such costs, which may rise in the future as a result of changes in these laws and regulations or in their interpretation could individually or in the aggregate make our products and services more expensive, delay the introduction of new products in one or more regions, or cause us to change or limit our business practices.  In addition, our larger competitors may be in a better position to absorb the costs of being a public company.  We have implemented policies and procedures designed to ensure compliance with applicable laws and regulations, but there can be no assurance that our employees, contractors or agents will not violate such laws and regulations or our policies and procedures.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, changes to existing accounting rules and standards and the implementation of new accounting rules or standards, such as tax accounting or revenue recognition rules, may adversely impact our reported financial results and business, and may further require us to incur greater accounting fees.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate.  The estimates and forecasts in this 10-K relating to the size and expected growth of our market, total available market, estimated test and placement volume and estimated pricing, may prove to be inaccurate, which may have negative consequences, such as us overestimating our potential market opportunity.  Even if the market in which we compete meets our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Our reputation</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;ability to do business and financial results may be impaired by improper conduct by any of our employees, agents or any business partners.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents or business partners that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, export and import compliance, money laundering and data privacy.  In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business.  Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks related to our</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">&#32;intellectual property</font></div><div style="line-height:174%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">If we are una</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ble to effectively protect our non-patented intellectual property, our business would be harmed.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to patent protection, we rely on trademark, copyright, trade secret protection and confidentiality agreements to protect the intellectual property rights related to our proprietary technologies, both in the United States and in other countries.  If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.  We own or exclusively license 12 issued U.S. patents and 16 pending U.S. patent applications, including provisional and non-provisional filings.  We also own or exclusively license 13 pending or granted counterpart applications worldwide.  In addition to our patents, we possess an array of unpatented proprietary technology and know-how, and we license intellectual property rights to and from third parties.  The strength of patents in our field involves complex legal and scientific questions.  Uncertainty created by these questions means that our patents may provide only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage.  In addition, competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of the protections provided by our intellectual property rights.  If our intellectual property, including licensed intellectual property, does not adequately protect our market position against competitors&#8217; products and methods, our competitive position could be adversely affected, as could our business.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further, if we are unable to prevent unauthorized disclosure of our non-patented intellectual property, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage.  In addition, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States.  As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may not be successful in our currently pending or future patent applications, and even if such applications are successful, we cannot guarantee that the resulting patents will sufficiently protect our products and proprietary technology.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot assure you that any of our currently pending or future patent applications will result in issued patents with claims that cover our products and technologies in the United States or in other foreign countries, and we cannot predict how long it will take for such patents to be issued.  Further, issuance of a patent is not conclusive as to its inventorship or scope, and there is no guarantee that our issued patents will include claims that are sufficiently broad to cover our technologies or to provide meaningful protection from our competitors.  Further, we cannot be certain that all relevant prior art relating to our patents and patent applications has been found.  Accordingly, there may be prior art that can invalidate our issued patents or prevent a patent from issuing from a pending patent application, at all or with claims that have a scope broad enough to provide meaningful protection from our competitors.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Even if patents do successfully issue and even if such patents cover our products and technologies, we cannot assure you that other parties will not challenge the validity, enforceability or scope of such issued patents in the United States and in foreign countries, including by proceedings such as reexamination, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">inter-partes</font><font style="font-family:Arial;font-size:10pt;">&#32;review, interference, opposition, or other patent office or court proceedings.  The strength of patents in our field involves complex legal and scientific questions.  Moreover, we cannot assure you that if such patents were challenged in court or before a regulatory agency that the patent claims will be held valid, enforceable, to be sufficiently broad to cover our technologies or to </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide meaningful protection from our competitors.  Nor can we assure you that the court or agency will uphold our ownership rights in such patents.  Accordingly, we cannot guarantee that we will be successful in defending challenges made against our patents and patent applications.  Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, or narrowing of claim scope, such that we could be deprived of patent protection necessary for the successful commercialization of our products and technologies, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our products and technologies or prevent others from designing around our claims.  Others may independently develop similar or alternative products and technologies or duplicate any of our products and technologies.  These products and technologies may not be covered by claims of issued patents we hold.  Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product under patent protection could be reduced.  Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to make the inventions covered by our pending patent applications, or that we were the first to file any patent application related to a product candidate.  Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.  In addition, patents have a limited lifespan.  In the United States, the natural expiration of a patent is generally 20 years after it is filed.  Various extensions may be available; however the life of a patent, and the protection it affords, is limited.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive and time consuming.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Third parties may infringe or misappropriate our intellectual property, including our existing patents and patents that we may issue to us in the future.  As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use.  Further, we may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we file an infringement action against a third party, that party may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings.  Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates.  They may also put our pending patent applications at risk of not issuing or issuing with limited and potentially inadequate scope to cover our product candidates.  The outcome following legal assertions of invalidity and unenforceability is unpredictable. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Enforcing our intellectual property rights through litigation is very expensive and time-consuming.  Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources.  Patent litigation and other proceedings may also absorb significant management time.  Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.  The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We could face claims that our proprietary technologies infringe on the intellectual property rights of others.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due to the significant number of U.S. and foreign patents issued to, and other intellectual property rights owned by, entities operating in the industry in which we operate, we believe that there is a risk of litigation arising from infringement of these patents and other rights.  Third parties may assert infringement or other intellectual property claims against us or our licensees.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after the earliest filing date for which a benefit is claimed.  For this reason, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications or that we were the first to invent </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the technology.  Another party may have filed or may in the future file patent applications covering our products or technology similar to ours.  Under the &#8220;first to invent&#8221; rules applicable to patents filed before March 2013, any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies.  If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the U.S. Patent and Trademark Office to determine priority of invention in the United States.  The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may have to pay substantial damages, including treble damages, for past infringement if it is ultimately determined that our products infringe on a third party&#8217;s proprietary rights.  In addition, even if such claims are without merit, defending a lawsuit may result in substantial expense to us and divert the efforts of our technical and management personnel.  We may also be subject to significant damages or injunctions against development and sale of some of our products.  Furthermore, claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties, and we may be unable to obtain royalty or license agreements on commercially acceptable terms, if at all.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.  Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer.  Litigation may be necessary to defend against these claims.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own.  Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.  Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks related to our research and development activities</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We have a single research and development facility and we may be unable to continue to conduct our research and development activities if we lose this facility.  If our facility or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently conduct all of our research and development and product development activities in our existing facility in Tucson, Arizona.  If this facility were to be damaged, destroyed or otherwise unable to operate, whether due to fire, floods, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if our business is disrupted for any other reason, we may not be able to finalize the development of the ID/AST System or any future products or test our products as promptly as our potential customers expect, or possibly not at all, and we would have no other means of conducting such activities until we were able to restore such capabilities at the current facility or develop an alternative facility.  Further, in such an event, we may lose revenue and significant time during which we might otherwise have conducted research and development and product development activities.  Further, we may not be able to maintain our relationships with our licensees or customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The manufacture of components of the ID/AST System involves complex processes, sophisticated equipment and strict adherence to specifications and quality systems procedures.  Any unforeseen manufacturing problems, such as contamination of our facility, equipment malfunction or failure to strictly follow procedures or meet specifications, could result in delays or shortfalls in production of our products.  Identifying and resolving the cause of any manufacturing issues could require substantial time and resources.  If we are unable to keep up with future demand for our products </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">by successfully manufacturing and shipping our products in a timely manner, our revenue growth could be impaired and market acceptance of our product candidates could be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While we carry a nominal amount of business interruption insurance to cover lost revenue and profits, this insurance does not cover all possible situations.  If we have underestimated our insurance needs with respect to an interruption, or if an interruption is not subject to coverage under our insurance policies, we may not be able to cover our losses.  In addition, our business interruption insurance would not compensate us for the loss of opportunity and potential adverse impact on relations with our licensees or customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We use hazardous materials in some of our research, development and manufacturing processes and face the accompanying risks and regulations governing environmental safety.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce.  In particular, our research activities sometimes involve the controlled use of various hazardous materials.  Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated, and we may not be in compliance with these regulations.  In addition, existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, causing us to incur additional compliance costs and/or change the manner in which we operate.  We could be held liable for any damages that might result from any accident or release involving hazardous materials.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Disruptions in the supply of raw materials, consumable goods or other key product components, or issues associated with their quality from our single source suppliers, could result in a significant disruption in sales and profitability.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We must manufacture or engage third parties to manufacture components of our products in sufficient quantities and on a timely basis, while maintaining product quality, acceptable manufacturing costs and complying with regulatory requirements.  Our components are custom-made by only a few outside suppliers.  In certain instances, we have a sole source supply for key product components of the ID/AST System.  We may be unable to satisfy our forecasted demand from existing suppliers for our products, or we may be unable to find alternative suppliers for key product components or ancillary items at reasonably comparable prices.  If this occurs, we may be unable to manufacture our products and/or meet our customers&#8217; needs in a timely manner or at all.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, we have entered into supply agreements with most of our suppliers to help ensure component availability and flexible purchasing terms with respect to the purchase of such components.  If our suppliers discontinue production of a key component for one or more of our products, we may be unable to identify or secure a viable alternative on reasonable terms, or at all, which could limit our ability to manufacture our products.  While we may be able to modify our product candidates to utilize a new source of components, we may need to secure marketing authorization from the FDA or other regulatory clearance for the modified product, and it could take considerable time and expense to perform the requisite tasks prior to seeking such authorization.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In determining the required quantities of our products and our manufacturing schedule, we will need to make significant judgments and estimates regarding factors such as market trends and any seasonality with respect to our sales.  Because of the inherent nature of estimates and our lack of experience marketing the ID/AST System, there could be significant differences between our estimates and the actual amounts of products we require.  This can result in shortages if we fail to anticipate demand, or excess inventory and write-offs if we order more than we need.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reliance on third-party manufacturers entails risk to which we would not be subject if we manufactured these components ourselves, including: </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">reliance on third parties for regulatory compliance and quality assurance;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">possible breaches of manufacturing agreements by the third parties because of factors beyond our control;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">possible regulatory violations or manufacturing problems experienced by our suppliers;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the potential obsolescence and/or inability of our suppliers to obtain required components;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the potential delays and expenses of seeking alternate sources of supply or manufacturing services;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the inability to qualify alternate sources without impacting performance claims of our products;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">reduced control over pricing, quality and timely delivery due to the difficulties in switching to alternate suppliers or assemblers; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">increases in prices of raw materials and key components.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The manufacturing operations for the ID/AST System use highly technical processes involving unique, proprietary techniques.  In addition, the manufacturing equipment we use would be costly to repair or replace and could require substantial lead time to repair or replace.  Any interruption in our operations or decrease in the production capacity of our manufacturing facility or the facilities of any of our suppliers because of equipment failure, natural disasters such as earthquakes, tornadoes and fires, or otherwise, would limit our ability to meet customer demand for our products.  In the event of a disruption, we may lose customers and we may be unable to regain those customers thereafter.  Our insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We have made and intend to make significant additional investments in research and development, but there is no guarantee that any of these investments will ultimately result in a commercial product that will generate revenues.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The ID/AST System integrates several of our component products, systems and processes.  We have dedicated significant resources on research and development activities, and we intend to spend significantly more on research and development activities.  Notwithstanding these investments, we anticipate that we will have to spend additional funds in the research and development of the ID/AST System, particularly with respect to its use for additional specimen types.  There can be no assurance that we will be able to obtain marketing authorization from the FDA of the ID/AST System or that we will be able to expand its use for additional specimen types.  There can also be no assurance that we will be able to develop additional types of tests and instruments in the future. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks related to government regulation</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We and our suppliers, contract manufacturers and customers are subject to various governmental laws and regulations, and we may incur significant expenses to comply with, and experience delays in our product commercialization as a result of, these laws and regulations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our operations are affected by various state, federal, and international healthcare, environmental, anti-corruption, fraud and abuse (including anti-kickback and false claims laws), privacy, and employment laws.  Violations of these laws can result in criminal or civil sanctions, including substantial fines and, in some cases, exclusion from participation in federal health care programs such as Medicare and Medicaid and individual liability and imprisonment.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are also subject to extensive regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act, by comparable agencies in foreign countries and by other regulatory agencies and governing bodies.  Following the introduction of a product, these and other government agencies will periodically review our manufacturing processes, product performance and compliance with applicable requirements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are also subject to various U.S. healthcare related laws regulating sales, contracting, marketing, and other business arrangements and the use and disclosure of individually identifiable health information.  These include but are not limited to:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal Anti-Kickback Statute, which prohibits persons from knowingly and willfully offering, providing, soliciting, or receiving any remuneration, directly or indirectly, in exchange for or to induce the referral of an individual, or the purchasing, leasing, ordering, recommending, furnishing or arranging for a good or service, for which payment may be made under a federal health care program, such as Medicare or Medicaid.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which prohibits knowingly and willfully (i) executing a scheme to defraud any health care benefit program, including private payors, or (ii) falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for items or services under a health care benefit program. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, which also restricts the use and disclosure of protected health information, mandates the adoption of standards relating to the privacy and security of protected health information, and requires us to report certain security breaches to health care provider customers with respect to such information where we are acting as a HIPAA business associate to that customer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal Physician Payment Sunshine Act, which requires manufacturers of certain medical devices to track payments or other transfers of value given to U.S. licensed physicians or teaching hospitals and to report this data to CMS annually for subsequent public disclosure. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program.  The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Similar requirements have been adopted by many states and foreign countries.  Violations of any of these laws can lead to additional legal risk such as risk of plaintiff class actions, state Attorney General actions, and investigations by the Federal Trade Commission, among others.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Failure to comply with applicable requirements, or later discovery of previously unknown problems with our products or manufacturing processes, including our failure or the failure of one of our contract manufacturers to take satisfactory corrective action in response to an adverse inspection, can result in, among other things:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">administrative or judicially imposed sanctions;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">injunctions or the imposition of civil penalties;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">recall or seizure of our products;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">total or partial suspension of production or distribution;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">withdrawal or suspension of marketing clearances or approvals;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">clinical holds;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">warning letters;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">refusal to permit the import or export of our products; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">criminal prosecution; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">exclusion or debarment from participation in federal health care programs such as Medicare and Medicaid.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any of these actions, in combination or alone, could prevent us from marketing, distributing and selling our products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, we have developed, configured and we intend to market our products to meet customer needs created by these various regulations.  Any significant change in these regulations could reduce demand for our products.  Governmental agencies may also impose new requirements regarding registration, labeling or prohibited materials that may require us to modify or re-register products already on the market or otherwise adversely impact our ability to market our products.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us.  We believe that the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception.  Regulatory agencies in other countries have similar authority to recall devices because of material deficiencies or defects in design or manufacture that could endanger health.  Any recall would divert management attention and financial resources, could cause the price of our shares of common stock to decline, expose us to product liability or other claims (including contractual claims from parties to whom we sold products) and harm our reputation with customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The use of our diagnostic products by our customers is also affected by the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) and related federal and state regulations that provide for regulation of laboratory testing.  CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, participation in proficiency testing, patient test management, quality assurance, quality control and inspections.  Current or future CLIA requirements or the promulgation of additional regulations affecting laboratory testing may prevent some laboratories, hospitals, providers or other customers with laboratories from using some or all of our diagnostic products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Maintaining adequate sales of our product may depend on the availability of adequate reimbursement to our customers from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans, and managed care programs.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Maintaining and growing sales of our product, if approved, may depend in part on the availability of adequate reimbursement to our customers from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs.  Hospitals, clinical laboratories and other healthcare provider customers that may purchase our products generally bill various third-party payors to cover all or a portion of the costs and fees associated with diagnostic tests, including the cost of the purchase of our products.  We currently expect that all of our diagnostic tests will be performed in a hospital inpatient setting, where governmental payors, such as Medicare, generally reimburse hospitals a single bundled payment that is based on the patient&#8217;s diagnosis under a classification system known as the Medicare severity diagnosis-related groups (MS-DRGs) classification for all items and services provided to the patient during a single hospitalization, regardless of whether our diagnostic tests are performed during such hospitalization.  As a result, our customers&#8217; access to adequate payment by government and private insurance plans is central to the acceptance of our products.  We may be unable to sell our products, if approved, on a profitable basis if third-party payors reduce their current levels of payment or if our costs of production increase faster than increases in reimbursement levels.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, third-party payors are increasingly reducing reimbursement for medical products and services.  In addition, the U.S. government, state legislatures, and foreign governments have and may continue to implement cost-containment measures and more restrictive policies, including price controls and restrictions on reimbursement.  For example, the Budget Control Act of 2011 (the &#8220;Budget Control Act&#8221;) established a process to reduce federal budget deficits through an automatic &#8220;sequestration&#8221; process if deficit reductions targets are not otherwise reached.  Under the terms of the Budget Control Act, sequestration imposes cuts to a wide range of federal programs, including Medicare, which is subject to a two percent cut.  The Bipartisan Budget Act of 2013 extended the two percent sequestration cut for Medicare through fiscal year 2023, and a bill signed by the President on February 15, 2014 further extended this cut for an additional year, through fiscal year 2024.  For fiscal year 2024, however, Medicare sequestration amounts will be realigned such that there will be a four percent sequester for the first six months and no sequester for the second six months, under the Protecting Access to Medicare Act of 2014.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While we cannot predict whether third-party reimbursement to our customers will be adequate, cost-containment measures and similar efforts by third-party payors, including government programs such as Medicare and Medicaid, could substantially impact the sales of our products and potentially limit our net revenue and results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may be adversely affected by healthcare policy changes, including additional healthcare reform and changes in managed healthcare.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Healthcare reform and the growth of managed care organizations have been considerable forces in the medical diagnostics industry and in recent political discussions.  These forces have placed, and are expected to continue to place, constraints on the levels of overall pricing for healthcare products and services as well as the coverage available by public and private insurance and thus, could have a material adverse effect on the future profit margins of our products or the amounts that we are able to receive from third parties for the licensing of our products.  Changes in </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the United States healthcare market could also force us to alter our approach to selling, marketing, distributing and servicing our products and customer base.  In and outside the United States, changes to government reimbursement policies could reduce the funding that healthcare service providers have available for diagnostic product expenditures, which could have a material adverse impact on the use of the products we are developing and our future sales, license and royalty fees and profit margin.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For example, the Affordable Care Act (the &#8220;ACA&#8221;), enacted in March 2010, made changes that have significantly impacted the medical device industry and other healthcare providers.  The legislation requires, among other mandates, that certain medical device manufacturers pay an excise tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices.  We will be subject to this tax once we begin selling the ID/AST System.  The ACA also requires CMS to reduce payments to hospitals reimbursed under Medicare&#8217;s Inpatient Prospective Payment System (&#8220;IPPS&#8221;) that have excess readmissions.  These and other applicable requirements set forth under the ACA and its current and future implementing regulations may significantly increase our costs, and/or reduce our customer&#8217;s ability to obtain adequate reimbursement for tests performed with our products, which could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In recent years, other legislative, regulatory, and political changes aimed at regulating healthcare delivery in general and clinical laboratory tests in particular have been proposed and adopted in the United States.  Reimbursement for the laboratory industry is under significant pressure.  In January 2015, HHS announced a plan to shift the Medicare program and the healthcare system at large, toward paying providers based on quality, rather than the quantity of care provided to patients.  On July 31, 2015, CMS issued a final rule addressing the IPPS for fiscal year 2016, which included penalties for readmissions and for hospitals in the worst performing quartile of the Hospital Acquired Condition Reduction Program.  With respect to clinical laboratory tests, on April 1, 2014, President Obama signed into law the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), revamping Medicare&#8217;s clinical laboratory reimbursement system to tie Medicare payment rates to private market rates beginning in 2017.  CMS then released a proposed rule on September 25, 2015 to implement such provisions of PAMA, requiring applicable clinical laboratories to report private payor reimbursement rates and volume data for tests on the clinical laboratory fee schedule.  These measures can result in reduced prices, added costs, and decreased test utilization for our customers, although the full impact on our business of the ACA, changes to the IPPS, PAMA, and other applicable laws, regulations, and policies is uncertain. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business, or the effect of any future legislation or regulation will have on our industry generally, our ability to successfully commercialize the ID/AST System, and our overall business operations.  Changes in healthcare policy could substantially impact the sales of our tests, increase costs and divert management&#8217;s attention from our business.  For example, expansion in the government&#8217;s regulation of the United States healthcare system may result in decreased profits to us, lower reimbursements to our customers for laboratory testing or reduced medical procedure volumes.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">The regulatory processes applicable to our products and operations are expensive, time-consuming, and uncertain and may prevent us from obtaining required approvals for the commercialization of our products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our products, including the ID/AST System, are regulated as medical device products by the FDA and comparable agencies of other countries.  In particular, FDA regulations govern activities such as product development, product testing, product labeling, product storage, premarket clearance or approval, manufacturing, advertising, promotion, product sales, reporting of certain product failures and distribution.  Some of our products, depending on their intended use, will require approval of a premarket approval application (&#8220;PMA&#8221;) or clearance of a 510(k) notification from the FDA prior to marketing.  The FDA has committed to review most 510(k) decisions within 90 days, but the review may be delayed due to requests for additional information.  A decision may take significantly longer, and clearance is never assured.  The PMA process is much more costly, lengthy and uncertain.  The FDA has committed to review most PMAs within 180 days where an advisory panel is not required and within 320 days where an advisory panel is required, but the review may be delayed due to requests for additional information.  A decision may take significantly longer, and approval is never assured.  In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing.  Clinical data is sometimes required to support substantial equivalence.  The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device based, in part, on extensive data, including technical, preclinical, clinical trial, manufacturing and labeling data.  The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.  However, some devices are automatically subject to the PMA pathway regardless of the level of risk they pose, because they have not previously </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">been classified into a lower risk class by the FDA.  Manufacturers of these devices may request that the FDA review such devices in accordance with the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">de novo </font><font style="font-family:Arial;font-size:10pt;">classification procedure, which allows a manufacturer whose novel device would otherwise require the submission and approval of a PMA prior to marketing to request down-classification of the device on the basis that the device presents low or moderate risk.  If the FDA agrees with the down-classification, the applicant will then receive authorization to market the device.  This device type can then be used as a predicate device for future 510(k) submissions.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we may not be able to demonstrate to the FDA&#8217;s satisfaction that our product candidates are safe and effective, sensitive and specific diagnostic tests, for their intended users;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the manufacturing process or facilities we or our contract manufacturers use may not meet applicable requirements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We intend to utilize the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:Arial;font-size:10pt;">&#32;classification procedures to seek marketing authorization for the ID/AST System.  If the FDA requires us to go through a lengthier, more rigorous examination for our product candidates than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our launch to be delayed or, in the future, our sales to decline.  In addition, the FDA may determine that our product candidates require the more costly, lengthy and uncertain PMA process.  For example, if the FDA disagrees with our determination that the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:Arial;font-size:10pt;">&#32;classification procedures are the appropriate path to obtain marketing authorizations for the ID/AST System product candidates, the FDA may require us to submit a PMA, which is generally more costly and uncertain.  The FDA has committed to review most PMAs within 180 days where an advisory panel is not required and within 320 days where an advisory panel is required, but the review may be delayed due to requests for additional information.  A decision may take significantly longer, and approval is never assured.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further, even with respect to those future products where a PMA is not required, we cannot assure you that we will be able to obtain 510(k) clearances with respect to those products.  The process of obtaining regulatory clearances or approvals, or completing the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:Arial;font-size:10pt;">&#32;classification process, to market a medical device can be costly and time consuming, and we may not be able to successfully obtain pre-market reviews on a timely basis, if at all.  Further, even if we were to obtain regulatory clearance, it may not be for the uses we believe are important or commercially attractive, in which case we would not be permitted to market our product for those uses.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clinical trial data is typically required to support a PMA and is sometimes required for a 510(k) pre-market notification.  Although many 510(k) pre-market notifications are cleared without clinical data, in some cases, the FDA requires significant clinical data to support substantial equivalence.  We are planning clinical trials for the ID/AST System.  Clinical trials are expensive and time-consuming.  In addition, the commencement or completion of any clinical trials may be delayed or halted for any number of reasons, including product performance, changes in intended use, changes in medical practice and the opinion of evaluator Institutional Review Boards.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, since 2009, the FDA has significantly increased the scrutiny applied to its oversight of companies subject to its regulations by hiring new investigators and increasing inspections of manufacturing facilities.  The FDA has also undertaken initiatives related to enhancement of the 510(k) review process and has proposed significant changes to the regulation of laboratory developed tests (&#8220;LDTs&#8221;).  We continue to monitor these developments and analyze how they will impact the approval of our products.  These and other actions proposed by the FDA&#8217;s Center for Devices and Radiological Health could result in significant changes to the 510(k) process, which could complicate the product approval process, although we cannot predict the effect of such changes and cannot ascertain if such changes will have a substantive impact on the approval of our products.  If we fail to adequately respond to the increased scrutiny and streamlined 510(k) submission process, our business may be adversely impacted.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Failure to comply with the applicable requirements can result in, among other things, warning letters, administrative or judicially imposed sanctions such as injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal to grant premarket clearance or PMA for devices, withdrawal of marketing clearances or approvals, or criminal prosecution.  With regard to products for which we seek 510(k) clearance or PMA approval from the FDA, any failure or material delay to obtain such clearance or approval could harm our business.  If the FDA were to disagree with our regulatory assessment and conclude that approval or clearance is necessary to </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">market the products, we could be forced to cease marketing the products and seek approval or clearance.  Once clearance or approval has been obtained for a product, there is an obligation to ensure that all applicable FDA and other regulatory requirements continue to be met.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, it is possible that the current regulatory framework could change or additional regulations could arise at any stage during our product development or marketing, which may adversely affect our ability to obtain or maintain approval of our products.  For example, in response to industry and healthcare provider concerns regarding the predictability, consistency and rigor of the 510(k) regulatory pathway, the FDA initiated an evaluation of the program, and in January 2011, announced several proposed actions intended to reform the review process governing the clearance of medical devices.  The FDA intends for these reform actions to improve the efficiency and transparency of the clearance process, as well as bolster patient safety.  In addition, as part of the Food and Drug Administration Safety and Innovation Act, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance goal commitments and enacted several &#8220;Medical Device Regulatory Improvements&#8221; and miscellaneous reforms that are further intended to clarify and improve medical device regulation both pre- and post-approval.  Any delay in, or failure to receive or maintain, clearance or approval for our product candidates could prevent us from generating revenue from these product candidates.  Additionally, the FDA and other regulatory authorities have broad enforcement powers.  Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our product candidates and dissuade our customers from using our product candidates, if and when they are authorized for marketing.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our manufacturing facility located in Tucson, Arizona, where we assemble and produce the ID/AST System, is subject to periodic regulatory inspections by the FDA and other federal and state and foreign regulatory agencies.  For example, this facility is subject to Quality System Regulations (&#8220;QSR&#8221;) of the FDA and is subject to annual inspection and licensing by the State of Arizona.  If we fail to maintain this facility in accordance with the QSR requirements, international quality standards or other regulatory requirements, our manufacturing process could be suspended or terminated, which would prevent us from being able to provide products to our customers in a timely fashion.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sales of our diagnostic product candidates outside the United States are subject to foreign regulatory requirements governing clinical studies, vigilance reporting, marketing approval, manufacturing, product licensing, pricing and reimbursement.  These regulatory requirements vary greatly from country to country.  As a result, the time required to obtain approvals outside the United States may differ from that required to obtain FDA marketing authorization from the FDA, and we may not be able to obtain foreign regulatory approvals on a timely basis or at all.  Marketing authorization from the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure clearance or approval by regulatory authorities in other countries or by the FDA.  Foreign regulatory authorities could require additional testing.  Failure to comply with these regulatory requirements, or to obtain required clearances or approvals, could impair our ability to commercialize our diagnostic product candidates outside of the United States.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Modifications to our products, if cleared or approved, may require new 510(k) clearances or pre-market approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any modification to a device authorized for marketing that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA supplement or new PMA.  The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision.  The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary.  If the FDA disagrees with our determination and requires us to submit new 510(k) notifications, PMA supplements or PMAs for modifications to previously cleared or approved products for which we conclude that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Furthermore, the FDA&#8217;s ongoing review of the 510(k) program may make it more difficult for us to make modifications to any products for which we obtain clearance, either by imposing more strict requirements on when a manufacturer must submit a new 510(k) for a modification to a previously cleared product, or by applying more onerous review criteria to such submissions.  The practical impact of the FDA&#8217;s continuing scrutiny of the 510(k) program remains unclear.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We rely on third parties to conduct studies of our products that may be required by the FDA or other regulatory authorities, and those third parties may not perform satisfactorily.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We rely on third parties, including medical investigators, to conduct studies on our products.  Our reliance on these third parties for clinical development activities will reduce our control over these activities.  These third parties may not complete activities on schedule or conduct studies in accordance with regulatory requirements or our study design.  If applicable, our reliance on third parties that we do not control will not relieve us of any applicable requirement to prepare, and ensure compliance with, various procedures required under good clinical practices.  If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our studies may be extended, delayed, suspended or terminated, and we may not be able to obtain marketing authorization from the FDA or regulatory clearance for our products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">If we obtain marketing authorization from the FDA, a recall of our products, either voluntarily or at the direction of the FDA, or the discovery of serious safety issues with our products that leads to corrective actions, could have a significant adverse impact on us.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products.  Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found.  A government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects or other deficiencies and issues.  Under the FDA&#8217;s medical device reporting regulations, we are required to report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury.  Repeated product malfunctions may result in a voluntary or involuntary product recall.  Recalls of any of our products would divert managerial and financial resources, have an adverse effect on our reputation, and may impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands.  Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide that we will need to obtain, new approvals or clearances for the device before we may market or distribute the corrected device.  Seeking such approvals or clearances may delay our ability to replace the recalled devices in a timely manner.  Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal fines.  We may also be required to bear other costs or take other actions that may have a negative impact on our sales as well as face significant adverse publicity or regulatory consequences, which could harm our ability to market our products in the future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action.  Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business and may harm our reputation.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks related to our common stock and this offering</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Our stock price has been volatile and may continue to be volatile and traded on low volumes.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The trading price of our common stock has been, and is likely to continue to be, highly volatile.  One factor contributing to volatility in the price of our common stock is the low trading volume currently prevailing in the market for our shares.  Further, due to the concentration of the stock the sale of one individual shareholder may have a material impact on the price of the stock.  The market value of your investment in our common stock may rise or fall sharply at any time because of this volatility and also because of significant short positions that may be taken by investors from time to time in our common stock.  During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, the sale price for our common stock ranged from </font><font style="font-family:Arial;font-size:10pt;">$11.01</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$31.86</font><font style="font-family:Arial;font-size:10pt;">&#32;per share, and during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the sale price for our common stock has ranged from </font><font style="font-family:Arial;font-size:10pt;">$14.77</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$31.29</font><font style="font-family:Arial;font-size:10pt;">.  The market prices for securities of medical technology companies like us historically have been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">The ownership of our common stock is highly concentrated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, our directors and executive officers, together with members of their immediate families, as a group, will beneficially own, in the aggregate, approximately </font><font style="font-family:Arial;font-size:10pt;">49%</font><font style="font-family:Arial;font-size:10pt;">&#32;of our outstanding capital stock, including </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26%</font><font style="font-family:Arial;font-size:10pt;">&#32;held by our director, Jack Schuler.  As a result, these stockholders will be able to affect the outcome of, or exert significant influence over, all matters requiring stockholder approval, including the election and removal of directors and any change in control.  In particular, this concentration of ownership of our common stock could have the effect of delaying or preventing a change in control of us or otherwise discouraging or preventing a potential acquirer from attempting to obtain control of us.  This, in turn, could have a negative effect on the market price of our common stock.  It could also prevent our stockholders from realizing a premium over the market prices for their shares of common stock.  Moreover, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders.  The concentration of ownership also contributes to the low trading volume and volatility of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Future sales of shares of our common stock may depress the price of our shares and be dilutive to our existing stockholders.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot predict whether future issuances of shares of our common stock or the availability of shares for resale in the open market will decrease the market price per share of our common stock.  Any sales by us or by our existing stockholders of a substantial number of shares of our common stock in the public market, or the perception that such sales might occur, may cause the market price of our shares to decline.  The exercise of any options or warrants, the issuance of our common stock in connection with acquisitions and other issuances of our common stock could have an adverse effect on the market price of the shares of our common stock. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To the extent that we raise additional funds through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders.  Investors purchasing shares or other securities in the future could have rights superior to existing stockholders.  The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.  In addition, we have a significant number of options and warrants outstanding.  If the holders of these options or warrants exercise such securities, you may incur further dilution.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We may require additional capital in the future, and you may incur dilution to your stock holdings.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have primarily relied upon capital from the sale of our securities to fund our operations, and we expect that we will continue to incur operating losses until we are able to finalize the development of and commercialize the ID/AST System and sell it into the marketplace or license it to a third party.  If capital requirements vary materially from those currently forecast by management, we may require additional capital sooner than expected.  We may also require additional capital in the future to expand our product offerings, expand our sales and marketing infrastructure, increase our manufacturing capacity, fund our operations, and continue our research and development activities.  Our future funding requirements will depend on many factors, including:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to obtain marketing authorization from the FDA or clearance from the FDA to market our product candidates;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">market acceptance of our product candidates, if cleared;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost and timing of establishing sales, marketing and distribution capabilities;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost of our research and development activities;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the ability of healthcare providers to obtain coverage and adequate reimbursement by third-party payors for procedures using our products;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost and timing of marketing authorization or regulatory clearances;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost of goods associated with our product candidates;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the effect of competing technological and market developments; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such transactions.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we require additional capital, we may attempt to raise it through a variety of strategies, including the issuance and sale of additional shares of our common stock.  Issuances of additional shares of our common stock or preferred stock in the future, whether in connection with a rights offering, follow-on offering or otherwise, would dilute existing stockholders and may adversely affect the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot assure you that we will be able to obtain additional funds on acceptable terms, or at all.  Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt.  Any debt or additional equity financing that we raise may contain terms that are not favorable to us or our stockholders.  If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us.  If we are unable to raise adequate funds, we may have to liquidate some or all of our assets or delay, reduce the scope of or eliminate some or all of our product development.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we do not have, or are not able to obtain, sufficient funds, we may be required to delay development or commercialization of the ID/AST System or license to third parties the rights to commercialize our products or technologies that we would otherwise seek to commercialize ourselves.  We also may have to reduce marketing, customer support or other resources devoted to our product candidates or cease operations.  Any of these factors could harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Negative reports issued by securities analysts, and the election by securities analysts not to cover us, may have a negative impact on the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The trading market for our common stock may be affected in part by the research and reports that industry or financial analysts publish about us or our business, and our failure to achieve analyst earnings estimates.  It may be difficult for companies such as ours, with smaller market capitalizations, to attract securities analysts that will cover our common stock.  The lack of research coverage may adversely affect the market price of our common stock.  If one or more of the analysts who elects to cover us downgrades our stock, our stock price may decline rapidly.  If one or more of these analysts ceases coverage of our company, we could lose visibility in the market, which in turn may cause our stock price to decline. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">We do not anticipate paying any cash dividends on our capital stock in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have never declared or paid cash dividends on our capital stock.  We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business.  Any future debt agreements may also preclude us from paying dividends.  As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Provisions in our certificate of incorporation and bylaws and Delaware law may delay or prevent acquisition of our Company, which could adversely affect the value of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Provisions contained in our certificate of incorporation and bylaws, as well as provisions of the Delaware General Corporation Law, could delay or make it more difficult to remove incumbent directors or for a third party to acquire us, even if a takeover would benefit our stockholders.  For example, our board of directors may fill any vacancy on the board of directors, whether such vacancy occurs as a result of an increase in the number of directors or otherwise.  Stockholders may only take action by written consent if acting unanimously.  Special meetings of the stockholders may be called only by the President, a Vice President, our board of directors or the holders of not less than one-tenth of all the shares entitled to vote at the meeting.  Additionally, our board of directors has the authority to cause us to issue, without any further vote or action by the stockholders, up to 5.0 million shares of preferred stock, par value $0.001 per share, in one or more series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series.  The issuance of shares of preferred stock may have the effect of delaying, deferring or preventing a change in control of our company without further action by the stockholders, even where stockholders are offered a premium for their shares.  Moreover, we are subject the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><a name="s3F3D8E358729BBE44BD8EFC22C61F4F0"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 1B.  Unresolved Staff Comments</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sE895422E039217F04517EFC22C641F36"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 2.  Properties</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our headquarters is located in Tucson, Arizona and we have another office in Barcelona, Spain.  As of December </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, we leased approximately </font><font style="font-family:Arial;font-size:10pt;">52,497</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">27,404</font><font style="font-family:Arial;font-size:10pt;">&#32;square feet of office, laboratory and manufacturing space, respectively.  For the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31,</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;monthly rent and utilities averaged approximately </font><font style="font-family:Arial;font-size:10pt;">$57,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$24,000</font><font style="font-family:Arial;font-size:10pt;">&#32;per month, respectively.  The leases have a remaining term through 2018.  See </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 14, Commitments</font><font style="font-family:Arial;font-size:10pt;">&#32;for additional details regarding the leases.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s083DBF23C737EB5FAEF5EFC22C6BA68E"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 3.  Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 19, 2015, a putative securities class action lawsuit was filed against Lawrence Mehren, and Steve Reichling, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504.  </font><font style="font-family:Arial;font-size:10pt;">The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System.  Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015.  On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class.  On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud.  Plaintiff seeks certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order.  Defendants moved to dismiss the amended complaint on July 21, 2015, which motion was pending before the Court as of December 31, 2015.  Subsequently, the Court granted the motion and dismissed the case with prejudice on January 28, 2016.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.  See </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 16, Subsequent Events</font><font style="font-family:Arial;font-size:10pt;">&#32;for an update on this lawsuit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s509029C9DC5030CBD180EFC22C8CED54"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 4.  Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s3AF3F3F7E930AF2E0B3CEFC22CBE0BD5"></a><div style="line-height:174%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART II</font></div><a name="s16FEEF9CD24CA6A9DA0FEFC21EABEE2E"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 5.  Market for Registrant's Common Equity, Related Stockholder Matters and Issue Purchases of Equity Securities</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Market Information</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information in the following table sets forth the quarterly high and low sales price per share of our Common Stock, as reported by the NASDAQ Capital market, for the period from January&#160;1, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:50.046339202965704%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="52%"></td><td width="24%"></td><td width="24%"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Common Stock Closing Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Quarter Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$21.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$11.01</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.53</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.50</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28.97</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21.29</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14.77</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.45</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following Performance Graph compares the cumulative 5-year total stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite index (XCMP) and the NASDAQ Biotechnology index (XNBI).  An investment of $100 (with reinvestment of all dividends) is assumed to have been made in our common stock and in each of the indexes on December 31, 2010 and its relative performance is tracked through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.  The Performance Graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;"><img src="axdx-123115_chartx42354a.jpg" style="height:480px;width:682px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="204px"></td><td width="80px"></td><td width="78px"></td><td width="80px"></td><td width="80px"></td><td width="80px"></td><td width="80px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dec-10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dec-11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dec-12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dec-13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dec-14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dec-15</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">122.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">407.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,232.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,938.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,170.71</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">NASDAQ Composite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">116.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">187.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">200.10</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">NASDAQ Biotechnology</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">148.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">246.09</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">330.75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">369.67</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">* $100 invested on 12/31/2010 in stock or index, including reinvestment of dividends</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Holders</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 8, 2016 we had approximately </font><font style="font-family:Arial;font-size:10pt;">140</font><font style="font-family:Arial;font-size:10pt;">&#32;record owners of our Common Stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dividends Paid and Dividend Policy</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Holders of Common Stock are entitled to receive dividends as may be declared by the Board of Directors out of funds legally available.  To date, no dividends have been declared by the Board of Directors.  We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our Common Stock for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Future cash dividends, if any, will be at the discretion of our Board of Directors and will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors as our Board of Directors may deem relevant.  We do not intend to pay any cash dividends on our Common Stock in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Compensation Plan Information</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table set forth below presents the securities authorized for issuance with respect to compensation plans under which equity securities are authorized for issuance as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.86376274328082%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="43%"></td><td width="18%"></td><td width="1%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Equity Compensation Plan</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Plan category</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of securities to be issued upon exercise of outstanding options, restricted stock,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">warrants and rights</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average exercise price of available outstanding options, restricted stock, warrants and rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of securities remaining for future issuance under equity compensation plans (excluding securities reflected in the 1st column)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity compensation plans approved by security holders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,207,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,945,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity compensation plans not approved by security holders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,207,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2,945,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sA0AD8BE774EDF12085EAEFC22D18451A"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 6.  Selected Financial Data</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following selected consolidated financial data has been derived from our audited consolidated financial statements.  The information below is not necessarily indicative of the results of future operations, and should be read in conjunction with </font><font style="font-family:Arial;font-size:10pt;">Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Arial;font-size:10pt;">&#32;and the consolidated financial statements and related notes thereto included in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Financial Statements and Supplementary Data</font><font style="font-family:Arial;font-size:10pt;">&#32;in order to fully understand factors that may affect the comparability of the information presented below.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="28%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Selected Consolidated Financial Data</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands except per share data)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2012</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2012</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7/31/2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Operating revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(45,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(30,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(15,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(8,124</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(3,400</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(5,311</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Basic and diluted loss per share (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash dividends</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="28%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2012</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12/31/2012</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7/31/2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">139,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">69,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">43,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Long-term obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">986</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:Arial;font-size:9pt;">(1)&#160;&#160;Loss per share has been adjusted for the effects of the rights offering (see </font><font style="font-family:Arial;font-size:9pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:9pt;">).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><a name="sA3FC7F8323B733A30190EFC22D3300CC"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 7.  Management's Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) summarizes our change in fiscal year, recent developments, the significant factors affecting our results of operations, capital resources and liquidity, off-balance sheet arrangements, contractual obligations, as well as discusses recent accounting pronouncements and our critical accounting policies and estimates.  You should read the following discussion and analysis together with our financial statements, including the related notes, which are included in this Annual Report on Form 10-K.  Certain information contained in the discussion and analysis set forth below and elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.  See &#8220;Risk Factors&#8221; in Item 1A of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements in this report.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><a name="s3bbebdccd61d4207925d4a1cdbe10f16"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Change in Fiscal Year</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective December 31, 2012, we changed our fiscal year end from July 31 to December 31.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s1c229eb771ad47c5bc156bb5c548a69f"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December, 2015, the Company finalized an underwritten public offering which resulted in gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$109.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;before costs associated with the transactions, which totaled $</font><font style="font-family:Arial;font-size:10pt;">5.9 million</font><font style="font-family:Arial;font-size:10pt;">.  The proceeds will be used for general corporate purposes.  Further details regarding this are included in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 9, Public Offering</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April, 2014, the Company finalized a rights offering which resulted in gross proceeds of $45.0 million before costs associated with the transactions, which totaled $125,000.  The proceeds will be used to fund continued operations, clinical trials, and product commercialization efforts.  Further details regarding this rights offering are included in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sDAA7C8AE47FCEF9CCD06EFC22D655CD0"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Changes in Results of Operations: Comparison of fiscal years ended </font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">, </font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;and </font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2013</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, total revenues were </font><font style="font-family:Arial;font-size:10pt;">$147,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$122,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">20%</font><font style="font-family:Arial;font-size:10pt;">.  The increase was due to sales of Research Use Only Accelerate ID/AST systems in 2015 which more than offsets declining royalty revenue on the legacy OptiChem product line.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, total revenues were </font><font style="font-family:Arial;font-size:10pt;">$122,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$48,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$74,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">154%</font><font style="font-family:Arial;font-size:10pt;">.  The increase was due to deferred royalties recognized in 2014.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;were </font><font style="font-family:Arial;font-size:10pt;">$26,022,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$19,526,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$6,496,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">33%</font><font style="font-family:Arial;font-size:10pt;">.  The increase was primarily the result of increasing employee headcount, pilot clinical trial fees, and increased purchases of laboratory and instrument engineering supplies to support research and development as well as pre-launch efforts.  Research and development expenses include non-cash equity-based compensation which decreased </font><font style="font-family:Arial;font-size:10pt;">$1,855,000</font><font style="font-family:Arial;font-size:10pt;">.  We do not capitalize our internally developed instruments prior to FDA approval in accordance with U.S. GAAP and, therefore, research and development expenses include instruments manufactured for sales, internal research and development, and trial or study use as expense which totaled </font><font style="font-family:Arial;font-size:10pt;">$2,667,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">&#32;for years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;were </font><font style="font-family:Arial;font-size:10pt;">$19,526,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$10,673,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$8,853,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">83%</font><font style="font-family:Arial;font-size:10pt;">.  The increase was primarily the result of increasing employee headcount, and increased purchases of laboratory and instrument engineering supplies to support research and development as well as pre-launch efforts.  Research and development expenses include non-cash equity-based compensation which increased </font><font style="font-family:Arial;font-size:10pt;">$2,679,000</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, sales, general and administrative expenses were </font><font style="font-family:Arial;font-size:10pt;">$17,882,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$10,695,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$7,187,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">67%</font><font style="font-family:Arial;font-size:10pt;">.  The increase was primarily driven by salaries and related expenses as we ramp up our operations.  Sales, general and administrative expenses include non-cash equity-based compensation which increased </font><font style="font-family:Arial;font-size:10pt;">$619,000</font><font style="font-family:Arial;font-size:10pt;">.  We do not capitalize our internally developed instruments prior to FDA approval in accordance with U.S. GAAP and, therefore, sales, general and administrative expenses include demonstration instruments as expense totaling </font><font style="font-family:Arial;font-size:10pt;">$804,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">&#32;for years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, sales, general and administrative expenses were </font><font style="font-family:Arial;font-size:10pt;">$10,695,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$4,312,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$6,383,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">148%</font><font style="font-family:Arial;font-size:10pt;">.  The increase was primarily driven by salaries and related expenses as we ramp up our operations.  Sales, general and administrative expenses include non-cash equity-based compensation which increased </font><font style="font-family:Arial;font-size:10pt;">$3,117,000</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, amortization was </font><font style="font-family:Arial;font-size:10pt;">$10,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$71,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, a decrease of </font><font style="font-family:Arial;font-size:10pt;">$61,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">86%</font><font style="font-family:Arial;font-size:10pt;">.  This decrease is the result of patents that became </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">fully amortized during the year.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, amortization was </font><font style="font-family:Arial;font-size:10pt;">$71,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$77,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, a decrease of </font><font style="font-family:Arial;font-size:10pt;">$6,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">8%</font><font style="font-family:Arial;font-size:10pt;">.  This decrease is the result of patents that became fully amortized during the year.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$1,782,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$817,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$965,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">118%</font><font style="font-family:Arial;font-size:10pt;">.  The increased depreciation was the result of purchases of equipment to support the Company&#8217;s Tucson facility laboratory, manufacturing and administrative space.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$817,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$286,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$531,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">186%</font><font style="font-family:Arial;font-size:10pt;">.  The increased depreciation was the result of purchases of equipment for the Company&#8217;s new Tucson facility laboratory, manufacturing and administrative space.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No impairment of intangibles was incurred for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;compared to </font><font style="font-family:Arial;font-size:10pt;">$3,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">.  Management routinely reviews intangible assets.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of intangibles for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$3,000</font><font style="font-family:Arial;font-size:10pt;">&#32;compared to </font><font style="font-family:Arial;font-size:10pt;">$11,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, a decrease of </font><font style="font-family:Arial;font-size:10pt;">$8,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">73%</font><font style="font-family:Arial;font-size:10pt;">.  Management routinely reviews intangible assets.  As a result, certain capitalized intellectual property amounts carried on our balance sheet were determined to be no longer recoverable and we abandoned our plan to pursue marketability resulting in the impairment charge.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of the above factors, loss from operations for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$45,549,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the loss of </font><font style="font-family:Arial;font-size:10pt;">$30,990,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, an increase in loss from operations of </font><font style="font-family:Arial;font-size:10pt;">$14,559,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">47%</font><font style="font-family:Arial;font-size:10pt;">&#32;which includes a decrease of </font><font style="font-family:Arial;font-size:10pt;">$1,236,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in non-cash equity-based compensation expenses.  This loss and further losses are anticipated and was the result of our continued investments in research and development, expanded laboratory and operational space, increased employee headcount and other factors as we develop and prepare to commercialize the Company&#8217;s products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of the above factors, loss from operations for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$30,990,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the loss of </font><font style="font-family:Arial;font-size:10pt;">$15,311,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase in loss from operations of </font><font style="font-family:Arial;font-size:10pt;">$15,679,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">102%</font><font style="font-family:Arial;font-size:10pt;">&#32;which includes an increase of </font><font style="font-family:Arial;font-size:10pt;">$5,796,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in non-cash equity-based compensation expenses.  This loss and further losses are anticipated and was the result of our continued investments in research and development, expanded laboratory and operational space, increased employee headcount and other factors as we develop and prepare to commercialize the Company&#8217;s products.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other non-operating income during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$51,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$57,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, a decrease of </font><font style="font-family:Arial;font-size:10pt;">$6,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">11%</font><font style="font-family:Arial;font-size:10pt;">.  This change was due to increased interest expense.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other non-operating income during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$57,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">$29,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase of </font><font style="font-family:Arial;font-size:10pt;">$28,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">97%</font><font style="font-family:Arial;font-size:10pt;">.  This change was due to increased interest and dividend income on our cash balances and investments, which increased year-over-year.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of these factors, net loss for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$45,498,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to a net loss of </font><font style="font-family:Arial;font-size:10pt;">$30,933,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, an increase in net loss of </font><font style="font-family:Arial;font-size:10pt;">$14,565,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">47%</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of these factors, net loss for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$30,933,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to a net loss of </font><font style="font-family:Arial;font-size:10pt;">$15,282,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, an increase in net loss of </font><font style="font-family:Arial;font-size:10pt;">$15,651,000</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">102%</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized loss on available-for-sale investments for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$20,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to a loss of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">.  The resulting comprehensive losses were </font><font style="font-family:Arial;font-size:10pt;">$45,517,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$30,948,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized loss on available-for-sale investments for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to a gain of </font><font style="font-family:Arial;font-size:10pt;">$22,000</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">.  The resulting comprehensive losses were </font><font style="font-family:Arial;font-size:10pt;">$30,948,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$15,260,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><a name="s82CB9C89864CF2A4A7BDEFC22D86DDC0"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Capital Resources and Liquidity</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our primary source of liquidity has been from sales of shares of common stock.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">$132.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in cash and cash equivalents and available-for-sale securities, an increase of </font><font style="font-family:Arial;font-size:10pt;">$65.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;from </font><font style="font-family:Arial;font-size:10pt;">$66.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">.  The primary reason for the change in these assets was the Company&#8217;s successful completion of the underwritten public offering in December, 2015 which resulted in net proceeds of </font><font style="font-family:Arial;font-size:10pt;">$103.4 million</font><font style="font-family:Arial;font-size:10pt;">.  Further information regarding this is described in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 9, Public Offering</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is subject to a Lease Agreement with Pima County of Arizona.  The future minimum lease payments under the Lease Agreement are included in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 14, Commitments</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, management believes that current cash balances will be more than sufficient to fund our capital and liquidity needs for the next twelve months.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following summarizes selected items in the Company&#8217;s consolidated statements of cash flows for years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="62%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash Flow Summary<br></font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(35,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(18,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,372</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">104,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our primary use of capital has been for the continued development and investment in commercialization readiness of the Accelerate ID/AST system.  We believe our capital requirements will continue to be met with our existing cash balance and those provided under grants, exercises of warrants and stock options and/or, additional issuance of equity or debt securities.  However, if capital requirements vary materially from those currently planned, we may require additional capital sooner than expected.  There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all.  Additional issuances of equity or convertible debt securities will result in dilution to our current common stockholders.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s41ed6e9eb32647a68b6e7b35f6f89b58"></a><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not have any off-balance sheet arrangements as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sb031196ffb6b4d0183474ae360af4400"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has certain contractual obligations and commercial commitments as disclosed in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 14, Commitments</font><font style="font-family:Arial;font-size:10pt;">&#32;that do not meet the definition of long term debt obligations, capital leases, operating leases or purchase obligations.  The Company has entered into Lease Agreements as described in </font><font style="font-family:Arial;font-size:10pt;">Item 2.  Properties</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 14, Commitments</font><font style="font-family:Arial;font-size:10pt;">.  The operating and capital lease obligations associated with Lease Agreements over the next five years are (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.6484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="34%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating Lease Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital Lease Obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sD2D4AA3384BFB01C31BFEFC22DB80486"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Arial;font-size:10pt;">.  This replaces the existing standards relating to leases for both lessees and lessors.  For </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard.  For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases.  For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria.  The ASU is required for us on January 1, 2019 with early adoption permitted.  We are currently assessing the impact this will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January, 2016, the FASB issued ASU 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall</font><font style="font-family:Arial;font-size:10pt;">.  This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets.  The ASU is required for us on January 1, 2018.  We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes-Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position rather than separating these amounts between current and noncurrent amounts.  The deferred tax liabilities and assets continue to be offset and presented as a single amount.  The ASU is required for us on January 1, 2017 and we have elected to adopt this standard retrospectively for the period ended December 31, 2015.   There was no significant impact on our consolidated financial statements as a result of adopting this ASU.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires entities that measure inventory using first-in, first-out or average cost inventory to report inventory at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The ASU will become effective for us on January 1, 2016 but will not have an impact on our financial statements as we do not capitalize the cost of pre-launch inventory.  We do not expect the adoption of ASU 2015-11 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2015, the FASB issued ASU 2015-05, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other - Internal-Use Software; Customer&#8217;s Accounting for Fees Paid in a Cloud Computing Arrangement</font><font style="font-family:Arial;font-size:10pt;">.  Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&#8217;s accounting for fees paid in a cloud computing arrangement.  Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements.  This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses.  If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract.  The ASU does not change the accounting for service contracts.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2015, the FASB issued ASU 2015-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement - Extraordinary and Unusual Items</font><font style="font-family:Arial;font-size:10pt;">.  The new standard eliminates from U.S. GAAP the concept of extraordinary items.  Prior to the adoption of this standard, extraordinary items have been segregated from the results of ordinary operations and shown separately in the income statement, net of tax, after income from continuing operations.  The new standard eliminates such segregation as well as the requirements to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&#8217;s ability to continue as a going concern and, if so, disclose that fact.  Management will also be required to evaluate and disclose whether its plans alleviate that doubt.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2014-15 to have a significant impact on our consolidated financial statements</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.  We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements.  The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.  We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements.  In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers Deferral of the Effective Date</font><font style="font-family:Arial;font-size:10pt;">, which deferred the effective date resulting in a new effective date of January 1, 2018 for us.  We are permitted to adopt early but not before the original effective date of January 1, 2017.  The standard allows for either &#8220;full retrospective&#8221; adoption, meaning the standard is applied to all of the periods presented, or &#8220;modified retrospective&#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements.  We are currently evaluating the transition method and the adoption date that will be elected.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s6995AEA30E1F2A62C1ECEFC21F0001E2"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We consider our accounting policies related to deferred taxes, equity-based compensation and inventory to be critical accounting policies.  A number of significant estimates, assumptions, and judgments are inherent in our calculations which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.  Actual results could differ materially from these estimates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Deferred Taxes</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recognize deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities.  We regularly review our deferred tax assets for recoverability and establish a valuation allowance based on historical taxable income, projected future taxable income, and the expected timing of the reversals of existing temporary differences.  As of December 31, 2015 and 2014, we have established a valuation allowance equal to our net deferred tax asset, as we have not been able to determine that we will generate sufficient future taxable income to allow us to realize the deferred tax assets prior to their limitations or expirations.  See </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 13, Income Taxes</font><font style="font-family:Arial;font-size:10pt;">&#32;for additional information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We account for equity-based compensation in accordance with FASB ASC 718.  Equity-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized over the requisite service period.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In determining the fair value of the award, we use the Black-Scholes option pricing model.  This model requires the input of subjective assumptions which are further discussed in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 12, Employee and Consultant Equity-Based Compensation</font><font style="font-family:Arial;font-size:10pt;">.  Once estimated, the Black-Scholes assumptions remain fixed throughout the requisite service period for employee grants.  For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested.  Changes in the inputs can materially affect the estimate of the fair value.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Employees who terminate employment prior to the requisite service period forfeit their unvested options and we derecognize the fair value of these shares.  In accordance with FASB ASC 718, we estimate the amount of such forfeitures.  Our estimate is based on the forfeiture rate of unvested awards in the previous twelve-month period.  The rate is calculated separately for awards to the board of directors/executives and all other awards.  The rate is adjusted at the end of each period and any change is recognized through a cumulative catch-up adjustment.  Rate changes will also impact the amount of equity-based compensation expense to be recognized in future periods.  Due to our relatively small employee base this estimate is particularly sensitive to termination activity and any change in this assumption can materially affect the estimate of fair value of equity-based compensation.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval.  We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance.  Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k) clearance, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted.  Inventory is reported as research and development costs, or if used in marketing evaluations reported to sales, general and administrative costs on the Statement of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s9A195FF86B2E47684956EFC22E0D01BA"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 7A.  Quantitative and Qualitative Disclosures</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Interest Rate Risk</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s interest income is sensitive to fluctuations in the general level of U.S. interest rates.  As such, changes in U.S. interest rates affect the interest earned on the Company&#8217;s cash and cash equivalents and investments.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our exposure to market risk is limited to our cash and cash equivalents, all of which have original maturities of less than three months and available-for-sale investments some of which have maturities under a year and some of which have maturities of more than a year.  The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments.  We also seek to maximize income from our investments without assuming significant risk.  To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality.  We currently do not hedge interest rate exposure.  Further information regarding our investments is included in </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 4, Investments</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sADF0230EDA79D45FA531EFC22E2DFBCC"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 8.  Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Financial Statements of Accelerate Diagnostics, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance Sheets as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Statements of Operations and Comprehensive Loss for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Statements of Stockholders&#8217; Equity for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Statements of Cash Flow for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><a name="sE68BC1A77350B4C367A2EFC22E5F1A89"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board of Directors and Stockholders of Accelerate Diagnostics, Inc. and Subsidiaries</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Accelerate Diagnostics, Inc. and subsidiaries as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.  These financial statements are the responsibility of the Company&#8217;s management.  Our responsibility is to express an opinion on these financial statements based on our audits.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Accelerate Diagnostics, Inc. and subsidiaries at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and the consolidated results of their operations and their cash flows for each of the three years in the period ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Accelerate Diagnostics, Inc.&#8217;s and subsidiaries' internal control over financial reporting as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated </font><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:Arial;font-size:10pt;">, expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Ernst&#160;&amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phoenix, Arizona</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><a name="sE68BC1A77350B4C367A2EFC22E5F1A89"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board of Directors and Stockholders of Accelerate Diagnostics, Inc. and Subsidiaries</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have audited Accelerate Diagnostics, Inc. and subsidiaries&#8217; internal control over financial reporting as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).  Accelerate Diagnostics, Inc.&#8217;s and subsidiaries' management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting.  Our responsibility is to express an opinion on the company&#8217;s internal control over financial reporting based on our audit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.  We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In our opinion, Accelerate Diagnostics, Inc. and subsidiaries maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, based on the COSO criteria.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Accelerate Diagnostics, Inc. and subsidiaries as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;of Accelerate Diagnostics, Inc. and subsidiaries and our report dated </font><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:Arial;font-size:10pt;">, expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Ernst&#160;&amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phoenix, Arizona</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><a name="s6DAADC4769AD94C8B91DEFC21A62E50B"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE SHEETS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands, except per share data)</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="74%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Current assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53,563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Trade accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">134,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,016</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intellectual property, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">139,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Current liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,129</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue and income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,783</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-term deferred income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-term capital lease obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commitments and contingencies see Note 14, Commitments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stockholders' equity:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Common stock, $0.001 par value;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55,000,000 common shares authorized 51,191,184 (as of December 31, 2015) and 44,639,829 (as of December 31, 2014) shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,000,000 preferred shares authorized and none outstanding as of December 31, 2015 and December 31, 2014</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contributed capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">243,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">131,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(110,915</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(65,417</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">133,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">139,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><a name="sB264DF546E6596B34653EFC21A3A77E7"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands, except per share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="61%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Licensing and royalty revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Product sales</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Costs and expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sales, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,695</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45,696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,359</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,549</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,990</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,311</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest expense and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest and dividend income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted average shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Other comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net unrealized (loss) gain on available-for-sale investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><a name="s8FF473C20796232C243DEFC21A9E2DE3"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="25%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Common<br>Stock<br>Amount</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Contributed<br>Capital</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Accumulated<br>Other<br>Comprehensive Income (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total<br>Stockholders&#8217;<br>Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balances, December 31, 2012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(19,202</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock and warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19,909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercise of options and warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,830</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,955</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gain on available-for-sale securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balances, December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">75,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">923</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">923</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized loss on available-for-sale securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balances, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">131,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(65,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized loss on available-for-sale securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balances, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51,191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">243,894</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(110,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">133,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><a name="sEC563A17619898811DEFEFC21A44EEBA"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STATEMENT OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="70%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Years Ended December 31,<br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of investment discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Increase) decrease in assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expense and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increase (decrease) in liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,336</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue and income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">168</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(35,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(18,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(9,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Purchases of equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Purchase of available-for-sale securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12,418</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,657</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12,014</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sales of available-for-sale securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Maturity of available-for-sale securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,357</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercise of warrants and options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock and warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">104,165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Payments on capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">104,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53,563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53,563</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><a name="sD7AD924291A594F47737EFC2301AB237"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s558ED7D4275DA220623EEFC21B020CD3"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1.  ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics, Inc. (&#8220;we&#8221; or &#8220;us&#8221; or &#8220;our&#8221; or &#8220;Accelerate&#8221; or &#8220;the Company&#8221;) is an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;">&#32;diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.  Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention (&#8220;CDC&#8221;) calls one of the most serious healthcare threats of our time, antibiotic resistance.  A significant contributor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (&#8220;U.S. GAAP&#8221;), and applicable rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;), regarding annual financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (including the newly formed Accelerate Diagnostics S.L.) after elimination of intercompany transactions and balances. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s5A32F737AD73787F7965EFC21A8ADC40"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s main financial institution for banking operations held </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">83%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the Company&#8217;s cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company grants credit to domestic and international clients in various industries.  Exposure to losses on accounts receivable is principally dependent on each client's financial position.  At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">66%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the outstanding receivable balance was with Denver Health.  See </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">&#32;for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Estimated Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC Topic 820, Fair Value Measurements and Disclosures</font><font style="font-family:Arial;font-size:10pt;">&#32;which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements.  The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">categories:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 2:  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 3:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See </font><font style="font-family:Arial;font-size:10pt;">Note 3, Fair Value of Financial Instruments</font><font style="font-family:Arial;font-size:10pt;">&#32;for further information and related disclosures regarding the Company&#8217;s fair value measurements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents.  Cash and cash equivalents include overnight repurchase agreement accounts.  As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank.  Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal.  We believe however, that the market risk arising from holding these financial instruments is minimal.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Investments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company invests excess funds in various short-term investments which are primarily held in the custody of a major financial institution.  Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper.  Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value.  Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity.  The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&#8217;s fair value remains less than its cost for more than twelve months.  This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs.  When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss.  The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost.  Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.  Gains and losses from retirement or replacement are included in costs and expenses.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years.  Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.  See </font><font style="font-family:Arial;font-size:10pt;">Note 5, Property and Equipment</font><font style="font-family:Arial;font-size:10pt;">&#32;below.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Long-lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval.  We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance.  Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k) clearance, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted.  Inventory is reported as research and development costs, or if used in marketing evaluations reported to sales, general and administrative costs on the Statement of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue in accordance with ASC 605, &#8220;Revenue Recognition,&#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue represents amounts received but not yet earned under existing agreements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Accounts Receivable Allowances</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable.  Receivables are written off if reasonable collection efforts prove unsuccessful.  The Company provides for allowances on a specific account basis.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company accounts for leases in accordance with ASC 840, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases,</font><font style="font-family:Arial;font-size:10pt;">&#32;which requires leases to be classified as either operating or capital leases.  In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception.  Other leases are classified as operating leases.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease rent is recorded as an operating expense monthly.  For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments.  The asset is included with property and equipment on the Balance Sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the Statements of Operations and Comprehensive Loss.  For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the Balance Sheet.  Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the Statements of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets.  The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period.  Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to the tax provision or benefit in the period of enactment.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows the provisions of ASC 740, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Arial;font-size:10pt;">, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return.  This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return.  Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit.  Interest and penalties, if any, would be recorded as tax expense in general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC 260, Earnings Per Share</font><font style="font-family:Arial;font-size:10pt;">, which requires companies to present basic earnings per share and diluted earnings per share.  Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.  Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued.  Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred. See </font><font style="font-family:Arial;font-size:10pt;">Note 11, Earnings Per Share</font><font style="font-family:Arial;font-size:10pt;">&#32;for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company awards stock options and other equity-based instruments to its employees, directors and consultants.  Compensation cost related to equity-based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method).  For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested.  The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model.  This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Volatility:  The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected term:  The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns.  For consultant awards, the estimated expected term is the same as the life of the award.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate:  The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield:  The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the future.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company estimates the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period.  The rate is calculated separately for awards to the board of directors/executives and all other awards. See </font><font style="font-family:Arial;font-size:10pt;">Note 12, Employee and Consultant Equity-Based Compensation</font><font style="font-family:Arial;font-size:10pt;">&#32;for further information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows ASC 830 </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign Currency Matters</font><font style="font-family:Arial;font-size:10pt;">, which provides guidance on foreign currency transactions and translation of financial statements.  Adjustments resulting from translating foreign functional currency financial statements into U.S.  Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholder's equity.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency.  These balance sheet items are subject to re-measurement, the impact of which is recorded in interest expense and other, within the consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC 220, Reporting Comprehensive Income</font><font style="font-family:Arial;font-size:10pt;">, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements.  The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).  The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Arial;font-size:10pt;">.  This replaces the existing standards relating to leases for both lessees and lessors.  For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized  much like the existing standard.  For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases.  For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria.  The ASU is required for us on January 1, 2019 with early adoption permitted.  We are currently assessing the impact this will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January, 2016, the FASB issued ASU 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall</font><font style="font-family:Arial;font-size:10pt;">.  This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets.  The ASU is required for us on January 1, 2018.  We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes-Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position rather than separating these amounts between current and noncurrent amounts.  The deferred tax liabilities and assets continue to be offset and presented as a single amount.  The ASU is required for us on January 1, 2017 and we have elected to adopt this standard retrospectively for the period ended December 31, 2015.   There was no significant impact on our consolidated financial statements as a result of adopting this ASU.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires entities that measure inventory using first-in, first-out or average cost inventory to report inventory at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The ASU will become effective for us on January 1, 2016.  We do not expect the adoption of ASU 2015-11 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2015, the FASB issued ASU 2015-05, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other - Internal-Use Software; Customer&#8217;s Accounting for Fees Paid in a Cloud Computing Arrangement</font><font style="font-family:Arial;font-size:10pt;">.  Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&#8217;s accounting for fees paid in a cloud computing arrangement.  Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements.  This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses.  If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract.  The ASU does not change the accounting for service contracts.  The new standard is effective for us on January 1, 2016 with early adoption </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">permitted.  We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2015, the FASB issued ASU 2015-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement - Extraordinary and Unusual Items</font><font style="font-family:Arial;font-size:10pt;">.  The new standard eliminates from U.S. GAAP the concept of extraordinary items.  Prior to the adoption of this standard, extraordinary items have been segregated from the results of ordinary operations and shown separately in the income statement, net of tax, after income from continuing operations.  The new standard eliminates such segregation as well as the requirements to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&#8217;s ability to continue as a going concern and, if so, disclose that fact.  Management will also be required to evaluate and disclose whether its plans alleviate that doubt.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2014-15 to have a significant impact on our consolidated financial statements</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.  We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements.  The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.  We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements.  In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers Deferral of the Effective Date</font><font style="font-family:Arial;font-size:10pt;">, which deferred the effective date resulting in a new effective date of January 1, 2018 for us.  We are permitted to adopt early but not before the original effective date of January 1, 2017.  The standard allows for either &#8220;full retrospective&#8221; adoption, meaning the standard is applied to all of the periods presented, or &#8220;modified retrospective&#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements.  We are currently evaluating the transition method and the adoption date that will be elected.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><a name="s02E8F321EBE402930CFBEFC21ABC9902"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3.  FAIR VALUE OF FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;(see </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">&#32;for further information):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Money market funds (cash equivalents)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1) &#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Money market funds (cash equivalents)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;Level 1 assets are priced using quoted prices in active markets for identical assets which include cash accounts and money market funds as these specific assets are liquid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data.  The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities.  The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.  There were no transfers between levels during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><a name="sD20D086E348C73ECD7F5EFC21ADA3E78"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4.  INVESTMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the Company&#8217;s available-for-sale investments at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;The following table summarizes the maturities of the Company&#8217;s available-for-sale securities at December 31, </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENT MATURITIES</font></div><div style="text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">At December 31, 2015</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">At December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 1-3 years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;For the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$141,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$861,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in proceeds from sales of marketable securities (including principle paydowns) were collected, respectively.  The Company determines gains and losses of marketable securities based on specific identification of the securities sold.  There were no gross realized gains and losses from sales of marketable securities for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">.  The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s5EED76EF119FF312E1ECEFC21A8A7EC0"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5.  PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost and consisted of the following at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;(in thousands).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="68%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Technical equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Facilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital lease &#8211; leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital projects in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,904</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated amortization &#8211; capital lease</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated depreciation - other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,311</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;Depreciation expense (which includes amortization of capital lease assets) for the for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$1.8 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$817,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$286,000</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sDD87C55D6303AD1DFE75EFC21A6CF29D"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6.  LICENSE AGREEMENTS AND GRANTS</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Defense Medical Research and Development Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (&#8220;DMRDP&#8221;) recommended </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;of funding for a proposed 35-month project.  The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections.  The project will apply the Accelerate ID/AST system to wound infections and other serious infections secondary to trauma.  The Company has invoiced a cumulative total of </font><font style="font-family:Arial;font-size:10pt;">$558,000</font><font style="font-family:Arial;font-size:10pt;">&#32;under this grant which is recorded as an offset to research and development expenses.  The amount invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$179,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$221,000</font><font style="font-family:Arial;font-size:10pt;">,  </font><font style="font-family:Arial;font-size:10pt;">$143,000</font><font style="font-family:Arial;font-size:10pt;">, respectively.  The period of performance for the grant ended September 2015.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">National Institute of Health Grant</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2015, the National Institute of Health awarded Denver Health and the Company a five year, </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood.  In June 2015, the Company executed a subaward agreement with Denver Health for the services we will provide as part of this grant which covers the period of February 15, 2015 through January 31, 2016 and totals </font><font style="font-family:Arial;font-size:10pt;">$689,000</font><font style="font-family:Arial;font-size:10pt;">.  The amounts invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;were </font><font style="font-family:Arial;font-size:10pt;">$483,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona Commerce Authority</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2012, the Company entered into a Grant Agreement (the &#8220;Grant Agreement&#8221;) with the Arizona Commerce Authority, an agency of the State of Arizona (the &#8220;Authority&#8221;), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the &#8220;Project&#8221;).  Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;(the &#8220;Grant&#8221;) for the use by the Company in the advancement of the Project.  The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 1 &#8211; Relocation of Company&#8217;s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 2 &#8211; Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 3 &#8211; Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 4 &#8211; Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For purposes of the Grant Agreement, a &#8220;Qualified Job&#8221; is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least </font><font style="font-family:Arial;font-size:10pt;">$63,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and offers health insurance benefits and pays at least </font><font style="font-family:Arial;font-size:10pt;">65%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the premiums associated with such benefits.  The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement.  The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company has collected all of the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in milestones.  The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are &#8220;claw-back&#8221; provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement.  Once the &#8220;claw-back&#8221; provisions expire in January 2018, we will recognize the grant as an offset to expense.  Further details are included in </font><font style="font-family:Arial;font-size:10pt;">Note 7, Deferred Revenue and Income</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&amp;D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has applied for and met the program requirements to receive a &#8220;Certificate of Qualification&#8221; from the Arizona Commerce Authority (&#8220;Authority&#8221;) which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&amp;D Refundable Tax Credit Program").  The amounts collected under this program are recorded as an offset to research and development expenses, and for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;were </font><font style="font-family:Arial;font-size:10pt;">$647,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$527,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively.  If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s7FF121F595D6FC2173D1EFC21A80B1AB"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7.  DEFERRED REVENUE AND INCOME</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue consists of amounts received for products or services not yet delivered or earned.  Deferred income consists of amounts received for commitments not yet fulfilled.  If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income.  A summary of the balances as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="74%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research Use Only Accelerate ID/AST systems</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2014, we received </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the &#8220;claw-back&#8221; provisions under the Grant Agreement expire in January 2018.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred income includes </font><font style="font-family:Arial;font-size:10pt;">$114,000</font><font style="font-family:Arial;font-size:10pt;">&#32;of payments received in December 2015, for Research Use Only Accelerate ID/AST systems.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sBFB2D3F9173ED6232200EFC21B0C180E"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8.  STOCK PURCHASE</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2012, we entered into a Securities Purchase Agreement with Abeja Ventures, LLC (&#8220;Abeja&#8221;), pursuant to which the Company agreed to sell and issue to Abeja at a purchase price of </font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;">&#32;per share for an aggregate </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">purchase price of </font><font style="font-family:Arial;font-size:10pt;">$14.4 million</font><font style="font-family:Arial;font-size:10pt;">; (i) </font><font style="font-family:Arial;font-size:10pt;">14.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company&#8217;s common stock (&#8220;Common Stock&#8221;); (ii) a warrant to purchase </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;">&#32;per share (the &#8220;</font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;">&#32;" Warrant&#8221;); and (iii) another warrant to purchase </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$2.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share (the &#8220;</font><font style="font-family:Arial;font-size:10pt;">$2.00</font><font style="font-family:Arial;font-size:10pt;">" Warrant&#8221;), with each warrant exercisable prior to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement (collectively, the &#8220;Investment&#8221;).  The purchase of Common Stock and warrants pursuant to the Investment, which was consummated in June, 2012, qualified for equity treatment under U.S. GAAP. The respective values of the warrants and Common Stock were calculated using their relative fair values and both are classified under Contributed Capital.  The value therefore recorded for the warrants was </font><font style="font-family:Arial;font-size:10pt;">$5.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and for the Common Stock was </font><font style="font-family:Arial;font-size:10pt;">$8.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Both warrants are exercisable until June 26, 2017, which was the fifth anniversary of the date on which the warrants were issued.  Other significant terms and conditions of the warrants are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the warrants provide for partial exercises, but they do not provide for a &#8220;cashless&#8221; exercise feature (i.e., they may only be exercised for cash);</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the warrants do not contain anti-dilution provisions that would trigger exercise price or other adjustments as a result of subsequent issuances of the Company&#8217;s equity securities, but they do contain customary provisions for equitable adjustments in connection with stock dividends, stock splits or reclassifications of Common Stock;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">following certain types of fundamental transactions involving the Company (e.g., a transaction resulting in a change in control of the Company), the holder of the warrants would continue to be entitled to exercise the warrants in exchange for the equity securities or alternate consideration receivable by a holder of Common Stock as a result of the fundamental transaction; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the holder of the warrants is entitled to certain demand and piggy-back registration rights, including for shelf registrations, with respect to the shares of Common Stock issuable upon its exercise of the warrants.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2013, Abeja exercised in full its warrant to purchase </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;">&#32;per share.  On the same date, Abeja also exercised the </font><font style="font-family:Arial;font-size:10pt;">92%</font><font style="font-family:Arial;font-size:10pt;">&#32;of its warrant to purchase an additional </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$2.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share (Abeja exercised such warrant for </font><font style="font-family:Arial;font-size:10pt;">6.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares, leaving </font><font style="font-family:Arial;font-size:10pt;">571,160</font><font style="font-family:Arial;font-size:10pt;">&#32;shares unexercised).  The Company received aggregate funds of </font><font style="font-family:Arial;font-size:10pt;">$20.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in connection with such exercises.  Shares issued by the Company in connection with the warrant exercises were issued directly to the members of Abeja on a pro rata basis in accordance with their membership interests and written exercise instructions provided to the Company by Abeja.  Immediately after giving effect to the warrant exercises, Abeja also distributed in kind to its members (on a pro rata basis in accordance with their membership interests) the remaining shares of Common Stock held by that entity. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s582ee0298bfd43f6ae25a3080c58e2d8"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9.  PUBLIC OFFERING</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 9, 2015, the Company published a prospectus supplement underwritten by J.P. Morgan and Piper Jaffray ("Underwriters") offering </font><font style="font-family:Arial;font-size:10pt;">5.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock with an option for the Underwriters to purchase up to </font><font style="font-family:Arial;font-size:10pt;">838,000</font><font style="font-family:Arial;font-size:10pt;">&#32;additional shares of common stock for a total of </font><font style="font-family:Arial;font-size:10pt;">6.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares.  The public offering price was </font><font style="font-family:Arial;font-size:10pt;">$17.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share and underwriting discounts and commissions were </font><font style="font-family:Arial;font-size:10pt;">$1.19</font><font style="font-family:Arial;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Affiliates, including entities affiliated with one of Company's directors, Jack Schuler, and which together are our largest stockholders,  purchased </font><font style="font-family:Arial;font-size:10pt;">2.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;of the offered shares at the public offering price of </font><font style="font-family:Arial;font-size:10pt;">$17.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share.  These shares are subject to lock-up agreements for a period of 90 days starting December 9, 2015.  In general, the lock-up agreement, with limited exceptions, requires J.P. Morgan Securities LLC's prior written approval for the sale (directly or indirectly) of AXDX common stock.  This includes various types of sales or offers to sell.  The underwriters did not receive any underwriting discount or commissions on the sale of </font><font style="font-family:Arial;font-size:10pt;">2.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares to such affiliates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The public offering was finalized and </font><font style="font-family:Arial;font-size:10pt;">6.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock were delivered to the purchasers on or around December 15, 2015.  Proceeds from the sale totaled </font><font style="font-family:Arial;font-size:10pt;">$109.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;less underwriting and other expenses of </font><font style="font-family:Arial;font-size:10pt;">$5.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for net proceeds of </font><font style="font-family:Arial;font-size:10pt;">$103.4 million</font><font style="font-family:Arial;font-size:10pt;">.  The net proceeds will be used for general corporate purposes.  We may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so.  Accordingly, we will retain broad discretion over the use of these proceeds.</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s787B8F13D6A01369C67EEFC21A58A4FD"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10.  RIGHTS OFFERING</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">April 2014 Offering</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 7, 2014, the Company commenced a rights offering to raise </font><font style="font-family:Arial;font-size:10pt;">$45.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to fund continued operations, clinical trials, and product commercialization efforts.  Under the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock as of March 14, 2014, which was established as the record date for the rights offering, </font><font style="font-family:Arial;font-size:10pt;">0.063921</font><font style="font-family:Arial;font-size:10pt;">&#32;non-transferable subscription rights for each share of Common Stock owned on the record date.  Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of </font><font style="font-family:Arial;font-size:10pt;">$16.80</font><font style="font-family:Arial;font-size:10pt;">&#32;per share which was lower than the market price of </font><font style="font-family:Arial;font-size:10pt;">$17.64</font><font style="font-family:Arial;font-size:10pt;">&#32;per share on the date of the rights offering commencement and the </font><font style="font-family:Arial;font-size:10pt;">$17.54</font><font style="font-family:Arial;font-size:10pt;">&#32;per share on the date the rights offering period expired.  In the aggregate, the Company intended to issue </font><font style="font-family:Arial;font-size:10pt;">2.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock in connection with the rights offering.  The purpose of the rights offering was to raise equity capital in a cost-effective manner that gives all of the Company&#8217;s existing stockholders the opportunity to participate on a pro rata basis.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the rights offering, the Company received standby commitments from the Jack W. Schuler Living Trust and the Schuler Family Foundation.  The standby purchasers agreed to purchase any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.  On May 1, 2014, the Company entered into an Assignment and Assumption Agreement with the standby purchasers, Oracle Institutional Partners, L.P. and Oracle Partners, L.P., pursuant to which each standby purchaser assigned and transferred its respective rights, responsibilities, liabilities and obligations under the Standby Purchase Agreement to purchase </font><font style="font-family:Arial;font-size:10pt;">297,619</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock not subscribed for by the Company&#8217;s stockholders in connection with the rights offering to (i) Oracle Institutional Partners, L.P., with respect to </font><font style="font-family:Arial;font-size:10pt;">119,047</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of such Common Stock, and (ii) Oracle Partners, L.P., with respect to the remaining </font><font style="font-family:Arial;font-size:10pt;">178,572</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of such Common Stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rights offering period expired on April 28, 2014, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company&#8217;s issuance of an aggregate of </font><font style="font-family:Arial;font-size:10pt;">2.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its Common Stock to the rights offering participants and standby purchasers) were completed on May 19, 2014.  The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$45.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;before costs associated with the transactions which totaled </font><font style="font-family:Arial;font-size:10pt;">$125,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and are treated as a reduction of contributed capital in the Stockholders&#8217; Equity section of the Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because the exercise price of the rights offering of </font><font style="font-family:Arial;font-size:10pt;">$16.80</font><font style="font-family:Arial;font-size:10pt;">&#32;was less than the fair value of the Company&#8217;s shares of Common Stock at the expiration of the offering, there is a bonus element that is treated similar to a stock dividend.  The weighted average shares outstanding, as well as the basic and diluted loss per share for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;have been revised for those effects.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">July 2013 Offering</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On July 12, 2013, the Company publicly announced the final terms of a rights offering.  Rights offering materials were subsequently distributed to the Company&#8217;s stockholders on July 18, 2013, at which time the rights offering period commenced.  Pursuant to the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock on July 8, 2013, which was established as the record date for the rights offering, </font><font style="font-family:Arial;font-size:10pt;">0.064038</font><font style="font-family:Arial;font-size:10pt;">&#32;non-transferable subscription rights for each share of Common Stock owned on the record date.  Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of </font><font style="font-family:Arial;font-size:10pt;">$8.04</font><font style="font-family:Arial;font-size:10pt;">&#32;per share.  In addition, any holder of subscription rights exercising his, her or its basic subscription privilege in full was eligible to subscribe to purchase additional shares of Common Stock at the same subscription price per share, subject to the conditions and limitations described further in the prospectus.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the rights offering, the Company received a standby commitment from Abeja to purchase, at </font><font style="font-family:Arial;font-size:10pt;">$8.04</font><font style="font-family:Arial;font-size:10pt;">&#32;per share, any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rights offering period expired on August 7, 2013, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company&#8217;s issuance of an aggregate of </font><font style="font-family:Arial;font-size:10pt;">2.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its Common Stock to the rights offering participants and standby purchaser) were completed on August 8, 2013.  The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$20.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;before costs associated with the transactions, which totaled </font><font style="font-family:Arial;font-size:10pt;">$88,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and are treated as a reduction of contributed capital in the Stockholders&#8217; Equity section of the </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sEFD456B350969525050DEFC21AD03887"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11.  EARNINGS PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The financial statements show basic earnings (loss) per share.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our Common Stock to be antidilutive.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, there were Common Stock options, restricted stocks and warrants exercisable for </font><font style="font-family:Arial;font-size:10pt;">6,778,580</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">6,174,886</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">5,731,246</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted average shares outstanding for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;">&#32;have been revised for the effects of the rights offering (See </font><font style="font-family:Arial;font-size:10pt;">Note 10, Rights Offering</font><font style="font-family:Arial;font-size:10pt;">).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sE07B3C578145B869A608EFC21A5887EC"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12.  EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has </font><font style="font-family:Arial;font-size:10pt;">4</font><font style="font-family:Arial;font-size:10pt;">&#32;equity-based compensation plans, which are discussed below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Qualified Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Qualified Stock Option Plan (the &#8220;Qualified Plan&#8221;) was a stockholder-approved plan that provided for stock option grants to employees, including executive officers.  The exercise price of each option, which has a maximum ten-year life, was established by the Company's Compensation Committee on the date of grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">527,500</font><font style="font-family:Arial;font-size:10pt;">&#32;options exercised under the Qualified Plan and </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">ne that remain outstanding.  The Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;further options are available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Non-Qualified Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Non-Qualified Stock Option Plan (the &#8220;Non-Qualified Plan&#8221;) was a stockholder-approved plan that provided for stock option grants to independent contractors, technical advisors and directors of the Company.  The exercise price of each option, which has a maximum </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;">&#32;year life, was established by the Company's Compensation Committee on the date of grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">270,000</font><font style="font-family:Arial;font-size:10pt;">&#32;options exercised under the Non-Qualified Plan and </font><font style="font-family:Arial;font-size:10pt;">10,000</font><font style="font-family:Arial;font-size:10pt;">&#32;that remain outstanding.  The Non-Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;further options are available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2004 Omnibus Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2004, the Company&#8217;s stockholders approved the Omnibus Stock Option Plan and reserved </font><font style="font-family:Arial;font-size:10pt;">500,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its authorized but unissued Common Stock for stock options to be granted to employees, independent contractors, technical advisors and directors of the Company.  The authorized shares in this plan were increased by </font><font style="font-family:Arial;font-size:10pt;">5,000,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares to an aggregate amount of </font><font style="font-family:Arial;font-size:10pt;">5,500,000</font><font style="font-family:Arial;font-size:10pt;">&#32;upon stockholder approval during the fiscal year ended July 31, 2012.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">403,474</font><font style="font-family:Arial;font-size:10pt;">&#32;options exercised under the 2004 Omnibus Stock Option Plan and </font><font style="font-family:Arial;font-size:10pt;">3,536,526</font><font style="font-family:Arial;font-size:10pt;">&#32;that remain outstanding.  The 2004 Omnibus Stock Option Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;further options are available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2012 Omnibus Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2012, the Company&#8217;s stockholders approved the Company&#8217;s 2012 Omnibus Equity Incentive Plan to replace the Qualified Stock Option Plan, Non-Qualified Stock Option Plan and 2004 Omnibus Stock Option Plan (&#8220;Prior Plans&#8221;).  The Prior Plans remain in effect until all awards granted under those plans have been exercised, forfeited, canceled, expired or otherwise terminated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the approval of such plan, all stock options, totaling </font><font style="font-family:Arial;font-size:10pt;">1,677,500</font><font style="font-family:Arial;font-size:10pt;">&#32;formerly available for new </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">awards under the Prior Plans were transferred to the 2012 Omnibus Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At the Company&#8217;s 2014 Annual Meeting of Stockholders held in May 2014, stockholders approved an amendment to the Company&#8217;s 2012 Omnibus Equity Incentive Plan increasing the number of stock options of Common Stock reserved and available for grant by </font><font style="font-family:Arial;font-size:10pt;">4,000,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">5,677,500</font><font style="font-family:Arial;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options granted under this plan typically vest either (i) one year after grant date, (ii) monthly over a one year period, or (iii) </font><font style="font-family:Arial;font-size:10pt;">40%</font><font style="font-family:Arial;font-size:10pt;">&#32;two years after grant date and the remaining </font><font style="font-family:Arial;font-size:10pt;">60%</font><font style="font-family:Arial;font-size:10pt;">&#32;monthly over the next three years.  The maximum term is ten years.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">71,147</font><font style="font-family:Arial;font-size:10pt;">&#32;options exercised under the 2012 Omnibus Equity Incentive Plan and </font><font style="font-family:Arial;font-size:10pt;">2,660,894</font><font style="font-family:Arial;font-size:10pt;">&#32;that remain outstanding, leaving </font><font style="font-family:Arial;font-size:10pt;">2,945,459</font><font style="font-family:Arial;font-size:10pt;">&#32;available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2015, the board of directors voted to restrict new grants under the 2012 Omnibus Equity Incentive Plan to 200,000 shares until such time as the Company&#8217;s total available shares are increased.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Combined Plans</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes option activity under all plans during the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and shows the exercisable shares as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="74%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding January 1, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5,185,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">769,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(13,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(311,737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5,628,726</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5.20</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">717,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(54,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(124,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercisable December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,536,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The cash received from the exercise of options during the year ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$805,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and the tax benefit realized was </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">&#32;for the same period.  Upon exercise, shares are issued from shares authorized and held in reserve.  The intrinsic value of options exercised was </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$3.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$2.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">,  </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The total fair value of shares vesting during the period was </font><font style="font-family:Arial;font-size:10pt;">$7.3 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$3.8 million</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">$600,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">, the Company accounts for all option grants using the Black-Scholes option pricing model in accordance with ASC 718 for options granted or extended.  </font><font style="font-family:Arial;font-size:10pt;">Note 2</font><font style="font-family:Arial;font-size:10pt;">&#32;also describes the significant assumptions utilized for estimating the various inputs required this pricing model.  The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="61%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Black-Scholes Assumptions for Option Granted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected dividends</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Estimated forfeitures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In general, option awards have a requisite service period and unvested options are forfeited upon employee or consultant termination.  The Company estimates a forfeiture rate which is applied to outstanding options to determine options expected to be forfeited with the remaining outstanding options being those expected to vest.  Further information regarding the forfeiture rate calculation is included in </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">.  The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="61%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Supplemental Information</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Exercisable</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Vested and Expected to Vest</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,536,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,088,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average remaining contractual term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Aggregate intrinsic value (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">86,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">85,804</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;The aggregate intrinsic value in the table above represents the total pretax intrinsic value that would have been received by the option holders had all option holders exercised their options on that date.  It is calculated as the difference between the Company&#8217;s closing stock price of </font><font style="font-family:Arial;font-size:10pt;">$21.49</font><font style="font-family:Arial;font-size:10pt;">&#32;on the last trading day of </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and the exercise price multiplied by the number of shares for options where the exercise price is below the closing stock price.  This amount changes based on the fair market value of the Company&#8217;s stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2015, in connection with the Company's public offering, we modified the stock options of three of our executive officers to restrict the ability to exercise until such time as additional available unissued shares have been authorized.&#160; Such authorization was obtained for a majority of our shareholders as of December 31, 2015 and was pending submission to the State of Delaware.&#160; There was an immaterial amount of incremental compensation associated with this modification.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes restricted stock activity during the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="74%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted Stock Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted stock outstanding December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">40,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested/released</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted stock outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expense and tax benefits recognized on Company&#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="61%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Equity-Based Compensation Expenses and Tax Benefit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,655</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Sales, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Recognized tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock was </font><font style="font-family:Arial;font-size:10pt;">$11.4 million</font><font style="font-family:Arial;font-size:10pt;">.  This is expected to be recognized over the years </font><font style="font-family:Arial;font-size:10pt;">2016</font><font style="font-family:Arial;font-size:10pt;">&#32;through </font><font style="font-family:Arial;font-size:10pt;">2020</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sA3FB89F03B1F6EE7381CEFC21A58A920"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 13.  INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The components of the pretax loss from operations for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Components of the Pretax Loss From Operations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S. Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(44,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,083</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pretax loss from operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company does not reflect income tax expense or benefit for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, as the Company has  a full valuation allowance.  The Company records the Arizona R&amp;D Refundable Tax Credit Program it has monetized as an offset to research and development expenses on the consolidated statement of operations and comprehensive loss as discussed in </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of the Company&#8217;s net deferred income taxes for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, are as are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.46875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="58%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Income Tax Components</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property &amp; equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible assets, definite-lived</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General business credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charitable contribution</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(37,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company has generated regular tax federal net operating losses of approximately </font><font style="font-family:Arial;font-size:10pt;">$85.0 million</font><font style="font-family:Arial;font-size:10pt;">.  The Company's ability to realize tax benefit from the net operating loss is subject to annual limitation under Internal Revenue Code Section 382.  Due to the change in control which occurred as a result of Abeja Ventures, LLC&#8217;s investment in the Company on June 26, 2012, the Company estimates that the annual Section 382 limitation on utilization of net operating losses will be </font><font style="font-family:Arial;font-size:10pt;">$420,000</font><font style="font-family:Arial;font-size:10pt;">.  As such, the Company will never get the benefit of </font><font style="font-family:Arial;font-size:10pt;">$4.2 million</font><font style="font-family:Arial;font-size:10pt;">&#32;of the net operating losses generated prior to June 26, 2012.  The deferred tax asset has been adjusted to reflect the Section 382 limitation.  Section 382 also applies to built-in losses at the time of the transaction.  The amounts of any unrealized built-in losses or gains were not calculated at the date of the transaction.  The gross net operating losses available for future use are approximately </font><font style="font-family:Arial;font-size:10pt;">$80.8 million</font><font style="font-family:Arial;font-size:10pt;">.  For federal purposes, net operating losses can be carried forward for up to 20 years.  The Company&#8217;s net operating losses will begin to expire in 2023.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company relocated its headquarters to Arizona in January 2013.  As of December 31, 2015, the Company has generated Arizona net operating losses of approximately </font><font style="font-family:Arial;font-size:10pt;">$69.6 million</font><font style="font-family:Arial;font-size:10pt;">.  The Company's Arizona net operating losses will begin to expire in 2033.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company created a Spanish subsidiary in January of 2015 which generated a tax net operating loss of approximately </font><font style="font-family:Arial;font-size:10pt;">$403,000</font><font style="font-family:Arial;font-size:10pt;">.  The Spanish net operating losses carry over indefinitely.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The net deferred tax asset valuation allowance is </font><font style="font-family:Arial;font-size:10pt;">$37.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;as of December 31, 2015 compared to </font><font style="font-family:Arial;font-size:10pt;">$21.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;as of December 31, 2014.  The valuation allowance is based on management&#8217;s assessment that it is more likely than not that the Company will not have taxable income in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The difference between the U.S. federal statutory income tax rate and the Company&#8217;s effective tax rate for years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="52%"></td><td width="15%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Effective Tax Rate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S. federal statutory income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">State taxes, net of federal tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rate differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nondeductible equity and other compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Limitation on net operating losses due to &#167;382 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Credit for increased research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company had uncertain tax positions of </font><font style="font-family:Arial;font-size:10pt;">$343,000</font><font style="font-family:Arial;font-size:10pt;">, determined as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="64%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increases for prior positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increases for current year positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Increases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Decreases due to settlements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expiration of the statute of limitations for the assessment of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Decreases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These uncertain positions are not expected to change within the next twelve months.  Of the </font><font style="font-family:Arial;font-size:10pt;">$343,000</font><font style="font-family:Arial;font-size:10pt;">&#32;of uncertain tax positions, none would impact the effective tax rate, if reversed.  The Company accounts for interest on uncertain tax positions within tax expense.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has incurred federal net operating losses (NOLs) dating to the tax year ended July 31, 2004.  As such, all loss carryovers are subject to adjustment under IRS and state examination, depending on the jurisdiction in which they were incurred.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s994E04D86E0893A94C63EFC21A6CB3AE"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 14.  COMMITMENTS</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into lease agreements, lease amendments, and lease extensions ("Lease Agreements") for office, laboratory and manufacturing space located in Tucson, Arizona, the last of which expires in 2018.  In addition to rental payments and other standard provisions, one of the leases requires the Company to relocate to Tucson and comply with certain employment provisions through the term of the lease.  If such requirements are not met, the rental rate is increased.  We are in compliance with the lease terms as of fiscal years ending December 31, 2015, 2014 and 2013, thus no increased rental rates were paid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2013, as a condition of a Lease Agreement, the Company expanded its lease premises whereby the landlord provided tenant improvements.  These tenant improvements are treated as a capital lease whereby both an asset and a liability have been recorded and periodic interest based on an annual rate of </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;and depreciation are recorded to amortize the value of this asset and the liability over the remaining lease term.  The Company incurred </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">interest cost of </font><font style="font-family:Arial;font-size:10pt;">$4,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$7,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">&#32;for and the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.  Further details regarding this capital lease are included in </font><font style="font-family:Arial;font-size:10pt;">Note 5, Property and Equipment</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The future minimum lease payments under the capital lease together with the present value of the net minimum lease payments as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.1796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="79%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Capital Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less amount representing interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Present value minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total rent expense for the Tucson facility, including common area charges was </font><font style="font-family:Arial;font-size:10pt;">$685,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$293,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$168,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.  Future minimum lease payments under this agreement are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.7421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="79%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trial Agreements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed.  These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;we had a payable of </font><font style="font-family:Arial;font-size:10pt;">$512,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to the clinical trial sites and incurred expense of </font><font style="font-family:Arial;font-size:10pt;">$1.6 million</font><font style="font-family:Arial;font-size:10pt;">.  No amounts were incurred for these arrangements through December 31, 2014.  The expense incurred as part of the clinical trial is included in research and development on the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 19, 2015, a putative securities class action lawsuit was filed against Lawrence Mehren, and Steve Reichling, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504.  </font><font style="font-family:Arial;font-size:10pt;">The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System.  Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015.  On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class.  On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud.  Plaintiff seeks certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as </font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the court may order.  Defendants moved to dismiss the amended complaint on July 21, 2015, which motion was pending before the Court as of December 31, 2015.  Subsequently, the Court granted the motion and dismissed the case with prejudice on January 28, 2016.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.  See </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 16, Subsequent Events</font><font style="font-family:Arial;font-size:10pt;">&#32;for an update on this lawsuit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Employment Agreement and Consulting Agreement</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2012, Thomas V. Geimer resigned as the Company&#8217;s Chief Executive Officer, Chief Financial Officer and Secretary.  In connection with his resignation, Mr. Geimer had an agreement with the Company to receive staggered payments due to him such that </font><font style="font-family:Arial;font-size:10pt;">$650,000</font><font style="font-family:Arial;font-size:10pt;">&#32;was paid upon the closing of the July 2013 Offering as described </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$700,000</font><font style="font-family:Arial;font-size:10pt;">&#32;payable to him on July 1, 2013.  From January 1, 2013 through December 31, 2013, Mr. Geimer&#8217;s aggregate consulting fee was </font><font style="font-family:Arial;font-size:10pt;">$96,000</font><font style="font-family:Arial;font-size:10pt;">.  As of December&#160;31, 2014, no additional amounts were due under the Agreement and no further amounts were incurred during the year ending December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s265C0A2BB8A74093B01CEFC21AB2EA46"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 15.  SEGMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company operates as </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;operating segment.  Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance.  The Company&#8217;s business operates in one operating segment because the Company&#8217;s chief operating decision maker evaluates the Company&#8217;s financial information and resources and assesses the performance of these resources on a consolidated basis.  Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s8456595222754104C766EFC21AA8C0EF"></a><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 16.  SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&amp;D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2016, we were notified by the Arizona Commerce Authority (&#8220;Authority&#8221;) that we meet the program requirements to receive a &#8220;Certificate of Qualification&#8221; and, therefore, are eligible for a partial refund of research and development investments amounting to a maximum of </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;">.  The &#8220;Certificate of Qualification&#8221; does not obligate the Arizona Department of Revenue to issue the refund.  Furthermore, the calculation of the actual refund due will be based on actual qualifying expenses and income tax liability for the 2015 tax year and if qualifying expenses decrease or income tax liability increases, the refund amount may be less than the </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;">.  If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On January 28, 2016, the United States District Court for the District of Arizona granted Accelerate Diagnostics&#8217; Motion to Dismiss the class action lawsuit filed against it in March of 2015.  In granting the company&#8217;s motion, the court ordered that the action be dismissed with prejudice in its entirety.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><a name="s3FED3928B6A07F82AC7DEFC21A9464DC"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 17.  SUPPLEMENTAL DATA QUARTERLY FINANCIAL INFORMATION (UNAUDITED)</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td width="20%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUARTERLY FINANCIAL INFORMATION</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unaudited</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the quarters ending:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">9/30/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6/30/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">9/30/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6/30/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12,252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,765</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic and diluted net loss per share (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:Arial;font-size:9pt;">(1)&#160;&#160;Loss per share has been adjusted for the effects of the rights offering (see </font><font style="font-family:Arial;font-size:9pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:9pt;">).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><a name="sEEA5231A35C16CC04A05EFC2330F980E"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><a name="s63E422093B69E3493E43EFC2335868E6"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 9A.  Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on an evaluation under the supervision and with the participation of the Company&#8217;s management, the Company&#8217;s Principal Executive Officer and Principal Financial Officer have concluded that the Company&#8217;s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and (ii)&#160;accumulated and communicated to the Company&#8217;s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Management&#8217;s Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting.  The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.  The Company&#8217;s internal control over financial reporting includes those policies and procedures that:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, does not expect that the Company&#8217;s internal controls will prevent or detect all errors and all fraud.  A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.  Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.  In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)&#160;in </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework</font><font style="font-family:Arial;font-size:10pt;">&#32;(2013 Framework).  Based on that assessment, management concluded that, during the period covered by this report, such internal controls and procedures were effective as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Attestation Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The attestation report required under this Item 9A is contained in Item 8 of Part II of this Annual Report on Form 10-K under the heading &#8220;Report of Independent Registered Public Accounting Firm&#8221;.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Changes in Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There was no change in the Company&#8217;s internal control over financial reporting during the period ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;that materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><a name="s17C90709FBADA0D66B96EFC233672511"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 9B.  Other Information</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not Applicable.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s9E711CCD62727F19E477EFC2339420CE"></a><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">PART&#160;III</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain information required by Part III is omitted from this Annual Report on Form 10-K because the required information will be incorporated by reference to our definitive proxy statement for our 2016 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A of the Exchange Act (the &#8220;Proxy Statement&#8221;) not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sA2BDFE79886EDB0E12FBEFC233B70D31"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 10.  Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sD910CB7413C01082783AEFC233E9B73A"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 11.  Executive Compensation</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sCB34CCB76114D28290F9EFC234095CC5"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s6EA541107FC7FF3AF59CEFC2343B83D0"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 13.  Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s044BBA6FC521ECD193D8EFC2345CDB8F"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 14.  Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="sE3FB3F14C39DE43ED91FEFC2348E667F"></a><div style="line-height:120%;padding-bottom:0px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:normal;font-weight:bold;text-decoration:none;">Item 15.  Exhibits, Financial Statement Schedules</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">a)&#160;&#160;&#160;&#160;Documents filed as part of this report</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">1)&#160;&#160;&#160;&#160;All financial statements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="92%"></td><td width="8%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sE68BC1A77350B4C367A2EFC22E5F1A89"><font style="font-family:Arial;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sE68BC1A77350B4C367A2EFC22E5F1A89">48</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6DAADC4769AD94C8B91DEFC21A62E50B"><font style="font-family:Arial;font-size:10pt;">Balance Sheets as of December 31, 2015 and 2014</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6DAADC4769AD94C8B91DEFC21A62E50B">50</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sB264DF546E6596B34653EFC21A3A77E7"><font style="font-family:Arial;font-size:10pt;">Statements of Operations and Comprehensive Loss for the years ended December 31, 2015, 2014 and 2013</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sB264DF546E6596B34653EFC21A3A77E7">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s8FF473C20796232C243DEFC21A9E2DE3"><font style="font-family:Arial;font-size:10pt;">Statements of Stockholders&#8217; Equity for the years ended December 31, 2015, 2014 and 2013</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s8FF473C20796232C243DEFC21A9E2DE3">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sEC563A17619898811DEFEFC21A44EEBA"><font style="font-family:Arial;font-size:10pt;">Statements of Cash Flow for the years ended December 31, 2015, 2014 and 2013</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sEC563A17619898811DEFEFC21A44EEBA">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD7AD924291A594F47737EFC2301AB237"><font style="font-family:Arial;font-size:10pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD7AD924291A594F47737EFC2301AB237">54</a></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statement of Schedules</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All financial statement schedules have been omitted, since the required information is not applicable or because the information required is included in the financial statements and notes thereto.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits required by Item 601 of Registration S-K</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this Item is set forth on the exhibit index that follows the signature page of this report.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><a name="sE296C9131D2086A3C2ADEFC234B19BC1"></a><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="6%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ACCELERATE DIAGNOSTICS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">By:&#160;&#160;/s/ Lawrence Mehren</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lawrence Mehren</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Power of Attorney</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lawrence Mehren, as his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form&#160;10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="36%"></td><td width="1%"></td><td width="31%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lawrence Mehren</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lawrence Mehren</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President, Chief Executive Officer and Director</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Steve Reichling</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Steve Reichling</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate Secretary, Chief Financial Officer and Chief Accounting Officer</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ John Patience</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">John Patience</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Jack Schuler</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jack Schuler</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Matthew W. Strobeck, Ph.D.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Matthew W. Strobeck, Ph.D.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Frank ten Brink</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Frank ten Brink</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark Miller</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark Miller</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><a name="s1150B826FD85B173363CEFC234E31EBA"></a><div style="line-height:174%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="11%"></td><td width="48%"></td><td width="3%"></td><td width="38%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Exhibit No.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Filing Information</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Certificate of Incorporation of Registrant</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Appendix B of the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.1.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Certificate of Amendment to Certificate of Incorporation of Registrant</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit A to the Registrant&#8217;s Definitive Information Statement on Schedule 14C filed on July 12, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Bylaws of Registrant</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 3.2 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Warrant No. 2 issued by Registrant to Abeja Ventures, LLC on June 26, 2012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 4.2 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Subscription and Information Agent Agreement, dated March 10, 2014, by and between the Registrant and Broadridge Corporate Issuer Solutions, Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 4.2 to the Form S-3 Registration Statement (No. 333-194474) filed by the Registrant on March 10, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Form of Non-Transferable Subscription Rights Certificate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-3/A (Amendment No. 1) (File No. 333-194474) filed by the Registrant on April 7, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Form of Senior Indenture</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Form S-3 Registration Statement (No. 333-192321), Amendment No. 1, filed on December 2, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4.5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Form of Subordinated Indenture</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Form S-3 Registration Statement (No. 333-192321), Amendment No. 1, filed on December 2, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Registrant&#8217;s 2004 Omnibus Stock Option Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Appendix A of the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on November 15, 2004</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Amendment to Registrant&#8217;s 2004 Omnibus Stock Option Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Annex C of the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on May 17, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Form of Stock Option Award Agreement under Registrant&#8217;s 2004 Omnibus Stock Option Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 4.4 filed with the Registrant&#8217;s Form S-8 Registration Statement (No. 333-182930) on July 30, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Securities Purchase Agreement between Registrant and Abeja Ventures, LLC, dated as of April 20, 2012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.1 filed with the Registrant&#8217;s Form 10-Q/A for the quarterly period ended April 30, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Registration Rights Agreement between Registrant and Abeja Ventures, LLC, dated as of June 26, 2012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.5 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.6</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Offer Letter between Registrant and Lawrence Mehren, dated as of June 24, 2012*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.9 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012</font></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="11%"></td><td width="48%"></td><td width="3%"></td><td width="38%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.7</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">CFO Offer Letter between Registrant and Steve Reichling, dated as of August 8, 2012*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.10 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.8</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Lease Agreement between Registrant and Pima County, dated as of August 20, 2012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.11 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.9</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Grant Agreement between Registrant and the Arizona Commerce Authority, dated as of August 22, 2012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.12 filed with the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended July 31, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.10</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Registrant&#8217;s 2012 Omnibus Equity Incentive Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Appendix C of the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.10.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">First Amendment to Registrant&#8217;s 2012 Omnibus Equity Incentive Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 99.2 to the Form S-8 Registration Statement (No. 333-187439) filed by the Registrant on March 22, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.10.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Form of Nonqualified Stock Option Award Agreement under Registrant&#8217;s 2012 Omnibus Equity Incentive Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 99.3 to the Form S-8 Registration Statement (No. 333-187439) filed by the Registrant on March 22, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.10.3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Form of Incentive Stock Option Award Agreement under Registrant&#8217;s 2012 Omnibus Equity Incentive Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 99.4 to the Form S-8 Registration Statement (No. 333-187439) filed by the Registrant on March 22, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.10.4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Second Amendment to Registrant&#8217;s 2012 Omnibus Equity Incentive Plan*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Appendix A of the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on April 15, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.11</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Standby Purchase Agreement, dated March 10, 2014, among the Registrant and the Jack W. Schuler Living Trust and the Schuler Family Foundation</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.1 to the Form S-3 Registration Statement (No. 333-194474) filed by the Registrant on March 10, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.12</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Assignment and Assumption Agreement, dated as of May 1, 2014, by and among Schuler Family Foundation, Jack Schuler, Trustee of the Jack W. Schuler Living Trust, Oracle Institutional Partners, L.P., Oracle Partners, L.P. and the Registrant</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on May 2, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">List of Subsidiaries</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">23.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Consent of Independent Registered Public Accounting Firm (Ernst &amp; Young LLP)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Filed herewith&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">32</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Certificate of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">XBRL Instance Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">XBRL Taxonomy Calculation Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">XBRL Taxonomy Label Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">101**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">XBRL Taxonomy Presentation Linkbase Document</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:174%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>accelerate-12312015xexh21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sFF44E0651BD3CA4A4CDBEFC221068663"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 21</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ACCELERATE DIAGNOSTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">LIST OF SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="341px"></td><td width="341px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Legal Entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Jurisdiction/Domicile</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics UK Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">England</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>accelerate-12312015xexh231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sDE2FBB8B86EAB478E949EFC221BC9A09"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 23.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Arial;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Registration Statement (Form S-8 No. 333-187439) pertaining to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Arial;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Registration Statement (Form S-3 No. 333-192321) of Accelerate Diagnostics, Inc., and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Arial;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Registration Statement (Form S-8 No. 333-199992) pertaining to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan; </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">of our reports dated </font><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:Arial;font-size:10pt;">, with respect to the financial statements of Accelerate Diagnostics, Inc. and the effectiveness of internal control over financial reporting of Accelerate Diagnostics, Inc., included in this Annual Report (Form 10-K) of Accelerate Diagnostics, Inc. for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phoenix, Arizona</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>accelerate-12312015xexh311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s802B565D31464D3624D1EFC22301B938"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Lawrence Mehren, certify that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I have reviewed this annual report on Form 10-K of Accelerate Diagnostics, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchanged Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">designed such internal control over financial reporting, caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lawrence Mehren</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lawrence Mehren</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>accelerate-12312015xexh312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s71D70A97C2D22D613B5EEFC2294BBAC9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:8px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Steve Reichling, certify that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I have reviewed this annual report on Form 10-K of Accelerate Diagnostics, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchanged Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">designed such internal control over financial reporting, caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Steve Reichling</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Steve Reichling</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>accelerate-12312015xexh32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sA7008EC96E2325C5308CEFC229F535B7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 32</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each of the undersigned officers of Accelerate Diagnostics, Inc. (the &#8220;Company&#8221;) hereby certifies that, to his knowledge, the Company&#8217;s Annual Report on Form 10-K for the period ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">&#32;to which this certification is attached (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ Lawrence Mehren</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lawrence Mehren</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March&#160;9, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ Steve Reichling</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Steve Reichling</font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>axdx-20151231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:1de21de17de64f31aa1674ef1aba6b53,x:cbe9af6ca65a400cac4334d7348f6048-->
<xbrli:xbrl xmlns:axdx="http://acceleratediagnostics.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="axdx-20151231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_axdx_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">axdx:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_axdx_RightsOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">axdx:RightsOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Mar8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_axdx_DenverHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">axdx:DenverHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">axdx:CorporateBondsandNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">axdx:UnrealizedGainsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">axdx:FairValueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainLossOnInvestmentsByCategoryAxis">axdx:UnrealizedLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">axdx:CostMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">axdx:CostMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">axdx:UnrealizedGainsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainLossOnInvestmentsByCategoryAxis">axdx:UnrealizedLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">axdx:FairValueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">axdx:DefenseMedicalResearchandDevelopmentProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">axdx:DefenseMedicalResearchandDevelopmentProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q3Aug">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-08-01</xbrli:startDate>
			<xbrli:endDate>2012-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">axdx:DefenseMedicalResearchandDevelopmentProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3Aug">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q2May01toMay31_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">axdx:DefenseMedicalResearchandDevelopmentProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-05-01</xbrli:startDate>
			<xbrli:endDate>2012-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Feb1-28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Mar_2012-Sep_2015_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">axdx:DefenseMedicalResearchandDevelopmentProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-03-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Feb15-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-15</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec1-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1Mar1-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1Mar06">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q2Apr">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Mar">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec9_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_AffiliatedEntityMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AffiliatedEntityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-09</xbrli:startDate>
			<xbrli:endDate>2015-12-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec9">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-09</xbrli:startDate>
			<xbrli:endDate>2015-12-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Dec9">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-09</xbrli:startDate>
			<xbrli:endDate>2015-12-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-09</xbrli:startDate>
			<xbrli:endDate>2015-12-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec9_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_AffiliatedEntityMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_axdx_OfferingExemptFromUnderwriterCommissionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AffiliatedEntityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axdx:OfferingExemptFromUnderwriterCommissionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-09</xbrli:startDate>
			<xbrli:endDate>2015-12-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_axdx_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axdx:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-09</xbrli:startDate>
			<xbrli:endDate>2015-12-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Mar14">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Apr28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q3Jul12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-07-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q3Aug08">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May19_us-gaap_CounterpartyNameAxis_axdx_OraclePartnersL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">axdx:OraclePartnersL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Apr7">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Apr7-May19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-07</xbrli:startDate>
			<xbrli:endDate>2014-05-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q3Jul12-Aug8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-12</xbrli:startDate>
			<xbrli:endDate>2013-08-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q3Jul08">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-07-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May19_us-gaap_CounterpartyNameAxis_axdx_OracleInstitutionalPartnersL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">axdx:OracleInstitutionalPartnersL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May19_us-gaap_CounterpartyNameAxis_axdx_StandbyPurchasersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">axdx:StandbyPurchasersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsExercisableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">axdx:OptionsExercisableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsVestedAndExpectedToVestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">axdx:OptionsVestedAndExpectedToVestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">axdx:OptionsOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2004Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2004-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q3Aug01toJul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-08-01</xbrli:startDate>
			<xbrli:endDate>2012-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2May">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-05-01</xbrli:startDate>
			<xbrli:endDate>2014-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_NonQualifiedStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axdx:NonQualifiedStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axdx:OmnibusEquityIncentivePlan2012Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axdx:OmnibusEquityIncentivePlan2012Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_axdx_SharebasedCompensationAwardTrancheFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axdx:OmnibusEquityIncentivePlan2012Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">axdx:SharebasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axdx:OmnibusEquityIncentivePlan2012Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axdx:OmnibusEquityIncentivePlan2012Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_TaxAuthoritySpainMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:TaxAuthoritySpainMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_IncomeTaxAuthorityNameAxis_axdx_ArizonaDepartmentofRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">axdx:ArizonaDepartmentofRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000727207</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>axdx:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="job">
		<xbrli:measure>axdx:job</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="y">
		<xbrli:measure>utreg:Y</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="milestone">
		<xbrli:measure>axdx:milestone</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="plan">
		<xbrli:measure>axdx:plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="USD_PER_warrant">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>axdx:warrant</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<axdx:AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="I2013Q1Mar06" decimals="2" id="Fact-A2C72CB5EE64C680AC67EFC218C81CE4" unitRef="USD_PER_warrant">2.00</axdx:AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
	<axdx:AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2 contextRef="I2012Q2Apr30" decimals="INF" id="Fact-8A292BDBB62CF231E9D7EFC218D27AAA" unitRef="USD_PER_warrant">2.00</axdx:AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2>
	<axdx:AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares contextRef="I2013Q1Mar06" decimals="-5" id="Fact-8A1332080BBE7E419DCDEFC218D2ABB9" unitRef="shares">6400000</axdx:AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares>
	<axdx:AdditionalOptionIndexedToIssuersEquityIndexedShares contextRef="I2012Q2Apr30" decimals="INF" id="Fact-32641F46D44CF860C9ABEFC218BEEF2F" unitRef="shares">7000000</axdx:AdditionalOptionIndexedToIssuersEquityIndexedShares>
	<axdx:AdditionalOptionIndexedToIssuersEquityIndexedShares contextRef="I2013Q1Mar1-31" decimals="INF" id="Fact-0BFBD96936AF176A2E7434D62B05BA23" unitRef="shares">7000000</axdx:AdditionalOptionIndexedToIssuersEquityIndexedShares>
	<axdx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3 contextRef="I2012Q2Apr30" decimals="INF" id="Fact-2ACBBF56102421A261DCEFC218B4AF03" unitRef="USD_PER_warrant">1.03</axdx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3>
	<axdx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3 contextRef="I2013Q1Mar1-31" decimals="INF" id="Fact-100754B332DE879F678D342ED37D71B0" unitRef="USD_PER_warrant">1.03</axdx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3>
	<axdx:ClinicalTrialAgreementExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5A170716F2C2CA51EC8D348B6CCC732E" unitRef="usd">1600000</axdx:ClinicalTrialAgreementExpense>
	<axdx:ClinicalTrialAgreementLiability contextRef="FI2015Q4" decimals="-3" id="Fact-8BE60A49B9A8F4C73ECC348ADE16FBF2" unitRef="usd">512000</axdx:ClinicalTrialAgreementLiability>
	<axdx:CommonStockAndWarrantsIssuedValue contextRef="D2012Q2Apr" decimals="-5" id="Fact-B8924EFDF145026566C75324DBB8C0F5" unitRef="usd">14400000</axdx:CommonStockAndWarrantsIssuedValue>
	<axdx:DeferredRevenueResearchUseOnly contextRef="FI2014Q4" decimals="-3" id="Fact-9AD6924052C87D0DDF791FF576E65CD8" unitRef="usd">0</axdx:DeferredRevenueResearchUseOnly>
	<axdx:DeferredRevenueResearchUseOnly contextRef="FI2015Q4" decimals="-3" id="Fact-541C9019AEFD82B0C3151FF576D6AFF3" unitRef="usd">114000</axdx:DeferredRevenueResearchUseOnly>
	<axdx:DeferredTaxAssetsFiniteLivedIntangibleAssets contextRef="FI2014Q4" decimals="-3" id="Fact-1FA403F4B1045A67D550EFC218D27219" unitRef="usd">421000</axdx:DeferredTaxAssetsFiniteLivedIntangibleAssets>
	<axdx:DeferredTaxAssetsFiniteLivedIntangibleAssets contextRef="FI2015Q4" decimals="-3" id="Fact-6068B62D417710D0E719EFC218D2A88B" unitRef="usd">333000</axdx:DeferredTaxAssetsFiniteLivedIntangibleAssets>
	<axdx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent contextRef="FD2013Q4YTD" decimals="4" id="Fact-2CDEB8E74D0CC803179C359C10C1D9D7" unitRef="number">0.0000</axdx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent>
	<axdx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent contextRef="FD2014Q4YTD" decimals="4" id="Fact-5EDAF5465746DA57DCA6359AB06565DA" unitRef="number">0.0000</axdx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent>
	<axdx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent contextRef="FD2015Q4YTD" decimals="4" id="Fact-77097CC5E7080E06E7A4359AB0590E43" unitRef="number">0.0011</axdx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent>
	<axdx:EmployeeServiceSharebasedCompensationNumberofPlans contextRef="FD2015Q4YTD" decimals="INF" id="Fact-6748368AD0CEDB35620751EC4B87DCB5" unitRef="plan">4</axdx:EmployeeServiceSharebasedCompensationNumberofPlans>
	<axdx:ExercisedWarrantAmountUnexercised contextRef="FI2015Q4" decimals="INF" id="Fact-CDD2592A1CEAC827838934D547CF5876" unitRef="shares">571160</axdx:ExercisedWarrantAmountUnexercised>
	<axdx:ExercisedWarrantPercentExercised contextRef="D2013Q4Mar" decimals="2" id="Fact-27785C65E1D698C0AC0F34D2D12BEE50" unitRef="number">0.92</axdx:ExercisedWarrantPercentExercised>
	<axdx:ExercisedlOptionIndexedToIssuersEquityIndexedShares contextRef="I2013Q1Mar06" decimals="INF" id="Fact-D02CDBD49350D700F732EFC2199A2E36" unitRef="shares">7000000</axdx:ExercisedlOptionIndexedToIssuersEquityIndexedShares>
	<axdx:OperatingLossCarryforwardLimitationsOnUseAmount contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-5DDF110D240424E4D9E33B699662A9F1" unitRef="usd">4200000</axdx:OperatingLossCarryforwardLimitationsOnUseAmount>
	<axdx:OperatingLossCarryforwardLimitationsOnUseAnnualAmount contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-3" id="Fact-59E9EE50C119BA079FDA3B651BB7B093" unitRef="usd">420000</axdx:OperatingLossCarryforwardLimitationsOnUseAnnualAmount>
	<axdx:OperatingLossCarryforwardsGross contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-6D91EB1086327D6EB7733B65094723C8" unitRef="usd">85000000</axdx:OperatingLossCarryforwardsGross>
	<axdx:ProceedsFromSaleofCommonStockGross contextRef="D2015Q4Dec9" decimals="-5" id="Fact-93C87D920DEEBAB1387D350EB71CF920" unitRef="usd">109300000</axdx:ProceedsFromSaleofCommonStockGross>
	<axdx:ProceedsfromIssuanceofWarrantsGross contextRef="D2013Q3Jul12-Aug8" decimals="-5" id="Fact-AB95631D62FAC921E57734F88264E9DC" unitRef="usd">20000000</axdx:ProceedsfromIssuanceofWarrantsGross>
	<axdx:ProceedsfromIssuanceofWarrantsGross contextRef="D2014Q2Apr7-May19" decimals="-5" id="Fact-1F023FD36CE8A58F002834F8BED17220" unitRef="usd">45000000</axdx:ProceedsfromIssuanceofWarrantsGross>
	<axdx:RevenueRecognitionMilestoneMethodAnnualWagesMinimum contextRef="D2012Q3Aug" decimals="INF" id="Fact-DFFB9E8F8D91386274203A503B608DCF" unitRef="usd">63000</axdx:RevenueRecognitionMilestoneMethodAnnualWagesMinimum>
	<axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour contextRef="D2012Q3Aug" decimals="INF" id="Fact-1670AA50B2F9C8551D0152DFA68ECACE" unitRef="job">65</axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour>
	<axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne contextRef="D2012Q3Aug" decimals="INF" id="Fact-1700C934FAB71B70E04552DE8E521088" unitRef="job">15</axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne>
	<axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree contextRef="D2012Q3Aug" decimals="INF" id="Fact-AF802BC467B0DF40A3B452DF31504B23" unitRef="job">40</axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree>
	<axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo contextRef="D2012Q3Aug" decimals="INF" id="Fact-4022862BAEC8DF5A018652DEE031BEAE" unitRef="job">30</axdx:RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo>
	<axdx:RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment contextRef="D2012Q3Aug" decimals="-5" id="Fact-A689AAE91C89891EE7753A4E69370B60" unitRef="usd">4500000</axdx:RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment>
	<axdx:RevenueRecognitionMilestoneMethodNumberOfMilestones contextRef="D2012Q3Aug" decimals="INF" id="Fact-EC46E221A4E3F2A6C19252DD3FB69082" unitRef="milestone">4</axdx:RevenueRecognitionMilestoneMethodNumberOfMilestones>
	<axdx:RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums contextRef="D2012Q3Aug" decimals="INF" id="Fact-E6B294D535CEBFEEA5243A5B1963CB49" unitRef="number">0.65</axdx:RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2 contextRef="FI2015Q4" decimals="INF" id="Fact-A0FF0393445F1DE74C5535F03239D997" unitRef="shares">0</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3 contextRef="FI2015Q4" decimals="INF" id="Fact-F101A44C0AA9C552AAE2EFC219A4E2DD" unitRef="shares">0</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4 contextRef="FI2015Q4" decimals="INF" id="Fact-C4571EBE9C2F3C5A284735E9DA55D6F6" unitRef="shares">2945459</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5 contextRef="FI2015Q4" decimals="INF" id="Fact-B33B6251F5AD9604CAF335F57F5B46EF" unitRef="shares">0</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1 contextRef="FD2013Q4YTD" decimals="3" id="Fact-EF0C3FA6E6931EB3A6F9333E7B60570F" unitRef="number">0.140</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1 contextRef="FD2014Q4YTD" decimals="3" id="Fact-7AFFCC87C852BBC08F86333E7B36C956" unitRef="number">0.004</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1 contextRef="FD2015Q4YTD" decimals="3" id="Fact-E5BA0A1D326140A36149333E7B5DA526" unitRef="number">0.056</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber contextRef="FI2015Q4" decimals="INF" id="Fact-A108E6657C68D99A976135EEB2E66E30" unitRef="shares">527500</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1 contextRef="FI2015Q4" decimals="INF" id="Fact-2635714E51F5328C1DBD35EF06795A13" unitRef="shares">270000</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2 contextRef="FI2015Q4" decimals="INF" id="Fact-658E95D9AE22954B530FEFC219A4AC64" unitRef="shares">403474</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3 contextRef="FI2015Q4" decimals="INF" id="Fact-A1250B8877FAE98FEFCEEFC2199A3143" unitRef="shares">71147</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="FI2014Q4" decimals="INF" id="Fact-9CFFAD2E0139E0C2D1ED360BBB5D4A4D" unitRef="shares">0</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="FI2015Q4" decimals="INF" id="Fact-3E446F1D3EDA4B6FFF03360BBB705391" unitRef="shares">40250</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1 contextRef="FI2015Q4" decimals="INF" id="Fact-F4B210573E53CFED95FB35EF7F0285C1" unitRef="shares">10000</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2 contextRef="FI2015Q4" decimals="INF" id="Fact-7AE07C86974D3A03CB45EFC2199A8A8A" unitRef="shares">3536526</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2>
	<axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3 contextRef="FI2015Q4" decimals="INF" id="Fact-0F1541A2DF68E37BC68D35E97A095F18" unitRef="shares">2660894</axdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3>
	<axdx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1 contextRef="FD2015Q4YTD" decimals="2" id="Fact-0715374CD5E8D1C31C98360CC8D87508" unitRef="usdPerShare">0.00</axdx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
	<axdx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1 contextRef="FD2015Q4YTD" decimals="2" id="Fact-A40546A00E023F56828F360C967E4D10" unitRef="usdPerShare">20.91</axdx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
	<axdx:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2 contextRef="FD2013Q4YTD" decimals="2" id="Fact-C92C9984757772EDB994333E7B589828" unitRef="y">6.28</axdx:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2>
	<axdx:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2 contextRef="FD2014Q4YTD" decimals="2" id="Fact-F57A8D99BBFD68EA0A61333E7B628364" unitRef="y">6.25</axdx:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2>
	<axdx:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2 contextRef="FD2015Q4YTD" decimals="2" id="Fact-EB379606BA1CFFC93E61333E7B4F5366" unitRef="y">6.26</axdx:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2>
	<axdx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsExercisableMember" decimals="2" id="Fact-ECB9E3F066EF6317AFBF333E8FBC29C3" unitRef="y">7.18</axdx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a>
	<axdx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsOutstandingMember" decimals="2" id="Fact-A945B7D0795E7B8DB14B333E8FBAC908" unitRef="y">7.19</axdx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a>
	<axdx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsVestedAndExpectedToVestMember" decimals="2" id="Fact-4928A65F7CE61627C533333E8FB46589" unitRef="y">7.18</axdx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a>
	<axdx:UnderwritingDiscountandCommissionFeesPerShare contextRef="D2015Q4Dec9" decimals="2" id="Fact-7E4FDEE81316081F6190350B965CACEF" unitRef="usdPerShare">1.19</axdx:UnderwritingDiscountandCommissionFeesPerShare>
	<axdx:UnrecognizedTaxBenefitsOtherDecrease contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C96C42281320BA9F28BE35DD1655D24E" unitRef="usd">0</axdx:UnrecognizedTaxBenefitsOtherDecrease>
	<axdx:UnrecognizedTaxBenefitsOtherDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7BF2EC7CE9E29BCFE9D135DC512FF220" unitRef="usd">0</axdx:UnrecognizedTaxBenefitsOtherDecrease>
	<axdx:UnrecognizedTaxBenefitsOtherDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4EE17C6661FD8BF4F33735DCBB74081B" unitRef="usd">0</axdx:UnrecognizedTaxBenefitsOtherDecrease>
	<axdx:UnrecognizedTaxBenefitsOtherIncrease contextRef="FD2013Q4YTD" decimals="-3" id="Fact-19E28ED51E67411F6DF235DD1366F6A9" unitRef="usd">0</axdx:UnrecognizedTaxBenefitsOtherIncrease>
	<axdx:UnrecognizedTaxBenefitsOtherIncrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-719459350E08ED90F3F5349199547CD2" unitRef="usd">0</axdx:UnrecognizedTaxBenefitsOtherIncrease>
	<axdx:UnrecognizedTaxBenefitsOtherIncrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-41CB4DF4AECDA9CF300435DCB8859A9E" unitRef="usd">0</axdx:UnrecognizedTaxBenefitsOtherIncrease>
	<dei:AmendmentFlag contextRef="FD2015Q4YTD" id="Fact-63ECE55B62C87B84EBCDEFC219A4DE82">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2015Q4YTD" id="Fact-0A437C02D9DA2C69A425EFC219E00C39">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2015Q4YTD" id="Fact-6A6A89F1B6B4C8927F2A3011CADBF044">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2015Q4YTD" id="Fact-7F2D139E51B094A874FA1FECD303047F">2015</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2015Q4YTD" id="Fact-3D942B2C7E45E4689724EFC21A0896D8">2015-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2015Q4YTD" id="Fact-5B3F0ACDEE32E2784FEFEFC219CCCB75">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2015Q4YTD" id="Fact-DAB94F265A983147A070EFC219B88AA1">0000727207</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q1Mar8" decimals="INF" id="Fact-71A353BE1056DF49B189EFC219D65DD3" unitRef="shares">51199017</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2015Q4YTD" id="Fact-065B421F230D5AAE575AEFC219FE605F">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2015Q4YTD" id="Fact-5FAEDEB304BEC461F92CEFC219D62C54">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2015Q2" decimals="-5" id="Fact-69B6E7AF254513B6B115EFC219CC3D2B" unitRef="usd">483400000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2015Q4YTD" id="Fact-F6165E9582AE93CDDCE0EFC2190E3434">Accelerate Diagnostics, Inc.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2015Q4YTD" id="Fact-B1CED7239DF29B9E0DA4EFC219F456CB">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2015Q4YTD" id="Fact-1436412844225CD141E5EFC2199ADF2C">No</dei:EntityWellKnownSeasonedIssuer>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-465F0B73DE1FCB0C2A31EFC2190ECCC1" unitRef="usd">494000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-30662B54CB9C4FEDED02EFC2192C2E24" unitRef="usd">2543000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-A68F0195D9D426BA9717EFC219180687" unitRef="usd">2129000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-3B544445657EBB57B337EFC2192CD872" unitRef="usd">2623000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F4DCB101CD5E51AE3DBA1FF576E06B58" unitRef="usd">13000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
	<us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-6E025A06CB013716D5D21FF576E9F4D3" unitRef="usd">127000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4" decimals="-3" id="Fact-D4E481B18D5A88F53728EFC219FE56EA" unitRef="usd">1311000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-305932371FECA49B00D7EFC21A1C6A01" unitRef="usd">2622000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities contextRef="FI2014Q4" decimals="-3" id="Fact-D6C259A235048DB65857EFC21904BF7B" unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities contextRef="FI2015Q4" decimals="-3" id="Fact-5ABFAE460BE5C5175C1BEFC21940D3A7" unitRef="usd">12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2014Q4" decimals="-3" id="Fact-EF106B1C0733D49BA989EFC219900D1F" unitRef="usd">131356000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-FB6A52BD18CE44074677EFC2190E4927" unitRef="usd">243894000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C33BBB6E05CE930ED6A7EFC21936ED46" unitRef="usd">77000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-39D2FDE59BBEA71131DEEFC218E6531B" unitRef="usd">71000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B1EBA1FACFC207638740EFC218B431AA" unitRef="usd">10000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2013Q4YTD" decimals="INF" id="Fact-2AA3B4E131855222C17851FA3876242E" unitRef="shares">5731246</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q4YTD" decimals="INF" id="Fact-71508564ACE801BF2906EFC218C82DCD" unitRef="shares">6174886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="INF" id="Fact-C55AEDB51DDFFE8845C6EFC219D6F366" unitRef="shares">6778580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2014Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember" decimals="-3" id="Fact-17D8AD61D8FEC0808332EFC218BE8720" unitRef="usd">141000</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2014Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember" decimals="-3" id="Fact-71509F207F2B15F427D7EFC2192CAB45" unitRef="usd">0</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2014Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember" decimals="-3" id="Fact-354D5530082CC6F6E334EFC21904ED45" unitRef="usd">0</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2014Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember" decimals="-3" id="Fact-6386E4CF0ECB8280B0C9EFC21918A846" unitRef="usd">141000</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2015Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember" decimals="-3" id="Fact-7A0BBBDE11EBA02AD239EFC2192211FB" unitRef="usd">2507000</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2015Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember" decimals="-3" id="Fact-15A385FF7DDD90B03A81EFC21936F8F1" unitRef="usd">0</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2015Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember" decimals="-3" id="Fact-A8A7D0F9CDCC118E3A6CEFC2192CC16D" unitRef="usd">-3000</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetBackedSecuritiesAtCarryingValue contextRef="FI2015Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember" decimals="-3" id="Fact-6E2DA03A447275C40B23EFC2199A93C8" unitRef="usd">2510000</us-gaap:AssetBackedSecuritiesAtCarryingValue>
	<us-gaap:AssetImpairmentCharges contextRef="FD2013Q4YTD" decimals="-3" id="Fact-B361F7D6E88BF88261D6EFC219AE6BAD" unitRef="usd">11000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2014Q4YTD" decimals="-3" id="Fact-21345A90D54F3ED42290EFC219183CF3" unitRef="usd">3000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FD2F07F2114690244045EFC21940ECBF" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-3" id="Fact-69282F63AA7777E7AEA0EFC21936E4B4" unitRef="usd">69801000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-637E7A477BE90B81F614EFC2190E14A9" unitRef="usd">139324000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-0EFE1B68FA41A207F2E8EFC219046CD7" unitRef="usd">67098000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-EC1E9628EA470E7BE399EFC2192CFA0E" unitRef="usd">134151000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4" decimals="-3" id="Fact-98BE1344B4145E4109C4EFC21922D753" unitRef="usd">26242000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember" decimals="-3" id="Fact-0107425E29D72816342BEFC2192C07C6" unitRef="usd">12974000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-158C25ECC7A521387002EFC219223215" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-18F05225ED1F044021B4EFC2192C01E2" unitRef="usd">12974000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-1110BDDBA995973E905DEFC219227EF7" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-AD8B6602082FDD63A9BBEFC2192C9673" unitRef="usd">141000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-946AFAC0F23D66A83280EFC21922D910" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-2F3F09594CC3A1043119EFC219228891" unitRef="usd">141000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-E5F67C477D88E71B4DA4EFC219226968" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-879E7B46C558222B09FCEFC219227902" unitRef="usd">13127000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-90B61A980154C2A404C1EFC21922EDFF" unitRef="usd">13127000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-C06D05372D5BC693F301EFC219225C78" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-5710F6C98E9CF2A1DA78EFC219224AE8" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-63A79283D07FB26B04FEEFC219225774" unitRef="usd">13127000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-8575D501CF987318302DEFC219220BD4" unitRef="usd">13115000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-434A0F41552D3AC658E7EFC2192256A1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember" decimals="-3" id="Fact-84A82884BAE0D9BBC2DFEFC219048195" unitRef="usd">12974000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember" decimals="-3" id="Fact-113AC1E1B6CA7022F270EFC219045223" unitRef="usd">10000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember" decimals="-3" id="Fact-28949605BE4A8F55DBEBEFC2192C75D5" unitRef="usd">-3000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember" decimals="-3" id="Fact-261352AB942C1566CA2FEFC219366661" unitRef="usd">12967000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4" decimals="-3" id="Fact-250DBC9B9D9FBC477185EFC21922FE49" unitRef="usd">17060000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember" decimals="-3" id="Fact-84D788917E967665F720EFC21922C7EF" unitRef="usd">9332000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-F23C1F9E825A62D369C9EFC219221372" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-8176CCB37A92ACE3089EEFC2192C26D0" unitRef="usd">9332000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_axdx_CorporateBondsandNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-F4A6F00196D1236D5FF6EFC21936C1EB" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember" decimals="-3" id="Fact-3EB96A6CBCAB93EDFD16EFC2190E9129" unitRef="usd">2507000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-5689FA6271C68199D7D1EFC219407BC4" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-8081CE65BA96D369C2B0EFC21918782C" unitRef="usd">2507000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-AAD8E215FCC386ABFE2FEFC2192CA302" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-E3D9D8D79EFCC5B08510EFC2190EFF35" unitRef="usd">5221000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-F7DD31C6E6FF470CFFC4EFC2190E9A65" unitRef="usd">5221000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-522D60901AEC1A3C24D8EFC2192C756B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-AD238B7CDC2319ADB0FCEFC21922CA93" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-2BC118AAFC0CF0E54AD8EFC219223823" unitRef="usd">5221000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-7FAF05A24B89C232F790EFC218E6127B" unitRef="usd">11839000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-62CAB827093AF53EA88CEFC219FE153B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember" decimals="-3" id="Fact-C2EA2D1501149434D201EFC219A44A69" unitRef="usd">9332000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember" decimals="-3" id="Fact-E839B80D4F4EFAE12A18EFC2199ABE83" unitRef="usd">1000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember" decimals="-3" id="Fact-5E9BE600307093E3829EEFC2199AA073" unitRef="usd">-10000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember" decimals="-3" id="Fact-A10476F156720860D48CEFC21918AB35" unitRef="usd">9341000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-90DFB88C8491F7B89D8FEFC219F45D38" unitRef="usd">22000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
	<us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C54B2FC9E8DC3B57AD22EFC218A024F2" unitRef="usd">22000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
	<us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6B35265E506C8223238AEFC219CCE174" unitRef="usd">-15000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
	<us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-5669550195AB8FA97BD5EFC218AAC739" unitRef="usd">-15000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
	<us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-736EBF10DC9E23984D67EFC219EA41B9" unitRef="usd">-20000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
	<us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F2F50283C718C9B59D0CEFC219AEA008" unitRef="usd">-20000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B6DE0D2C81EE8E8BB87AEFC218966F74" unitRef="usd">10585000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2014Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember" decimals="-3" id="Fact-8C6953D7A4E538DF637FEFC219D6BCBD" unitRef="usd">10586000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-EE0CD5E53709F6DA14BFEFC218AA3214" unitRef="usd">11839000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2015Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember" decimals="-3" id="Fact-C0DE7333E3C8981ED6ECEFC219A48D1B" unitRef="usd">11851000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5EFB79E20C683C4AFCD5EFC219229B2E" unitRef="usd">2530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2014Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember" decimals="-3" id="Fact-BAC9BB79BC1D94805C65EFC21A08E529" unitRef="usd">2522000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7DEBAA87AD670A60CD47EFC2192CE70A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2015Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember" decimals="-3" id="Fact-E93A54AA30363A8FC17EEFC219CC9DAA" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:CapitalLeaseObligations contextRef="FI2014Q4" decimals="-3" id="Fact-21FF81959CF55B15368DEFC21940075A" unitRef="usd">147000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q4" decimals="-3" id="Fact-9CC844D86669E2F21782EFC21918EB41" unitRef="usd">13000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeasedAssetsGross contextRef="FI2014Q4" decimals="-3" id="Fact-EDC59815E7608B6D16ACEFC219FE4D84" unitRef="usd">266000</us-gaap:CapitalLeasedAssetsGross>
	<us-gaap:CapitalLeasedAssetsGross contextRef="FI2015Q4" decimals="-3" id="Fact-E0FB8B919CB5E24D1C26EFC219FEEDC6" unitRef="usd">266000</us-gaap:CapitalLeasedAssetsGross>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="FI2015Q4" decimals="-3" id="Fact-DA49073511F5500E7474345E81B02AE7" unitRef="usd">13000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-6F229D3FFEC04DA9E4AEEFC219C2613A" unitRef="usd">13000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2015Q4" decimals="-3" id="Fact-2945C973022D59178048345E81B8C6A6" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2015Q4" decimals="-3" id="Fact-A018D1D420B84D9875A6EFC2190E78D1" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2015Q4" decimals="-3" id="Fact-4ABFF19EC8FC3B5C6CDAEFC219C2D58F" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2015Q4" decimals="-3" id="Fact-0CC8AC804AEA08E84893EFC219A4BF55" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="FI2015Q4" decimals="-3" id="Fact-069DB3F57839CCCC2FDAEFC219044A12" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="FI2015Q4" decimals="-3" id="Fact-353EB31C702ED4A4C4EC345E81A9BF66" unitRef="usd">13000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
	<us-gaap:CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization contextRef="FI2014Q4" decimals="-3" id="Fact-577C200A15966C0C7C04EFC21A26EBE1" unitRef="usd">-133000</us-gaap:CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization>
	<us-gaap:CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization contextRef="FI2015Q4" decimals="-3" id="Fact-716C473741B2777D5AD1EFC21A1C0284" unitRef="usd">-266000</us-gaap:CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2012Q4" decimals="-3" id="Fact-A18287EB9151EC6C3155EFC219EA5AA4" unitRef="usd">12069000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-3E5E687BECCC7978DDEDEFC219C2F144" unitRef="usd">30029000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-0BF6CF2F452359FE6866EFC21940A5F3" unitRef="usd">53563000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-13DF79BB6FAE67FA1CA8EFC2199ACD35" unitRef="usd">120585000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2013Q4YTD" decimals="-3" id="Fact-77836585B61477AF8E81EFC21A08DF90" unitRef="usd">17960000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F9C8534993C24012E4E7EFC219C25F90" unitRef="usd">23534000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-57D96E6A000049813FFFEFC219EAE436" unitRef="usd">67022000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2014Q4" id="Fact-10D8038ADB0218152F233EA17CED67C8" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-77258DFFDDB8B07D49A13EA17C13543B" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockOtherSharesOutstanding contextRef="I2012Q2Apr30" decimals="INF" id="Fact-5A8E8E752D4711048402EFC218B4AE56" unitRef="shares">14000000</us-gaap:CommonStockOtherSharesOutstanding>
	<us-gaap:CommonStockOtherValueOutstanding contextRef="FI2014Q4" decimals="-3" id="Fact-1BE1DD8A5055300893A0EFC219404EB4" unitRef="usd">45000</us-gaap:CommonStockOtherValueOutstanding>
	<us-gaap:CommonStockOtherValueOutstanding contextRef="FI2015Q4" decimals="-3" id="Fact-A9C7C1939B1828EAFD8AEFC21936FD1D" unitRef="usd">51000</us-gaap:CommonStockOtherValueOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-642F1BDF30A5BA3AD785EFC219F4F4EB" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-C84F9B66D22C0F8682EEEFC219EA87F7" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q4" decimals="INF" id="Fact-56C554A90F70E8D4B190EFC219FE4C8C" unitRef="shares">55000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-49AC9C3DA086BB48D578EFC2192C0E35" unitRef="shares">55000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2014Q4" decimals="INF" id="Fact-8862D7FBE9D794F6F1AFEFC21A08106C" unitRef="shares">44639829</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-9577521B2499A02AC8CBEFC219FE959E" unitRef="shares">51199017</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4" decimals="INF" id="Fact-CF56CA78F60FE751BC2EEFC219F43D6E" unitRef="shares">44639829</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-E2A8637367953D55A11BEFC219FE34A0" unitRef="shares">51199017</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesSubscriptions contextRef="I2012Q2Apr30" decimals="-5" id="Fact-4E8AD6912139D850C48DEFC218C82F36" unitRef="usd">8500000</us-gaap:CommonStockSharesSubscriptions>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-2D2107AA493CEAEBDB7FEFC219EA7971" unitRef="usd">-15260000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-AF9D4102909441C6A01FEFC218E64DE2" unitRef="usd">-30948000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-085C21DC3D3723D48B7BEFC218D2FF1F" unitRef="usd">-45517000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" decimals="2" id="Fact-8E05D69EA3D443E027D733A08318F41B" unitRef="number">0.83</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_us-gaap_MajorCustomersAxis_axdx_DenverHealthMember" decimals="2" id="Fact-54BBA6BF5A66FCAC52A633A7C18DE716" unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" decimals="2" id="Fact-D1F0591239B8D2241C8333A030B07A63" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ContractualObligation contextRef="FI2015Q4" decimals="-3" id="Fact-5758E29849DA9C629305345E7D7BD950" unitRef="usd">1129000</us-gaap:ContractualObligation>
	<us-gaap:CostsAndExpenses contextRef="FD2013Q4YTD" decimals="-3" id="Fact-105F6D71F160F8DE1417EFC218B44C2C" unitRef="usd">15359000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-05644E94FF7400D2700BEFC2194A2197" unitRef="usd">31112000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DDC6C77A1131B023E0CBEFC2190EB47D" unitRef="usd">45696000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2012Q2Apr30" decimals="INF" id="Fact-491FC74B32C05DC9B178EFC218BE6B5D" unitRef="usdPerShare">1.03</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2013Q3Jul12" decimals="INF" id="Fact-985173DA88753E8FA3BB34FAAAA37038" unitRef="usdPerShare">8.04</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2014Q1Mar14" decimals="INF" id="Fact-BCB7D7A4FAB15875E708EFC21A12797F" unitRef="usdPerShare">16.80</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="2" id="Fact-4EAB4BEE60C0E8E0EB563ABCB55F79C6" unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredCompensationLiabilityCurrent contextRef="FI2012Q4" decimals="-4" id="Fact-E24700233ED1D97E49CB3AA7DFF63B30" unitRef="usd">650000</us-gaap:DeferredCompensationLiabilityCurrent>
	<us-gaap:DeferredCompensationLiabilityCurrent contextRef="FI2013Q2" decimals="-4" id="Fact-C27B0F3FDDC0A5EF378C3AA85138C199" unitRef="usd">700000</us-gaap:DeferredCompensationLiabilityCurrent>
	<us-gaap:DeferredCreditsAndOtherLiabilities contextRef="FI2014Q4" decimals="-5" id="Fact-01019A473254DE52F9943A641414225B" unitRef="usd">1000000</us-gaap:DeferredCreditsAndOtherLiabilities>
	<us-gaap:DeferredCreditsAndOtherLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-DE334673EA2764E91A061FF576D3D96A" unitRef="usd">1000000</us-gaap:DeferredCreditsAndOtherLiabilities>
	<us-gaap:DeferredCreditsAndOtherLiabilities contextRef="FI2015Q4" decimals="-5" id="Fact-D327E51579A9C0249DD73A64EA92FF6D" unitRef="usd">1000000</us-gaap:DeferredCreditsAndOtherLiabilities>
	<us-gaap:DeferredCreditsAndOtherLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-2DA7D3BDA7752B6291A51FF576EC87B7" unitRef="usd">1000000</us-gaap:DeferredCreditsAndOtherLiabilities>
	<us-gaap:DeferredCreditsAndOtherLiabilities contextRef="I2012Q3Aug" decimals="-5" id="Fact-4090BF8B6E173958E3283A6CEFD4B8C8" unitRef="usd">1000000</us-gaap:DeferredCreditsAndOtherLiabilities>
	<us-gaap:DeferredRevenue contextRef="FI2014Q4" decimals="-3" id="Fact-8C9BAAD3903FD1AFEBFAEFC219407A39" unitRef="usd">13000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4" decimals="-3" id="Fact-D26484CC4A2F0022D6E7EFC2194AD84E" unitRef="usd">127000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueAndCreditsNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-9E2376E9D707BB174265340AC4DFE7AA" unitRef="usd">1014000</us-gaap:DeferredRevenueAndCreditsNoncurrent>
	<us-gaap:DeferredRevenueAndCreditsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-A444E40404A04BFF9FE8340AC39BDE86" unitRef="usd">1000000</us-gaap:DeferredRevenueAndCreditsNoncurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-59AB7F033006F87A04401FF576E362B5" unitRef="usd">13000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-39CA7AB6358BD0CADC6F1FF576DEB374" unitRef="usd">13000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-82591F0B045D593B5A751FF576D807EE" unitRef="usd">14000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-CDF4B95D881FB830D1CD1FF576DB3F90" unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueRevenueRecognized contextRef="D2015Q4Dec1-31" decimals="-3" id="Fact-A05E0BB7A4B88EA3483034128ABDBDAB" unitRef="usd">114000</us-gaap:DeferredRevenueRevenueRecognized>
	<us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="FI2014Q4" decimals="-3" id="Fact-0FC97849CB990A23F4EE34919E9EE8A0" unitRef="usd">13000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
	<us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-47D54F064E6ACBBCF0B934919E9A9B5A" unitRef="usd">18000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2014Q4" decimals="-3" id="Fact-6448AC208F838C753775EFC218C8ACC1" unitRef="usd">380000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2015Q4" decimals="-3" id="Fact-CE76718B297817F8CC11EFC218DC6BC6" unitRef="usd">372000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2014Q4" decimals="-3" id="Fact-9D8458A8728A35303A16EFC218C8AE7B" unitRef="usd">620000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2015Q4" decimals="-3" id="Fact-8B65FFB2091150130F48EFC218D22A61" unitRef="usd">864000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2014Q4" decimals="-3" id="Fact-1D2F34CCB03135FDAA8034919E98A5E9" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2015Q4" decimals="-3" id="Fact-2717811113C736051A2134919E9C321E" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2014Q4" decimals="-3" id="Fact-16DD2523BE883CA565CAEFC218D25B9B" unitRef="usd">15492000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-968128ECAF422E7A3F2AEFC218DC7D40" unitRef="usd">28584000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2014Q4" decimals="-3" id="Fact-B978BCAB808E7DAD4937EFC218D2527D" unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2015Q4" decimals="-3" id="Fact-CA3F2891854EC6486E67EFC218C8016C" unitRef="usd">187000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2014Q4" decimals="-3" id="Fact-8D5ADDC449126284D284EFC218D24BA2" unitRef="usd">77000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-AC7141ECA1514DABB4B5EFC218C85B56" unitRef="usd">339000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="FI2014Q4" decimals="-3" id="Fact-3F88CBF737D218D4A749EFC218DC147F" unitRef="usd">885000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="FI2015Q4" decimals="-3" id="Fact-CCD36728EB4E08DC420BEFC218C8CF7D" unitRef="usd">1915000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2014Q4" decimals="-3" id="Fact-8D8D65B8799566272FB7EFC218D2D1C3" unitRef="usd">3644000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-3" id="Fact-64A564D9E14D2C0658F7EFC218D20B56" unitRef="usd">5208000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2014Q4" decimals="-5" id="Fact-FFEE69541AF788721BB23B756BDD7AB9" unitRef="usd">21500000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2014Q4" decimals="-3" id="Fact-79AE4AD65A152ACD86E0EFC218BEADB4" unitRef="usd">21532000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-5" id="Fact-39B587BF0B8FB2AED2463B755FAC751F" unitRef="usd">37800000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-25C5FB4F5F22E432F7E2EFC218D2067F" unitRef="usd">37820000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:Depreciation contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1A1694EBA868850BD1FBEFC21940B9C6" unitRef="usd">286000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B6C5313198B81D48D78CEFC219369D9F" unitRef="usd">817000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DB4B960228DCC80FED26EFC219229A2C" unitRef="usd">1782000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2013Q4YTD" decimals="-3" id="Fact-489D73501B908D08F9B8EFC2190ED837" unitRef="usd">286000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q4YTD" decimals="-3" id="Fact-02E4E7F46A094BE577DDEFC21918B879" unitRef="usd">817000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0E7A1C52ADD7EEC6C648EFC218A0BC7B" unitRef="usd">1782000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q4YTD" decimals="2" id="Fact-20B5B58801A0291D6E62EFC21904F75C" unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-6C513DE67D7B617F5349EFC21918E3F7" unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-F318C325B4794152F838EFC2190E0CF3" unitRef="usdPerShare">-1.01</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2013Q4YTD" decimals="4" id="Fact-6139368A8AF5E71A705D359C15F73F93" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2014Q4YTD" decimals="4" id="Fact-72BB15677D3EE71A2240359510B25A6D" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="4" id="Fact-E86DD81DD2F340CDEFEF359510B4DCD5" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2013Q4YTD" decimals="INF" id="Fact-B32BACD2D7EE38DD8A67359C0F722A5F" unitRef="number">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-19F62C7C34CA6382561FEFC218FA2CEA" unitRef="number">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-6FB4395C3D50E7CB3985EFC218F0DDA3" unitRef="number">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2013Q4YTD" decimals="4" id="Fact-E7BC54CE532EED67AA4A359C154F9A20" unitRef="number">0.3880</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2014Q4YTD" decimals="4" id="Fact-4DC0C1A2C6969B1F34EA3594D8E57D90" unitRef="number">0.3380</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="4" id="Fact-C7C53E0CDAAB8290FF143594D8E76011" unitRef="number">0.3581</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="FD2013Q4YTD" decimals="4" id="Fact-833EA8C1F7FEB99D7444359C14A865EE" unitRef="number">0.0320</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="FD2014Q4YTD" decimals="4" id="Fact-9A92DD984B541D361148359466F3E076" unitRef="number">0.0080</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="FD2015Q4YTD" decimals="4" id="Fact-1FA34EA6DB3D071A74FF359466FA8E13" unitRef="number">0.0267</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2013Q4YTD" decimals="4" id="Fact-40CDA5DF1E4D91ABA961359C11CD59CE" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q4YTD" decimals="4" id="Fact-06AD7E4F3979794C4A3AEFC218FA37DD" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q4YTD" decimals="4" id="Fact-BD25E52A931D995992FBEFC218F0B3A3" unitRef="number">0.0042</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2013Q4YTD" decimals="4" id="Fact-E6A542EEB6DF4C6A7117359C1402FF77" unitRef="number">0.0100</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2014Q4YTD" decimals="4" id="Fact-241EAA4A1200F18E20D6EFC218F09BAA" unitRef="number">0.0050</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2015Q4YTD" decimals="4" id="Fact-571E3013E16A996AE9A7EFC218F05844" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2013Q4YTD" decimals="4" id="Fact-D77CBF03E510B93C3B0A359C12C5A1FA" unitRef="number">0.0120</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2014Q4YTD" decimals="4" id="Fact-4B239931284CB2DA3069EFC218FAFFF3" unitRef="number">0.0370</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2015Q4YTD" decimals="4" id="Fact-2E0223AAF788F60E90EFEFC218F0125F" unitRef="number">0.0286</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2013Q4YTD" decimals="4" id="Fact-EE312E47C46AFD423450359C10281CE5" unitRef="number">-0.0380</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q4YTD" decimals="4" id="Fact-FAD38E0D92FB5EE34026EFC218F079FA" unitRef="number">-0.0320</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="4" id="Fact-1C7397E6D3A6F23C1BC8EFC218FA5623" unitRef="number">-0.0293</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="FD2013Q4YTD" decimals="4" id="Fact-66CAE5B0BCA75078AC00359C124CD22F" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="FD2014Q4YTD" decimals="4" id="Fact-F5E0439FED2F206D6EC2EFC218F034AC" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="FD2015Q4YTD" decimals="4" id="Fact-A68E0EECF2E838430B26EFC218F04143" unitRef="number">0.0040</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3A58F59BB2854E81CDCE333E6B8F08E9" unitRef="usd">3828000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-ED5F1188B7277C7AD89535C437D8381A" unitRef="usd">1655000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-8D3505D7EDEF52D1B36D35C43B5875A2" unitRef="usd">2173000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C0F8D76A991731955E33333E6B881364" unitRef="usd">9624000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F09DD3C175094AA1FEFC35C436DC49EC" unitRef="usd">4334000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-AB110EFC25A1CC5F423735C43A414B8B" unitRef="usd">5290000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-64C5A8E3D06087B238B7333E6B7B35C7" unitRef="usd">8388000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-B7425DC0F04960B1A28435C43604B8F3" unitRef="usd">2479000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-DF85B13C0442C8299C8035C4394BECE9" unitRef="usd">5909000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2015Q4" decimals="-5" id="Fact-F65067A0CA8FBCB2BCDE3608F4AE4201" unitRef="usd">11400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:FairValueInputsPriceEarningsRatioMultiple contextRef="FD2013Q4YTD" decimals="2" id="Fact-3450CF1D9E0CC9C243FA333E7B48F747" unitRef="usdPerShare">6.05</us-gaap:FairValueInputsPriceEarningsRatioMultiple>
	<us-gaap:FairValueInputsPriceEarningsRatioMultiple contextRef="FD2014Q4YTD" decimals="2" id="Fact-043AC9C3C9D134E54F2C333E7B632557" unitRef="usdPerShare">12.63</us-gaap:FairValueInputsPriceEarningsRatioMultiple>
	<us-gaap:FairValueInputsPriceEarningsRatioMultiple contextRef="FD2015Q4YTD" decimals="2" id="Fact-BAC3C3CF42D8C6231ED5333E7B4DA95E" unitRef="usdPerShare">16.69</us-gaap:FairValueInputsPriceEarningsRatioMultiple>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B82A3F515F316D85ED9FEFC2190488E3" unitRef="usd">13115000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2014Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember" decimals="-3" id="Fact-CDA33173F9F0602A6D0FEFC2193629BA" unitRef="usd">13115000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2014Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember" decimals="-3" id="Fact-6D779269F6B27DA2DF1AEFC219049434" unitRef="usd">10000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2014Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember" decimals="-3" id="Fact-8678E0EBBF2518A19211EFC219224E99" unitRef="usd">-3000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2014Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember" decimals="-3" id="Fact-53DD507844BD194D9EDEEFC218C8BCAB" unitRef="usd">13108000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2014Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember" decimals="-3" id="Fact-4DFEFEC2C61A10A15532EFC219E00551" unitRef="usd">13108000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BE4B267FBEABFF1D56BBEFC219CC8C21" unitRef="usd">11839000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2015Q4_us-gaap_FairValueByMeasurementBasisAxis_axdx_FairValueMember" decimals="-3" id="Fact-8E5B6297843D52F0A723EFC219364959" unitRef="usd">11839000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2015Q4_us-gaap_GainContingenciesByNatureAxis_axdx_UnrealizedGainsMember" decimals="-3" id="Fact-8288BB3E2066FB7D285EEFC2199AA492" unitRef="usd">1000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2015Q4_us-gaap_GainLossOnInvestmentsByCategoryAxis_axdx_UnrealizedLossesMember" decimals="-3" id="Fact-494976F4BFBC969E78E9EFC21936A2E9" unitRef="usd">-13000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2015Q4_us-gaap_NatureOfExpenseAxis_axdx_CostMember" decimals="-3" id="Fact-7F56E31EF7E03B59A653EFC219362E11" unitRef="usd">11851000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="FI2015Q4_us-gaap_NatureOfExpenseAxis_us-gaap_AvailableforsaleSecuritiesMember" decimals="-3" id="Fact-8C6341713B71F25B835AEFC219CCC9FC" unitRef="usd">11851000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4" decimals="-3" id="Fact-3A7BE5A4B70B2CB43A6CEFC21936AB50" unitRef="usd">167000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4" decimals="-3" id="Fact-0A8DE350168F4F65BF73EFC2192C80F0" unitRef="usd">157000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FixturesAndEquipmentGross contextRef="FI2014Q4" decimals="-3" id="Fact-B63D01FB83748F1DF5FDEFC21A08F5B9" unitRef="usd">1625000</us-gaap:FixturesAndEquipmentGross>
	<us-gaap:FixturesAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-F19B395A70D59D0D4B03EFC219FEB5C4" unitRef="usd">1806000</us-gaap:FixturesAndEquipmentGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2014Q4" decimals="-3" id="Fact-A206CA67D905CD3F657EEFC219F4410F" unitRef="usd">842000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2015Q4" decimals="-3" id="Fact-1A66544C071415FCE337EFC21A0807A1" unitRef="usd">1772000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0F3257DECFBF342B3579EFC21896E650" unitRef="usd">4312000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-644DA80FF23BEDB9954DEFC2190EC197" unitRef="usd">10695000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A4F90382FACD0E21E874EFC2190E7F64" unitRef="usd">17882000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2013Q4YTD" decimals="-3" id="Fact-BB1DB17BCFF63BDE0DBA34AD3AAAF503" unitRef="usd">-15282000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2014Q4YTD" decimals="-3" id="Fact-ED0D795371AB520D71FA34AD29BD8785" unitRef="usd">-30933000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7BCA9E374FF13932C3934AB019D6DFD" unitRef="usd">-44415000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2013Q4YTD" decimals="-3" id="Fact-EF5FF756115A80C5778C34AD3B53FC59" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3B33F3D5837283A6167834AD2A628C45" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2015Q4YTD" decimals="-3" id="Fact-56BA9E3A3686004EC8C534ABC5AD353B" unitRef="usd">-1083000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F4D9CC3FCC1A1B43CC4234AD3BFD373E" unitRef="usd">-15282000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4ACC3EE5060971D11D4534AD2B0EFAC1" unitRef="usd">-30933000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1C12EB07CD4E11AF514034ACE68BEEDE" unitRef="usd">-45498000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q1QTD" decimals="2" id="Fact-007B750613A9F0E3A85DEFC219AEBD75" unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q2QTD" decimals="2" id="Fact-25A9E46A805E3FE27766EFC219A4A9B4" unitRef="usdPerShare">-0.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q3QTD" decimals="2" id="Fact-A992BBEF72CB74BBC920EFC218D2B670" unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q4QTD" decimals="2" id="Fact-5C5FA62B36A0A2F23C5BEFC218DC40BB" unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q1QTD" decimals="2" id="Fact-99081E38F25A52EBDA25EFC218AA7F18" unitRef="usdPerShare">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q2QTD" decimals="2" id="Fact-153C71906C26411FFB65EFC218C8FE54" unitRef="usdPerShare">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q3QTD" decimals="2" id="Fact-46C1277E7C336EFF0A87EFC219B84E8B" unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q4QTD" decimals="2" id="Fact-4FB93FCE8DAA127C3B3EEFC2199A9242" unitRef="usdPerShare">-0.29</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2013Q4YTD" decimals="-3" id="Fact-CB9E187F2B57FC0B1B52EFC219D6675D" unitRef="usd">205000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-24BA2BDDCF321D9DD430EFC2199AEDE0" unitRef="usd">1336000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2DEF7893A2472E1D86BFEFC218AAD530" unitRef="usd">329000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2013Q4YTD" decimals="-3" id="Fact-241B4F20B49C28A7C665EFC219D6B136" unitRef="usd">-739000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D9F22C3BA31575CA256CEFC219B8F7DE" unitRef="usd">54000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5DD7F193EBF4EC7116F8EFC2199A2CD7" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-819927DC01362917DE0FEFC219362F16" unitRef="usd">-356000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F971CE1CA8B32A5189BDEFC219CCBF1C" unitRef="usd">80000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C247A51777473DA527DEEFC219B85C72" unitRef="usd">827000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-CE65E0ECF6E135B3E0A8EFC21A26E32C" unitRef="usd">781000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-081B86245CF991D7CFB2EFC219D67B03" unitRef="usd">168000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B86CB1E385DFBE4CCFB2EFC21A12B9B5" unitRef="usd">100000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-5CFAF8355A4B761D10641FE78442CA6A" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-59C1A10D33D7DB93A5D41FE7844ADDF8" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BEB754EF1AA6617267DC1FE78438BBED" unitRef="usd">12000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-D9CC2C08A2E1C5BFF5F0EFC21A12F82F" unitRef="usd">114000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CBE198924ECCB8D6C947EFC219362E12" unitRef="usd">166000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3A102812FA9404022B47EFC21A269973" unitRef="usd">1241000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IndefiniteLivedContractualRights contextRef="I2013Q3Aug08" decimals="-3" id="Fact-86CDDFFAE05412411B1AEFC21A1C3B0E" unitRef="usd">88000</us-gaap:IndefiniteLivedContractualRights>
	<us-gaap:IndefiniteLivedContractualRights contextRef="I2014Q2May19" decimals="-3" id="Fact-4B8CC9A74D2A08BE67EDEFC21A1CBCD3" unitRef="usd">125000</us-gaap:IndefiniteLivedContractualRights>
	<us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3940CF063218B4F524663A9453F76ED4" unitRef="usd">0</us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease>
	<us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1F5EFE60B80E670E766934655A7F8CCC" unitRef="usd">7000</us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease>
	<us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1CBB48B2E5694DC6254734651FE68490" unitRef="usd">4000</us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease>
	<us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="FD2013Q4YTD" decimals="-3" id="Fact-2EC5B1386F67A894F6DCEFC219A4A05C" unitRef="usd">-76000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
	<us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9CAE33A52934672CEEAEEFC219D6182D" unitRef="usd">-269000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
	<us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B3FC4E825F1F9B043495EFC218C8B078" unitRef="usd">-188000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
	<us-gaap:InvestmentIncomeInterestAndDividend contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6BA7046D010DA0D7A6FFEFC21A26178C" unitRef="usd">29000</us-gaap:InvestmentIncomeInterestAndDividend>
	<us-gaap:InvestmentIncomeInterestAndDividend contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F40280FF9B836B0EDA93EFC2191835D2" unitRef="usd">64000</us-gaap:InvestmentIncomeInterestAndDividend>
	<us-gaap:InvestmentIncomeInterestAndDividend contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5F85AE30B9381D5C1F10EFC21A264BC0" unitRef="usd">74000</us-gaap:InvestmentIncomeInterestAndDividend>
	<us-gaap:Investments contextRef="FI2014Q4" decimals="-3" id="Fact-08CD1C526064A58337CDEFC219180BB0" unitRef="usd">13115000</us-gaap:Investments>
	<us-gaap:Investments contextRef="FI2015Q4" decimals="-3" id="Fact-C19450F729541BE561E6EFC219403797" unitRef="usd">11839000</us-gaap:Investments>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2013Q4YTD" decimals="-3" id="Fact-E572D5BE534056E1A378EFC2199A5F00" unitRef="usd">19912000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2014Q4YTD" decimals="-3" id="Fact-711F45BD293DCB574080EFC219A45D68" unitRef="usd">44875000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CCF3BF768DCDF2D5399AEFC21A1C0B0F" unitRef="usd">104165000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-E14DD621BD50890A5CC5346C378E1C8E" unitRef="usd">168000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2A4AA6CAB0C24A9A8508346C2933ADD1" unitRef="usd">293000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FF607CF8694970BC40B3346BFCD69DE4" unitRef="usd">685000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-3" id="Fact-6EA49A1DA76F6E236461EFC219181AF9" unitRef="usd">3810000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-A7E0D286298567942D14EFC21922E99E" unitRef="usd">6306000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-F507DD6D194996009A3CEFC2194018AB" unitRef="usd">69801000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-84A8696ED42C613739A5EFC21918282E" unitRef="usd">139324000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-8532B110D1A7FFD823A3EFC2192287CB" unitRef="usd">2783000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-7CB710B80382494E67EFEFC219360352" unitRef="usd">5306000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-0415415D755EED9CAD2EEFC219401189" unitRef="usd">1014000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
	<us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-A50D0C40D9174FBFBC33EFC21936428B" unitRef="usd">1000000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C2CE37D92230C3E5A03DEFC2192C15CE" unitRef="usd">48000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5A0F927A0649080D19B3EFC218A07F4C" unitRef="usd">122000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A6F9C34210F7AC0217C7EFC218E6E61A" unitRef="usd">71000</us-gaap:LicensesRevenue>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2014Q4" decimals="-3" id="Fact-4FBEF4FB3E990E2832D6EFC219402FEB" unitRef="usd">13000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2015Q4" decimals="-3" id="Fact-DDB262991BB28CC077BBEFC219409C0D" unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2014Q4" decimals="-3" id="Fact-3CF122B69EC4A1BC12A5EFC21A08E60C" unitRef="usd">1020000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-CBC4DDEE52773B4D5752EFC21A1C1B23" unitRef="usd">1877000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3DD821DF42FC06A04DF1EFC21A12D241" unitRef="usd">40881000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-37010492C6EBF4503BF2EFC21A1217BF" unitRef="usd">45691000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2F60E0E7CC556796830AEFC219185AE0" unitRef="usd">104823000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1F829F3EB86DB089FA95EFC219E08DCD" unitRef="usd">-13172000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9D4983BC35E4C737526EEFC21A264730" unitRef="usd">-3372000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CB4E42DAE6431E376708EFC21A1202FE" unitRef="usd">-2675000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0A81DACBFF18A1319FD0EFC219049922" unitRef="usd">-9749000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7C443592F27D9E107130EFC2194AC64D" unitRef="usd">-18785000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CDF729E37B900FEC066AEFC219CCA8AD" unitRef="usd">-35126000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F5317B6C93F3C6674244EFC21A26543F" unitRef="usd">-15282000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-5088F667215F083978B3EFC219EA27E9" unitRef="usd">-15282000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q1QTD" decimals="-3" id="Fact-E3970F1497FFD83866DDEFC219CCB28B" unitRef="usd">-5202000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-F79E05DAFD2299F92049EFC218DC640D" unitRef="usd">-8152000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-4E38DB87BEB85F75570AEFC219EA5A3C" unitRef="usd">-8814000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4QTD" decimals="-3" id="Fact-A1B0A21290CEF14249ACEFC218DC3851" unitRef="usd">-8765000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7D468567072D93B36796EFC219047C29" unitRef="usd">-30933000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BC8A643049E875304A37EFC219EA724D" unitRef="usd">-30933000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD" decimals="-3" id="Fact-8DB30FA8909AF3594BFFEFC219AEE5CA" unitRef="usd">-8897000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-CA61BF946E01A9AF52DEEFC218D2920A" unitRef="usd">-12252000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-6DA6C357725A1AED93BAEFC218DC386F" unitRef="usd">-11186000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4QTD" decimals="-3" id="Fact-CB2E9AC20E956191B7B0EFC219C2EF9B" unitRef="usd">-13163000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F4AE883B962884EFC208EFC2190E9283" unitRef="usd">-45498000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-6014753DF2AD027306F6EFC219F4F839" unitRef="usd">-45498000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2015Q4YTD" decimals="INF" id="Fact-9BA9680D1315AC090E2E3A9EE5425110" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-B9A14FE90D0032C15C57EFC218E68B5E" unitRef="usd">-15311000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BAD3B984993DC6550E75EFC21A3064A4" unitRef="usd">-30990000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C955295FBD7C53195F5CEFC2190EFF49" unitRef="usd">-45549000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-DFE2D81FC70475CFE198345E7D82D5B2" unitRef="usd">954000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2015Q4" decimals="-3" id="Fact-55C5D6DB85A520B8E2E5345E7D8C740B" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2015Q4" decimals="-3" id="Fact-20960E2FCA063A3995A5345E7D6FB8D1" unitRef="usd">4000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2015Q4" decimals="-3" id="Fact-E6AEA26E2BA379E5C5EB345E7D8A5FC8" unitRef="usd">171000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2015Q4" decimals="-3" id="Fact-D0307A3B87421304E476345E7D93E1EC" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-1E7DDA2178B25B5F530E3B69C2FE459F" unitRef="usd">80800000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_TaxAuthoritySpainMember" decimals="-3" id="Fact-25E8E7590B218085D5773B7471F28FC7" unitRef="usd">403000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_IncomeTaxAuthorityNameAxis_axdx_ArizonaDepartmentofRevenueMember" decimals="-5" id="Fact-2D3B69FE54B7EE8C6D833B746074566D" unitRef="usd">69600000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OptionIndexedToIssuersEquityIndexedShares contextRef="I2012Q2Apr30" decimals="INF" id="Fact-AC880E71AB240965F5C0EFC218C828CD" unitRef="shares">7000000</us-gaap:OptionIndexedToIssuersEquityIndexedShares>
	<us-gaap:OtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-150A3DD741A0B999A7CA2FC9CDBE0CD4" unitRef="usd">0</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-7EAE68F330F56AB9EF5C2FC9A0CF4460" unitRef="usd">12000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-178D410D1E335A8C7E2B302D3388553A" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-323185CE379A70D0B266302D3376CDD0" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-94B056C5E0A82EC2D5A8302D0A031DFC" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-26C71E8A2275E6CCFC1E335806D36A5C" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherCostAndExpenseOperating contextRef="FD2013Q4YTD" decimals="-3" id="Fact-230C3152E4FD65C77643EFC219044E40" unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
	<us-gaap:OtherCostAndExpenseOperating contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2998624E56F33EE55CEBEFC218AAE567" unitRef="usd">7000</us-gaap:OtherCostAndExpenseOperating>
	<us-gaap:OtherCostAndExpenseOperating contextRef="FD2015Q4YTD" decimals="-3" id="Fact-759DB38B49187A746FADEFC2190E4150" unitRef="usd">23000</us-gaap:OtherCostAndExpenseOperating>
	<us-gaap:OtherExpenses contextRef="FD2013Q4YTD" decimals="-3" id="Fact-63D9985FCFF3696651CFEFC2193622AD" unitRef="usd">11000</us-gaap:OtherExpenses>
	<us-gaap:OtherExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2F66560E93EB8A04E2EEEFC219047152" unitRef="usd">3000</us-gaap:OtherExpenses>
	<us-gaap:OtherExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3462DC71F766792DE082EFC219186A69" unitRef="usd">0</us-gaap:OtherExpenses>
	<us-gaap:OtherNonoperatingIncome contextRef="FD2013Q4YTD" decimals="-3" id="Fact-70622E981BA4F678AD93EFC218DC1BD0" unitRef="usd">29000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherNonoperatingIncome contextRef="FD2014Q4YTD" decimals="-3" id="Fact-FD3F316B68C63DF6F53BEFC218C82EA9" unitRef="usd">57000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherNonoperatingIncome contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FCD1AFCC64F9C9036877EFC219047353" unitRef="usd">51000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-3" id="Fact-FCA1DD4B8A52A813A132333E6B8D5472" unitRef="usd">0</us-gaap:OtherTaxExpenseBenefit>
	<us-gaap:OtherTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E514DB168A6D0539DDC5333E6B869D86" unitRef="usd">0</us-gaap:OtherTaxExpenseBenefit>
	<us-gaap:OtherTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1439C86F861F7FF2D7D0333E6B8A61BE" unitRef="usd">0</us-gaap:OtherTaxExpenseBenefit>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2015Q4Dec9" decimals="-5" id="Fact-2B939CFC0F85A8B02D5A350F96B038BA" unitRef="usd">5900000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-5E13F6AF26A9035BFDEBEFC21A1C2848" unitRef="usd">12014000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-84DCB394B453FA1067C6EFC218F05754" unitRef="usd">7657000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4D81BE1DCB13DE40B532EFC219048A50" unitRef="usd">12418000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-79287DB4CD6CF6AE29A8EFC2192CA417" unitRef="usd">1158000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DD1610D4DCC7F91DA282EFC219C2E32E" unitRef="usd">1933000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EE8CB164743CE217FC4EEFC2194AC317" unitRef="usd">3656000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToSuppliersAndEmployees contextRef="FD2013Q4YTD" decimals="-3" id="Fact-FA1B4285FD313ABF504C3A98DFC86AB8" unitRef="usd">96000</us-gaap:PaymentsToSuppliersAndEmployees>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-6CEFA59A81EF123B7AC0EFC2192CC1E2" unitRef="usdPerShare">0</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-C17EF3686B70B34CBEF1EFC219F451D5" unitRef="usdPerShare">0</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2014Q4" decimals="INF" id="Fact-EDEE0685701D82511972EFC219F4A3D9" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-3C3EDA0942A2766394B6EFC219400E42" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2014Q4" decimals="INF" id="Fact-9E9CDC5B5D6932553DBCEFC21A1C4A0C" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-BA2142C2E6774EFEB160EFC219F4F6E1" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2014Q4" decimals="INF" id="Fact-E8951821E37C0DA288D5EFC21A080EC0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-D8146F56A028090727E4EFC219FE6693" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-77FD9DAAA9FCD116D1D8EFC219228CB1" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-35831ABB77FE1FE5E27EEFC219401308" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-B5EA091ADB49194FCF6FEFC219189AB8" unitRef="usd">342000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2CDA305D2887F1C9D7ADEFC219409836" unitRef="usd">1638000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B7A34FD04A26231F072EEFC2199AEC74" unitRef="usd">0</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2015Q4Dec9" decimals="-5" id="Fact-2FC6A643376F8F182DE4351022B99198" unitRef="usd">103400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1796D1802D93E0CEA917EFC2199AE094" unitRef="usd">805000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-584667F3222E187DA5C4EFC219F40977" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3EDC3BAA091FBC9FE1CDEFC219EACC6C" unitRef="usd">861000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ABF0F2FA49AAFB470AC0EFC21A082825" unitRef="usd">141000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F3A582DC927E1ADB5094EFC219EA28B3" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C7C68DB5FC2227FC68AFEFC21A127377" unitRef="usd">5357000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C9FBEA40A974675BAE50EFC219C25C91" unitRef="usd">13258000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2013Q4YTD" decimals="-3" id="Fact-E0DFCA9DEF2A5C131EC4EFC21A1C8C0E" unitRef="usd">20969000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0D527FD8DE1EFE9FF854EFC2188CA187" unitRef="usd">923000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-63C9E7C5C4B30124FF78EFC219FE0CAC" unitRef="usd">805000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromWarrantExercises contextRef="D2013Q4Mar" decimals="-5" id="Fact-FCFB3789BF91613C1AA9345446EE60C9" unitRef="usd">20100000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProfitLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-FC9AA778B93DCCEEEE49EFC218D26E4E" unitRef="usd">-15282000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A5B2DD9AF0462EDD23BEEFC218FA40A1" unitRef="usd">-30933000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D80A60C9B70BE8BC006FEFC218B4C5D8" unitRef="usd">-45498000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4" decimals="-3" id="Fact-41FB3D2BEFA6C9EBA01FEFC219F4D195" unitRef="usd">3980000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-B574E87752AE4F20B367EFC219F4AB60" unitRef="usd">7904000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-3" id="Fact-11CC15DFE1F2CF34818BEFC21940B3B9" unitRef="usd">2536000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-DFD5E83DA73DB34206A1EFC2192C8451" unitRef="usd">5016000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentOther contextRef="FI2014Q4" decimals="-3" id="Fact-4A380D63B35E28AA2579EFC21A080A3A" unitRef="usd">227000</us-gaap:PropertyPlantAndEquipmentOther>
	<us-gaap:PropertyPlantAndEquipmentOther contextRef="FI2015Q4" decimals="-3" id="Fact-4C9BA50FF5D62F494BB1EFC219FEED94" unitRef="usd">2183000</us-gaap:PropertyPlantAndEquipmentOther>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-873B941C143DBC7A63A4EFC2199058D9" unitRef="usd">78000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-FECC6A0F740E830039B3EFC2192CCB63" unitRef="usd">77000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:RefundsDueUnderGovernmentContracts contextRef="I2016Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-FB7ECC79D3AF961013E23457225CA657" unitRef="usd">1200000</us-gaap:RefundsDueUnderGovernmentContracts>
	<us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9A6D98642C6D387DDD00EFC2199A6C5C" unitRef="usd">0</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
	<us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F008CCC8E908C9C9F429EFC21A08BDE2" unitRef="usd">107000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
	<us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E1A952049402402C5E9FEFC219A4504B" unitRef="usd">147000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="D2012Q2May01toMay31_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember" decimals="-5" id="Fact-09D22466C1D58BE08D913A357E53BFDB" unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="D2015Q1Feb1-28" decimals="-5" id="Fact-13BC61A4C1CFAB1258D333E954299B79" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="D2015Q4Feb15-Dec31" decimals="-3" id="Fact-417CE03459AAF8935DFC33EB4D7E00A8" unitRef="usd">689000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A7CD7CF9E2B72258EDF333F0BAC3D64C" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2014Q4YTD" decimals="-3" id="Fact-143F416702D96A537F8133F0ACAF5B67" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2015Q4YTD" decimals="-3" id="Fact-81372DBEFB2DE013A22733F09F7688E2" unitRef="usd">483000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-D680A8CC0D4EFD7375F8EFC218E67306" unitRef="usd">10673000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-461D06D280624CF73F46EFC21904CB85" unitRef="usd">19526000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-86AD85BF4CB744089530EFC219046301" unitRef="usd">26022000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="D2015Q3Mar_2012-Sep_2015_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember" decimals="-3" id="Fact-FCA0FCBAA13C6043F16233FCB706DEAB" unitRef="usd">558000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2013Q4YTD" decimals="0" id="Fact-720B2BCEF456B4137D055C1C5A755B5A" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2013Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember" decimals="-3" id="Fact-A99A93C096894E27C9D233FC2A914145" unitRef="usd">143000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2014Q4YTD" decimals="0" id="Fact-24BF873BD859D283B03B5C1BD400C69A" unitRef="usd">527000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2014Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember" decimals="-3" id="Fact-8761AC52E88E9F66357733FC114636EC" unitRef="usd">221000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q4YTD" decimals="0" id="Fact-AD57CE11D8D0EEEF8A1B5C1C1B04831F" unitRef="usd">647000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_axdx_DefenseMedicalResearchandDevelopmentProgramMember" decimals="-3" id="Fact-D652E809931E98FEEF6933FC044E0204" unitRef="usd">179000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q4" decimals="-3" id="Fact-3A2EA5F03264949CF49DEFC2192CF583" unitRef="usd">-65417000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-16A8168A24568FE1F342EFC21918D421" unitRef="usd">-110915000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SalesRevenueGoodsGross contextRef="FD2013Q4YTD" decimals="-3" id="Fact-618126DE641E0C97BC3330185281B880" unitRef="usd">0</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueGoodsGross contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D65074438D1EA865341630185285379D" unitRef="usd">0</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueGoodsGross contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BD3867692052E3C6C5ED301852835A82" unitRef="usd">76000</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueNet contextRef="FD2013Q4YTD" decimals="-3" id="Fact-BD4BF83851358B62B52FEFC218966F09" unitRef="usd">48000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q1QTD" decimals="-3" id="Fact-850B9110E0322C23271AEFC219CC61E8" unitRef="usd">14000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD" decimals="-3" id="Fact-534AEA5E6767863387F5EFC218DC2A6E" unitRef="usd">13000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q3QTD" decimals="-3" id="Fact-629709519D295D1F61A0EFC218C849A4" unitRef="usd">16000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q4QTD" decimals="-3" id="Fact-AF3507BA37FDF9F48B1DEFC218DCE826" unitRef="usd">79000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D40313749E60A903D61BEFC218E682C4" unitRef="usd">122000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q1QTD" decimals="-3" id="Fact-32320BF19A301355C610EFC218D27954" unitRef="usd">14000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q2QTD" decimals="-3" id="Fact-A9FE7AB4AE0D66F9D410EFC218F07A71" unitRef="usd">19000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q3QTD" decimals="-3" id="Fact-70A2A07D2C6F3B792852EFC219AED05B" unitRef="usd">92000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q4QTD" decimals="-3" id="Fact-06BC433C53979C0275C7EFC219D67190" unitRef="usd">22000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A9B4AA0607DBCD9B70EDEFC218F062C2" unitRef="usd">147000</us-gaap:SalesRevenueNet>
	<us-gaap:ShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-3" id="Fact-694DBF80704470315AD6EFC219F4A224" unitRef="usd">3828000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D219560DFDAD4C8887A5EFC219F42719" unitRef="usd">3828000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5EF44B04E6FC31034050EFC218DC8203" unitRef="usd">9624000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9D331B1E7087A2E88629EFC2199AAC94" unitRef="usd">9624000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-89C3A441551DFE47FE93EFC218A0C206" unitRef="usd">8388000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1740C041DB1FA86AE4CFEFC218FA3F34" unitRef="usd">8388000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_axdx_SharebasedCompensationAwardTrancheFourMember" id="Fact-E612A3328636C84368B0362112B80C0D">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact-7C7191596F7E162933AB362112B59913">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact-C2786AE6365A8872CB8F362112BD8F3F">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact-FEF2C6E4BA858C84B0AE362112C25238">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-0B559AEC9A085C5CD08D360C11483D91" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-C7381D8A8AA9ACDF1D98360BF4769650" unitRef="shares">40250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2014Q4" decimals="2" id="Fact-09D329377CC2DE73DD51360C6C0D26C4" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4" decimals="2" id="Fact-74115B68466C819E50A5360C6BF4CB14" unitRef="usdPerShare">20.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-84D80ED4CB408FB193A2360C3395A0D8" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-E18343EEA60C733F4A4B360CE9E5689E" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="FD2013Q4YTD" decimals="INF" id="Fact-F51F0BBB268C71DCC2AB333E7B4A965E" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="FD2015Q4YTD" decimals="INF" id="Fact-B2F6CC2971BD7662D7BB333E7B3961D2" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2013Q4YTD" decimals="2" id="Fact-F0C0BDC9342469EC5BF2333E7B5FADBB" unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2014Q4YTD" decimals="2" id="Fact-F466476E659896288335333E7B5AA24B" unitRef="number">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2015Q4YTD" decimals="2" id="Fact-2CBC9C97D135FCF3FB02333E7B565ECA" unitRef="number">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2013Q4YTD" decimals="3" id="Fact-21423C887B0C80A4BFC4333E7B53F4C3" unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD" decimals="3" id="Fact-514CEA20BC26C059BBD8333E7B43889B" unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD" decimals="3" id="Fact-8A2379A426BF3E50DDED333E7B29E3FA" unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="I2013Q3Aug08" decimals="-5" id="Fact-96083BB39F74E797E7D3EFC21A1CB140" unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="I2014Q2May19" decimals="-5" id="Fact-9A7E211904530D67DCBBEFC21A1C7515" unitRef="shares">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="I2014Q2May19_us-gaap_CounterpartyNameAxis_axdx_OracleInstitutionalPartnersL.P.Member" decimals="INF" id="Fact-3D5D9B90074612EB261F34FDBC69D3F7" unitRef="shares">119047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="I2014Q2May19_us-gaap_CounterpartyNameAxis_axdx_OraclePartnersL.P.Member" decimals="INF" id="Fact-5F8C254058726B9A838034FDCA251619" unitRef="shares">178572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="I2014Q2May19_us-gaap_CounterpartyNameAxis_axdx_StandbyPurchasersMember" decimals="INF" id="Fact-5493EFE8A704E6EA21CD34FDDEEC248B" unitRef="shares">297619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2012Q3Aug01toJul31" decimals="INF" id="Fact-24017B8D0302EF73EE8135F8A70C1F99" unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2014Q2May" decimals="INF" id="Fact-B85390AF62985E96A4A535EB0EEF52AF" unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-E2C862185254A23A4EAFEFC219A4E069" unitRef="shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2004Q4" decimals="INF" id="Fact-4D7F84EDD886C29F997B35F82E4C17FB" unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2012Q4" decimals="INF" id="Fact-B7190C11EF3227B8DD6B35EA7F945FE4" unitRef="shares">1677500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2014Q2May" decimals="INF" id="Fact-5C00E9E4EB184E986B94EFC219A4D714" unitRef="shares">5677500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q4" decimals="INF" id="Fact-E7291DE708D839AE86D3360251727B6B" unitRef="shares">1536520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-97C8BCB42864626F7F1E3602A5C1562B" unitRef="usdPerShare">7.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2014Q4YTD" decimals="INF" id="Fact-C71D2817F1E0389668B5EFC218AA635A" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-A2F04F72BBFCF927C14CEFC218B4B0D0" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2014Q4YTD" decimals="INF" id="Fact-4D816B42FE2332B489B1EFC218B43E2C" unitRef="shares">13678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-742DFD63B8FACCC61A1EEFC218AABCD5" unitRef="shares">54505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2014Q4YTD" decimals="INF" id="Fact-12645DA9BC32E90AF016EFC219184D9B" unitRef="shares">769055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD" decimals="INF" id="Fact-C1848E4191CA48E3AD08EFC21A269797" unitRef="shares">717833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2013Q4" decimals="INF" id="Fact-341ACE85B1F83FC1BA46EFC218963BE7" unitRef="shares">5185086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4" decimals="INF" id="Fact-C85C747AC4C4D7600FBBEFC21A12F83C" unitRef="shares">5628726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-D42FC4E3BD554EA42DD5EFC21A267FA3" unitRef="shares">6167170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4" decimals="2" id="Fact-26003EF3B3BEA993EB57EFC21A26FE20" unitRef="usdPerShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4" decimals="2" id="Fact-92A39DC0257BFB6141B7EFC218A010FB" unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-C4CFD820CF9D79C25D94EFC2188C337A" unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-F840D03FF15E1A04FAC135F4492CBCFE" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD" decimals="2" id="Fact-D837F6D80BB9C649FC4EEFC218A01FC3" unitRef="usdPerShare">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-AFFC47C39DC05A8BDA3BEFC218A0C398" unitRef="usdPerShare">6.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD" decimals="2" id="Fact-57AEA726EC5577C2BF80EFC2188C4018" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-C1E4F8ACDB78320A1BA2EFC21A1C92F1" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD" decimals="2" id="Fact-B888907BB02ED8358C1CEFC219A4E41F" unitRef="usdPerShare">13.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-89589AA73CFA87363322EFC218C8350A" unitRef="usdPerShare">11.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD" decimals="2" id="Fact-F9B59B732F67AEAD29EEEFC218A0C522" unitRef="usdPerShare">16.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-8E953ADD098E6A199BC0EFC21936CB3C" unitRef="usdPerShare">20.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsExercisableMember" decimals="INF" id="Fact-9BA0B293017B592CD777333E8FAF607D" unitRef="shares">1536520</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsOutstandingMember" decimals="INF" id="Fact-A92F1BB43E3D145404BC333E8FC419E4" unitRef="shares">6167170</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsVestedAndExpectedToVestMember" decimals="INF" id="Fact-779838699DEA92DF1518333E8FCAC1D1" unitRef="shares">6088562</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:SharePrice contextRef="FI2015Q4" decimals="2" id="Fact-1F7104C7FD3963E4194536057A147305" unitRef="usdPerShare">21.49</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2014Q2Apr28" decimals="2" id="Fact-C16E57883C693564F24B34F1DDCCCF86" unitRef="usdPerShare">17.54</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2014Q2Apr7" decimals="2" id="Fact-05FCAC1E1DFCFD6B771234F195D8E14A" unitRef="usdPerShare">17.64</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q4Dec9" decimals="2" id="Fact-211968367B6CE8D22C0A35088732B012" unitRef="usdPerShare">17.00</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_axdx_SharebasedCompensationAwardTrancheFourMember" decimals="INF" id="Fact-BD79DF287BBEC236FBB53622361E57D6" unitRef="number">0.6</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" decimals="INF" id="Fact-CB3CABFEC2C75BE337603621C9F51357" unitRef="number">0.4</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_NonQualifiedStockOptionPlanMember" id="Fact-5171119DBB16168F657A3A8A9BD4AA40">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axdx_OmnibusEquityIncentivePlan2012Member" id="Fact-5BFAD6E91611A6F3F87436215660482F">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsExercisableMember" decimals="-3" id="Fact-E70EE03B60668CA94D21333E8FC99B9B" unitRef="usd">21734000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsOutstandingMember" decimals="-3" id="Fact-6D138101E7A49838108A333E8FC6768B" unitRef="usd">86102000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsVestedAndExpectedToVestMember" decimals="-3" id="Fact-49D1F4FD794B9D6D29CB333E8FC30AD5" unitRef="usd">85804000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="I2012Q2Apr30" decimals="-5" id="Fact-F49A764CA4DE5FA20701EFC218C8B721" unitRef="usd">5900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsExercisableMember" decimals="2" id="Fact-DD254018815B89B70EF6333E8FB12DE5" unitRef="usdPerShare">5.48</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsOutstandingMember" decimals="2" id="Fact-C671B8941A118ACA1B4F333E8FBFF254" unitRef="usdPerShare">5.43</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsVestedAndExpectedToVestMember" decimals="2" id="Fact-7CDFE9B8A410CC32C58B333E8FC7365F" unitRef="usdPerShare">5.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2013Q4YTD" decimals="-5" id="Fact-05E62EE9679FF4CCFF10EFC219A44122" unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B1D06C14C9F9D61E0678EFC2199A4D6A" unitRef="usd">3800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2015Q4YTD" decimals="-5" id="Fact-504B14C763EA49EB2F06EFC2199AC229" unitRef="usd">7300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsExercisableMember" decimals="2" id="Fact-BDE764DC7F447AC6B091333E8FC1B66F" unitRef="usdPerShare">7.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsOutstandingMember" decimals="2" id="Fact-1CAF6DBB8447D42E6EFC333E8FA36EDE" unitRef="usdPerShare">6.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2015Q4_us-gaap_OptionIndexedToIssuersEquityTypeAxis_axdx_OptionsVestedAndExpectedToVestMember" decimals="2" id="Fact-71384D048C7C725A08E8333E8FB959DC" unitRef="usdPerShare">6.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharesIssued contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8FB1A3D3BADEE59CC9DDEFC21A126B7B" unitRef="shares">25332000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D2928763E89AFAE17D12EFC219F4A787" unitRef="shares">41650000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C2D2BD0CA8C3BE9A8463EFC219CC4A8C" unitRef="shares">44640000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F310F65C2D38F059F049EFC219CC3EF4" unitRef="shares">51191000</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-59DD95FEE8B7FB656A73EFC21A081EB8" unitRef="shares">13830000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9759FBE387D45758AB55EFC219F4227F" unitRef="shares">312000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8867E8C6B1B977FDE3EAEFC218A07E37" unitRef="shares">125000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4Dec9_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_AffiliatedEntityMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-881908349E8FD5678919350BEB68C139" unitRef="shares">2900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4Dec9_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_AffiliatedEntityMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_axdx_OfferingExemptFromUnderwriterCommissionMember" decimals="-5" id="Fact-BD1449F670FC7C55BD2B3A7D83A7C07A" unitRef="shares">2400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4Dec9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-576AFE82D7E0D7CAC7D43507585FB790" unitRef="shares">6400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4Dec9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_axdx_PublicOfferingMember" decimals="-5" id="Fact-2E9E3E29449DCD5728C8350733E3C253" unitRef="shares">5600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4Dec9_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-C8AF8B58019612961D6B35074631829B" unitRef="shares">838000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-49D2D5B0F1530A5F9A32EFC218DC0C83" unitRef="shares">2488000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8C4582CE6F05B57AB55DEFC219E00E96" unitRef="shares">2678000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2568C09BDD23FCA39793EFC218E6B510" unitRef="shares">6426000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD" decimals="INF" id="Fact-415B5A40FFC166B11933EFC218B4AC99" unitRef="shares">311737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD" decimals="INF" id="Fact-5B8ACA193B843E9AA7E2EFC219B8EA0C" unitRef="shares">124884</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2013Q4YTD" decimals="-3" id="Fact-D97E876A768B179B3DA5EFC21A08E6C3" unitRef="usd">20969000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8B81E4994637796935AAEFC218DC1790" unitRef="usd">20955000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D40501F01F74D41F017FEFC218A0FDF5" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2014Q4YTD" decimals="-3" id="Fact-73BF5234C26DC7F95243EFC219409705" unitRef="usd">923000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1DA65040884307E619C3EFC2194087C5" unitRef="usd">923000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-07CB58E61930E5C8DFBFEFC218DCF61A" unitRef="usd">805000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-28736FC8326656C1F6B0EFC219C211DF" unitRef="usd">805000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F359C9F7504F6207702EEFC219E02948" unitRef="usd">19912000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1F7CB4D28E2ACE37E5E3EFC21A268BFA" unitRef="usd">19909000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8BB05B613EE4DEDA58DAEFC219C2FFD4" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9BF0258B0EDD919EAE25EFC218C833F1" unitRef="usd">44875000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A6BE242878A058AC3C08EFC218FA2704" unitRef="usd">44872000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5933617666B0CE40AC3EEFC219CC1ED4" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E3D4CD917A4D14BC5757EFC2193665B9" unitRef="usd">103351000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-587CA434FD3AF53CDD78EFC218DC39DA" unitRef="usd">103345000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-15ECE52E6ACFB58BF498EFC21A1C7908" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-69D38D1F0DCD9B094A8435FDEEE37FF3" unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E8B666A4D86371A99B3AEFC219A48F4B" unitRef="usd">3800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B1F49A42C78DBB7BEC34EFC219A4463D" unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4" decimals="-3" id="Fact-6FB6685085C4B15194DFEFC218C80244" unitRef="usd">12068000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E593AD2FA5CD65D1452BEFC219CC364A" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DE60C3CB0D8CA695EB6EEFC219FE22F9" unitRef="usd">31245000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-12F65C41303863DC2779EFC219FE378B" unitRef="usd">25000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D22E97A56586017FB6ACEFC21922266C" unitRef="usd">-19202000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-22DB8D667E2AA19B9403EFC2199AC6E4" unitRef="usd">41517000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-DA474956AAE7796A69F3EFC21940E6F5" unitRef="usd">22000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5A46378CAF8CEBA167BCEFC219C24643" unitRef="usd">75937000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E443A9088627A1C7BE18EFC2193651F6" unitRef="usd">42000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8958EB9C75C332EBE606EFC219FEA87C" unitRef="usd">-34484000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-8E0BB1AB46305F1A00CBEFC2192C4525" unitRef="usd">65991000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C6C516DD28385D8A04ACEFC219F4018D" unitRef="usd">7000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AA47EE02E05B866C1E6AEFC219D68026" unitRef="usd">131356000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-61B5E35975D4771174F1EFC21A08BC97" unitRef="usd">45000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-0DCB38A110B9DB80E74AEFC219A4BE5D" unitRef="usd">-65417000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-7B02C6366954452A1747EFC2194A050D" unitRef="usd">133018000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F40784989173F086FD31EFC21A08907D" unitRef="usd">-12000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-24CB8DA417D7F89EECF5EFC218E60074" unitRef="usd">243894000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-10C2FBB3CC47A54BE5ECEFC218F05674" unitRef="usd">51000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C0595C64EF6E3ACE4C5EEFC218A006AF" unitRef="usd">-110915000</us-gaap:StockholdersEquity>
	<us-gaap:TemporaryEquityShareSubscriptions contextRef="I2013Q3Jul08" decimals="INF" id="Fact-795F65099612804CAD94EFC21A1205C3" unitRef="shares">0.064038</us-gaap:TemporaryEquityShareSubscriptions>
	<us-gaap:TemporaryEquityShareSubscriptions contextRef="I2014Q1Mar14" decimals="INF" id="Fact-CCA1885E16A1E3887DEEEFC21A129EC4" unitRef="shares">0.063921</us-gaap:TemporaryEquityShareSubscriptions>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-7C691EF103771A5FFAABEFC218E688F4" unitRef="usd">22000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2B8978BFBA6FD900CFC8EFC21A260DF6" unitRef="usd">-15000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D145A6091A7476ABE83BEFC2199070B0" unitRef="usd">-20000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2012Q4" decimals="-3" id="Fact-6F561B0B36B4A03C714F35DD1079DBE4" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2013Q4" decimals="-3" id="Fact-42F4AD190E609F40D3F235DD174EA0EA" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-3" id="Fact-1FE67465BCE5C080366D35DCB5996ED2" unitRef="usd">161000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-3" id="Fact-003DD1D68D9E990CD6FE35DCBC71D7D5" unitRef="usd">343000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-5804A58DA99671C900A635DD14602F6D" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A6B6350B04CCB79ED8CE35DB930E984D" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0A52615C488A7148E57735DCB9803C3C" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6222AA50C686CF3E900D35DD126D2362" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-3" id="Fact-43CEE6CBF8CC4FC1046C3491994EE036" unitRef="usd">83000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-284C5AEF10F80AB3209135DCB78BC2A7" unitRef="usd">182000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A202D2C4C1215094C2AB35DD117BEAE4" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C9F2183EED01A579A45F34919956DBA5" unitRef="usd">78000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A6DBF028B0880414AA0835DCB692CDA5" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2013Q4YTD" decimals="-3" id="Fact-B0A6EFC497FFD3E6E44E35DD155B4A91" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8AA98DB45C36B4244EFD35DBD2B2FA04" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-84B27BD4E48438187A4F35DCBA799A99" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="I2014Q2Apr7" decimals="-5" id="Fact-C98A966E10CBE4841FDB34F007ECAAB5" unitRef="usd">45000000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2013Q4YTD" decimals="-3" id="Fact-76F1BF62A0D64981D74BEFC21896D4BA" unitRef="shares">37599000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B0519C6C6A76EFC32652EFC218E687F0" unitRef="shares">43626000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="-3" id="Fact-73D285D9E424F7BF182FEFC21A26B8EB" unitRef="shares">44998000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<axdx:LicenseAgreement contextRef="FD2015Q4YTD" id="Fact-8E5A25FE4BA73C6A87CAEFC218FA62DF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 6.  LICENSE AGREEMENTS AND GRANTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Defense Medical Research and Development Program&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (&amp;#8220;DMRDP&amp;#8221;) recommended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of funding for a proposed 35-month project.  The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections.  The project will apply the Accelerate ID/AST system to wound infections and other serious infections secondary to trauma.  The Company has invoiced a cumulative total of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$558,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; under this grant which is recorded as an offset to research and development expenses.  The amount invoiced for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$179,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$221,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;,  &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$143,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.  The period of performance for the grant ended September 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;National Institute of Health Grant&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2015, the National Institute of Health awarded Denver Health and the Company a five year, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood.  In June 2015, the Company executed a subaward agreement with Denver Health for the services we will provide as part of this grant which covers the period of February 15, 2015 through January 31, 2016 and totals &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$689,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The amounts invoiced for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$483,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Arizona Commerce Authority&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2012, the Company entered into a Grant Agreement (the &amp;#8220;Grant Agreement&amp;#8221;) with the Arizona Commerce Authority, an agency of the State of Arizona (the &amp;#8220;Authority&amp;#8221;), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the &amp;#8220;Project&amp;#8221;).  Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (the &amp;#8220;Grant&amp;#8221;) for the use by the Company in the advancement of the Project.  The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Milestone 1 &amp;#8211; Relocation of Company&amp;#8217;s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Milestone 2 &amp;#8211; Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Milestone 3 &amp;#8211; Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Milestone 4 &amp;#8211; Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For purposes of the Grant Agreement, a &amp;#8220;Qualified Job&amp;#8221; is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$63,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and offers health insurance benefits and pays at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;65%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the premiums associated with such benefits.  The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement.  The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties.  As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company has collected all of the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in milestones.  The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are &amp;#8220;claw-back&amp;#8221; provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement.  Once the &amp;#8220;claw-back&amp;#8221; provisions expire in January 2018, we will recognize the grant as an offset to expense.  Further details are included in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 7, Deferred Revenue and Income&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Arizona R&amp;amp;D Refundable Tax Credit Program&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has applied for and met the program requirements to receive a &amp;#8220;Certificate of Qualification&amp;#8221; from the Arizona Commerce Authority (&amp;#8220;Authority&amp;#8221;) which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&amp;amp;D Refundable Tax Credit Program").  The amounts collected under this program are recorded as an offset to research and development expenses, and for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$647,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$527,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.  If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</axdx:LicenseAgreement>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock contextRef="FD2015Q4YTD" id="Fact-0BCE0B91E6AA78A5BA14EFC219E07BCB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following tables summarize the Company&amp;#8217;s available-for-sale investments at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;AVAILABLE-FOR-SALE INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;AVAILABLE-FOR-SALE INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;The following table summarizes the maturities of the Company&amp;#8217;s available-for-sale securities at December 31, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;AVAILABLE-FOR-SALE INVESTMENT MATURITIES&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;At December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;At December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Due in less than 1 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,585&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Due in 1-3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2015Q4YTD" id="Fact-243B56A1E6013D540F34EFC21922CC8D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 1.  ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accelerate Diagnostics, Inc. (&amp;#8220;we&amp;#8221; or &amp;#8220;us&amp;#8221; or &amp;#8220;our&amp;#8221; or &amp;#8220;Accelerate&amp;#8221; or &amp;#8220;the Company&amp;#8221;) is an &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;in vitro&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.  Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention (&amp;#8220;CDC&amp;#8221;) calls one of the most serious healthcare threats of our time, antibiotic resistance.  A significant contributor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (&amp;#8220;U.S. GAAP&amp;#8221;), and applicable rules and regulations of the United States Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;), regarding annual financial reporting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;All amounts are rounded to the nearest thousand dollars unless otherwise indicated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (including the newly formed Accelerate Diagnostics S.L.) after elimination of intercompany transactions and balances. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Reclassification&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-04D3C53CBC4793B73971EFC219C23AF5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The future minimum lease payments under the capital lease together with the present value of the net minimum lease payments as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.1796875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="79%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Capital Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Year ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Less amount representing interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Present value minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-A59E34C452B828F5C20FEFC219B88111">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents.  Cash and cash equivalents include overnight repurchase agreement accounts.  As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank.  Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal.  We believe however, that the market risk arising from holding these financial instruments is minimal.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-01C38E7AA69CE7E8B02BEFC219AE35B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 14.  COMMITMENTS&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has entered into lease agreements, lease amendments, and lease extensions ("Lease Agreements") for office, laboratory and manufacturing space located in Tucson, Arizona, the last of which expires in 2018.  In addition to rental payments and other standard provisions, one of the leases requires the Company to relocate to Tucson and comply with certain employment provisions through the term of the lease.  If such requirements are not met, the rental rate is increased.  We are in compliance with the lease terms as of fiscal years ending December 31, 2015, 2014 and 2013, thus no increased rental rates were paid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In October 2013, as a condition of a Lease Agreement, the Company expanded its lease premises whereby the landlord provided tenant improvements.  These tenant improvements are treated as a capital lease whereby both an asset and a liability have been recorded and periodic interest based on an annual rate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and depreciation are recorded to amortize the value of this asset and the liability over the remaining lease term.  The Company incurred interest cost of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$4,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$7,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for and the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; , &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.  Further details regarding this capital lease are included in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 5, Property and Equipment&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The future minimum lease payments under the capital lease together with the present value of the net minimum lease payments as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.1796875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="79%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Capital Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Year ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Less amount representing interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Present value minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total rent expense for the Tucson facility, including common area charges was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$685,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$293,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$168,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.  Future minimum lease payments under this agreement are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.7421875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="79%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Operating Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Year ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;954&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total operating lease obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Clinical Trial Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed.  These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation.  As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; we had a payable of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$512,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to the clinical trial sites and incurred expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  No amounts were incurred for these arrangements through December 31, 2014.  The expense incurred as part of the clinical trial is included in research and development on the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On March 19, 2015, a putative securities class action lawsuit was filed against Lawrence Mehren, and Steve Reichling, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504.  &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System.  Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015.  On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class.  On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud.  Plaintiff seeks certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order.  Defendants moved to dismiss the amended complaint on July 21, 2015, which motion was pending before the Court as of December 31, 2015.  Subsequently, the Court granted the motion and dismissed the case with prejudice on January 28, 2016.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&amp;#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.  See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Item 8, Note 16, Subsequent Events&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for an update on this lawsuit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Employment Agreement and Consulting Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In 2012, Thomas V. Geimer resigned as the Company&amp;#8217;s Chief Executive Officer, Chief Financial Officer and Secretary.  In connection with his resignation, Mr. Geimer had an agreement with the Company to receive staggered payments due to him such that &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$650,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was paid upon the closing of the July 2013 Offering as described &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Item 8, Note 10, Rights Offering&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$700,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payable to him on July 1, 2013.  From January 1, 2013 through December 31, 2013, Mr. Geimer&amp;#8217;s aggregate consulting fee was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$96,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  As of December&amp;#160;31, 2014, no additional amounts were due under the Agreement and no further amounts were incurred during the year ending December&amp;#160;31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-06C96505DA6C54F5EC0EEFC219AE5627">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company awards stock options and other equity-based instruments to its employees, directors and consultants.  Compensation cost related to equity-based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method).  For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested.  The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model.  This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Volatility:  The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected term:  The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns.  For consultant awards, the estimated expected term is the same as the life of the award.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Risk-free interest rate:  The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dividend yield:  The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company estimates the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period.  The rate is calculated separately for awards to the board of directors/executives and all other awards.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-18BEBE2EBFA9D852F703EFC219C274DC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;ASC 220, Reporting Comprehensive Income&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements.  The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).  The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2015Q4YTD" id="Fact-B0D70C4FFD051E1E4342EFC2192C140D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s main financial institution for banking operations held &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;83%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the Company&amp;#8217;s cash and cash equivalents as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company grants credit to domestic and international clients in various industries.  Exposure to losses on accounts receivable is principally dependent on each client's financial position.  At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;66%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the outstanding receivable balance was with Denver Health.  See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 6, License Agreements and Grants&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for more information.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-AD02E07B8AB367D3FC6F3417EC812F6A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Deferred Revenue and Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Fisher agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research Use Only Accelerate ID/AST systems&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total current deferred revenue and income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Arizona Commerce Authority grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Fisher agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total long-term deferred income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2015Q4YTD" id="Fact-3FFCD1A3BB075BFD1BA9EFC219A46632">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 12.  EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; equity-based compensation plans, which are discussed below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Qualified Stock Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Qualified Stock Option Plan (the &amp;#8220;Qualified Plan&amp;#8221;) was a stockholder-approved plan that provided for stock option grants to employees, including executive officers.  The exercise price of each option, which has a maximum ten-year life, was established by the Company's Compensation Committee on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;527,500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; options exercised under the Qualified Plan and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ne that remain outstanding.  The Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; further options are available for grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Non-Qualified Stock Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Non-Qualified Stock Option Plan (the &amp;#8220;Non-Qualified Plan&amp;#8221;) was a stockholder-approved plan that provided for stock option grants to independent contractors, technical advisors and directors of the Company.  The exercise price of each option, which has a maximum &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; year life, was established by the Company's Compensation Committee on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;270,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; options exercised under the Non-Qualified Plan and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; that remain outstanding.  The Non-Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; further options are available for grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;2004 Omnibus Stock Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In December 2004, the Company&amp;#8217;s stockholders approved the Omnibus Stock Option Plan and reserved &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;500,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its authorized but unissued Common Stock for stock options to be granted to employees, independent contractors, technical advisors and directors of the Company.  The authorized shares in this plan were increased by &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares to an aggregate amount of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,500,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; upon stockholder approval during the fiscal year ended July 31, 2012.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;403,474&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; options exercised under the 2004 Omnibus Stock Option Plan and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,536,526&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; that remain outstanding.  The 2004 Omnibus Stock Option Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; further options are available for grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;2012 Omnibus Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In December 2012, the Company&amp;#8217;s stockholders approved the Company&amp;#8217;s 2012 Omnibus Equity Incentive Plan to replace the Qualified Stock Option Plan, Non-Qualified Stock Option Plan and 2004 Omnibus Stock Option Plan (&amp;#8220;Prior Plans&amp;#8221;).  The Prior Plans remain in effect until all awards granted under those plans have been exercised, forfeited, canceled, expired or otherwise terminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In connection with the approval of such plan, all stock options, totaling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,677,500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; formerly available for new awards under the Prior Plans were transferred to the 2012 Omnibus Equity Incentive Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At the Company&amp;#8217;s 2014 Annual Meeting of Stockholders held in May 2014, stockholders approved an amendment to the Company&amp;#8217;s 2012 Omnibus Equity Incentive Plan increasing the number of stock options of Common Stock reserved and available for grant by &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,677,500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options granted under this plan typically vest either (i) one year after grant date, (ii) monthly over a one year period, or (iii) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; two years after grant date and the remaining &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; monthly over the next three years.  The maximum term is ten years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;71,147&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; options exercised under the 2012 Omnibus Equity Incentive Plan and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,660,894&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; that remain outstanding, leaving &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,945,459&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; available for grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In December 2015, the board of directors voted to restrict new grants under the 2012 Omnibus Equity Incentive Plan to 200,000 shares until such time as the Company&amp;#8217;s total available shares are increased.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Combined Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following table summarizes option activity under all plans during the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and shows the exercisable shares as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Stock Option Activity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Number of&amp;#160;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Outstanding January 1, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;5,185,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;3.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;769,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;16.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(13,678&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;13.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(311,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Outstanding December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;5,628,726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;5.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;717,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;20.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(54,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;11.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(124,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Outstanding December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;6,167,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercisable December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,536,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The cash received from the exercise of options during the year ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$805,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and the tax benefit realized was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the same period.  Upon exercise, shares are issued from shares authorized and held in reserve.  The intrinsic value of options exercised was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;,  &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The total fair value of shares vesting during the period was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$600,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As discussed in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 2, Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company accounts for all option grants using the Black-Scholes option pricing model in accordance with ASC 718 for options granted or extended.  &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 2&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; also describes the significant assumptions utilized for estimating the various inputs required this pricing model.  The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Black-Scholes Assumptions for Option Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Risk free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Estimated forfeitures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;14.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;16.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;12.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In general, option awards have a requisite service period and unvested options are forfeited upon employee or consultant termination.  The Company estimates a forfeiture rate which is applied to outstanding options to determine options expected to be forfeited with the remaining outstanding options being those expected to vest.  Further information regarding the forfeiture rate calculation is included in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 2, Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Stock Option Supplemental Information&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Vested and Expected to Vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Number of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,167,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,536,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,088,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average remaining contractual term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Aggregate intrinsic value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;86,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;21,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;85,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;The aggregate intrinsic value in the table above represents the total pretax intrinsic value that would have been received by the option holders had all option holders exercised their options on that date.  It is calculated as the difference between the Company&amp;#8217;s closing stock price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$21.49&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; on the last trading day of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and the exercise price multiplied by the number of shares for options where the exercise price is below the closing stock price.  This amount changes based on the fair market value of the Company&amp;#8217;s stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In December 2015, in connection with the Company's public offering, we modified the stock options of three of our executive officers to restrict the ability to exercise until such time as additional available unissued shares have been authorized.&amp;#160; Such authorization was obtained for a majority of our shareholders as of December 31, 2015 and was pending submission to the State of Delaware.&amp;#160; There was an immaterial amount of incremental compensation associated with this modification.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following table summarizes restricted stock activity during the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Restricted Stock Activity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Number of&amp;#160;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Restricted stock outstanding December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;40,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;20.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Vested/released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Restricted stock outstanding December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;40,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;20.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The expense and tax benefits recognized on Company&amp;#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Equity-Based Compensation Expenses and Tax Benefit&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Sales, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Equity-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Recognized tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$11.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  This is expected to be recognized over the years &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="FD2015Q4YTD" id="Fact-7B7A60DDE9CF09D2A08EEFC219A4EE17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The expense and tax benefits recognized on Company&amp;#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Equity-Based Compensation Expenses and Tax Benefit&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Sales, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Equity-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Recognized tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-5047D984DEEEA8DF04A3534B38274511">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Earnings Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;ASC 260, Earnings Per Share&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which requires companies to present basic earnings per share and diluted earnings per share.  Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.  Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued.  Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2015Q4YTD" id="Fact-1BC4AA0D1603F1F51B20EFC218C887BA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 11.  EARNINGS PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The financial statements show basic earnings (loss) per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our Common Stock to be antidilutive.  As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were Common Stock options, restricted stocks and warrants exercisable for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6,778,580&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6,174,886&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,731,246&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Weighted average shares outstanding for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; have been revised for the effects of the rights offering (See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 10, Rights Offering&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2015Q4YTD" id="Fact-A6445E6B5B255618978DEFC2190E75C0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (see &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 2, Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for further information):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Identical&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Money market funds (cash equivalents)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Identical&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 1) &amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Significant Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Money market funds (cash equivalents)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;26,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2015Q4YTD" id="Fact-26CE235BFAFD6FE8319AEFC219CCCF4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 3.  FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (see &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 2, Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for further information):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Identical&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Money market funds (cash equivalents)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Identical&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 1) &amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Significant Other Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Significant Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Money market funds (cash equivalents)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;26,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;Level 1 assets are priced using quoted prices in active markets for identical assets which include cash accounts and money market funds as these specific assets are liquid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data.  The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities.  The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.  There were no transfers between levels during the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2015Q4YTD" id="Fact-F14AF3CD053F121DE1EEEFC21A12F6AE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Estimated Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;ASC Topic 820, Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements.  The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2:  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 3:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock contextRef="FD2015Q4YTD" id="Fact-95AF2E9B8D71BD49C123EFC21904D088">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Long-lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-9D3CB19D0C6FAE35BF78EFC219A4978F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 13.  INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The components of the pretax loss from operations for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="49%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Components of the Pretax Loss From Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;U.S. Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(44,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(30,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(15,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(1,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Pretax loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(45,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(30,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(15,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company does not reflect income tax expense or benefit for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, as the Company has  a full valuation allowance.  The Company records the Arizona R&amp;amp;D Refundable Tax Credit Program it has monetized as an offset to research and development expenses on the consolidated statement of operations and comprehensive loss as discussed in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 6, License Agreements and Grants&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of the Company&amp;#8217;s net deferred income taxes for the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, are as are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.46875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="58%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Deferred Income Tax Components&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;28,584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;15,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property &amp;amp; equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Intangible assets, definite-lived&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;General business credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;372&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Charitable contribution&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(37,820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(21,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company has generated regular tax federal net operating losses of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$85.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The Company's ability to realize tax benefit from the net operating loss is subject to annual limitation under Internal Revenue Code Section 382.  Due to the change in control which occurred as a result of Abeja Ventures, LLC&amp;#8217;s investment in the Company on June 26, 2012, the Company estimates that the annual Section 382 limitation on utilization of net operating losses will be &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$420,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  As such, the Company will never get the benefit of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the net operating losses generated prior to June 26, 2012.  The deferred tax asset has been adjusted to reflect the Section 382 limitation.  Section 382 also applies to built-in losses at the time of the transaction.  The amounts of any unrealized built-in losses or gains were not calculated at the date of the transaction.  The gross net operating losses available for future use are approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$80.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  For federal purposes, net operating losses can be carried forward for up to 20 years.  The Company&amp;#8217;s net operating losses will begin to expire in 2023.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company relocated its headquarters to Arizona in January 2013.  As of December 31, 2015, the Company has generated Arizona net operating losses of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$69.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The Company's Arizona net operating losses will begin to expire in 2033.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company created a Spanish subsidiary in January of 2015 which generated a tax net operating loss of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$403,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The Spanish net operating losses carry over indefinitely.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The net deferred tax asset valuation allowance is &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$37.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of December 31, 2015 compared to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$21.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of December 31, 2014.  The valuation allowance is based on management&amp;#8217;s assessment that it is more likely than not that the Company will not have taxable income in the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The difference between the U.S. federal statutory income tax rate and the Company&amp;#8217;s effective tax rate for years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="52%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Effective Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;U.S. federal statutory income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;State taxes, net of federal tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(2.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Rate differential&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unrecognized tax benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Nondeductible equity and other compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Limitation on net operating losses due to &amp;#167;382 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Credit for increased research activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Change in Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;35.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;33.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;38.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had uncertain tax positions of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$343,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, determined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="64%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Balance at beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Increases for prior positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Increases for current year positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Other Increases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Decreases due to settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Other Decreases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Balance at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;These uncertain positions are not expected to change within the next twelve months.  Of the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$343,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of uncertain tax positions, none would impact the effective tax rate, if reversed.  The Company accounts for interest on uncertain tax positions within tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has incurred federal net operating losses (NOLs) dating to the tax year ended July 31, 2004.  As such, all loss carryovers are subject to adjustment under IRS and state examination, depending on the jurisdiction in which they were incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-A54A30DEEA320BC06B68EFC219228160">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets.  The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period.  Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows the provisions of ASC 740, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return.  This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return.  Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit.  Interest and penalties, if any, would be recorded as tax expense in general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-7EF24B2171407EDDD789EFC219362313">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or other regulatory agency approval.  We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance.  Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k) clearance, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted.  Inventory is reported as research and development costs, or if used in marketing evaluations reported to sales, general and administrative costs on the Statement of Operations and Comprehensive Loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-D9320016089EAB4B486FEFC2192C1688">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company invests excess funds in various short-term investments which are primarily held in the custody of a major financial institution.  Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper.  Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value.  Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&amp;#8217; equity.  The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&amp;#8217;s fair value remains less than its cost for more than twelve months.  This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs.  When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss.  The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="FD2015Q4YTD" id="Fact-046B0DACFFFCDC83CA05EFC219D6AE56">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 4.  INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following tables summarize the Company&amp;#8217;s available-for-sale investments at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;AVAILABLE-FOR-SALE INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;AVAILABLE-FOR-SALE INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Asset-backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Corporate notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;12,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;The following table summarizes the maturities of the Company&amp;#8217;s available-for-sale securities at December 31, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="48%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;AVAILABLE-FOR-SALE INVESTMENT MATURITIES&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;At December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;At December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Due in less than 1 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,585&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Due in 1-3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;For the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$141,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$861,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in proceeds from sales of marketable securities (including principle paydowns) were collected, respectively.  The Company determines gains and losses of marketable securities based on specific identification of the securities sold.  There were no gross realized gains and losses from sales of marketable securities for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
	<us-gaap:LeasePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-7FAB217403C995F927F4EFC2194A25CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company accounts for leases in accordance with ASC 840, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; which requires leases to be classified as either operating or capital leases.  In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception.  Other leases are classified as operating leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Operating lease rent is recorded as an operating expense monthly.  For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments.  The asset is included with property and equipment on the Balance Sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the Statements of Operations and Comprehensive Loss.  For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the Balance Sheet.  Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the Statements of Operations and Comprehensive Loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-07085128B232813C3CA7EFC219049328">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-02, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  This replaces the existing standards relating to leases for both lessees and lessors.  For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized  much like the existing standard.  For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases.  For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria.  The ASU is required for us on January 1, 2019 with early adoption permitted.  We are currently assessing the impact this will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January, 2016, the FASB issued ASU 2016-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets.  The ASU is required for us on January 1, 2018.  We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In November 2015, the FASB issued ASU 2015-17, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Income Taxes-Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard requires that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position rather than separating these amounts between current and noncurrent amounts.  The deferred tax liabilities and assets continue to be offset and presented as a single amount.  The ASU is required for us on January 1, 2017 and we have elected to adopt this standard retrospectively for the period ended December 31, 2015.   There was no significant impact on our consolidated financial statements as a result of adopting this ASU.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard requires entities that measure inventory using first-in, first-out or average cost inventory to report inventory at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The ASU will become effective for us on January 1, 2016.  We do not expect the adoption of ASU 2015-11 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2015, the FASB issued ASU 2015-05, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Intangibles-Goodwill and Other - Internal-Use Software; Customer&amp;#8217;s Accounting for Fees Paid in a Cloud Computing Arrangement&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&amp;#8217;s accounting for fees paid in a cloud computing arrangement.  Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements.  This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses.  If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract.  The ASU does not change the accounting for service contracts.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2015, the FASB issued ASU 2015-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Income Statement - Extraordinary and Unusual Items&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard eliminates from U.S. GAAP the concept of extraordinary items.  Prior to the adoption of this standard, extraordinary items have been segregated from the results of ordinary operations and shown separately in the income statement, net of tax, after income from continuing operations.  The new standard eliminates such segregation as well as the requirements to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-01 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&amp;#8217;s ability to continue as a going concern and, if so, disclose that fact.  Management will also be required to evaluate and disclose whether its plans alleviate that doubt.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2014-15 to have a significant impact on our consolidated financial statements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.  We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements.  The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.  We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements.  In August 2015, the FASB issued ASU 2015-14, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which deferred the effective date resulting in a new effective date of January 1, 2018 for us.  We are permitted to adopt early but not before the original effective date of January 1, 2017.  The standard allows for either &amp;#8220;full retrospective&amp;#8221; adoption, meaning the standard is applied to all of the periods presented, or &amp;#8220;modified retrospective&amp;#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements.  We are currently evaluating the transition method and the adoption date that will be elected.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-5B754F94F132543EF6B7361807C2E740">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following table summarizes restricted stock activity during the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Restricted Stock Activity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Number of&amp;#160;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Restricted stock outstanding December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;40,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;20.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Vested/released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Restricted stock outstanding December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;40,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;20.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
	<us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-02BEF84397C61604AC19EFC219B874D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Future minimum lease payments under this agreement are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.7421875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="79%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Operating Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Year ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;954&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total operating lease obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-FE3AA1FB78EF8FA97F24EFC219C29692">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 5.  PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment are recorded at cost and consisted of the following at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (in thousands).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.953125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="68%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Technical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Facilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Capital lease &amp;#8211; leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Capital projects in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accumulated amortization &amp;#8211; capital lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accumulated depreciation - other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(2,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(1,311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Net property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;Depreciation expense (which includes amortization of capital lease assets) for the for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$817,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$286,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-95FB6B9724037D835BF0EFC2192C15D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment are recorded at cost.  Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.  Gains and losses from retirement or replacement are included in costs and expenses.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years.  Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.  See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 5, Property and Equipment&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2015Q4YTD" id="Fact-48244A8E9E58A51F53B3EFC2190E255C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment are recorded at cost and consisted of the following at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (in thousands).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.953125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="68%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Technical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Facilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Capital lease &amp;#8211; leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Capital projects in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accumulated amortization &amp;#8211; capital lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accumulated depreciation - other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(2,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(1,311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Net property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2015Q4YTD" id="Fact-17E3186CC1EC5218005EEFC218E62933">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 17.  SUPPLEMENTAL DATA QUARTERLY FINANCIAL INFORMATION (UNAUDITED)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="20%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;QUARTERLY FINANCIAL INFORMATION&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unaudited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For the quarters ending:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;9/30/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;6/30/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;3/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;9/30/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;6/30/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;3/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(13,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(11,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(12,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(5,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Basic and diluted net loss per share (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(1)&amp;#160;&amp;#160;Loss per share has been adjusted for the effects of the rights offering (see &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Item 8, Note 10, Rights Offering&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="FD2015Q4YTD" id="Fact-74055FA2CEE305202B9DEFC219CC909A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable.  Receivables are written off if reasonable collection efforts prove unsuccessful.  The Company provides for allowances on a specific account basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
	<us-gaap:RevenueRecognitionDeferredRevenue contextRef="FD2015Q4YTD" id="Fact-19F146F975FDB4A2202CEFC21A2618F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 7.  DEFERRED REVENUE AND INCOME&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred revenue consists of amounts received for products or services not yet delivered or earned.  Deferred income consists of amounts received for commitments not yet fulfilled.  If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income.  A summary of the balances as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Deferred Revenue and Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Fisher agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research Use Only Accelerate ID/AST systems&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total current deferred revenue and income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Arizona Commerce Authority grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Fisher agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total long-term deferred income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Through December 31, 2014, we received &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 6, License Agreements and Grants&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the &amp;#8220;claw-back&amp;#8221; provisions under the Grant Agreement expire in January 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred income includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$114,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of payments received in December 2015, for Research Use Only Accelerate ID/AST systems.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-25BF8ED3A1D861CB0D32EFC219221F60">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recognizes revenue in accordance with ASC 605, &amp;#8220;Revenue Recognition,&amp;#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred revenue represents amounts received but not yet earned under existing agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2015Q4YTD" id="Fact-C6510E0BFA0EF741292B34B5DCA98D80">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-163E9080E13057652370EFC219A4A116">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Significant components of the Company&amp;#8217;s net deferred income taxes for the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, are as are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.46875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="58%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Deferred Income Tax Components&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;28,584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;15,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property &amp;amp; equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Intangible assets, definite-lived&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;General business credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;372&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Charitable contribution&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(37,820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(21,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-F2B8AC84BACDB807603DEFC219C25FCD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The difference between the U.S. federal statutory income tax rate and the Company&amp;#8217;s effective tax rate for years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="52%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Effective Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;U.S. federal statutory income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;State taxes, net of federal tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(2.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Rate differential&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unrecognized tax benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Nondeductible equity and other compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Limitation on net operating losses due to &amp;#167;382 &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Credit for increased research activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(3.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Change in Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;35.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;33.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;38.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="FD2015Q4YTD" id="Fact-DA8839178232F586143D34B07D79AF5D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The components of the pretax loss from operations for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="49%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Components of the Pretax Loss From Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;U.S. Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(44,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(30,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(15,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(1,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Pretax loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(45,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(30,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(15,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-44D383243D7210431BFFEFC218E6AE34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="20%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;QUARTERLY FINANCIAL INFORMATION&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unaudited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For the quarters ending:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;9/30/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;6/30/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;3/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;9/30/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;6/30/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;3/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(13,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(11,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(12,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,152&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(5,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Basic and diluted net loss per share (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(1)&amp;#160;&amp;#160;Loss per share has been adjusted for the effects of the rights offering (see &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Item 8, Note 10, Rights Offering&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-0996EA5F837FFA3AC390EFC219A4D7DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following table summarizes option activity under all plans during the years ending &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and shows the exercisable shares as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="74%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Stock Option Activity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Number of&amp;#160;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Outstanding January 1, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;5,185,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;3.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;769,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;16.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(13,678&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;13.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(311,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Outstanding December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;5,628,726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;5.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;717,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;20.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(54,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;11.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(124,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Outstanding December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;6,167,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercisable December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,536,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-FB943F90FFD4DE0C9C01EFC219A48346">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Stock Option Supplemental Information&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Options Vested and Expected to Vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Number of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,167,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,536,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,088,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average remaining contractual term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Aggregate intrinsic value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;86,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;21,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;85,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-B5F2935989824B84849DEFC219A46237">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Black-Scholes Assumptions for Option Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Risk free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Estimated forfeitures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;14.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Weighted average fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;16.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;12.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-C1FD1B54CE48EC931F7CEFC218D26D8D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 15.  SEGMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company operates as &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; operating segment.  Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance.  The Company&amp;#8217;s business operates in one operating segment because the Company&amp;#8217;s chief operating decision maker evaluates the Company&amp;#8217;s financial information and resources and assesses the performance of these resources on a consolidated basis.  Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2015Q4YTD" id="Fact-41DC817E6275AD2A7883EFC218B4EF61">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s main financial institution for banking operations held &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;83%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the Company&amp;#8217;s cash and cash equivalents as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company grants credit to domestic and international clients in various industries.  Exposure to losses on accounts receivable is principally dependent on each client's financial position.  At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;66%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the outstanding receivable balance was with Denver Health.  See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 6, License Agreements and Grants&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Estimated Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;ASC Topic 820, Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements.  The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2:  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 3:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 3, Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for further information and related disclosures regarding the Company&amp;#8217;s fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents.  Cash and cash equivalents include overnight repurchase agreement accounts.  As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank.  Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal.  We believe however, that the market risk arising from holding these financial instruments is minimal.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company invests excess funds in various short-term investments which are primarily held in the custody of a major financial institution.  Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper.  Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value.  Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&amp;#8217; equity.  The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&amp;#8217;s fair value remains less than its cost for more than twelve months.  This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs.  When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss.  The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment are recorded at cost.  Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.  Gains and losses from retirement or replacement are included in costs and expenses.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years.  Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.  See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 5, Property and Equipment&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Long-lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or other regulatory agency approval.  We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance.  Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k) clearance, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted.  Inventory is reported as research and development costs, or if used in marketing evaluations reported to sales, general and administrative costs on the Statement of Operations and Comprehensive Loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recognizes revenue in accordance with ASC 605, &amp;#8220;Revenue Recognition,&amp;#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred revenue represents amounts received but not yet earned under existing agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable.  Receivables are written off if reasonable collection efforts prove unsuccessful.  The Company provides for allowances on a specific account basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company accounts for leases in accordance with ASC 840, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; which requires leases to be classified as either operating or capital leases.  In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception.  Other leases are classified as operating leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Operating lease rent is recorded as an operating expense monthly.  For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments.  The asset is included with property and equipment on the Balance Sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the Statements of Operations and Comprehensive Loss.  For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the Balance Sheet.  Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the Statements of Operations and Comprehensive Loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets.  The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period.  Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows the provisions of ASC 740, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return.  This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return.  Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit.  Interest and penalties, if any, would be recorded as tax expense in general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Earnings Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;ASC 260, Earnings Per Share&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which requires companies to present basic earnings per share and diluted earnings per share.  Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.  Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued.  Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred. See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 11, Earnings Per Share&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company awards stock options and other equity-based instruments to its employees, directors and consultants.  Compensation cost related to equity-based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method).  For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested.  The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model.  This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Volatility:  The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected term:  The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns.  For consultant awards, the estimated expected term is the same as the life of the award.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Risk-free interest rate:  The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dividend yield:  The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company estimates the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period.  The rate is calculated separately for awards to the board of directors/executives and all other awards. See &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Note 12, Employee and Consultant Equity-Based Compensation&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for further information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Foreign Currency Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows ASC 830 &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Foreign Currency Matters&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which provides guidance on foreign currency transactions and translation of financial statements.  Adjustments resulting from translating foreign functional currency financial statements into U.S.  Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholder's equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency.  These balance sheet items are subject to re-measurement, the impact of which is recorded in interest expense and other, within the consolidated statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company follows &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;ASC 220, Reporting Comprehensive Income&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements.  The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).  The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-02, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  This replaces the existing standards relating to leases for both lessees and lessors.  For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized  much like the existing standard.  For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases.  For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria.  The ASU is required for us on January 1, 2019 with early adoption permitted.  We are currently assessing the impact this will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January, 2016, the FASB issued ASU 2016-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets.  The ASU is required for us on January 1, 2018.  We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In November 2015, the FASB issued ASU 2015-17, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Income Taxes-Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard requires that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position rather than separating these amounts between current and noncurrent amounts.  The deferred tax liabilities and assets continue to be offset and presented as a single amount.  The ASU is required for us on January 1, 2017 and we have elected to adopt this standard retrospectively for the period ended December 31, 2015.   There was no significant impact on our consolidated financial statements as a result of adopting this ASU.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard requires entities that measure inventory using first-in, first-out or average cost inventory to report inventory at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The ASU will become effective for us on January 1, 2016.  We do not expect the adoption of ASU 2015-11 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2015, the FASB issued ASU 2015-05, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Intangibles-Goodwill and Other - Internal-Use Software; Customer&amp;#8217;s Accounting for Fees Paid in a Cloud Computing Arrangement&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&amp;#8217;s accounting for fees paid in a cloud computing arrangement.  Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements.  This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses.  If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract.  The ASU does not change the accounting for service contracts.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2015, the FASB issued ASU 2015-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Income Statement - Extraordinary and Unusual Items&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard eliminates from U.S. GAAP the concept of extraordinary items.  Prior to the adoption of this standard, extraordinary items have been segregated from the results of ordinary operations and shown separately in the income statement, net of tax, after income from continuing operations.  The new standard eliminates such segregation as well as the requirements to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-01 to have a significant impact on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&amp;#8217;s ability to continue as a going concern and, if so, disclose that fact.  Management will also be required to evaluate and disclose whether its plans alleviate that doubt.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2014-15 to have a significant impact on our consolidated financial statements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.  We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements.  The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.  We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements.  In August 2015, the FASB issued ASU 2015-14, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which deferred the effective date resulting in a new effective date of January 1, 2018 for us.  We are permitted to adopt early but not before the original effective date of January 1, 2017.  The standard allows for either &amp;#8220;full retrospective&amp;#8221; adoption, meaning the standard is applied to all of the periods presented, or &amp;#8220;modified retrospective&amp;#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements.  We are currently evaluating the transition method and the adoption date that will be elected.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_axdx_RightsOfferingMember" id="Fact-E4FE468C5C9796095CD9EFC21A1250BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 10.  RIGHTS OFFERING&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;April 2014 Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On April 7, 2014, the Company commenced a rights offering to raise &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to fund continued operations, clinical trials, and product commercialization efforts.  Under the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock as of March 14, 2014, which was established as the record date for the rights offering, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.063921&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; non-transferable subscription rights for each share of Common Stock owned on the record date.  Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$16.80&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share which was lower than the market price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$17.64&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share on the date of the rights offering commencement and the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$17.54&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share on the date the rights offering period expired.  In the aggregate, the Company intended to issue &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.7 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock in connection with the rights offering.  The purpose of the rights offering was to raise equity capital in a cost-effective manner that gives all of the Company&amp;#8217;s existing stockholders the opportunity to participate on a pro rata basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In connection with the rights offering, the Company received standby commitments from the Jack W. Schuler Living Trust and the Schuler Family Foundation.  The standby purchasers agreed to purchase any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.  On May 1, 2014, the Company entered into an Assignment and Assumption Agreement with the standby purchasers, Oracle Institutional Partners, L.P. and Oracle Partners, L.P., pursuant to which each standby purchaser assigned and transferred its respective rights, responsibilities, liabilities and obligations under the Standby Purchase Agreement to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;297,619&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock not subscribed for by the Company&amp;#8217;s stockholders in connection with the rights offering to (i) Oracle Institutional Partners, L.P., with respect to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;119,047&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of such Common Stock, and (ii) Oracle Partners, L.P., with respect to the remaining &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;178,572&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of such Common Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The rights offering period expired on April 28, 2014, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company&amp;#8217;s issuance of an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.7 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its Common Stock to the rights offering participants and standby purchasers) were completed on May 19, 2014.  The Company received gross proceeds of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; before costs associated with the transactions which totaled &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$125,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and are treated as a reduction of contributed capital in the Stockholders&amp;#8217; Equity section of the Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Because the exercise price of the rights offering of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$16.80&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was less than the fair value of the Company&amp;#8217;s shares of Common Stock at the expiration of the offering, there is a bonus element that is treated similar to a stock dividend.  The weighted average shares outstanding, as well as the basic and diluted loss per share for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; have been revised for those effects.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;July 2013 Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On July 12, 2013, the Company publicly announced the final terms of a rights offering.  Rights offering materials were subsequently distributed to the Company&amp;#8217;s stockholders on July 18, 2013, at which time the rights offering period commenced.  Pursuant to the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock on July 8, 2013, which was established as the record date for the rights offering, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.064038&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; non-transferable subscription rights for each share of Common Stock owned on the record date.  Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8.04&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share.  In addition, any holder of subscription rights exercising his, her or its basic subscription privilege in full was eligible to subscribe to purchase additional shares of Common Stock at the same subscription price per share, subject to the conditions and limitations described further in the prospectus.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In connection with the rights offering, the Company received a standby commitment from Abeja to purchase, at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8.04&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share, any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The rights offering period expired on August 7, 2013, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company&amp;#8217;s issuance of an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its Common Stock to the rights offering participants and standby purchaser) were completed on August 8, 2013.  The Company received gross proceeds of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; before costs associated with the transactions, which totaled &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$88,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and are treated as a reduction of contributed capital in the Stockholders&amp;#8217; Equity section of the Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_axdx_PublicOfferingMember" id="Fact-E0048EB78AA10F36BE5735306FD24F76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 9.  PUBLIC OFFERING&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 9, 2015, the Company published a prospectus supplement underwritten by J.P. Morgan and Piper Jaffray ("Underwriters") offering &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock with an option for the Underwriters to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;838,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; additional shares of common stock for a total of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares.  The public offering price was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$17.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share and underwriting discounts and commissions were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.19&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Affiliates, including entities affiliated with one of Company's directors, Jack Schuler, and which together are our largest stockholders,  purchased &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the offered shares at the public offering price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$17.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share.  These shares are subject to lock-up agreements for a period of 90 days starting December 9, 2015.  In general, the lock-up agreement, with limited exceptions, requires J.P. Morgan Securities LLC's prior written approval for the sale (directly or indirectly) of AXDX common stock.  This includes various types of sales or offers to sell.  The underwriters did not receive any underwriting discount or commissions on the sale of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares to such affiliates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The public offering was finalized and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock were delivered to the purchasers on or around December 15, 2015.  Proceeds from the sale totaled &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$109.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; less underwriting and other expenses of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for net proceeds of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$103.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The net proceeds will be used for general corporate purposes.  We may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so.  Accordingly, we will retain broad discretion over the use of these proceeds.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2015Q4YTD" id="Fact-9AEAD643353AF07CF054EFC219D61A33">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 16.  SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Arizona R&amp;amp;D Refundable Tax Credit Program&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2016, we were notified by the Arizona Commerce Authority (&amp;#8220;Authority&amp;#8221;) that we meet the program requirements to receive a &amp;#8220;Certificate of Qualification&amp;#8221; and, therefore, are eligible for a partial refund of research and development investments amounting to a maximum of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The &amp;#8220;Certificate of Qualification&amp;#8221; does not obligate the Arizona Department of Revenue to issue the refund.  Furthermore, the calculation of the actual refund due will be based on actual qualifying expenses and income tax liability for the 2015 tax year and if qualifying expenses decrease or income tax liability increases, the refund amount may be less than the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On January 28, 2016, the United States District Court for the District of Arizona granted Accelerate Diagnostics&amp;#8217; Motion to Dismiss the class action lawsuit filed against it in March of 2015.  In granting the company&amp;#8217;s motion, the court ordered that the action be dismissed with prejudice in its entirety.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&amp;#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock contextRef="FD2015Q4YTD" id="Fact-26B56D7FF369E573912EEFC219AEB39C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had uncertain tax positions of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$343,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, determined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="64%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12/31/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Balance at beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Increases for prior positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Increases for current year positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Other Increases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Decreases due to settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Other Decreases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Balance at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
	<us-gaap:TransfersAndServicingOfFinancialAssetsTextBlock contextRef="FD2015Q4YTD" id="Fact-A7EE532B0F2AB1A3F48DEFC218D26927">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 8.  STOCK PURCHASE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2012, we entered into a Securities Purchase Agreement with Abeja Ventures, LLC (&amp;#8220;Abeja&amp;#8221;), pursuant to which the Company agreed to sell and issue to Abeja at a purchase price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.03&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share for an aggregate purchase price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$14.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;; (i) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;14.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock (&amp;#8220;Common Stock&amp;#8221;); (ii) a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.03&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share (the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.03&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; " Warrant&amp;#8221;); and (iii) another warrant to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share (the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;" Warrant&amp;#8221;), with each warrant exercisable prior to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement (collectively, the &amp;#8220;Investment&amp;#8221;).  The purchase of Common Stock and warrants pursuant to the Investment, which was consummated in June, 2012, qualified for equity treatment under U.S. GAAP. The respective values of the warrants and Common Stock were calculated using their relative fair values and both are classified under Contributed Capital.  The value therefore recorded for the warrants was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and for the Common Stock was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Both warrants are exercisable until June 26, 2017, which was the fifth anniversary of the date on which the warrants were issued.  Other significant terms and conditions of the warrants are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;the warrants provide for partial exercises, but they do not provide for a &amp;#8220;cashless&amp;#8221; exercise feature (i.e., they may only be exercised for cash);&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;the warrants do not contain anti-dilution provisions that would trigger exercise price or other adjustments as a result of subsequent issuances of the Company&amp;#8217;s equity securities, but they do contain customary provisions for equitable adjustments in connection with stock dividends, stock splits or reclassifications of Common Stock;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;following certain types of fundamental transactions involving the Company (e.g., a transaction resulting in a change in control of the Company), the holder of the warrants would continue to be entitled to exercise the warrants in exchange for the equity securities or alternate consideration receivable by a holder of Common Stock as a result of the fundamental transaction; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;the holder of the warrants is entitled to certain demand and piggy-back registration rights, including for shelf registrations, with respect to the shares of Common Stock issuable upon its exercise of the warrants.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2013, Abeja exercised in full its warrant to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.03&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share.  On the same date, Abeja also exercised the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;92%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of its warrant to purchase an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share (Abeja exercised such warrant for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares, leaving &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;571,160&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares unexercised).  The Company received aggregate funds of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in connection with such exercises.  Shares issued by the Company in connection with the warrant exercises were issued directly to the members of Abeja on a pro rata basis in accordance with their membership interests and written exercise instructions provided to the Company by Abeja.  Immediately after giving effect to the warrant exercises, Abeja also distributed in kind to its members (on a pro rata basis in accordance with their membership interests) the remaining shares of Common Stock held by that entity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TransfersAndServicingOfFinancialAssetsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2015Q4YTD" id="Fact-57403F7676AE92232353EFC218E6BA50">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>axdx-20151231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://acceleratediagnostics.com/20151231" xmlns:axdx="http://acceleratediagnostics.com/20151231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axdx-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axdx-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axdx-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axdx-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Commitments" roleURI="http://acceleratediagnostics.com/role/Commitments">
        <link:definition>2115100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsCapitalLeaseObligationsDetails" roleURI="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails">
        <link:definition>2415402 - Disclosure - Commitments - Capital Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative">
        <link:definition>2415404 - Disclosure - Commitments - (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsOperatingLeaseObligationsDetails" roleURI="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails">
        <link:definition>2415403 - Disclosure - Commitments - Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://acceleratediagnostics.com/role/CommitmentsTables">
        <link:definition>2315301 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueAndIncome" roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome">
        <link:definition>2107100 - Disclosure - Deferred Revenue and Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueAndIncomeDetails" roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails">
        <link:definition>2407402 - Disclosure - Deferred Revenue and Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueAndIncomeDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative">
        <link:definition>2407403 - Disclosure - Deferred Revenue and Income (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRevenueAndIncomeTables" roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables">
        <link:definition>2307301 - Disclosure - Deferred Revenue and Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://acceleratediagnostics.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://acceleratediagnostics.com/role/EarningsPerShare">
        <link:definition>2112100 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative">
        <link:definition>2412401 - Disclosure - Earnings Per Share (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensation" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation">
        <link:definition>2113100 - Disclosure - Employee and Consultant Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails">
        <link:definition>2413403 - Disclosure - Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative">
        <link:definition>2413408 - Disclosure - Employee and Consultant Equity-Based Compensation - (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails">
        <link:definition>2413406 - Disclosure - Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails">
        <link:definition>2413405 - Disclosure - Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails">
        <link:definition>2413402 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails">
        <link:definition>2413404 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails">
        <link:definition>2413407 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Options Vesting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeAndConsultantEquityBasedCompensationTables" roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables">
        <link:definition>2313301 - Disclosure - Employee and Consultant Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstruments" roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments">
        <link:definition>2103100 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsDetails" roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails">
        <link:definition>2403402 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsTables" roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables">
        <link:definition>2303301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://acceleratediagnostics.com/role/IncomeTaxes">
        <link:definition>2114100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd">
        <link:definition>2414403 - Disclosure - Income Taxes - Deferred Income Taxes Components (Details) (USD $)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsNarrativeUsd" roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd">
        <link:definition>2414406 - Disclosure - Income Taxes (Details Narrative) (USD $)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveTaxRateDetails" roleURI="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails">
        <link:definition>2414404 - Disclosure - Income Taxes - Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" roleURI="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails">
        <link:definition>2414402 - Disclosure - Income Taxes Income Taxes - Components of the Pretax Loss From Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://acceleratediagnostics.com/role/IncomeTaxesTables">
        <link:definition>2314301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUncertainTaxPositionsDetails" roleURI="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails">
        <link:definition>2414405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://acceleratediagnostics.com/role/Investments">
        <link:definition>2104100 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails">
        <link:definition>2404402 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails1" roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails1">
        <link:definition>2404403 - Disclosure - Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://acceleratediagnostics.com/role/InvestmentsTables">
        <link:definition>2304301 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAndGrants" roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants">
        <link:definition>2106100 - Disclosure - License Agreements and Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAndGrantsDetailsNarrative1" roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1">
        <link:definition>2406401 - Disclosure - License Agreements and Grants - (Details Narrative 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" roleURI="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation">
        <link:definition>2101100 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipment">
        <link:definition>2105100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative">
        <link:definition>2405403 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd">
        <link:definition>2405402 - Disclosure - Property and Equipment - Property and Equipment (Details) (USD $)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables">
        <link:definition>2305301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PublicOfferingDetails" roleURI="http://acceleratediagnostics.com/role/PublicOfferingDetails">
        <link:definition>2409401 - Disclosure - Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PublicOfferingNotes" roleURI="http://acceleratediagnostics.com/role/PublicOfferingNotes">
        <link:definition>2109100 - Disclosure - Public Offering (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightsOffering" roleURI="http://acceleratediagnostics.com/role/RightsOffering">
        <link:definition>2110100 - Disclosure - Rights Offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightsOfferingDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative">
        <link:definition>2410401 - Disclosure - Rights Offering (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://acceleratediagnostics.com/role/Segments">
        <link:definition>2116100 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails">
        <link:definition>2416401 - Disclosure - Segments Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchase" roleURI="http://acceleratediagnostics.com/role/StockPurchase">
        <link:definition>2108100 - Disclosure - Stock Purchase</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative">
        <link:definition>2408401 - Disclosure - Stock Purchase (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://acceleratediagnostics.com/role/SubsequentEvents">
        <link:definition>2117100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative">
        <link:definition>2417401 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>2402402 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalDataQuarterlyFinancialInformation" roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation">
        <link:definition>2118100 - Disclosure - Supplemental Data: Quarterly Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalDataQuarterlyFinancialInformationDetails" roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails">
        <link:definition>2418402 - Disclosure - Supplemental Data: Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalDataQuarterlyFinancialInformationTables" roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables">
        <link:definition>2318301 - Disclosure - Supplemental Data: Quarterly Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" name="AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" name="AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares" name="AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares" name="AdditionalOptionIndexedToIssuersEquityIndexedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="axdx_ArizonaDepartmentofRevenueMember" name="ArizonaDepartmentofRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_CertificateOfQualificationAbstract" name="CertificateOfQualificationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ClinicalTrialAgreementExpense" name="ClinicalTrialAgreementExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="axdx_ClinicalTrialAgreementLiability" name="ClinicalTrialAgreementLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="axdx_CommonStockAndWarrantsIssuedValue" name="CommonStockAndWarrantsIssuedValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_CorporateBondsandNotesMember" name="CorporateBondsandNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_CostMember" name="CostMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_DefenseMedicalResearchandDevelopmentProgramMember" name="DefenseMedicalResearchandDevelopmentProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_DeferredRevenueResearchUseOnly" name="DeferredRevenueResearchUseOnly" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets" name="DeferredTaxAssetsFiniteLivedIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="axdx_DenverHealthMember" name="DenverHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_EmployeeServiceSharebasedCompensationNumberofPlans" name="EmployeeServiceSharebasedCompensationNumberofPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ExercisedWarrantAmountUnexercised" name="ExercisedWarrantAmountUnexercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ExercisedWarrantPercentExercised" name="ExercisedWarrantPercentExercised" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares" name="ExercisedlOptionIndexedToIssuersEquityIndexedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_FairValueMember" name="FairValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_IncomeTaxesDetailsNarrativeUsdAbstract" name="IncomeTaxesDetailsNarrativeUsdAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract" name="IncomeTaxesEffectiveTaxRateDetailsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract" name="IncomeTaxesUncertainTaxPositionsDetailsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_LicenseAgreement" name="LicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract" name="LicenseAgreementsandGrantsResearchandDevelopmentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_NonQualifiedStockOptionPlanMember" name="NonQualifiedStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_OfferingExemptFromUnderwriterCommissionMember" name="OfferingExemptFromUnderwriterCommissionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_OmnibusEquityIncentivePlan2012Member" name="OmnibusEquityIncentivePlan2012Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_OperatingLossCarryforwardLimitationsOnUseAmount" name="OperatingLossCarryforwardLimitationsOnUseAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount" name="OperatingLossCarryforwardLimitationsOnUseAnnualAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="axdx_OperatingLossCarryforwardsGross" name="OperatingLossCarryforwardsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="axdx_OptionsExercisableMember" name="OptionsExercisableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_OptionsOutstandingMember" name="OptionsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_OptionsVestedAndExpectedToVestMember" name="OptionsVestedAndExpectedToVestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_OracleInstitutionalPartnersL.P.Member" name="OracleInstitutionalPartnersL.P.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_OraclePartnersL.P.Member" name="OraclePartnersL.P.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ProceedsFromSaleofCommonStockGross" name="ProceedsFromSaleofCommonStockGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="axdx_ProceedsfromIssuanceofWarrantsGross" name="ProceedsfromIssuanceofWarrantsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_PropertyAndEquipmentDetailsNarrativeAbstract" name="PropertyAndEquipmentDetailsNarrativeAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract" name="PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_PublicOfferingMember" name="PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum" name="RevenueRecognitionMilestoneMethodAnnualWagesMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour" name="RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne" name="RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree" name="RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo" name="RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment" name="RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones" name="RevenueRecognitionMilestoneMethodNumberOfMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums" name="RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_RightsOfferingMember" name="RightsOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2" name="SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_SharebasedCompensationAwardTrancheFourMember" name="SharebasedCompensationAwardTrancheFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_StandbyPurchasersMember" name="StandbyPurchasersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" name="SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_UnderwritingDiscountandCommissionFeesPerShare" name="UnderwritingDiscountandCommissionFeesPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_UnrealizedGainsMember" name="UnrealizedGainsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_UnrealizedLossesMember" name="UnrealizedLossesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="axdx_UnrecognizedTaxBenefitsOtherDecrease" name="UnrecognizedTaxBenefitsOtherDecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="axdx_UnrecognizedTaxBenefitsOtherIncrease" name="UnrecognizedTaxBenefitsOtherIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>axdx-20151231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://acceleratediagnostics.com/role/Commitments" xlink:href="axdx-20151231.xsd#Commitments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails" xlink:href="axdx-20151231.xsd#CommitmentsCapitalLeaseObligationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative" xlink:href="axdx-20151231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails" xlink:href="axdx-20151231.xsd#CommitmentsOperatingLeaseObligationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsTables" xlink:href="axdx-20151231.xsd#CommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets" xlink:href="axdx-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="axdx-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncome" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DocumentAndEntityInformation" xlink:href="axdx-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EarningsPerShare" xlink:href="axdx-20151231.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative" xlink:href="axdx-20151231.xsd#EarningsPerShareDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxes" xlink:href="axdx-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:href="axdx-20151231.xsd#IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd" xlink:href="axdx-20151231.xsd#IncomeTaxesDetailsNarrativeUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesEffectiveTaxRateDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesTables" xlink:href="axdx-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/Investments" xlink:href="axdx-20151231.xsd#Investments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails" xlink:href="axdx-20151231.xsd#InvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails1" xlink:href="axdx-20151231.xsd#InvestmentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsTables" xlink:href="axdx-20151231.xsd#InvestmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants" xlink:href="axdx-20151231.xsd#LicenseAgreementsAndGrants" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1" xlink:href="axdx-20151231.xsd#LicenseAgreementsAndGrantsDetailsNarrative1" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:href="axdx-20151231.xsd#OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipment" xlink:href="axdx-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PublicOfferingDetails" xlink:href="axdx-20151231.xsd#PublicOfferingDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PublicOfferingNotes" xlink:href="axdx-20151231.xsd#PublicOfferingNotes" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/RightsOffering" xlink:href="axdx-20151231.xsd#RightsOffering" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative" xlink:href="axdx-20151231.xsd#RightsOfferingDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/Segments" xlink:href="axdx-20151231.xsd#Segments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails" xlink:href="axdx-20151231.xsd#SegmentsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/StockPurchase" xlink:href="axdx-20151231.xsd#StockPurchase" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative" xlink:href="axdx-20151231.xsd#StockPurchaseDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SubsequentEvents" xlink:href="axdx-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:href="axdx-20151231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformationTables" xlink:type="simple" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/Commitments" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_a61b82b7-ad08-281e-e312-ce66af899f87" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_a61b82b7-ad08-281e-e312-ce66af899f87" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_e3cd86d5-3ed8-757b-6677-a0d23830c6ac" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_e3cd86d5-3ed8-757b-6677-a0d23830c6ac" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_96758b91-3e32-7021-71f0-7f00c6f170b8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_96758b91-3e32-7021-71f0-7f00c6f170b8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_c6c61bdb-7d40-5aa5-ee14-dd7f97a8f4fc" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_c6c61bdb-7d40-5aa5-ee14-dd7f97a8f4fc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_013e722d-3ffa-873f-3749-9676612475c5" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_013e722d-3ffa-873f-3749-9676612475c5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_dd72900f-6af3-6b48-6cc3-cad792bce9d9" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_c4caf5d5-78a3-6d34-8149-1cb46b32bec9" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_dd72900f-6af3-6b48-6cc3-cad792bce9d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_94f0df1c-7cd7-be99-d16c-37af6cedcf76" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_a61b82b7-ad08-281e-e312-ce66af899f87" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_94f0df1c-7cd7-be99-d16c-37af6cedcf76" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_d39c4e5b-c56e-7bef-78a0-aaaecb217a7a" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a329292c-67ac-0030-2d90-e18d188691fe" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_d39c4e5b-c56e-7bef-78a0-aaaecb217a7a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a329292c-67ac-0030-2d90-e18d188691fe" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d0d481f0-55e7-c97c-ec8d-df7b34e55256" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_d39c4e5b-c56e-7bef-78a0-aaaecb217a7a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d0d481f0-55e7-c97c-ec8d-df7b34e55256" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b90d3e1a-4d8a-a6c8-154e-2ac9658c1ba3" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_d39c4e5b-c56e-7bef-78a0-aaaecb217a7a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b90d3e1a-4d8a-a6c8-154e-2ac9658c1ba3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_50b4cfc1-5417-1ddf-07f2-e739d063c669" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_d39c4e5b-c56e-7bef-78a0-aaaecb217a7a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_50b4cfc1-5417-1ddf-07f2-e739d063c669" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_ff03b31f-ab4a-63f9-1de9-6e9385f8247b" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_d39c4e5b-c56e-7bef-78a0-aaaecb217a7a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_ff03b31f-ab4a-63f9-1de9-6e9385f8247b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_c1b68c4d-8f36-1473-28ec-224ae4a344b2" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_DeferredRevenue_c1b68c4d-8f36-1473-28ec-224ae4a344b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_e718d067-326d-eb90-55c1-75a38f63cf87" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_CapitalLeaseObligations_e718d067-326d-eb90-55c1-75a38f63cf87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_b519efac-6da3-82b7-2e09-bb4b6acc6a19" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_b519efac-6da3-82b7-2e09-bb4b6acc6a19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_9856332c-a857-2f1c-dc17-705e13149892" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_9856332c-a857-2f1c-dc17-705e13149892" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="loc_us-gaap_CommonStockOtherValueOutstanding_6313f23f-c481-ab3f-3c1b-7875816b6221" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockOtherValueOutstanding_6313f23f-c481-ab3f-3c1b-7875816b6221" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c55800a-0ae8-71c7-e1d1-5e4859c50246" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c55800a-0ae8-71c7-e1d1-5e4859c50246" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_c4a43708-2c0a-2828-3508-547aefaaa1b5" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_c4a43708-2c0a-2828-3508-547aefaaa1b5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments_329c453d-c782-00f9-2004-9bb98c37a0aa" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_Investments_329c453d-c782-00f9-2004-9bb98c37a0aa" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1a174c70-bae7-a93c-896e-3bca354d2c55" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_1a174c70-bae7-a93c-896e-3bca354d2c55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_14f3514d-b887-3e26-e467-f2a9d9f3f19e" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_OtherAssetsCurrent_14f3514d-b887-3e26-e467-f2a9d9f3f19e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5eebb39-2b5a-2098-5917-f925f42760f7" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5eebb39-2b5a-2098-5917-f925f42760f7" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4f049ff7-8681-dc23-b792-3ce76999634c" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4f049ff7-8681-dc23-b792-3ce76999634c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f35aaa1f-2797-0f16-115f-747efa62767b" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f35aaa1f-2797-0f16-115f-747efa62767b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_53119f44-eb2a-17e0-a798-9c895f2fa8ae" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_53119f44-eb2a-17e0-a798-9c895f2fa8ae" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_dc21ea28-0889-1d9c-8c89-fcbd632656b7" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_dc21ea28-0889-1d9c-8c89-fcbd632656b7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_cf2a4e30-8780-8fd7-6557-96b8ab982b19" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_cf2a4e30-8780-8fd7-6557-96b8ab982b19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_ea338a10-0904-2f10-80f3-3f09dfa9aa6f" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_ea338a10-0904-2f10-80f3-3f09dfa9aa6f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_296ac298-3acc-b888-34a0-99e6da446889" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_Depreciation_296ac298-3acc-b888-34a0-99e6da446889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_a681e3a6-1345-a173-1ad7-00e6bad44d10" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_a681e3a6-1345-a173-1ad7-00e6bad44d10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_e0c47166-10e0-b00a-6c1c-0a652da2ca7e" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_AssetImpairmentCharges_e0c47166-10e0-b00a-6c1c-0a652da2ca7e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc73bf45-b7cf-c894-bf3a-f56c9d39cbe4" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc73bf45-b7cf-c894-bf3a-f56c9d39cbe4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_e8d4ae79-a40a-c59b-cfc8-5b339045a986" xlink:type="locator" />
    <calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_e8d4ae79-a40a-c59b-cfc8-5b339045a986" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9fb8522-752c-3209-8cca-60e64f420ad5" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9fb8522-752c-3209-8cca-60e64f420ad5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5cb9a7e8-dd26-27c7-9313-c478703eadea" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5cb9a7e8-dd26-27c7-9313-c478703eadea" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_54734d8c-7af1-eb6f-7e56-5940fde2abb1" xlink:type="locator" />
    <calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_54734d8c-7af1-eb6f-7e56-5940fde2abb1" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:to="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="loc_us-gaap_SalesRevenueGoodsGross_04b980a9-d8e2-30b5-079d-a9ead3bce8e6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:to="loc_us-gaap_SalesRevenueGoodsGross_04b980a9-d8e2-30b5-079d-a9ead3bce8e6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_6982214d-e1f9-d26c-21f0-f509adb3ec07" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_OtherExpenses_6982214d-e1f9-d26c-21f0-f509adb3ec07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_35cb5177-efbf-f3ba-55ac-5a075fecc3e0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:to="loc_us-gaap_OtherNonoperatingIncome_35cb5177-efbf-f3ba-55ac-5a075fecc3e0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_67f9ebc3-3b28-5f22-4658-d01dbd0b9830" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncome_35cb5177-efbf-f3ba-55ac-5a075fecc3e0" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_67f9ebc3-3b28-5f22-4658-d01dbd0b9830" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_00233b3c-2c82-d677-6e44-556e1a8aa7a9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncome_35cb5177-efbf-f3ba-55ac-5a075fecc3e0" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_00233b3c-2c82-d677-6e44-556e1a8aa7a9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b0038b96-3060-7d4e-323c-bf1a58d62741" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b0038b96-3060-7d4e-323c-bf1a58d62741" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7fd63b12-05a5-a417-a943-a2dd6e58d717" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7fd63b12-05a5-a417-a943-a2dd6e58d717" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EarningsPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3a1af413-3358-8911-7861-13a95e291501" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3a1af413-3358-8911-7861-13a95e291501" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_70b5dec9-12bf-951f-98e3-0007ffe2e754" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_70b5dec9-12bf-951f-98e3-0007ffe2e754" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_d50b15a8-4b37-d432-9855-10a5a9927f6a" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_d50b15a8-4b37-d432-9855-10a5a9927f6a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_772f9e14-fdcf-0b3c-d185-e9c8ad74796e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_772f9e14-fdcf-0b3c-d185-e9c8ad74796e" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets" xlink:label="loc_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_347BBA54A16E3799EC4535CCA12633CD" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_347BBA54A16E3799EC4535CCA12633CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_a389aadd-88e0-5204-c954-85d1ad0adee8" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_a389aadd-88e0-5204-c954-85d1ad0adee8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_9f110c72-2314-b477-9ead-2d2caab54bc9" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_9f110c72-2314-b477-9ead-2d2caab54bc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a52f840f-bf1f-9973-7bec-feb61e7fa225" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a52f840f-bf1f-9973-7bec-feb61e7fa225" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_e4f82ad1-e90c-9c75-f0ed-65ffac49e820" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_e4f82ad1-e90c-9c75-f0ed-65ffac49e820" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="locator" />
    <calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_406aac40-50cd-6dac-9616-1ad8d5e1be85" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_55be6f60-8111-2336-cf66-f877a3b48db1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_55be6f60-8111-2336-cf66-f877a3b48db1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_72ae94ba-db0a-f76c-be66-6d2c81fa2faa" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_72ae94ba-db0a-f76c-be66-6d2c81fa2faa" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" xlink:label="loc_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_E7C13EFF9909E7D36757359AA3265980" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_E7C13EFF9909E7D36757359AA3265980" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_600e1ce2-d67d-c632-9dc0-17621aaafa46" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_600e1ce2-d67d-c632-9dc0-17621aaafa46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_f9b894e9-4739-16ea-d6f6-990994a86418" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_f9b894e9-4739-16ea-d6f6-990994a86418" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7c72534e-ef48-b3cf-6a02-3847687d670a" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7c72534e-ef48-b3cf-6a02-3847687d670a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_12705e28-9f78-d31d-49fc-8ce5ba5a8dd9" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_12705e28-9f78-d31d-49fc-8ce5ba5a8dd9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_9135c224-eb3e-a0a4-073c-13460b988068" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_9135c224-eb3e-a0a4-073c-13460b988068" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a2a6b89f-874c-eb7f-8f7d-6c46aabf3f01" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ddb71af-ee72-e71c-9687-36f2fcccd6a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a2a6b89f-874c-eb7f-8f7d-6c46aabf3f01" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/Investments" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_3a6e7e0f-bbb1-d2b4-30f7-bf28b11ef037" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7dc8bbe0-f83a-0d20-d797-6531d0d590d5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_3a6e7e0f-bbb1-d2b4-30f7-bf28b11ef037" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7dc8bbe0-f83a-0d20-d797-6531d0d590d5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3b2f26c9-c13c-2634-06c0-087e329e4c3b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_3a6e7e0f-bbb1-d2b4-30f7-bf28b11ef037" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3b2f26c9-c13c-2634-06c0-087e329e4c3b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_9776c06d-1f02-6437-69bc-75a10eb689a4" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_9776c06d-1f02-6437-69bc-75a10eb689a4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross_65485020-59c0-96ee-0d78-7f3d91b760ac" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:to="loc_us-gaap_FixturesAndEquipmentGross_65485020-59c0-96ee-0d78-7f3d91b760ac" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_dc2b42df-f998-acc8-baa5-ac2c40676775" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_dc2b42df-f998-acc8-baa5-ac2c40676775" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaap_CapitalLeasedAssetsGross_c46fae3b-0b33-f9bb-e4fe-94de2c27ce2c" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:to="loc_us-gaap_CapitalLeasedAssetsGross_c46fae3b-0b33-f9bb-e4fe-94de2c27ce2c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_da2f2068-41ff-ba19-9357-9c5e5498d481" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_da2f2068-41ff-ba19-9357-9c5e5498d481" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_e3d89e2e-3bc7-d9e2-8e7f-6471b231b5e3" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_e3d89e2e-3bc7-d9e2-8e7f-6471b231b5e3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c0591e3-817a-5563-df1e-5c3ede33266d" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c0591e3-817a-5563-df1e-5c3ede33266d" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/PublicOfferingDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/PublicOfferingNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/RightsOffering" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/Segments" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/StockPurchase" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>axdx-20151231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://acceleratediagnostics.com/role/Commitments" xlink:href="axdx-20151231.xsd#Commitments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails" xlink:href="axdx-20151231.xsd#CommitmentsCapitalLeaseObligationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative" xlink:href="axdx-20151231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails" xlink:href="axdx-20151231.xsd#CommitmentsOperatingLeaseObligationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsTables" xlink:href="axdx-20151231.xsd#CommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets" xlink:href="axdx-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="axdx-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncome" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DocumentAndEntityInformation" xlink:href="axdx-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EarningsPerShare" xlink:href="axdx-20151231.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative" xlink:href="axdx-20151231.xsd#EarningsPerShareDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxes" xlink:href="axdx-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:href="axdx-20151231.xsd#IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd" xlink:href="axdx-20151231.xsd#IncomeTaxesDetailsNarrativeUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesEffectiveTaxRateDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesTables" xlink:href="axdx-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/Investments" xlink:href="axdx-20151231.xsd#Investments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails" xlink:href="axdx-20151231.xsd#InvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails1" xlink:href="axdx-20151231.xsd#InvestmentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsTables" xlink:href="axdx-20151231.xsd#InvestmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants" xlink:href="axdx-20151231.xsd#LicenseAgreementsAndGrants" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1" xlink:href="axdx-20151231.xsd#LicenseAgreementsAndGrantsDetailsNarrative1" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:href="axdx-20151231.xsd#OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipment" xlink:href="axdx-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PublicOfferingDetails" xlink:href="axdx-20151231.xsd#PublicOfferingDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PublicOfferingNotes" xlink:href="axdx-20151231.xsd#PublicOfferingNotes" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/RightsOffering" xlink:href="axdx-20151231.xsd#RightsOffering" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative" xlink:href="axdx-20151231.xsd#RightsOfferingDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/Segments" xlink:href="axdx-20151231.xsd#Segments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails" xlink:href="axdx-20151231.xsd#SegmentsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/StockPurchase" xlink:href="axdx-20151231.xsd#StockPurchase" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative" xlink:href="axdx-20151231.xsd#StockPurchaseDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SubsequentEvents" xlink:href="axdx-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:href="axdx-20151231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformationTables" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/Commitments" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:label="loc_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ClinicalTrialAgreementLiability" xlink:label="loc_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ClinicalTrialAgreementExpense" xlink:label="loc_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToSuppliersAndEmployees" xlink:label="loc_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:to="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:to="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C76E181EAEB858D073C75C57D1DA3020" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_CommonStockMember_C76E181EAEB858D073C75C57D1DA3020" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6F1A40A0EC2E184A71985C57D1DBD72A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_NetIncomeLoss_6F1A40A0EC2E184A71985C57D1DBD72A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17C44AD63A963EB053435C57D1DB9365" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17C44AD63A963EB053435C57D1DB9365" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EarningsPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:to="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OptionsOutstandingMember" xlink:label="loc_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="loc_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OptionsExercisableMember" xlink:label="loc_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="loc_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OptionsVestedAndExpectedToVestMember" xlink:label="loc_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="loc_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a" xlink:label="loc_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:to="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:to="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OmnibusEquityIncentivePlan2012Member" xlink:label="loc_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:to="loc_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_NonQualifiedStockOptionPlanMember" xlink:label="loc_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:to="loc_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:to="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:to="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationAwardTrancheFourMember" xlink:label="loc_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:to="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CorporateBondsandNotesMember" xlink:label="loc_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="loc_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="loc_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="loc_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ArizonaDepartmentofRevenueMember" xlink:label="loc_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="loc_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxAuthoritySpainMember" xlink:label="loc_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="loc_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesDetailsNarrativeUsdAbstract" xlink:label="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:to="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardsGross" xlink:label="loc_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount" xlink:label="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardLimitationsOnUseAmount" xlink:label="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/Investments" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CostMember" xlink:label="loc_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D" xlink:to="loc_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:to="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:to="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnrealizedGainsMember" xlink:label="loc_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:to="loc_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsByCategoryAxis" xlink:label="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:to="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:to="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnrealizedLossesMember" xlink:label="loc_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:to="loc_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_FairValueMember" xlink:label="loc_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:to="loc_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:label="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E5C0F19069E6EE0D24125D419B3B186C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E5C0F19069E6EE0D24125D419B3B186C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:to="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:to="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:to="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DefenseMedicalResearchandDevelopmentProgramMember" xlink:label="loc_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:to="loc_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/PublicOfferingDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:to="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:to="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AffiliatedEntityMember" xlink:label="loc_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:to="loc_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_PublicOfferingMember" xlink:label="loc_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="loc_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OfferingExemptFromUnderwriterCommissionMember" xlink:label="loc_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="loc_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:to="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:to="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:to="loc_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_CB2EAD5911155E6547025C6948B66CEE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_SharePrice_CB2EAD5911155E6547025C6948B66CEE" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnderwritingDiscountandCommissionFeesPerShare" xlink:label="loc_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ProceedsFromSaleofCommonStockGross" xlink:label="loc_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/PublicOfferingNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_059750F4535E3CF4047C5CC9D947B284" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_059750F4535E3CF4047C5CC9D947B284" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:to="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:to="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_PublicOfferingMember" xlink:label="loc_axdx_PublicOfferingMember_CA593AB965A455FE29895CCAE16DE66C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:to="loc_axdx_PublicOfferingMember_CA593AB965A455FE29895CCAE16DE66C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_04FC50D7FAA4C50958235C6948B8148E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_059750F4535E3CF4047C5CC9D947B284" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_04FC50D7FAA4C50958235C6948B8148E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/RightsOffering" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7EC75BAAAC0263C9503F5CCF6C4FF9E5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9B3145FC9A8643403FA85CCF6C4F68BC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7EC75BAAAC0263C9503F5CCF6C4FF9E5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9B3145FC9A8643403FA85CCF6C4F68BC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9B3145FC9A8643403FA85CCF6C4F68BC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RightsOfferingMember" xlink:label="loc_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:to="loc_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7EC75BAAAC0263C9503F5CCF6C4FF9E5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:to="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_StandbyPurchasersMember" xlink:label="loc_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="loc_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OracleInstitutionalPartnersL.P.Member" xlink:label="loc_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="loc_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OraclePartnersL.P.Member" xlink:label="loc_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="loc_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="loc_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ProceedsfromIssuanceofWarrantsGross" xlink:label="loc_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/Segments" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/StockPurchase" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SubsequentEvents" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:to="loc_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:to="loc_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CertificateOfQualificationAbstract" xlink:label="loc_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:to="loc_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AC82353D3B62304341C33471849A7C97" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AC82353D3B62304341C33471849A7C97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RefundsDueUnderGovernmentContracts" xlink:label="loc_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:to="loc_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:to="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:to="loc_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DenverHealthMember" xlink:label="loc_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:to="loc_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>axdx-20151231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:to="lab_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:type="arc" />
    <link:label id="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE_terseLabel_en-US" xlink:label="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Purchasers</link:label>
    <link:label id="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE_label_en-US" xlink:label="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Purchasers [Member]</link:label>
    <link:label id="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE_documentation_en-US" xlink:label="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standby Purchasers [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_StandbyPurchasersMember" xlink:label="loc_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:to="lab_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:type="arc" />
    <link:label id="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15_terseLabel_en-US" xlink:label="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oracle Institutional Partners, L.P.</link:label>
    <link:label id="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15_label_en-US" xlink:label="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oracle Institutional Partners, L.P. [Member]</link:label>
    <link:label id="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15_documentation_en-US" xlink:label="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oracle Institutional Partners, L.P. [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OracleInstitutionalPartnersL.P.Member" xlink:label="loc_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:to="lab_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:type="arc" />
    <link:label id="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360_terseLabel_en-US" xlink:label="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oracle Partners, L.P.</link:label>
    <link:label id="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360_label_en-US" xlink:label="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oracle Partners, L.P. [Member]</link:label>
    <link:label id="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360_documentation_en-US" xlink:label="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oracle Partners, L.P. [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OraclePartnersL.P.Member" xlink:label="loc_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:to="lab_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-transferable subscription rights for each share of common stock owned on the record date (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Share Subscriptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="loc_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:to="lab_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subscription right to purchase common stock (dollar per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723_label_en-US" xlink:label="lab_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:to="lab_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby purchase agreement issuance of unsubscribed shares to related party (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:type="arc" />
    <link:label id="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E_terseLabel_en-US" xlink:label="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from issuance of warrants</link:label>
    <link:label id="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E_label_en-US" xlink:label="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants, Gross</link:label>
    <link:label id="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E_documentation_en-US" xlink:label="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants, Gross</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ProceedsfromIssuanceofWarrantsGross" xlink:label="loc_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:to="lab_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with rights offering</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Contractual Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:to="lab_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC_label_en-US" xlink:label="lab_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:to="lab_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:to="lab_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:type="arc" />
    <link:label id="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817_terseLabel_en-US" xlink:label="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817_label_en-US" xlink:label="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bonds and Notes [Member]</link:label>
    <link:label id="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817_documentation_en-US" xlink:label="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Bonds and Notes [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_CorporateBondsandNotesMember" xlink:label="loc_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:to="lab_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_AD2D47F1905E017409A833B9087FC0B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_322C98C78BA44A20BB9133B9087F6FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:to="lab_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="lab_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77_label_en-US" xlink:label="lab_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Net of Interest Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesNetOfInterestExpenseAbstract" xlink:label="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:to="lab_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing and royalty revenues</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:to="lab_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="loc_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:to="lab_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF_totalLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:to="lab_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangibles</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E_label_en-US" xlink:label="lab_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:to="lab_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:to="lab_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:to="lab_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense and other</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:to="lab_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:to="lab_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:to="lab_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E" xlink:to="lab_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F" xlink:to="lab_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive common stock instruments outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887_label_en-US" xlink:label="lab_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:to="lab_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of investment discount</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Amortization of Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:to="lab_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:to="lab_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in assets:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue and income</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:type="arc" />
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and warrants</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="lab_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fisher agreement</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:to="lab_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:type="arc" />
    <link:label id="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1_terseLabel_en-US" xlink:label="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Use Only Accelerate ID/AST systems</link:label>
    <link:label id="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1_label_en-US" xlink:label="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Research Use Only</link:label>
    <link:label id="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1_documentation_en-US" xlink:label="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Research Use Only</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_DeferredRevenueResearchUseOnly" xlink:label="loc_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:to="lab_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Use Only Accelerate ID/AST systems</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Arizona Commerce Authority grant</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fisher agreement</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total long-term deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue and Credits, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:to="lab_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:type="arc" />
    <link:label id="lab_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E_label_en-US" xlink:label="lab_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property And Equipment Details Narrative</link:label>
    <link:label id="lab_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E_documentation_en-US" xlink:label="lab_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_PropertyAndEquipmentDetailsNarrativeAbstract" xlink:label="loc_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:to="lab_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_661F9CCABD3F2AE82F365CCF6C4F08E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_3FCCFF05199B842829F75CCF6C4FA11A" xlink:type="arc" />
    <link:label id="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC_terseLabel_en-US" xlink:label="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights Offering</link:label>
    <link:label id="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC_label_en-US" xlink:label="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rights Offering [Member]</link:label>
    <link:label id="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC_documentation_en-US" xlink:label="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rights Offering [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RightsOfferingMember" xlink:label="loc_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:to="lab_axdx_RightsOfferingMember_7E5E1451C2FCDB215A3D5CCF6C4FE7DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46F3F965C30F559D57965CCF6C505353" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2016</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease obligations</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:to="lab_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF_label_en-US" xlink:label="lab_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Financing Transactions Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:to="lab_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Financing Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6_label_en-US" xlink:label="lab_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Financing Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionsAbstract" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="lab_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF" xlink:type="arc" />
    <link:label id="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA_terseLabel_en-US" xlink:label="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock and warrants purchase price</link:label>
    <link:label id="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA_label_en-US" xlink:label="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock And Warrants Issued, Value</link:label>
    <link:label id="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA_documentation_en-US" xlink:label="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock And Warrants Issued, Value</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_CommonStockAndWarrantsIssuedValue" xlink:label="loc_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:to="lab_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Indexed Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:type="arc" />
    <link:label id="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8_terseLabel_en-US" xlink:label="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per warrant</link:label>
    <link:label id="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8_label_en-US" xlink:label="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Price per warrant</link:label>
    <link:label id="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8_documentation_en-US" xlink:label="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3" xlink:label="loc_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:to="lab_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:type="arc" />
    <link:label id="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD_terseLabel_en-US" xlink:label="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised warrants (percent)</link:label>
    <link:label id="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD_label_en-US" xlink:label="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised Warrant, Percent Exercised</link:label>
    <link:label id="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD_documentation_en-US" xlink:label="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercised Warrant, Percent Exercised</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ExercisedWarrantPercentExercised" xlink:label="loc_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:to="lab_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:type="arc" />
    <link:label id="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F_terseLabel_en-US" xlink:label="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised warrant per purchase agreement</link:label>
    <link:label id="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F_label_en-US" xlink:label="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised warrant per purchase agreement</link:label>
    <link:label id="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F_documentation_en-US" xlink:label="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of issuer's shares to which the option contract is indexed.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:to="lab_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:type="arc" />
    <link:label id="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868_terseLabel_en-US" xlink:label="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional warrant to purchase common stock</link:label>
    <link:label id="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868_label_en-US" xlink:label="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional warrant to purchase common stock</link:label>
    <link:label id="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868_documentation_en-US" xlink:label="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of issuer's shares to which the option contract is indexed.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:to="lab_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:type="arc" />
    <link:label id="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B_verboseLabel_en-US" xlink:label="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Price per warrant</link:label>
    <link:label id="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B_label_en-US" xlink:label="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2</link:label>
    <link:label id="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B_documentation_en-US" xlink:label="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional exercise price per share or per unit of warrants or rights outstanding.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:to="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:type="arc" />
    <link:label id="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2_terseLabel_en-US" xlink:label="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional exercised warrant per purchase agreement</link:label>
    <link:label id="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2_label_en-US" xlink:label="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional exercised warrant per purchase agreement</link:label>
    <link:label id="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2_documentation_en-US" xlink:label="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of issuer's shares to which the option contract is indexed.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:to="lab_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:type="arc" />
    <link:label id="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238_terseLabel_en-US" xlink:label="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unexercised warrants</link:label>
    <link:label id="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238_label_en-US" xlink:label="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised Warrant, Amount Unexercised</link:label>
    <link:label id="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238_documentation_en-US" xlink:label="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercised Warrant, Amount Unexercised</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ExercisedWarrantAmountUnexercised" xlink:label="loc_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:to="lab_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:type="arc" />
    <link:label id="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89_verboseLabel_en-US" xlink:label="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Price per warrant</link:label>
    <link:label id="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89_label_en-US" xlink:label="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</link:label>
    <link:label id="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89_documentation_en-US" xlink:label="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share or per unit of warrants or rights outstanding.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:to="lab_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of warrants</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:to="lab_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in less than 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in 1-3 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Owned, at Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:to="lab_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_D58941E34E23ECF8FEED353E3941CA51_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_D58941E34E23ECF8FEED353E3941CA51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_D58941E34E23ECF8FEED353E3941CA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_D58941E34E23ECF8FEED353E3941CA51" xlink:to="lab_us-gaap_SalesRevenueNet_D58941E34E23ECF8FEED353E3941CA51" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9C9B3613F0AFB8A73868353E3941C76D_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9C9B3613F0AFB8A73868353E3941C76D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9C9B3613F0AFB8A73868353E3941C76D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9C9B3613F0AFB8A73868353E3941C76D" xlink:to="lab_us-gaap_NetIncomeLoss_9C9B3613F0AFB8A73868353E3941C76D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8E8E633ED26A5C14835D353E3941C799" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes Assumptions for Option Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Supplemental Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Compensation Expense and Tax Benefit</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:to="lab_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:to="lab_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:type="arc" />
    <link:label id="lab_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195_label_en-US" xlink:label="lab_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:label id="lab_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195_documentation_en-US" xlink:label="lab_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_DocumentAndEntityInformationAbstract" xlink:label="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="lab_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83_label_en-US" xlink:label="lab_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:to="lab_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:to="lab_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89_label_en-US" xlink:label="lab_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:to="lab_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:to="lab_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427_label_en-US" xlink:label="lab_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:to="lab_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:to="lab_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:to="lab_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:to="lab_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4_label_en-US" xlink:label="lab_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:to="lab_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919_label_en-US" xlink:label="lab_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:to="lab_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:to="lab_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:to="lab_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:to="lab_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="lab_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B_terseLabel_en-US" xlink:label="lab_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B_label_en-US" xlink:label="lab_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:to="lab_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:to="lab_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:to="lab_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:to="lab_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F_label_en-US" xlink:label="lab_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:to="lab_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:to="lab_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue and income</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:to="lab_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligations</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:to="lab_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:to="lab_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred income</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Other than Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:to="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term capital lease obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38_label_en-US" xlink:label="lab_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:to="lab_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:to="lab_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="lab_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 55,000,000 common shares authorized 51,191,184 (as of December 31, 2015) and 44,639,829 (as of December 31, 2014) shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="loc_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:to="lab_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 preferred shares authorized and none outstanding as of December 31, 2015 and December 31, 2014</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:to="lab_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:to="lab_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC" xlink:to="lab_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:to="lab_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Indexed To Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:type="arc" />
    <link:label id="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972_terseLabel_en-US" xlink:label="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972_label_en-US" xlink:label="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972_documentation_en-US" xlink:label="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OptionsOutstandingMember" xlink:label="loc_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:to="lab_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:type="arc" />
    <link:label id="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626_terseLabel_en-US" xlink:label="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626_label_en-US" xlink:label="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626_documentation_en-US" xlink:label="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Exercisable</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OptionsExercisableMember" xlink:label="loc_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:to="lab_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:type="arc" />
    <link:label id="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A_terseLabel_en-US" xlink:label="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Vested and Expected to Vest</link:label>
    <link:label id="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A_label_en-US" xlink:label="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Vested and Expected To Vest</link:label>
    <link:label id="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A_documentation_en-US" xlink:label="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Vested and Expected To Vest</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OptionsVestedAndExpectedToVestMember" xlink:label="loc_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:to="lab_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:type="arc" />
    <link:label id="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC_terseLabel_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC_label_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC_documentation_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average period between the balance sheet date and expiration for all awards outstanding under the plan, which may be expressed in a decimal value for number of years.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a" xlink:label="loc_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:to="lab_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value (in thousands)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:type="arc" />
    <link:label id="lab_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83_label_en-US" xlink:label="lab_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements and Grants - Research and Development [Abstract]</link:label>
    <link:label id="lab_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83_documentation_en-US" xlink:label="lab_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements and Grants - Research and Development [Abstract]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract" xlink:label="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="lab_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F_label_en-US" xlink:label="lab_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:to="lab_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:type="arc" />
    <link:label id="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56_terseLabel_en-US" xlink:label="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defense Medical Research and Development Program [Member]</link:label>
    <link:label id="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56_label_en-US" xlink:label="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defense Medical Research and Development Program [Member]</link:label>
    <link:label id="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56_documentation_en-US" xlink:label="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defense Medical Research and Development Program [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_DefenseMedicalResearchandDevelopmentProgramMember" xlink:label="loc_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:to="lab_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total grant funding</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offset to research and development project</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified jobs created, milestone one</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone One</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone One</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified jobs created, milestone two</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Two</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Two</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified jobs created, milestone three</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Three</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Three</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified jobs created, milestone four</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Four</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Four</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital investment milestone</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Minimum Capital Investment</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestone, Minimum Capital Investment</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant related minimum annual wages</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Annual Wages, Minimum</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Annual Wages, Minimum</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:type="arc" />
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242_terseLabel_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of company paid premiums</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242_label_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Percent of Company Paid Premiums</link:label>
    <link:label id="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242_documentation_en-US" xlink:label="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Percent of Company Paid Premiums</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:to="lab_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:type="arc" />
    <link:label id="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C_terseLabel_en-US" xlink:label="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity-based compensation plans</link:label>
    <link:label id="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C_label_en-US" xlink:label="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Number of Plans</link:label>
    <link:label id="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C_documentation_en-US" xlink:label="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Number of Plans</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_EmployeeServiceSharebasedCompensationNumberofPlans" xlink:label="loc_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:to="lab_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:type="arc" />
    <link:label id="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119_terseLabel_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified Stock Option Plan</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119_label_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Plan One [Abstract]</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119_documentation_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Plan One [Abstract]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract" xlink:label="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:to="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options available (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options available</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:type="arc" />
    <link:label id="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000_terseLabel_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Qualified Stock Option Plan</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000_label_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Plan Two [Abstract]</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000_documentation_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Plan Two [Abstract]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract" xlink:label="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:to="lab_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E_verboseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F_verboseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1_verboseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options available (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2004 Omnibus Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options available (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2012 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional shares authorized (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8_verboseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03_verboseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6_verboseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options available (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received from the exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from share-based compensation</link:label>
    <link:label id="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F_label_en-US" xlink:label="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds and Excess Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:to="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized equity-based compensation cos</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C" xlink:to="lab_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:to="lab_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD_terseLabel_en-US" xlink:label="lab_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:label id="lab_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD_label_en-US" xlink:label="lab_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AffiliatedEntityMember" xlink:label="loc_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:to="lab_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:type="arc" />
    <link:label id="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D_terseLabel_en-US" xlink:label="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D_label_en-US" xlink:label="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D_documentation_en-US" xlink:label="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_PublicOfferingMember" xlink:label="loc_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:to="lab_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:to="lab_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:type="arc" />
    <link:label id="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788_terseLabel_en-US" xlink:label="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering Exempt From Underwriter Commission [Member]</link:label>
    <link:label id="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788_label_en-US" xlink:label="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Exempt From Underwriter Commission [Member]</link:label>
    <link:label id="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788_documentation_en-US" xlink:label="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Exempt From Underwriter Commission [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OfferingExemptFromUnderwriterCommissionMember" xlink:label="loc_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:to="lab_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:to="lab_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:to="lab_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="lab_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and warrants (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:type="arc" />
    <link:label id="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB_terseLabel_en-US" xlink:label="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting discount and commission fees (dollars per share)</link:label>
    <link:label id="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB_label_en-US" xlink:label="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriting Discount and Commission Fees, Per Share</link:label>
    <link:label id="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB_documentation_en-US" xlink:label="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriting Discount and Commission Fees, Per Share</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_UnderwritingDiscountandCommissionFeesPerShare" xlink:label="loc_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:to="lab_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:type="arc" />
    <link:label id="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785_terseLabel_en-US" xlink:label="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
    <link:label id="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785_label_en-US" xlink:label="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of Common Stock, Gross</link:label>
    <link:label id="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785_documentation_en-US" xlink:label="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of Common Stock, Gross</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ProceedsFromSaleofCommonStockGross" xlink:label="loc_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:to="lab_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Nature of Business; Basis of Presentation; Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:to="lab_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:to="lab_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:type="arc" />
    <link:label id="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7_terseLabel_en-US" xlink:label="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arizona Department of Revenue</link:label>
    <link:label id="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7_label_en-US" xlink:label="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arizona Department of Revenue [Member]</link:label>
    <link:label id="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7_documentation_en-US" xlink:label="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arizona Department of Revenue [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ArizonaDepartmentofRevenueMember" xlink:label="loc_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:to="lab_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732_terseLabel_en-US" xlink:label="lab_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spanish Tax Authority</link:label>
    <link:label id="lab_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732_label_en-US" xlink:label="lab_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Authority, Spain [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxAuthoritySpainMember" xlink:label="loc_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:to="lab_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:type="arc" />
    <link:label id="lab_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E_label_en-US" xlink:label="lab_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Details Narrative Usd</link:label>
    <link:label id="lab_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E_documentation_en-US" xlink:label="lab_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesDetailsNarrativeUsdAbstract" xlink:label="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="lab_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:type="arc" />
    <link:label id="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D_terseLabel_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross operating loss carryforwards</link:label>
    <link:label id="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D_label_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Gross</link:label>
    <link:label id="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D_documentation_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Gross</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardsGross" xlink:label="loc_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:to="lab_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:type="arc" />
    <link:label id="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02_terseLabel_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, Sec. 382 limitation</link:label>
    <link:label id="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02_label_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Limitations On Use, Annual Amount</link:label>
    <link:label id="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02_documentation_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Limitations On Use, Annual Amount</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount" xlink:label="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:to="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:type="arc" />
    <link:label id="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2_terseLabel_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, expected to be unrealized</link:label>
    <link:label id="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2_label_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Limitations On Use, Amount</link:label>
    <link:label id="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2_documentation_en-US" xlink:label="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Limitations On Use, Amount</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardLimitationsOnUseAmount" xlink:label="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:to="lab_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:to="lab_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expired (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, ending balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaudited Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:type="arc" />
    <link:label id="lab_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D_label_en-US" xlink:label="lab_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies Details Narrative</link:label>
    <link:label id="lab_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D_documentation_en-US" xlink:label="lab_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:label="loc_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:to="lab_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="lab_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:to="lab_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:to="lab_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:to="lab_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:type="arc" />
    <link:label id="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389_terseLabel_en-US" xlink:label="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denver Health</link:label>
    <link:label id="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389_label_en-US" xlink:label="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denver Health [Member]</link:label>
    <link:label id="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389_documentation_en-US" xlink:label="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denver Health [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_DenverHealthMember" xlink:label="loc_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:to="lab_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk concentration</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:to="lab_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:to="lab_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB_label_en-US" xlink:label="lab_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:to="lab_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and warrants (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Change in Net Unrealized Holding Gain (Loss) before Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:to="lab_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A" xlink:to="lab_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C" xlink:to="lab_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue and Income</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Deferred Revenue [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="loc_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C" xlink:to="lab_us-gaap_RevenueRecognitionDeferredRevenue_4D02A47CBA8326CBFC64341AC66A819C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2016</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2017</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2018</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2019</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31, 2020</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less amount representing interest</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value minimum lease payments</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Purchase</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers and Servicing of Financial Assets [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee and Consultant Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3_label_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefits and Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized tax benefit</link:label>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5_label_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:to="lab_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Pretax Loss from Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain Tax Positions</link:label>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514_label_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:to="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:type="arc" />
    <link:label id="lab_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6_label_en-US" xlink:label="lab_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes - Effective Tax Rate Details</link:label>
    <link:label id="lab_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6_documentation_en-US" xlink:label="lab_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract" xlink:label="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="lab_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:type="arc" />
    <link:label id="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA_terseLabel_en-US" xlink:label="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA_label_en-US" xlink:label="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences, Percent</link:label>
    <link:label id="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA_documentation_en-US" xlink:label="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences, Percent</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" xlink:label="loc_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:to="lab_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible equity and other compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limitation on net operating losses due to &#167;382</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Credit for increased research activities</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814_periodStartLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted stock outstanding, including both vested and non-vested options.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested/Released (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD_periodEndLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Outstanding, ending balance (shares)</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Outstanding, beginning balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (dollars per share)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:to="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (dollars per share)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:to="lab_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested/Released (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Outstanding, ending balance (dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533" xlink:type="arc" />
    <link:label id="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6_terseLabel_en-US" xlink:label="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements and Grants</link:label>
    <link:label id="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6_label_en-US" xlink:label="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements and Grants</link:label>
    <link:label id="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6_documentation_en-US" xlink:label="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreements</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_LicenseAgreement" xlink:label="loc_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:to="lab_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue and Income Summary</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A" xlink:to="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_BFA8231AC546EE0392C0341B1187B36A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:to="lab_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable Allowances</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330_terseLabel_en-US" xlink:label="lab_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330_label_en-US" xlink:label="lab_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="loc_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:to="lab_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases in Financial Statements of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:to="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases Obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases of Lessee Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:to="lab_us-gaap_SubsequentEventTable_73058E934B7B040D5ED5345952BAFA0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_EE5473B2687B5509BBBF345952BA3DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_F9E6D71B48CE3117C3F2345952BA3030" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:to="lab_us-gaap_SubsequentEventMember_FB8B62612C93AC67E33D345952BA31D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:to="lab_us-gaap_SubsequentEventLineItems_A0238A5FE5F3AAD6A9F8345952BA8B52" xlink:type="arc" />
    <link:label id="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC_terseLabel_en-US" xlink:label="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificate of Qualification</link:label>
    <link:label id="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC_label_en-US" xlink:label="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificate of Qualification</link:label>
    <link:label id="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC_documentation_en-US" xlink:label="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certificate of Qualification</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_CertificateOfQualificationAbstract" xlink:label="loc_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:to="lab_axdx_CertificateOfQualificationAbstract_A18CE53D1445598091A2345952BABCDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A_terseLabel_en-US" xlink:label="lab_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A_label_en-US" xlink:label="lab_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds Due under Government Contracts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RefundsDueUnderGovernmentContracts" xlink:label="loc_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:to="lab_us-gaap_RefundsDueUnderGovernmentContracts_1D7561B3BD4F8FFE2EB5345952BAB52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:to="lab_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:to="lab_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:type="arc" />
    <link:label id="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1_terseLabel_en-US" xlink:label="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2012 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1_label_en-US" xlink:label="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omnibus Equity Incentive Plan, 2012 [Member]</link:label>
    <link:label id="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1_documentation_en-US" xlink:label="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omnibus Equity Incentive Plan, 2012 [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_OmnibusEquityIncentivePlan2012Member" xlink:label="loc_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:to="lab_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:type="arc" />
    <link:label id="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5_terseLabel_en-US" xlink:label="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Qualified Stock Option Plan [Member]</link:label>
    <link:label id="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5_label_en-US" xlink:label="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Qualified Stock Option Plan [Member]</link:label>
    <link:label id="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5_documentation_en-US" xlink:label="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Qualified Stock Option Plan [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_NonQualifiedStockOptionPlanMember" xlink:label="loc_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:to="lab_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:to="lab_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:to="lab_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920_label_en-US" xlink:label="lab_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:to="lab_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D_label_en-US" xlink:label="lab_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="lab_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting terms (i), cliff vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting terms (ii), monthly vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting terms (iii), cliff vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:type="arc" />
    <link:label id="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A_terseLabel_en-US" xlink:label="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting terms (iii), monthly vesting</link:label>
    <link:label id="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A_label_en-US" xlink:label="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Four [Member]</link:label>
    <link:label id="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A_documentation_en-US" xlink:label="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Four [Member]</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationAwardTrancheFourMember" xlink:label="loc_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:to="lab_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property &amp; equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:type="arc" />
    <link:label id="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C_terseLabel_en-US" xlink:label="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, definite-lived</link:label>
    <link:label id="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C_label_en-US" xlink:label="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C_documentation_en-US" xlink:label="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Finite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets" xlink:label="loc_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:to="lab_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General business credit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charitable contribution</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:to="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:type="arc" />
    <link:label id="lab_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67_label_en-US" xlink:label="lab_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property And Equipment - Property And Equipment Details Usd</link:label>
    <link:label id="lab_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67_documentation_en-US" xlink:label="lab_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract" xlink:label="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="lab_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:to="lab_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF_terseLabel_en-US" xlink:label="lab_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technical equipment</link:label>
    <link:label id="lab_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF_label_en-US" xlink:label="lab_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixtures and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:to="lab_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease &#8211; leasehold improvements</link:label>
    <link:label id="lab_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2_label_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leased Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:to="lab_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital projects in progress</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization &#8211; capital lease</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Net Investment in Direct Financing Leases, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:to="lab_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation - other</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:to="lab_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:to="lab_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capital Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capital Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:to="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19_label_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="lab_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289_label_en-US" xlink:label="lab_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Lessee, Assets under Capital Lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:label="loc_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:to="lab_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense for Tuscan facility</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:to="lab_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:type="arc" />
    <link:label id="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C_terseLabel_en-US" xlink:label="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement Liability</link:label>
    <link:label id="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C_label_en-US" xlink:label="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement Liability</link:label>
    <link:label id="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C_documentation_en-US" xlink:label="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement Liability</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ClinicalTrialAgreementLiability" xlink:label="loc_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:to="lab_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:type="arc" />
    <link:label id="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F_terseLabel_en-US" xlink:label="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement Expense</link:label>
    <link:label id="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F_label_en-US" xlink:label="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement Expense</link:label>
    <link:label id="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F_documentation_en-US" xlink:label="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement Expense</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ClinicalTrialAgreementExpense" xlink:label="loc_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:to="lab_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting fees</link:label>
    <link:label id="lab_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB_label_en-US" xlink:label="lab_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Suppliers and Employees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToSuppliersAndEmployees" xlink:label="loc_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:to="lab_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:type="arc" />
    <link:label id="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8_terseLabel_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in year)</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8_label_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (in year)</link:label>
    <link:label id="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8_documentation_en-US" xlink:label="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time an equity-based award is expected to be outstanding. An equity-based award's expected term is generally determined based on, among other factors, the instrument's contractual term and the effects of employees' expected exercise and post-vesting employment termination behavior.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2" xlink:label="loc_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:to="lab_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rates (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:type="arc" />
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA_terseLabel_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated forfeitures (percent)</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA_label_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated forfeitures</link:label>
    <link:label id="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA_documentation_en-US" xlink:label="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of shares under option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:to="lab_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per share (dollars per share)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2_label_en-US" xlink:label="lab_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Price Earnings Ratio Multiple</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsPriceEarningsRatioMultiple" xlink:label="loc_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:to="lab_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:type="arc" />
    <link:label id="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7_terseLabel_en-US" xlink:label="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7_label_en-US" xlink:label="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7_documentation_en-US" xlink:label="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_CostMember" xlink:label="loc_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:to="lab_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:to="lab_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:type="arc" />
    <link:label id="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F_terseLabel_en-US" xlink:label="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F_label_en-US" xlink:label="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F_documentation_en-US" xlink:label="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_UnrealizedGainsMember" xlink:label="loc_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:to="lab_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Category [Axis]</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments by Category [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsByCategoryAxis" xlink:label="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:to="lab_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Investments Held at Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities and Investments Held at Cost [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:to="lab_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:type="arc" />
    <link:label id="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133_terseLabel_en-US" xlink:label="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133_label_en-US" xlink:label="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133_documentation_en-US" xlink:label="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_UnrealizedLossesMember" xlink:label="loc_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:to="lab_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:type="arc" />
    <link:label id="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA_terseLabel_en-US" xlink:label="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA_label_en-US" xlink:label="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA_documentation_en-US" xlink:label="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_FairValueMember" xlink:label="loc_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:to="lab_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:label="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:to="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:type="arc" />
    <link:label id="lab_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF_label_en-US" xlink:label="lab_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes - Uncertain Tax Positions Details</link:label>
    <link:label id="lab_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF_documentation_en-US" xlink:label="lab_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract" xlink:label="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="lab_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for prior positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:type="arc" />
    <link:label id="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291_terseLabel_en-US" xlink:label="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Increases</link:label>
    <link:label id="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291_label_en-US" xlink:label="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Other Increase</link:label>
    <link:label id="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291_documentation_en-US" xlink:label="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Other Increase</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_UnrecognizedTaxBenefitsOtherIncrease" xlink:label="loc_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:to="lab_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases due to settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expiration of the statute of limitations for the assessment of taxes</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:type="arc" />
    <link:label id="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7_negatedTerseLabel_en-US" xlink:label="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other Decreases</link:label>
    <link:label id="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7_label_en-US" xlink:label="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Other Decrease</link:label>
    <link:label id="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7_documentation_en-US" xlink:label="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Other Decrease</link:label>
    <link:loc xlink:href="axdx-20151231.xsd#axdx_UnrecognizedTaxBenefitsOtherDecrease" xlink:label="loc_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:to="lab_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>axdx-20151231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://acceleratediagnostics.com/role/Commitments" xlink:href="axdx-20151231.xsd#Commitments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails" xlink:href="axdx-20151231.xsd#CommitmentsCapitalLeaseObligationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative" xlink:href="axdx-20151231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails" xlink:href="axdx-20151231.xsd#CommitmentsOperatingLeaseObligationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/CommitmentsTables" xlink:href="axdx-20151231.xsd#CommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets" xlink:href="axdx-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="axdx-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="axdx-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncome" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables" xlink:href="axdx-20151231.xsd#DeferredRevenueAndIncomeTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/DocumentAndEntityInformation" xlink:href="axdx-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EarningsPerShare" xlink:href="axdx-20151231.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative" xlink:href="axdx-20151231.xsd#EarningsPerShareDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables" xlink:href="axdx-20151231.xsd#EmployeeAndConsultantEquityBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="axdx-20151231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxes" xlink:href="axdx-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:href="axdx-20151231.xsd#IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd" xlink:href="axdx-20151231.xsd#IncomeTaxesDetailsNarrativeUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesEffectiveTaxRateDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesTables" xlink:href="axdx-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="axdx-20151231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/Investments" xlink:href="axdx-20151231.xsd#Investments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails" xlink:href="axdx-20151231.xsd#InvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsDetails1" xlink:href="axdx-20151231.xsd#InvestmentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/InvestmentsTables" xlink:href="axdx-20151231.xsd#InvestmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants" xlink:href="axdx-20151231.xsd#LicenseAgreementsAndGrants" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1" xlink:href="axdx-20151231.xsd#LicenseAgreementsAndGrantsDetailsNarrative1" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:href="axdx-20151231.xsd#OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipment" xlink:href="axdx-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables" xlink:href="axdx-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PublicOfferingDetails" xlink:href="axdx-20151231.xsd#PublicOfferingDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/PublicOfferingNotes" xlink:href="axdx-20151231.xsd#PublicOfferingNotes" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/RightsOffering" xlink:href="axdx-20151231.xsd#RightsOffering" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative" xlink:href="axdx-20151231.xsd#RightsOfferingDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/Segments" xlink:href="axdx-20151231.xsd#Segments" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails" xlink:href="axdx-20151231.xsd#SegmentsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/StockPurchase" xlink:href="axdx-20151231.xsd#StockPurchase" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative" xlink:href="axdx-20151231.xsd#StockPurchaseDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SubsequentEvents" xlink:href="axdx-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:href="axdx-20151231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="axdx-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformation" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables" xlink:href="axdx-20151231.xsd#SupplementalDataQuarterlyFinancialInformationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/Commitments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3190456C25EB59071D25EFC21A6CC869" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_9392EEFF4BD481D524D7EFC21A6CA479" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_D4A0E971E237C11BAA54348273508182" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_0FAFB9472B659EA67F1C34827350BD37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_663224C47EE45F986409348273502C60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9B70866C2677089AA6AA348273509E1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_A4DB0E4231416D9A66F43482735001E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_4F18AF48713E7091CB5434827350E44D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_3CB1036DC3778E9DA7C6348273502EA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B9D8773FD835B88EA060348273462C56" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_DE2E487C9B5C4EFE6EFC34827351DF12" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D6BCE50481F8F7370C7351FAECCA3248" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D6BCE50481F8F7370C7351FAECCA3248" xlink:to="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81EA247463C10E7D495A51FAECCA8BCC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1A1FF3D1D8FD6DB67A8151FAECCACF98" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_3CB74E5B14997A32617F51FAECCA0628" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_F8ED65F64C5A76E80A0F51FAECCA8F9F" xlink:to="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9C2B579C1400DF8DD5A151FAECCB94EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:label="loc_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_BA4C6FEF4F8DB8F675A851FAECCB5289" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_LeaseAndRentalExpense_A66795390C504BADB14B51FAECCB61FB" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ClinicalTrialAgreementLiability" xlink:label="loc_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_axdx_ClinicalTrialAgreementLiability_ACC87CC673363C24CC9E51FAECCB665C" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ClinicalTrialAgreementExpense" xlink:label="loc_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_axdx_ClinicalTrialAgreementExpense_EAC618A2D6711F09BCB851FAECCB041F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_B618CB5F02DDB6D76BC251FAECCBE4F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToSuppliersAndEmployees" xlink:label="loc_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B91FDFA0A95B9D04BC0751FAECCB7F19" xlink:to="loc_us-gaap_PaymentsToSuppliersAndEmployees_D1DE1EAD6F55FC79E04E51FAECCBEBFB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_B2BBA360276F6EA7E72B347AD81EFA30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8706E8DE76AE5C48ED66347A0E642736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_61A6244029561E0FD1D1347A0E64F44A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E807707916E294370B3E347A0E648DBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F754032AD103704AC269347A0E64AE0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9008EDFE9E6D6891C026347A0E62EA9A" xlink:to="loc_us-gaap_ContractualObligation_729939A3C10739B455C0347A0E644F8F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/CommitmentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_682782C2A182301BD4CF35A76CFC9574" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_682782C2A182301BD4CF35A76CFC9574" xlink:to="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_160A88F8763FE891F91E35A76D02EDE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_682782C2A182301BD4CF35A76CFC9574" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E115A17E230C105E477435A76D01BE24" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0E604F74031EF53782AD44300E21E7F1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0E604F74031EF53782AD44300E21E7F1" xlink:to="loc_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69EFACBD4BBB871312AA44300E210F2F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C86855C3CD179AA99B4744300E220D11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_Investments_2F4AB7B6277DD02A3FBC44300E22462B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_1DD6450DA0F0E5ABDAB244300E220E03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ED816F0577D3C3BCC7F44300E221627" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_OtherAssetsCurrent_36A5A2CCA01E8FDA5E9144300E22AAB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_AssetsCurrent_916E5A3C815FDA33473844300E22F174" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9B64979F59482567633D44300E223EBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3F8CCF42C48E89E1213A44300E22E918" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93BB65716E91AF063B7144300E21E6B8" xlink:to="loc_us-gaap_Assets_9193130E781F5198E41A44300E22FE5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0E604F74031EF53782AD44300E21E7F1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_AccountsPayableCurrent_ADA091A135B3562E92CB44300E22048C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5BC6219436762F7178F944300E2203EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_DeferredRevenue_3F8D4542D4C2930C672644300E22E7BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_CapitalLeaseObligations_AA79ED20BDB4743A367044300E2278BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_LiabilitiesCurrent_32500E10EF2FD2AF9EDE44300E2279AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_46E3985E20806ABDBF0C44300E22B400" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_41903472F94E359650C844300E223E59" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_141C9F605376D1D409A944300E22B477" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:to="loc_us-gaap_Liabilities_3D68970451F786919EBC44300E22AA38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_228C57DA1A7840BEE43A44300E23A55D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AE9AC73422B4AF2D61244300E22D3C2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="loc_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_CommonStockOtherValueOutstanding_0A2393B2AE60B63169B244300E23D771" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_PreferredStockValue_AD2301C0D1C947C26B9A44300E23F9DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_783EE1AEE57E00BE08A444300E23D447" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1EF2C1A5F7DB87CB5E1B44300E23F451" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities_E6438F1AE446507E361044300E23F1FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_StockholdersEquity_1522B6D399A46155FBCA44300E23216B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38793857F0005FD6971744300E23922A" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24D8EA5E8E7E5C871D0E44300E23110A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_43D122127342C3349DC0EFC21A4E0E47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_FD3F3490912374B0B3FDEFC21A4E70EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_CommonStockSharesIssued_4A71F5385E33BD945298EFC21A4EB8A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B25A270D3CFFDCBC2BE0EFC21A4E5D06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_D15269ABA3BB5AA45AA2EFC21A4E93A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1184FEFD6BC48E2921B2EFC21A4EFE5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_PreferredStockSharesIssued_A425E82286F7954108BAEFC21A4E789A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE1888215346B7A9C36EEFC21A4E7AAF" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_28BC1724503496861C6AEFC21A4E09EB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_ABE39DF88177B05B32B85716E8796E10" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2CBD4B058633699EB6805716E8795DE3" xlink:to="loc_us-gaap_NetIncomeLoss_ABE39DF88177B05B32B85716E8796E10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:to="loc_us-gaap_Depreciation_3744DD9ADC0063D532155716E87A5887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_C5BE00C2E1B52E718B985716E87AC87A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_19FFF970494A61DDF2BA5716E87AE19E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:to="loc_us-gaap_ShareBasedCompensation_CFE17106432B13F608EB5716E87A3CF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2435B28B647B0A2BA46D5716E87A9D26" xlink:to="loc_us-gaap_AssetImpairmentCharges_D09A3FD0168CE653BBF55716E87AE6DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2508C7CCBDFBD0DD3BBA5716E87A0BEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_F36E63828791CCF045FF5716E87AF88E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_CA5A9A55D3C11D24D34A5716E87A928E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42B475379A8FD504B7EB5716E87F864A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7F193CDCE35047323AF45716E87FC7B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_09E3DA58136D515D71A25716E880D79A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract_3032C455463ABF5B17075716E87FB455" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6C18B9ADE60E182531E45716E8809C01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3709352B267B8D77CD1E5716E88068FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_46878972EC093A69EB8E5716E880D326" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_C7F186DD6AD3EBED84315716E880C3C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11E4A75F4063E975B71C5716EB2EBF21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AF6B1A8684D1F2E0837D5716E8809BC8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2C0B09F1038229A8D84D5716E8806E7C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98A7B66B2A8FCE75DBEF5716E880D151" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6A193DCFFBE19CF2FE815716E8802884" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5BB903DC29088AAA800F5716E8804E96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_575BBD67194E3602CF715716E8802E4F" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_C1411534691DCCEF9E9F5716E8805A6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08FE7B59E5741B02D0C05716E88095CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_03E662B15A57C004D9C05716E881FDE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C82A6F29445D66BC2A645716E8819C83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4C6DC9DDBDA3CA1A28565716E8795E5D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9A92D831853F797C5C275716E88173B6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesNetOfInterestExpenseAbstract" xlink:label="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:to="loc_us-gaap_LicensesRevenue_56C60E7809FFAC091E965D594311F544" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="loc_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:to="loc_us-gaap_SalesRevenueGoodsGross_BFFA8E77C27237AD72B45D594311F0BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesNetOfInterestExpenseAbstract_F675FCF9EABCC956BA755D594311EA77" xlink:to="loc_us-gaap_SalesRevenueNet_4F947DEE94C5F16042E75D594311E5CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_137B0F36AEC6FD241A925D594312A8F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_53D4B2BACC9A123E39565D59431231CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7441BD0D439C08AD36F65D594312CFED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_648894DAC42C9C615B895D5943123E6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="loc_us-gaap_OtherExpenses_D0C578937C8C3DB480F65D594312682E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FF4499AD14E63C7178A5D594312583A" xlink:to="loc_us-gaap_CostsAndExpenses_64322F318B4D446B24535D594312C995" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_OperatingIncomeLoss_A532C896C8CE2466BBD95D594312FDD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_EA358DB2D5E5D95E1E5F5D5943122842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_7448CD3EE4FA45BF388D5D5943127949" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_OtherNonoperatingIncome_556BF4BE2E577306F1425D5943125FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_DC0598393ECE230471595D59431279AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_NetIncomeLoss_D36BB756CD044DDE2AD35D594312A633" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_69A26E356857196008CF5D5943127DF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FDED75650581559E776F5D594312DB9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_ProfitLoss_C96432DCBEE0DFA5D2E35D5943129D44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_CCB6C8FF12D1C9D9F1CA5D594311E7BE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:to="loc_us-gaap_NetIncomeLoss_A5FD1044141DFE7D37745D594312908E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_74D2212247CC36C20D715D5943137FD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8873C802411DE89735CA5D594313897A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DB13D47851B8BF0BB6755D594312B109" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_677DF5D55C215B0525455D5943130E00" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3F8743DF6E18492A46795C57D1DA0E1B" xlink:to="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1DFF3DB57186662C5C7E5C57D1DA534D" xlink:to="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C76E181EAEB858D073C75C57D1DA3020" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_CommonStockMember_C76E181EAEB858D073C75C57D1DA3020" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B093CDDFDC3FAE6E2BC95C57D1DAC3B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_RetainedEarningsMember_7A754D3AE2629C89EF4B5C57D1DAC2AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_103E74556E0A0F0ED84A5C57D1DAFA31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CB132B19CAFE7221C4355C57D1DAEA8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EFC7D0D174F578D5CD515C57D1DA854E" xlink:to="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockholdersEquity_CAF2012E191A3B0F42005C57D1DBBC78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_SharesIssued_2AEDBCC67DBF7674C59A5C57D1DBB7EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6F1A40A0EC2E184A71985C57D1DBD72A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_NetIncomeLoss_6F1A40A0EC2E184A71985C57D1DBD72A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_303EF37A7B036184DA175C57D1DB9B0B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17C44AD63A963EB053435C57D1DB9365" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17C44AD63A963EB053435C57D1DB9365" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_C94B7F8998F7C540F4775C57D1DB5E52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7284531588A4A40B29765C57D1DB4681" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_355602382A596AAD32F35C57D1DBDA95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5DF94D01DEC47383A2415C57D1DB4905" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_ShareBasedCompensation_D7A0BD096A0CB5CFB9EE5C57D1E01DE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_StockholdersEquity_A1702F1FAEA7578FDBA65C57D1E0457A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3C1C50508864BEA4A54A5C57D1DA7F97" xlink:to="loc_us-gaap_SharesIssued_7010B6F8888C86B093EC5C57D1E0B10C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncome" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_F5D5F7EEF8FD9158D4A5341AC6672FF3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="loc_us-gaap_RevenueRecognitionDeferredRevenue_65FD76D7B06A56A1FE0B3403293A59DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_F5D5F7EEF8FD9158D4A5341AC6672FF3" xlink:to="loc_us-gaap_RevenueRecognitionDeferredRevenue_65FD76D7B06A56A1FE0B3403293A59DD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="loc_us-gaap_DeferredRevenueCurrent_5F2A05DEAF6CBADFFFA752C88A53E385" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DeferredRevenueResearchUseOnly" xlink:label="loc_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="loc_axdx_DeferredRevenueResearchUseOnly_F6A619BCD695942EF99152C88A5357F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_B0067103E16D4C36F22F52C88A549FAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_3AFD5781B696CBE85CA152C88A54DB28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_C8CC0887138DE49543DF52C88A546DB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_C163D637AFAB4BF6D9E952C88A53028F" xlink:to="loc_us-gaap_DeferredRevenueAndCreditsNoncurrent_2C82C2347D623874C57B52C88A54EECD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_6AE00086C90A5DC3DBFE52C88A504A05" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_C81C9FAA09757B7E7CC052C88A51202F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_6AE00086C90A5DC3DBFE52C88A504A05" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_C81C9FAA09757B7E7CC052C88A51202F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_6AE00086C90A5DC3DBFE52C88A504A05" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized_4A0A829000C8AD9818A552C88A519668" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_FA1083F05D7643D07BEB341B117F5C20" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_DD7E251599A4F37FC2DA340329398577" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_FA1083F05D7643D07BEB341B117F5C20" xlink:to="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_DD7E251599A4F37FC2DA340329398577" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="axdx-20151231.xsd#axdx_DocumentAndEntityInformationAbstract" xlink:label="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityRegistrantName_FE336A36A89E8550729A1FECC2727C83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityCentralIndexKey_FCE7D8826F1AF791EDDA1FECC2728356" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_DocumentType_FC435164DB96A45BBDC41FECC2726F89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_DocumentPeriodEndDate_776E7C781CA312A052B51FECC27374AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_AmendmentFlag_CCDF810A6A06B6AEC2C01FECC2734427" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_CurrentFiscalYearEndDate_2609C800CF12C6BCE6F41FECC2736090" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8BA35492BA5E9535B1DB1FECC2733515" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityVoluntaryFilers_DC5B57DF89A18020BFFF1FECC2736BDC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityCurrentReportingStatus_707984889AD624A233581FECC2737E0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityFilerCategory_E9C749A6A44127661FD91FECC273EBE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityPublicFloat_D936CD5BBCD4DCCC6CB71FECC2734919" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4312F5057EAA4092BC7A1FECC2737021" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5451B3D51CB826166CAD1FECC2739397" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_DocumentAndEntityInformationAbstract_D8E14CAE255F467FA5AF1FECC2723195" xlink:to="loc_dei_DocumentFiscalYearFocus_959B9F294A5E83244ED81FECC273D1F3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EarningsPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_826FE385952F16D43858534A4042C93F" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_15805FF21BE2577C9967534B7A5468D7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_F3C61A56C569664840AF52148DF4F812" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_F3C61A56C569664840AF52148DF4F812" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDA0C75231C409B84ED652148DF46BAC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA795F2EE4BD96124534EFC21AC69CFF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA795F2EE4BD96124534EFC21AC69CFF" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_D868AC45A0DECA3D5CAEEFC21AC60AC9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:type="locator" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2" xlink:label="loc_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:to="loc_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2_C0FBBC39235A220DB1BB37D7C2FAE5B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_99DC0418414D4A0A708D37D7C2FB78FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_665390A9001F4023945C37D7C2FCD044" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8320E560D02AB52CFA5A37D7C2FCF71A" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1_D25374FD083C33EC715837D7C2FCA4AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsPriceEarningsRatioMultiple" xlink:label="loc_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AE567AB143978D71A8737D7C2FAFFFB" xlink:to="loc_us-gaap_FairValueInputsPriceEarningsRatioMultiple_D43588F1CB22D8FB2BA337D7C2FC10C2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:type="locator" />
    <loc xlink:href="axdx-20151231.xsd#axdx_EmployeeServiceSharebasedCompensationNumberofPlans" xlink:label="loc_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_axdx_EmployeeServiceSharebasedCompensationNumberofPlans_922E6584A91F8F6A706A52EBEF9FEF2C" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract" xlink:label="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber_39C51D938F917FDDFD5B52EBEF9F6395" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_86768D49297BA2A56F9852EBEF9F80A3" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract_D908DF275DB74379FB9F52EBEF9F1119" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5_767126C674E007EFEEB552EBEF9F1C18" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract" xlink:label="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1_92DD7E302CF7885B21E852EBEFA0413E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_AB4766A442C6FD9F393B52EBEFA0115F" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract_B3158AB9378D67AC44BA52EBEFA04000" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2_B00D1065473EF187910E52EBEFA09DF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F91337568448378F6F9452EBEFA0116A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_FC48EDC65B00C619FDC352EBEFA062B9" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2_BC1ABE565503C237D8F252EBEFA030F9" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2_F401A49329D7BE011BFB52EBEFA04202" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_4F77D343A607EEA42D0F52EBEFA09C5E" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3_6E64F92A3FC7F4C855D352EBEFA0EC8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91E4095244D592D5185B52EBEFA02DA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_AE381576B4F5C059B27952EBEFA049EC" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3_0F8735CD01939EB524CD52EBEFA52DA8" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3_0FAFAA4F2B76CA676B0F52EBEFA64A03" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_1E0D2DC127867F83A9FA52EBEFA0E93C" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4_5306B59531EBBC091CB452EBEFA67BC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_D14DD8E69B3492FA8CEC52EBEFA6C671" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_C3D7D81040869BA2F99952EBEFA78B1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1D472DB9CAC31B88C05452EBEFA749DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_A7D26E02F48391698D0E52EBEFA7E7A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_DA18FFD48459E633B3F252EBEFA7A894" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_SharePrice_DA18FFD48459E633B3F252EBEFA7A894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C423E003CB4BB6750BE52EBEF9FC891" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FC76BA40C9DA2CAD7B6152EBEFA7340D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44F858C51B6AC9135D6435CA18ECADC3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44F858C51B6AC9135D6435CA18ECADC3" xlink:to="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08225808338F8B720A7F35CA18EC7AE0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ACE8C80834A67798F3935CA18EC6325" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_068922FFEAEB4D901F6035CA18EC4CE5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2AAF5234F882152C56A135CA18EC98FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90E7AE6A4703BA0A93EA35CA18EC6FD2" xlink:to="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0B8B50AAFB5E95BB31B135CA18ECB4B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_24BE9A2F006168DC913435CA18EC36D2" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_BD3330121714BF7C120635CA18ED80F5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2CC4FB3BAE541D8C505E534C43E2E05C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2CC4FB3BAE541D8C505E534C43E2E05C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_646B8FCA8879FCC6750C534C43E21814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8D1B832EA4E405D68D0534C43E2FCAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_53D58D81ECA43B7EE54D534C43E2E4B0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87F272CAFE3D8D6B2011534C43E26038" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9A99FB9F9B5DBD692DF9534C43E2EAC8" xlink:to="loc_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_35F413EE1FD2C1264A1C534C43E2C8FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2CC4FB3BAE541D8C505E534C43E2E05C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96BA973F421502F4573A534C43E32A15" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:to="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_304C49B077EE663BFA5A534C43E3607D" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:to="loc_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_C49D0B423EB5DBFAFE69534C43E36C40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0B420AAED41E0878C912534C43E39D8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CB7EBC4AB53902A2A453534C43E3BCDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E429C9CAA11049B97149534C43E3E533" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_616682CCFB25C9A7E3BF52EBEFEDFFCD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_616682CCFB25C9A7E3BF52EBEFEDFFCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2F30F010A72AC925025C52EBEFEDFF4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C05AAF3B4FDEB0418D152EBEFED6274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF09E6D5C83414D62E7352EBEFED5689" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2046187E4A5990490AC252EBEFED35C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22832FEFB10E98CC276552EBEFEDB277" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4233E3264934EFA80F7552EBEFED566E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65D1A398C50A2A672D2752EBEFEE4420" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_616682CCFB25C9A7E3BF52EBEFEDFFCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_74D28B0AF446125329DF52EBEFEE6A8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_616682CCFB25C9A7E3BF52EBEFEDFFCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E130FE7AE75D883161B52EBEFEE3989" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43644023CA91D8E57D7852EBEFEE4CD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_D8D40173E13CDDDD4E1F52EBEFEE5F73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70BB8D36470A46CE9F6452EBEFEEB32C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_F60025E1BED04F641C9652EBEFEE018D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_C35EDFC238D7D930524552EBEFEE2427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AEAF12EA6DCA7C7DCDF652EBEFEE8C8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_616682CCFB25C9A7E3BF52EBEFEDFFCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DCFCF79E9BE969D3202752EBEFEEF3D3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B06C6DB7F3747795F55237D7C47792F6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B06C6DB7F3747795F55237D7C47792F6" xlink:to="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_30AFD46092F5F4809DE637D7C478C21D" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OptionsOutstandingMember" xlink:label="loc_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="loc_axdx_OptionsOutstandingMember_7A5ABF883ED259019B3637D7C478D972" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OptionsExercisableMember" xlink:label="loc_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="loc_axdx_OptionsExercisableMember_EF75454EB6035166749937D7C478E626" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OptionsVestedAndExpectedToVestMember" xlink:label="loc_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_E66356370664EAC583DE37D7C478D25E" xlink:to="loc_axdx_OptionsVestedAndExpectedToVestMember_40AC4DCCD0FF519E045537D7C478FA0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FCFD13967E8BA47D741537D7C4783A64" xlink:to="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_8C1CAB86698E23E32C6037D7C478185B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a" xlink:label="loc_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a_270A721320C40AF434AB37D7C47868FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2AB0FC7AC16F063CE71F37D7C4781C90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_519629895A91E09AB80937D7C478D5CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3202FAB134EE4BB368D137D7C478EEC9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_77D4BE7D27B58EEBB60537D7C478D4C1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C00851250EDF051AF1393A8256108487" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C00851250EDF051AF1393A8256108487" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D17A82D2DE082A3A42653A82561521E3" xlink:to="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OmnibusEquityIncentivePlan2012Member" xlink:label="loc_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:to="loc_axdx_OmnibusEquityIncentivePlan2012Member_DFC7D4E65B40E1FBD31E3A8256154FB1" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_NonQualifiedStockOptionPlanMember" xlink:label="loc_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_43FD38FE0A19F6E395443A8256152168" xlink:to="loc_axdx_NonQualifiedStockOptionPlanMember_88167F4756590E74C3303A8E3EE124D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8884287D1650FE47F9403A825615DA2C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EDC9CB3586D180B959B83A825615C999" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BE5CC34679B4DFA894BE3A8256156159" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_C3875DF8F4FF04E704C53A8256156920" xlink:to="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4A2B507EC416B6FFBA323A8256156842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_E7FF1D8B894C8C7128A83A8256167534" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_C4ED76A79AF36D4DA4783A825616C89A" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_SharebasedCompensationAwardTrancheFourMember" xlink:label="loc_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2F39DF5EA7AB48BF52C03A8256158E3D" xlink:to="loc_axdx_SharebasedCompensationAwardTrancheFourMember_A27B7F02B97BB4371FE43A825616AF9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F33C49A5CA95121DE2F83A8256155BC4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4BD41AD6BE0719BCE9823A825616FF5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_038B03480E169CE547CB3A82561696C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0C6CDAD94179D4C0422A3A825616996F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF47300A3C35E6C1033A3A825616A342" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A02C35FE1AF1D3C3799A3610DE80BAB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1B1DA06DFB20A0301C6C3610DE81FC72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_E3D71B4A368A2089E2093610DE81B5FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1302CD442292FFE821C9361807AF0543" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD0987997947A70C79033610DE808FA7" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_A03612673198F3CF605D3610DE81B51A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FBE3CECCC4F7903AE611EFC21B20418E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FBE3CECCC4F7903AE611EFC21B20418E" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_616D3601F1EE74B15284EFC21B20822A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_738BC71CA1675F9F8E5933B9087DFF64" xlink:to="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1968A930153E8C4BE80333C1A5FFC04B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B8CA654D6881092C250D33C2968ADD5B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CorporateBondsandNotesMember" xlink:label="loc_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="loc_axdx_CorporateBondsandNotesMember_7AA4E7BF0B788115AFE133C5784C8817" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_215CA2E08EF8337A104333C33AF06B37" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_A96B94A0E6F6D9237D7D33C5D804A862" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_19254946DB56224BD82033B9087F71FF" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_F4B2E0F9B83A8D89CA9733B9087FBE58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B4817617028EBF78FCA933B9087F897B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B4817617028EBF78FCA933B9087F897B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_13DC78FC69AC54D5424E33B908842F7F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BAD07ACC88728A6AD93E33BA656B5592" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_13DC78FC69AC54D5424E33B908842F7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B0493D12E206724A68A633B9087FF0FC" xlink:to="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_601AE0D21E20B1190DEF33B90884D3EB" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3211C2BD72A64ED8EDD533B9088461A1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_55C7463791B5E8BFFA3B33B90885E859" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_72AE72B31323DFC15447EFC21ABCB938" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72AE72B31323DFC15447EFC21ABCB938" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_E648B0473871DCDDEAFCEFC21ABC5F8F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_853991BBD1E9B511ACD2EFC21ABCE77F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_853991BBD1E9B511ACD2EFC21ABCE77F" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4EBF65998C5D2A2C99BCEFC21ABC10D8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3D90CAD2E93EA2BDE962443226E9AB3A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D90CAD2E93EA2BDE962443226E9AB3A" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_100146225047EEFB483C443226EAA933" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_D08C272AC01F53E54356443226E9114E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_3E65DBFCAD3114FD7FD6443226EA4ABB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7DB8C26E04151A0C90CB443226EADFB6" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets" xlink:label="loc_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets_9574A9CA9AD722EE3110443226E9335C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6738713A12EADDDF591E443226EA3F60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1F3D2506FF65D33AD4D9443226EA6691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5BD4DA514C129B2C7C23443226EA884C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_372EFB2F1999F3740DE6443226EA517B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E9A0B7224A9DB575D12D443226EA819F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1B6BB199CDEECEFE44E1443226E9807A" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9D6EA875C7C911B9F5CD443226EBEB8F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FCF43F96ABF3AD6CD0545D419A61F2E1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="loc_us-gaap_DomesticCountryMember_3BE3158F587A14CD673B5D419A619851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_8A55229BD031F9B8A66B5D419A6114AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3581D39D7F2FD320AFEA5D419A61E721" xlink:to="loc_us-gaap_ForeignCountryMember_A8C6D4D89D8910BE51045D419A61E9FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_39390D33E0A8ABC0C85D5D419A612C85" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_29C2CF417F9CCB7435845D419A62885E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ArizonaDepartmentofRevenueMember" xlink:label="loc_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="loc_axdx_ArizonaDepartmentofRevenueMember_3A5FF30C4DF8D3BCCBF15D419A62BFE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxAuthoritySpainMember" xlink:label="loc_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7E5E765CEE7F1CB2DC135D419A6124C0" xlink:to="loc_us-gaap_TaxAuthoritySpainMember_1016B5F6D90F6B90BD605D419A620732" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_F1E71398958FBB350D5C5D419A61DD34" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesDetailsNarrativeUsdAbstract" xlink:label="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:type="locator" />
    <presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7916129D1471470621F25D419A625B38" xlink:to="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardsGross" xlink:label="loc_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_axdx_OperatingLossCarryforwardsGross_3A41BADBEDEDE2284F4B5D419A62C05D" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount" xlink:label="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount_0CF2C85C0972CD6E61E55D419A628D02" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OperatingLossCarryforwardLimitationsOnUseAmount" xlink:label="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_axdx_OperatingLossCarryforwardLimitationsOnUseAmount_88916F09C5DBD58ED7085D419A62ADE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesDetailsNarrativeUsdAbstract_133F280645E3BA732AC85D419A62703E" xlink:to="loc_us-gaap_OperatingLossCarryforwards_4E4E410E59C26E2140E55D419A62C8CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_97D4347B183A85AF90105D419A62ABF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2B0BFA817059DE39F14A5D419A6126A0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_41AD86041560B033250E5D419A627DBB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E9E871DF3B0B6DDAE2005D419A71A0E4" xlink:type="locator" />
    <loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract" xlink:label="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:type="locator" />
    <presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E9E871DF3B0B6DDAE2005D419A71A0E4" xlink:to="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8764C5F4F4A11558E3195D419A715F2B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1C43FB27E42948059EAD5D419A711C71" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" xlink:label="loc_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_FB20F9B8DCA76BB8140F5D419A7166CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BD450A0A97EADA99EEF25D419A722D1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_4FD6F41690F44C1719C75D419A72644A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_A4AE4610A4A3DCF9E29A5D419A72546C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_BC7791F58F9CE7718C335D419A729376" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_2115743A185FEF10AC9A5D419A722AA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04ABFE0596FFFAD4ADA35D419A727765" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract_64090543C9B401EB92DE5D419A719BF6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BAB4FB19C0D064FCC6E55D419A72AFC0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E5D89309C37111056507358A4C763F44" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E5D89309C37111056507358A4C763F44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_BC80507AB551AED902EE358A4C76B633" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E5D89309C37111056507358A4C763F44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_B3BB9CC2D630D97D3B02358A4C76C3D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_44CFA81A46778878822E358A4C77BCE0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E5D89309C37111056507358A4C763F44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_44CFA81A46778878822E358A4C77BCE0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D471918C81CB169CEFA3358611CBE70C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D471918C81CB169CEFA3358611CBE70C" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_123B51F4F9C7FA247851358611CBBA29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D471918C81CB169CEFA3358611CBE70C" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E17FB8834F4D9D2BEB38358611CB7D95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D471918C81CB169CEFA3358611CBE70C" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B0BF8946DB6E08342128358611CBAB23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D471918C81CB169CEFA3358611CBE70C" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3537A3ACA99EF62EBDFC358611CC6100" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D471918C81CB169CEFA3358611CBE70C" xlink:to="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_06F9D8A761251FC4DBFE358611CC4514" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D39119385D1D38522A12380B5F1E7FE6" xlink:type="locator" />
    <loc xlink:href="axdx-20151231.xsd#axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract" xlink:label="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:type="locator" />
    <presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D39119385D1D38522A12380B5F1E7FE6" xlink:to="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_06C8FF6BE1855D38A7A837ED9022359F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BC1C1D29A93F8ADEB99B37ED9022E953" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_34409DDBCEB75525209B37ED902221AA" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnrecognizedTaxBenefitsOtherIncrease" xlink:label="loc_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_axdx_UnrecognizedTaxBenefitsOtherIncrease_C35B35EC8F097B88BF6737ED90229291" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6313E86B8CC142ABD3BE37ED90236120" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B89F42108BB87A6B17B537ED90232F50" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnrecognizedTaxBenefitsOtherDecrease" xlink:label="loc_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_axdx_UnrecognizedTaxBenefitsOtherDecrease_AF4A75C6708DC995AB3137ED9023A8E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract_41DA99FCECBC988966CE37ED902254FF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_A0F04F1D35244527AAC937ED9023079E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/Investments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EF80F1B57D8ACA4C6E39EFC21B02E30C" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_AE5811E748914A552B2BEFC21B0252A5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_C16842C13443AE0635A55D419B3A24F5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_C16842C13443AE0635A55D419B3A24F5" xlink:to="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_DCAEF9C66C79A73566705D419B3AF132" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CostMember" xlink:label="loc_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_B92D81AF11565A05EE595D419B3A4E0D" xlink:to="loc_axdx_CostMember_79F930A9DE9B3CE2DC695D419B3A7EA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C96B8A1F8BF8B4B630AF5D419B3A4F30" xlink:to="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnrealizedGainsMember" xlink:label="loc_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_6F6893AC527D836C8DB85D419B3A0C61" xlink:to="loc_axdx_UnrealizedGainsMember_97255F151A73F7A2D2705D419B3AFE4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsByCategoryAxis" xlink:label="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainLossOnInvestmentsByCategoryAxis_B960BF1DEABF0CE0AD445D419B3AC67F" xlink:to="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnrealizedLossesMember" xlink:label="loc_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostCategoriesOfInvestmentsDomain_DFE8A90A13975D6778A75D419B3A7D19" xlink:to="loc_axdx_UnrealizedLossesMember_47E8F1CB0698F3E1A1D25D419B3B8133" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4860D10FB601E42CE5235D419B3BC5A1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2B85CB4969345C8F17665D419B3B357A" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_FairValueMember" xlink:label="loc_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2D9CB9EA015A375C5BE45D419B3BB047" xlink:to="loc_axdx_FairValueMember_608E60FA320F386C8FAD5D419B3B2EFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56C1D36BE7BE02E4E2AB5D419B3A29C3" xlink:to="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_EC9A16AA12D33570DD105D419B3BAF49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:label="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_8D4B235CB5A4291CEA2B5D419B3B4646" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_DE96C67F388CA466D22F5D419B3B808A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E5C0F19069E6EE0D24125D419B3B186C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19025DED5B95EE8DA08D5D419B3BEFF9" xlink:to="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E5C0F19069E6EE0D24125D419B3B186C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_985B3F40D6FD8AED47413634002C9DB0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_985B3F40D6FD8AED47413634002C9DB0" xlink:to="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:to="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_87B10EE0EF38B21929783634002C7FB6" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_926C16DBE7F2BD053A4D3634002CC6CB" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_34437F7A281A7600168B3634002CBD06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_C85BAD3F5EEEF2647DFF3634002C4E0E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_C6A5A980C1EEC63AFBA73634002CB09E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BBE216CA5A159F6305AE3634002D07DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7C92720CCF599F35F3103634002C0663" xlink:to="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3920CE9824FD57F42C153634002D256C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BFFE4C71A0C3D5C470213634002DBF39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2F36C406E037C344C3E13634002D4D74" xlink:to="loc_us-gaap_FinancialInstrumentsOwnedAtFairValue_E342EAA6CD6972FDF7BD3634002DF46D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/InvestmentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_45EB44E5D10920C7A619EFC21B165A66" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_45EB44E5D10920C7A619EFC21B165A66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_30A90876263E1634FE52EFC21B16F3D4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants" xlink:type="extended">
    <loc xlink:href="axdx-20151231.xsd#axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract" xlink:label="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_786DCB5F5A65020C33A4534C441383FC" xlink:type="locator" />
    <loc xlink:href="axdx-20151231.xsd#axdx_LicenseAgreement" xlink:label="loc_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_786DCB5F5A65020C33A4534C441383FC" xlink:to="loc_axdx_LicenseAgreement_1F94B82115CFCADCEA3A534C44138DB6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1" xlink:type="extended">
    <loc xlink:href="axdx-20151231.xsd#axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract" xlink:label="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_462C360AF1A9353DEF945C6500F063A5" xlink:to="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DefenseMedicalResearchandDevelopmentProgramMember" xlink:label="loc_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_53DF6ADDB64D4DBDFFD45C650722831F" xlink:to="loc_axdx_DefenseMedicalResearchandDevelopmentProgramMember_17280B70CA3713D863275C66C9073E56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_263AADEC936CB786E16E5C64A830469A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8F84EEF305FCD638E8A75C5FAF87C288" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_EA4D993A64EE6B0D61765C64A8337B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_D137B3F3C30454E28B235C5FAF88C048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_7395468D1976C3F328D05C5FAF880BA0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_7395468D1976C3F328D05C5FAF880BA0" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones_77E009BED725BC1AFBC45C5FAF88C76B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne_8C32EEA12BB158669B035C5FAF882C6F" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo_733EB6F59D8AA4648AC35C5FAF88D72B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree_8D4FE51FD344840BEB105C5FAF89C7D9" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour_14A0B035E8FCF9746B805C5FAF897464" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment_AEEF1B6A7136DCEDD8455C5FAF89822C" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum_D19D3B16CDF0AA6DBBE55C5FAF8942E8" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums" xlink:label="loc_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract_5B7C8911DC52C9294D115C5FAF85BA83" xlink:to="loc_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums_15537A7F75614E60DA8B5C5FAF899242" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7299BBF9667B92BAA0DDEFC21B02E7FA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7299BBF9667B92BAA0DDEFC21B02E7FA" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_D380EE46550348DC0374EFC21B02855D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipment" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7466720E9BBFF9250BDAEFC21AA8A4D5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7466720E9BBFF9250BDAEFC21AA8A4D5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C9B1213CBE77E5F32D33EFC21AA8E880" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:type="extended">
    <loc xlink:href="axdx-20151231.xsd#axdx_PropertyAndEquipmentDetailsNarrativeAbstract" xlink:label="loc_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9F4BE981F1220C1FEA92350469D37939" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentDetailsNarrativeAbstract_D408E6351445CF4F0AD5350469D3A85E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9F4BE981F1220C1FEA92350469D37939" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd" xlink:type="extended">
    <loc xlink:href="axdx-20151231.xsd#axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract" xlink:label="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_8E352E86F0BC0CF6A68C52EBF079A72E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_FixturesAndEquipmentGross_09EC323EFDF8484FA0F652EBF079C2CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_231B407449F36B45AD9152EBF079CC83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_CapitalLeasedAssetsGross_6F59508450DBAE4DAB4352EBF07983F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_31C804494C2CF842ECFB52EBF079AD0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_00AF6B33CA2A706A2D8952EBF079509F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization_3ACD6E254347EC04A11952EBF079216E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A81C6C7B7EE0B638F5D52EBF0797AF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract_7C85524B7D963D740DF752EBF0780B67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_CBCD8505D91851902FCC52EBF0799B9B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D2FEFC7BD859E72DA572EFC21B206B52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4B0C3518FD0C06E8045AEFC21B2061B4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/PublicOfferingDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E4F40E2C5DC77ECA57A15C6948B5924C" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0C3760972E0A3B6EBAD85C6948B5195C" xlink:to="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AffiliatedEntityMember" xlink:label="loc_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8C1E579F0B81E60D1B685C6948B506CA" xlink:to="loc_us-gaap_AffiliatedEntityMember_A8C9D80095D27CF768DC5C6948B5E2FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B20C04833F5088DA2B325C6948B5A519" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_PublicOfferingMember" xlink:label="loc_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="loc_axdx_PublicOfferingMember_6E9A12F1C619EB3546F85C6948B5518D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8F5056EA861654CFF8DB5C6948B57BEA" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OfferingExemptFromUnderwriterCommissionMember" xlink:label="loc_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87A314378D7D02D83D475C6948B5F337" xlink:to="loc_axdx_OfferingExemptFromUnderwriterCommissionMember_A990EF58B981F4881A565C6948B59788" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6F29946EB10DD556C2A75C6948B53343" xlink:to="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CEA89F0B4C8E00809F665C6948B5790F" xlink:to="loc_us-gaap_CommonStockMember_63D9E391B07AFE69A0FA5C6948B5F114" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A88E12F290443E8297CF5C6948B56A97" xlink:to="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86F2B44A46ABB8D5A6395C6948B5B831" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_CB2EAD5911155E6547025C6948B66CEE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_SharePrice_CB2EAD5911155E6547025C6948B66CEE" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_UnderwritingDiscountandCommissionFeesPerShare" xlink:label="loc_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_axdx_UnderwritingDiscountandCommissionFeesPerShare_5951DDEFB0DD8128B8BA5C6948B652CB" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ProceedsFromSaleofCommonStockGross" xlink:label="loc_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_axdx_ProceedsFromSaleofCommonStockGross_4A192B5FBCF4E807E5D05C6948B6D785" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_892457883845257810405C6948B6D078" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF5DC6A8476519980FB5C6948B5245D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A407B1A89C1B7183BA8E5C6948B6DF39" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/PublicOfferingNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C1A0B9404B4A55514F385C6948B83CD3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C1A0B9404B4A55514F385C6948B83CD3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F8CEAF6B9CA729BAF6D5CCAADFA79FB" xlink:to="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_PublicOfferingMember" xlink:label="loc_axdx_PublicOfferingMember_CA593AB965A455FE29895CCAE16DE66C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2106F4859C94D90AF46E5CCAADFAA875" xlink:to="loc_axdx_PublicOfferingMember_CA593AB965A455FE29895CCAE16DE66C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_059750F4535E3CF4047C5CC9D947B284" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE1095A2A5A8EBE7335CC9D9475E17" xlink:to="loc_us-gaap_ClassOfStockLineItems_059750F4535E3CF4047C5CC9D947B284" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_04FC50D7FAA4C50958235C6948B8148E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_059750F4535E3CF4047C5CC9D947B284" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_04FC50D7FAA4C50958235C6948B8148E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/RightsOffering" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_BA0AAD37B2091FE7EF445CC6CB022224" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_811A013BC8FD36E53BD15CCF6C48859A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_BA0AAD37B2091FE7EF445CC6CB022224" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_B8CB3370C7A12A9C9D935CC6CB02A365" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA0AAD37B2091FE7EF445CC6CB022224" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_B8CB3370C7A12A9C9D935CC6CB02A365" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A906F6D2268BFDA3E98A5CC6CB0248F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_B8CB3370C7A12A9C9D935CC6CB02A365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A906F6D2268BFDA3E98A5CC6CB0248F7" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_RightsOfferingMember" xlink:label="loc_axdx_RightsOfferingMember_492DBAFEF433E018A7B15CC967B4EA9C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A906F6D2268BFDA3E98A5CC6CB0248F7" xlink:to="loc_axdx_RightsOfferingMember_492DBAFEF433E018A7B15CC967B4EA9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1210174AFAB4AF4F545C5CC6CB020832" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA0AAD37B2091FE7EF445CC6CB022224" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_1210174AFAB4AF4F545C5CC6CB020832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_DBCDA31D7350A266C6A45CC10BF79282" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1210174AFAB4AF4F545C5CC6CB020832" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_DBCDA31D7350A266C6A45CC10BF79282" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_569F0A663A54C2264A83534C43F5FA04" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:to="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_BBD6DC547F202605C7BF534C43F57F37" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_StandbyPurchasersMember" xlink:label="loc_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="loc_axdx_StandbyPurchasersMember_FDCED18F48F2B2566D0A534C43F5A2DE" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OracleInstitutionalPartnersL.P.Member" xlink:label="loc_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="loc_axdx_OracleInstitutionalPartnersL.P.Member_66283822200E26D29630534C43F5AB15" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_OraclePartnersL.P.Member" xlink:label="loc_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_03E4962AEBBBC605D177534C43F564A1" xlink:to="loc_axdx_OraclePartnersL.P.Member_7A12D11C7136A8E47A8A534C43F5E360" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4A71A801D3A0F5CA8379534C43F51DB2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_614C4FB654CE992D0E4F534C43F580F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="loc_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_TemporaryEquityShareSubscriptions_EE4109ADC732B7AFF30E534C43F57783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_C00D92A118B730DF2BF9534C43F55773" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_SharePrice_436B73D03BF847ED7B27534C43F6B723" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_F579908415AB4733CF92534C43F606CC" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ProceedsfromIssuanceofWarrantsGross" xlink:label="loc_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_axdx_ProceedsfromIssuanceofWarrantsGross_5910A863C245A54F7EEF534C43F6189E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A4209A2F6B907DD4BC5E534C43F5E8FF" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights_29258E11CCD06F3578F1534C43F6AA1E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/Segments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C30B0324C44B2922D0023A9E13CFD0E2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_C30B0324C44B2922D0023A9E13CFD0E2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_70F05F6238DF68B94D733A9E13CFAD2D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7F50C69794D9757651AA534C435A57AC" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1B47ECA1D61D031B1FEE534C435A3188" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/StockPurchase" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_1E56385FE37EDC105F45534C44062E28" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_1E56385FE37EDC105F45534C44062E28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock_321FAB75EE59D8C4A52E534C4406AE7C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesFinancingTransactionsAbstract" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32037867448F205C9A1E5C6948BC4BEF" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CommonStockAndWarrantsIssuedValue" xlink:label="loc_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_CommonStockAndWarrantsIssuedValue_4CDCEE0CB557E77386B55C6948BDA0DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_44368806D0D7169BBEDB5C6948BD9382" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityIndexedShares_08EC78012AE3969820AF5C6948BDBBDA" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3" xlink:label="loc_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3_361500B9534CE2995C6A5C6948BD43E8" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ExercisedWarrantPercentExercised" xlink:label="loc_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_ExercisedWarrantPercentExercised_101D7C75C5AAEDBD59B15C6948BD23FD" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares_218FC4EAAB9D068392155C6948BDAD4F" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares_0D961B223F7CDF60A7115C6948BD5868" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_74E45FB8BE5BEF4178A65C6948BDE01B" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares" xlink:label="loc_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares_399E39114AF78C48134C5C6948BD37D2" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_ExercisedWarrantAmountUnexercised" xlink:label="loc_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_ExercisedWarrantAmountUnexercised_0F859C376AFAA7C8F2B75C6948BD8238" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_C4333FC47DEA0FA3A07E5C6948BDBB89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_AEBA34DD4B8F5C7EC94E5C6948BD9FB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsAbstract_03F900B21C9758AD12C85C6948BC4BA6" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_9DD3FFF2914487556B1A5C6948BD83F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract_9B55FFD665AE2C17FE645C6948BC91CF" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_CF710024232A1B7703E05CBF6CBF7EED" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0A4CC9C39D8DE8C727D3EFC21AD0961C" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_8520159D8FF9D9B263D6EFC21AD072CE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_DF3CA6C4E9F7065B97D6345952B085AF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_6BAEB1D7B8E11F4874A434583B6A1059" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_DF3CA6C4E9F7065B97D6345952B085AF" xlink:to="loc_us-gaap_SubsequentEventTable_6BAEB1D7B8E11F4874A434583B6A1059" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0BE870858D749A43BDB434586E38094F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6BAEB1D7B8E11F4874A434583B6A1059" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0BE870858D749A43BDB434586E38094F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_327E0C0EE92970AE7ED434589F070FAF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0BE870858D749A43BDB434586E38094F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_327E0C0EE92970AE7ED434589F070FAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_33E4321A74A0690A5D5C3458D4CE2DD6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_327E0C0EE92970AE7ED434589F070FAF" xlink:to="loc_us-gaap_SubsequentEventMember_33E4321A74A0690A5D5C3458D4CE2DD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2017C9ABEC6C36D20E0D34583B6EAE9D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6BAEB1D7B8E11F4874A434583B6A1059" xlink:to="loc_us-gaap_SubsequentEventLineItems_2017C9ABEC6C36D20E0D34583B6EAE9D" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_CertificateOfQualificationAbstract" xlink:label="loc_axdx_CertificateOfQualificationAbstract_84CF21DD2148369D97D5340327C4FA57" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2017C9ABEC6C36D20E0D34583B6EAE9D" xlink:to="loc_axdx_CertificateOfQualificationAbstract_84CF21DD2148369D97D5340327C4FA57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E7FBCD3A635D83039C473471849904E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_CertificateOfQualificationAbstract_84CF21DD2148369D97D5340327C4FA57" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_E7FBCD3A635D83039C473471849904E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RefundsDueUnderGovernmentContracts" xlink:label="loc_us-gaap_RefundsDueUnderGovernmentContracts_DA336C18D61D4A53AFDD340327C4D82F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_CertificateOfQualificationAbstract_84CF21DD2148369D97D5340327C4FA57" xlink:to="loc_us-gaap_RefundsDueUnderGovernmentContracts_DA336C18D61D4A53AFDD340327C4D82F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5AEF532F63D26E2676B4EFC21A8A05CF" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C9CBB0D20F297516E8FFEFC21A8A2DA0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="extended">
    <loc xlink:href="axdx-20151231.xsd#axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:label="loc_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axdx_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_617545DDE85F6EC7DD5736340040D92D" xlink:to="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_42FD79438738943F0A9736529A034582" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0180DAE8B22BBC74285836547ADB5322" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_84F5E6843F9CD2180C6E3658B8169823" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D81D7219DD088748DB365265F2F33A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_B96E302880E2E236EC243659A46CD0C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CB353F10A169C1A2D8AA3655305EB881" xlink:to="loc_us-gaap_AccountsReceivableMember_2A5479BF60E33E54054E365AC88F193E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_7DE0C494295A41DE4CCF365BD5CA02D3" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:type="arc" />
    <loc xlink:href="axdx-20151231.xsd#axdx_DenverHealthMember" xlink:label="loc_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_BFC05CD6C2BC6C35F36A365C5F9AACBD" xlink:to="loc_axdx_DenverHealthMember_9EDD0C50C7E0182A435E365D5E129389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_BE6EC2DE020A9374FCAD3652253298EF" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83E6A74377459C2A4F8036522536778B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5453DAD30D4716449A1E3653E6BC2D91" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_UseOfEstimates_877780ED3C2C8D8575735345A73529F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_66F5AB87169E00D290F25345A7351F85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_D1C15A03764226A5E0F65345A735F9CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_46D50AB595D88B6F4D5E5345A735BB31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_08ADF342ECE094B92DF15345A7367902" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A65C19E434479C85BC765345A7368FDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock_3E094ED058BF6C4F089B5345A73667B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_576C9C14C65BD1B10D565345A736162F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_00FCB0E6ACF7118744885345A7360998" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_F79B16D82A137715C52E5345A73634DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="loc_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_LeasePolicyTextBlock_74600A01590F6B78DFF25345A7363330" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5288E0EBAB896C20C5945345A73634E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_63307748DC7C9AF2E367534C11F87E63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A747C678542787CE2A985345A7363F4A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68820849C19DCC2AD2C85345A7361CB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D1916819D6995EBEFF15345A73577CF" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70648C91F3BA73022CD55345A73641ED" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8D8441C5EC7944F4D5D5EFC21B2A71EF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8D8441C5EC7944F4D5D5EFC21B2A71EF" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_7305ED0DA65D4992FF55EFC21B2A1F62" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_F5EBD6DD2831FCB2E6D93504630E8068" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:to="loc_us-gaap_SalesRevenueNet_F5EBD6DD2831FCB2E6D93504630E8068" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F1075CD8273E519FB9223504630E9F48" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:to="loc_us-gaap_NetIncomeLoss_F1075CD8273E519FB9223504630E9F48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_0572EA42F63834E89CC23504630ECFD9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BD5C4F06916971B4CCDE353E393E49D5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_0572EA42F63834E89CC23504630ECFD9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_AC86645999B6E00373EFEFC21A945472" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_AC86645999B6E00373EFEFC21A945472" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2F82FE85716D1AFF69BFEFC21A94123A" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>axdx-123115_chartx42354a.jpg
<TEXT>
begin 644 axdx-123115_chartx42354a.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ JH# 2(  A$! Q$!_\0
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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MI!=77]J66GF\\--J+QZ4DT=K;L_ZP?\ !<#P[^SWXJ_8=ET+]JKXG?'GX-?
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M-4LY_P"T[:T\#W>FV<#6=Y>>7U7_  4%_;!\4_'#_@F#X'_8G_9?_;5\"_\
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M?#BP6Q2V^'FEZKXLTWPBFE6?C'Q-%J8!]2T444 %%%% !1110 4444 %%%%
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ML'_A)-+];[_P3ZU_\KJ/^$DTOUOO_!/K7_RNH WJ*P?^$DTOUOO_  3ZU_\
M*ZC_ (232_6^_P#!/K7_ ,KJ -ZBL'_A)-+];[_P3ZU_\KJ/^$DTOUOO_!/K
M7_RNH WJ*P?^$DTOUOO_  3ZU_\ *ZC_ (232_6^_P#!/K7_ ,KJ -ZBL'_A
M)-+];[_P3ZU_\KJ/^$DTOUOO_!/K7_RNH WJ*P?^$DTOUOO_  3ZU_\ *ZC_
M (232_6^_P#!/K7_ ,KJ -ZBL'_A)-+];[_P3ZU_\KJ/^$DTOUOO_!/K7_RN
MH WJ*P?^$DTOUOO_  3ZU_\ *ZC_ (232_6^_P#!/K7_ ,KJ -ZBL'_A)-+]
M;[_P3ZU_\KJ/^$DTOUOO_!/K7_RNH WJ*P?^$DTOUOO_  3ZU_\ *ZC_ (23
M2_6^_P#!/K7_ ,KJ -ZBL'_A)-+];[_P3ZU_\KJ/^$DTOUOO_!/K7_RNH WJ
M*P?^$DTOUOO_  3ZU_\ *ZC_ (232_6^_P#!/K7_ ,KJ -ZBL'_A)-+];[_P
M3ZU_\KJ/^$DTOUOO_!/K7_RNH WJ*P?^$DTOUOO_  3ZU_\ *ZC_ (232_6^
M_P#!/K7_ ,KJ -ZBL'_A)-+];[_P3ZU_\KJ/^$DTOUOO_!/K7_RNH WJ*PAX
MCTLD#-]EB%'_ !)]9ZL0!R=/ ')ZD@#J2!S6[0 4444 ,D^Z/]^/_P!&+7^&
M+_P4$_Y/T_;<_P"SN_VD_P#U<OC2O]SJ3[H_WX__ $8M?X8O_!03_D_3]MS_
M +.[_:3_ /5R^-* /]??_@B9_P HD?\ @G1_V:#\$?\ U#[*OU&K\N?^")G_
M "B1_P""='_9H/P1_P#4/LJ_4:@ K\T_VW/V,/CI^U+\4?@=XK\(_'7X2>'_
M (6?!DZCXHF_9_\ C9\ ?%WQG^&'CWXP#5=/O/!'Q4\:Z;X2^/WP5'B>\^$U
MMI\EQ\-?"/BA-?\ "&A^,=3G^(=UI.H^+="\%:AX7_2RB@#XB\9?"S]KWXA:
M!>_#;5_V@=$^'Z:S\!)[*\^-OP.^&D'@OQ/X<_:/L?'^EZQX<\9^#_#?CCXB
M?$]#X"/ANTGL/%/PW\3?VO!K%J;FR/CF1=>N+?1?$/%7_!//Q_\ &&;XR_$3
MXW_M!Z/??M"?$#0?V:=#^&GCSX4_!X>"/ /P3;]DCXT7_P"T;\'M7TOX<>,/
MB)\2M4\<:C??'#4;KQ7\15\3>/(;3Q#X8-IX T&'PM8V]WK.I_J910!^5&N_
M\$YO&?CR;XB_%SQ_\>=%G_:T\6?&O]GKXV^#?BCX2^$MSHOPJ^&E[^R[8ZKI
M/PL\!:;\']9^)/B/7?$G@74-*\:?%FT^(S:U\5(_%GB5OBSXGE\/>(O!PTCP
MA%H?U?\ LR?L[Z[\%;GXT^./B'X\T[XF_&7]HCXHP_%+XH>+=!\''X?>$;>?
M1? /@OX5^!O!?@;P;+XC\7ZAHWA/P1\// 'AS2()M=\6>)/$/B#77\0>*-7U
M19M:CTW3?JBB@ K\</\ @X'9E_X(U_\ !0(JS*?^%$W71F'_ #-_A)>Q]&8?
M0D=":_8^OQO_ .#@G_E#7_P4"_[(3=?^ICX1H _5[X=DGP%X+R2?^*2\,]>?
M^8#IY_F2?J:[*N,^'7_(A>"_^Q2\,?\ IATZNSH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#K_D0O!?_8I>&/\ TPZ=79UQGPZ_Y$+P7_V*7AC_ -,.G5V= !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBJE[?V.FVEQJ&H7EK8V-G"]Q=W
MMY<0VMG:P1#=)-<W4[QV\$48R7DED1% RQ II.348IN3:223;;;LDDM6V]$E
MJV)M13<FHI)MMM))+5MMZ)):MO1=2W17YE?'G_@K[^P3\ 9+W3-5^-6F_$;Q
M99RBW'@WX-VK_$;5Y[H[E-I_:NDR1^#;.Z611%)#J/BBTECD8(T>XA:^0C_P
M4,_X*2?M2;[7]BK]@G4? 'A&\B9+7XP?M/WKZ#8O;S;6CU73=!N;GPII<QBB
M=76/3-2\=QN2&-M(,1M^BY9X4<;YAA89EBLJAPYDT[2_MOBW&83AC+'3:3]I
M1JYQ5PM7&Q=U:.7T,74DW:,)/0_.LS\5N"<OQ4\MPN:5.(\YCI_8O"6#Q7$^
M9\Z;7LZM')Z6*I8.2L[O,*^$A%)N4XJU_L?_ (*0_P#!1_X<?L%?#?)_L_QA
M\=O&6G79^&'PR^U%=X!DM3XU\:-;N+G2? VD78*LX,6H>*-1A;0="*R+JFIZ
M-YG_ ,$O/^"I'@[]N3PDG@;QRVC^#?VEO">EB?Q-X4M6-GI'CO2K0)%-XY\
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M(9_8(4444 %%%% !1110 R3[H_WX_P#T8M?X8O\ P4$_Y/T_;<_[.[_:3_\
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M?P1?^,Y?@]J>AQ>&;76[>;6)-7LO&?AF.ZTY;-,R&[MY;2>.6$X9'C<'A6(
M/W&^'7_(A>"_^Q2\,?\ IATZNSKS'X>>)?#Z^ _!8.L6&?\ A$O#'_+=>^@Z
M=CKCJ,$>Q'?BNQ_X2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\  A/\:/\
MA)_#W_08L/\ P(3_ !H W:*PO^$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_Q
MH W:*PO^$G\/?]!BP_\  A/\:/\ A)_#W_08L/\ P(3_ !H W:*PO^$G\/?]
M!BP_\"$_QH_X2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\  A/\:/\ A)_#
MW_08L/\ P(3_ !H W:*PO^$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_QH W:
M*PO^$G\/?]!BP_\  A/\:/\ A)_#W_08L/\ P(3_ !H W:*PO^$G\/?]!BP_
M\"$_QH_X2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\  A/\:/\ A)_#W_08
ML/\ P(3_ !H W:*PO^$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_QH W:*PO^
M$G\/?]!BP_\  A/\:/\ A)_#W_08L/\ P(3_ !H W:*PO^$G\/?]!BP_\"$_
MQH_X2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\  A/\:/\ A)_#W_08L/\
MP(3_ !H W:*PO^$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_QH W:*PO^$G\/
M?]!BP_\  A/\:/\ A)_#W_08L/\ P(3_ !H W:*PO^$G\/?]!BP_\"$_QH_X
M2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\  A/\:/\ A)_#W_08L/\ P(3_
M !H W:*PO^$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!B
MP_\  A/\:/\ A)_#W_08L/\ P(3_ !H W:*PO^$G\/?]!BP_\"$_QH_X2?P]
M_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\  A/\:/\ A)_#W_08L/\ P(3_ !H
MW:*PO^$G\/?]!BP_\"$_QH_X2?P]_P!!BP_\"$_QH W:*PO^$G\/?]!BP_\
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M_&C ]_S/^-+10 F![_F?\:,#W_,_XTM% "8'O^9_QHP/?\S_ (TM% "8'O\
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M_&C ]_S/^-+10 F![_F?\:,#W_,_XTM% "8'O^9_QHP/?\S_ (TM% "8'O\
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M$K^+O]D3[/+_ 'D<GBC4+34O+8NP.J?#F_1P5>"TRL=>B> ?^"''[/=SK_\
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M^E87"X7!4*6%P>&H83#48J%'#X:C3H4*4%M&G2I1C3A%=%&*7D)@>_YG_&C
M]_S/^-+17.;B8'O^9_QHP/?\S_C2T4 )@>_YG_&C ]_S/^-+10 F![_F?\:,
M#W_,_P"-+10 F![_ )G_ !HP/?\ ,_XTM% "8'O^9_QHP/?\S_C2T4 )@>_Y
MG_&EHHH **** &2?='^_'_Z,6O\ #%_X*"?\GZ?MN?\ 9W?[2?\ ZN7QI7^Y
MU)]T?[\?_HQ:_P ,7_@H)_R?I^VY_P!G=_M)_P#JY?&E '^OO_P1,_Y1(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO(/C
MO\=OA?\ LV_"_P 3_%_XO^)[3PKX)\*VGGWEY.#->ZA>S$QZ=H.A:=&1<ZSX
MAUFZVV6CZ/9*]U>W+@ 1P1SSP]&$PF*Q^*P^!P.'K8O&8NM2PV%PN&I3K8C$
M8BM-4Z5&C2IJ4ZE6I.480A"+E*322;9SXO%X7 87$8W'8BAA,'A*-3$8K%8F
MK"CA\/0HP=2K6K5:CC"G3IPC*<YRDHQBFVTD7?C/\9_AM^S]\-O%'Q:^+7BF
MP\(>!?"&GM?ZOJ]^S,Q+,(K/3=.LX@UWJNM:M=M%I^C:-I\4^H:KJ$\-I9P2
M2OQ_.[X8\(_'?_@N+\7M&^)'Q.TGQ7\%_P#@G%\,]=DO/!'@=[TV&O\ QJUS
M39Y[&ZO)KRQE\N\U"5X[K3]<\4V33:/X%TR2Z\)^!;J_\57OB#Q/:6OAM\)_
MCW_P6P^*.A_'W]HJTU;X4?L ^ ?$U[<_"/X,6UW=V.L?%N6SEEM)-5OKZU=!
M>1W"QMIOBGQ["\=O;6\FI>"_ADD+2>(/%:_TH>'/#F@>$-!T;PMX6T;3/#OA
MOP]IECHNA:%HMC;Z;I&CZ1IMNEII^F:9I]I'%;65C96T4<%M;01I%#$BJJCG
M/[;5Q& \&,-4PF J83,_%G$T:M',,SHSABL!X=T:T'3JY=E=2#E0Q?%TZ<IT
M\?F4'4HY*G+!X*4\5[>N?B%/#YAXSXF&*Q]/%Y7X386M2KX#+*T)87,/$2O0
MG&K2S#-*<E&OA.$85(QJ8#+IJG7SIJ.,QJAA?88<I^#/!GA3X>>%=!\$>!O#
MVC^%/"/A?3+;1O#WAS0+"WTS1]'TNS3R[:RL+&U2.&W@B7)PJEI)&>:9Y)I)
M)'Z:BBOPVK5J5JE2M6J3JUJLY5*M6I*4ZE2I.3E.I4G)N4YSDW*4I-RE)MMM
ML_<Z5*E0I4Z-&G"C1HTX4J5*E",*=*E3BH4Z=.$4HPA"*480BE&,4DDDD@HH
MHJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2?
M='^_'_Z,6O\ #%_X*"?\GZ?MN?\ 9W?[2?\ ZN7QI7^YU)]T?[\?_HQ:_P ,
M7_@H)_R?I^VY_P!G=_M)_P#JY?&E '^OO_P1,_Y1(_\ !.C_ +-!^"/_ *A]
ME7ZC5^7/_!$S_E$C_P $Z/\ LT'X(_\ J'V5?J-0 445\"_\%$/VS_$W[$OP
M1N/B9X1^!OC'XT:Q)=:?%+)82VF@_#CP%H\WBWP=X9U7Q9\4/&][<H^D65HG
MB^"3PUX6\.:;X@\:>/=8MWTK0](M]-L_$'B+0 #[ZHKYT_:U_:"TO]E?]E_X
M_?M'ZQ9Z?J5K\%/A-X^^(L.CZIK$?A_3]>U/PMH5]>Z'X>N]>FBN(M&A\0ZW
M'INBOJLEO.FG_P!H?:FAF$7EO\#>$O\ @HC\3T^ WQ2^*NNK^Q7\9O%VG?%'
MX(? +X2>"?V3_P!ICQC\1--U3XX?'3XCZ)\*_#'A7XN^)/&7PD\)77PXT1?$
M7C+PIK\FMZ7X?\4WMSX!A\2^)M-T:_%GH]KJP!^PE%?D)K/_  4.^,?P\NO'
MWP!^(7PC^&^H_MB:+\:_V;_@I\/-+\'^._%,'P)^("_M7:9XJUWX=_$W4?$6
ML^%9_'O@SP]X(T;X9_&>[^(WA(^'O$GB"<_"PCPMJ-[%XXT:;2_K[]E+]H/Q
MM\7KKXX_#3XO>%?"GA#XW?LV?%#3/AC\2+7P!K^K>)/ 'B.+Q1\,O GQ?\">
M.O!=_P"(-)T;Q!9:3XG\$?$'25U'PYX@LVU;PMXJTKQ#H9U'7M-M=,\0ZL ?
M7M?C?_P<$_\ *&O_ (*!?]D)NO\ U,?"-?LA7X/_ /!?CXW?!G5_^"1W_!0#
MP?I?Q;^&&H^+7^#.I:2GABR^(/@^Z\1/JEIXR\,+=::FAP:U)JCZA;O;7$<U
MDEH;J*2&2-XE=2H /VM^'7_(A>"_^Q2\,?\ IATZNSKS?X>:[HB^ _!8;6-*
M!_X1+PQQ_:5C_P! '3O2X[]1Z@@C(()['^W]#_Z#.E?^#*R_^/T :]%9']OZ
M'_T&=*_\&5E_\?H_M_0_^@SI7_@RLO\ X_0!KT5D?V_H?_09TK_P967_ ,?H
M_M_0_P#H,Z5_X,K+_P"/T :]%9']OZ'_ -!G2O\ P967_P ?H_M_0_\ H,Z5
M_P"#*R_^/T :]%9']OZ'_P!!G2O_  967_Q^C^W]#_Z#.E?^#*R_^/T :]%9
M']OZ'_T&=*_\&5E_\?H_M_0_^@SI7_@RLO\ X_0!KT5D?V_H?_09TK_P967_
M ,?H_M_0_P#H,Z5_X,K+_P"/T :]%9']OZ'_ -!G2O\ P967_P ?H_M_0_\
MH,Z5_P"#*R_^/T :]%9']OZ'_P!!G2O_  967_Q^C^W]#_Z#.E?^#*R_^/T
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M]XFU?[/*EAIMN5542:^OY['2[2]OK;\%/@E\!_C3_P %D?BQ8?M6?M<V6O>
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M:/LMM_S[P?\ ?F/_ .)J>B@"#[+;?\^\'_?F/_XFC[+;?\^\'_?F/_XFIZ*
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MO!_WYC_^)H^RVW_/O!_WYC_^)J>B@"#[+;?\^\'_ 'YC_P#B:/LMM_S[P?\
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M_GW@_P"_,?\ \34]%?B&^Y^X;;$'V6V_Y]X/^_,?_P 31]EMO^?>#_OS'_\
M$U/10!!]EMO^?>#_ +\Q_P#Q-'V6V_Y]X/\ OS'_ /$U/10!!]EMO^?>#_OS
M'_\ $T?9;;_GW@_[\Q__ !-3T4 0?9;;_GW@_P"_,?\ \31]EMO^?>#_ +\Q
M_P#Q-3T4 0?9;;_GW@_[\Q__ !-'V6V_Y]X/^_,?_P 34]% $'V6V_Y]X/\
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M?_JY?&E?[G4GW1_OQ_\ HQ:_PQ?^"@G_ "?I^VY_V=W^TG_ZN7QI0!_K[_\
M!$S_ )1(_P#!.C_LT'X(_P#J'V5?J-7Y<_\ !$S_ )1(_P#!.C_LT'X(_P#J
M'V5?J-0 4444 %%%% !1110 5^-__!P3_P H:_\ @H%_V0FZ_P#4Q\(U^R%?
MC?\ \'!/_*&O_@H%_P!D)NO_ %,?"- 'ZN_#K_D0O!?_ &*7AC_TPZ=79UQG
MPZ_Y$+P7_P!BEX8_],.G5V= !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&V@\;Z9=>*_#FHVA !^HM%?E?K'_  4>\2^"(_B)\,OB)\ +?3?VL?"'QE^
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MHGASPSX;TNQT30-!T6WL]-TC1M(TVW2UT_3=-L+41V]G96=M''!;V\**D<:
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M(?A#PJ=)\+Z9\6-?\4WGPF\+3:-H_B6\\+Z!I_\ PL#Q'IS:AJX\'Z)^WU%
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ME?\ @MLO_C%:]% &1_8&A_\ 0&TK_P %ME_\8H_L#0_^@-I7_@MLO_C%:]%
M&1_8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5KT4 9']@:'_T!M*_\%ME
M_P#&*/[ T/\ Z VE?^"VR_\ C%:]% &1_8&A_P#0&TK_ ,%ME_\ &*/[ T/_
M * VE?\ @MLO_C%:]% &1_8&A_\ 0&TK_P %ME_\8H_L#0_^@-I7_@MLO_C%
M:]% &1_8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5KT4 9']@:'_T!M*_
M\%ME_P#&*/[ T/\ Z VE?^"VR_\ C%:]% &1_8&A_P#0&TK_ ,%ME_\ &*/[
M T/_ * VE?\ @MLO_C%:]% &1_8&A_\ 0&TK_P %ME_\8H_L#0_^@-I7_@ML
MO_C%:]% &1_8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5KT4 9']@:'_T
M!M*_\%ME_P#&*/[ T/\ Z VE?^"VR_\ C%:]% &1_8&A_P#0&TK_ ,%ME_\
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ME?\ @MLO_C%:]% &1_8&A_\ 0&TK_P %ME_\8H_L#0_^@-I7_@MLO_C%:]%
M&1_8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5KT4 9']@:'_T!M*_\%ME
M_P#&*/[ T/\ Z VE?^"VR_\ C%:]% &1_8&A_P#0&TK_ ,%ME_\ &*/[ T/_
M * VE?\ @MLO_C%:]% &1_8&A_\ 0&TK_P %ME_\8H_L#0_^@-I7_@MLO_C%
M:]% &1_8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5KT4 9']@:'_T!M*_
M\%ME_P#&*/[ T/\ Z VE?^"VR_\ C%:]% &1_8&A_P#0&TK_ ,%ME_\ &*/[
M T/_ * VE?\ @MLO_C%:]% &1_8&A_\ 0&TK_P %ME_\8H_L#0_^@-I7_@ML
MO_C%:]% &1_8&A_] ;2O_!;9?_&*/[ T/_H#:5_X+;+_ .,5KT4 9']@:'_T
M!M*_\%ME_P#&*/[ T/\ Z VE?^"VR_\ C%:]% &1_8&A_P#0&TK_ ,%ME_\
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M^R$W7_J8^$:_9"OQO_X."?\ E#7_ ,% O^R$W7_J8^$: /U=^'7_ "(7@O\
M[%+PQ_Z8=.KLZXSX=?\ (A>"_P#L4O#'_IATZNSH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *_,C_@I5_P4(T3]BWX?:9X8\%647CK]IOXL@:'\&?AG9Q2ZE>F\U.Y;1K;Q
MKKFE6D<MS<:#IVL2PV.DZ/&([WQKXC:#P[I;+"FM:AI7J_[>O[<7PW_86^"U
M]\0_%C1:YXUUTW>B?"OX<V]TD>K^./%HMFDBC,:/]JLO"^C%X+SQ;KZ12)I=
MA)#:VJ7.MZIH^GWOP;_P39_8=^)/B7Q]J7_!1+]N1;CQ%^TU\4#_ &U\._!N
MN6UQ!;_!?PK?VQATR3^P+[S1H'B;^QY1IGAKP^CN?A]X7E:UF=_%NL:Y-9?J
M_!7#&4Y?E4_$3CFA*?"^!Q$\/D>1<[H8OCC/:%I++<-*W/2R3!3<9Y_FD8N%
M*E_L&&]IC:W+2_*.->*,VQ^:Q\.^!J\8<48W#0Q&>9YR>VPO!&1UVHO,L0KJ
M%7.\;#GAD.62DI5:O^W8GV>#H\U7U7_@F1_P3WUGX 6^O_M-?M+WC^//VS?C
M:;S7O'/B/6Y;;5+OX=V?B%X[S4/!^EW]N\EC-KM^Z6Y\9:SIB0V0-M:>$O#X
MB\,:,C:G^OM'3I17Q/%/%&;\89UB\]SJM&IB\2X0IT:,%1P> P=&*IX3+LNP
MT7[/"8#!4(QH8;#PTC"/-.4ZLZE2?VW"W#&4\'Y+A,BR:C*GA,*I3J5JTW6Q
MF/Q=:3J8O,<PQ,DIXK'XVLY5\37G;FG+EA&%*-.G HHHKYX^A"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &2?='^_'_Z,6O\ #%_X*"?\GZ?MN?\ 9W?[
M2?\ ZN7QI7^YU)]T?[\?_HQ:_P ,7_@H)_R?I^VY_P!G=_M)_P#JY?&E '^O
MO_P1,_Y1(_\ !.C_ +-!^"/_ *A]E7ZC5^7/_!$S_E$C_P $Z/\ LT'X(_\
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M[_D?\*,CW_(_X4 +129'O^1_PHR/?\C_ (4 +129'O\ D?\ "C(]_P C_A0
MM%)D>_Y'_"C(]_R/^% "T4F1[_D?\*,CW_(_X4 +129'O^1_PHR/?\C_ (4
M+129'O\ D?\ "C(]_P C_A0 M%)D>_Y'_"C(]_R/^% "T4F1[_D?\*,CW_(_
MX4 +129'O^1_PHR/?\C_ (4 +129'O\ D?\ "C(]_P C_A0 M%)D>_Y'_"C(
M]_R/^% "T4F1[_D?\*,CW_(_X4 +129'O^1_PHR/?\C_ (4 +129'O\ D?\
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M_@.G^%9/PZ_Y$+P7_P!BEX8_],.G5V= &%_PC'A[_H#V'_@.G^%'_",>'O\
MH#V'_@.G^%;M% &%_P (QX>_Z ]A_P" Z?X4?\(QX>_Z ]A_X#I_A6[10!A?
M\(QX>_Z ]A_X#I_A1_PC'A[_ * ]A_X#I_A6[10!A?\ ",>'O^@/8?\ @.G^
M%'_",>'O^@/8?^ Z?X5NT4 87_",>'O^@/8?^ Z?X4?\(QX>_P"@/8?^ Z?X
M5NT4 87_  C'A[_H#V'_ (#I_A1_PC'A[_H#V'_@.G^%;M% &%_PC'A[_H#V
M'_@.G^%'_",>'O\ H#V'_@.G^%;M% &%_P (QX>_Z ]A_P" Z?X4?\(QX>_Z
M ]A_X#I_A6[10!A?\(QX>_Z ]A_X#I_A1_PC'A[_ * ]A_X#I_A6[10!A?\
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M,>'O^@/8?^ Z?X4?\(QX>_Z ]A_X#I_A6[10!A?\(QX>_P"@/8?^ Z?X4?\
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M3(S%"&SA_,4-'APPS2?\+/\ VK;TE[']G;1;)% 0KJGC[33(9#E@ZA+JU#1
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ME 7+ 52'[3WCO65+>#/V;/BGK,,@'D7FL0KH%LQ8*RLSM87D>PJ6((N!_!R
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M\$O_ /@G_97,%W!^R=\&O.MY!+%YWAI[J+> 0/,M[J]GMIDPQS'/#)&W&5)
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MOV0K\</^#@=6?_@C9_P4""JS'_A1-T/E5C_S.'A(]AZ*Q^@)Z T ?JY\.O\
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MX;?.9'8[_F^=F / ^4 5^YG]HV'_ #^VG_@5;_\ QVC^T;#_ )_;3_P*M_\
MX[7M8?P6\.<+_ R"-&VB]CC,=A^5-QE)+ZOB*6DI13:=]4GNKG0OI <2TK+"
M<!> .!6\EA?HY^!\>=W33E[7@*J_=L[<O*KN[O96_%:S_P"";/[<DFZ^O?\
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MNEBA^Q:1 8HY&^9XT(5V.6!/->@?VC8?\_MI_P"!5O\ _':/[1L/^?VT_P#
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MT;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*M_\
MX[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;
M_P#QV@"[15+^T;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_
M )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*M_\ X[1_
M:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#Q
MV@"[15+^T;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;
M3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*M_\ X[1_:-A_
MS^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[
M15+^T;#_ )_;3_P*M_\ X[1_:-A_S^VG_@5;_P#QV@"[15+^T;#_ )_;3_P*
MM_\ X[1_:-A_S^VG_@5;_P#QV@"[15(:C8$X%Y:$G@ 7-ODGT_UE7: "BBB@
M!DGW1_OQ_P#HQ:_PQ?\ @H)_R?I^VY_V=W^TG_ZN7QI7^YU)]T?[\?\ Z,6O
M\,7_ (*"?\GZ?MN?]G=_M)_^KE\:4 ?Z^_\ P1,_Y1(_\$Z/^S0?@C_ZA]E7
MZC5^7/\ P1,_Y1(_\$Z/^S0?@C_ZA]E7ZC4 %%%% !1110!\"?MX^"OB!J!_
M9-^,WP_\"^(?B@W[+G[5WAWXU>,_AYX0^PW?C#Q%\/-6^#OQJ^!WBR]\':%J
M=[IMGXE\2^";?XQVOC^T\/)?P:OK.F^&-8TWPS%J/B:ZTC2K\_86\'^/H=4_
M:^^./COP'XH^%T/[47[4UU\6_ G@#QR+*U\<:+\._"WP%^!/P#\.:KXQT.PO
M+^'PMK?C:X^#FJ^.+?PO<WDNM:#X<\0>']/\30:;XECU;1].^^B 000"#U!&
M0?J#0      .@ P!] * %KY'^*'[#'[,WQKT#Q;X2^+7@36?B'X/\=FY'B_P
M;XM^*/QAUGP=X@@N[]=3FL]2\)W7Q!;P[-IWVZ.*YATT::FGVSP0"VMH4@A5
M/KBB@#\>/^' /_!'#_I'W\ /_!3XE_\ FGH_X< _\$</^D??P _\%/B7_P":
M>OV'HH _'C_AP#_P1P_Z1]_ #_P4^)?_ )IZ/^' /_!'#_I'W\ /_!3XE_\
MFGK]AZ^"_'O_  45^!7P_P#B_P#$_P"#-YX0_:7\6ZY\%+CP[:_%OQ-\+/V5
M?CY\7/A_\/[CQ/X!T+XGZ9;Z]XS^&W@;Q-IGVH>!O$NBZ_=V6G"_O;2VOHHI
M;87.80 ?-G_#@'_@CA_TC[^ '_@I\2__ #3T?\. ?^".'_2/OX ?^"GQ+_\
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M_P#S3U^D'P,^/OPS_:)\):CXO^&>J:M<V_A_Q1K/@7QCX?\ %'A;Q-X$\<>
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M6)X)6M;^VBN[=I()0LD,AAF0O%(H>-B4<!E(K0H _'C_ (< _P#!'#_I'W\
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M\$</^D??P _\%/B7_P":>OV'HH _'C_AP#_P1P_Z1]_ #_P4^)?_ )IZ/^'
M/_!'#_I'W\ /_!3XE_\ FGK]AZ* /QX_X< _\$</^D??P _\%/B7_P":>C_A
MP#_P1P_Z1]_ #_P4^)?_ )IZ_1O]HCX__#O]E[X0^*/C;\59_$,'@GPG=>%-
M.OT\)^%-?\<^)K[5?''C/P[\/O"FD:#X2\+6.I>(->U76_%WBO0M'LK'3+*X
MG>:^5V588Y'7S+X*_MK_  8^-GCB/X6V-C\6_AA\5;KPMJ_CG2/AG\?_ ('_
M !6^ OC/Q-X*T#5=,T/7O%7@[3?BCX5\.VWC31O#^JZUHMEXDE\*7^L7/AF3
M7-!D\0VNF6^O:/->@'QC_P . ?\ @CA_TC[^ '_@I\2__-/1_P . ?\ @CA_
MTC[^ '_@I\2__-/7["A@21R,=<JRC\"0 W3^$FA6#9QN&/[RLOY;@,CW&10!
M^/7_  X!_P"".'_2/OX ?^"GQ+_\T]'_  X!_P"".'_2/OX ?^"GQ+_\T]?H
M=\4/VF_@9\&_B'\%OA)\1/B+H.@_$_\ :'\8S>!O@[X ,[7WB[QMK5EH.M^)
MM5N=/T"P6YU*W\.:)HWA[4;C7/%E_;VOAK2;@Z=IEYJD6JZQI-E>^:7'[>/[
M,]M\97^!\GC/73XDA^)6G_!&Z\6Q?#OXAS_!ZR^.VK:-9>(M-^!M_P#&R#PS
M)\+++XMWNC:C83Q>";GQ3'J:ZG?6'A>81>+M0L=!N #X\_X< _\ !'#_ *1]
M_ #_ ,%/B7_YIZ/^' /_  1P_P"D??P _P#!3XE_^:>OV&!! (Y! (/L>E+0
M!^/'_#@'_@CA_P!(^_@!_P""GQ+_ /-/1_PX!_X(X?\ 2/OX ?\ @I\2_P#S
M3U^P]% 'X\?\. ?^".'_ $C[^ '_ (*?$O\ \T]'_#@'_@CA_P!(^_@!_P""
MGQ+_ /-/7[#T4 ?CQ_PX!_X(X?\ 2/OX ?\ @I\2_P#S3T?\. ?^".'_ $C[
M^ '_ (*?$O\ \T]?=_[2O[5WPT_99L?AO-X^TCXH^*-7^+OCRY^&WPZ\'?![
MX3^.OC)XY\4>*['P-XO^)&HV=AX1^'VCZUK7V73/!7@3Q3K^HZE-;1V-G9Z3
M,9YU=XE>_P# ;]J3X2?M%2>,-+\"7GB[1O&OPZD\.Q?$7X8?%#X=>._A!\5O
M @\7Z=<:MX2O/$WPZ^)7A_PUXHL]%\5:?9ZA-X9\2V]A>>&O$$FE:W9Z1K%W
M?:'K%K8@'P#_ ,. ?^".'_2/OX ?^"GQ+_\ -/1_PX!_X(X?](^_@!_X*?$O
M_P T]?L*'!!;#8'JC@_@I4,?P!I0P(R,@?[2E3QZA@"/Q% 'X\_\. ?^".'_
M $C[^ '_ (*?$O\ \T]'_#@'_@CA_P!(^_@!_P""GQ+_ /-/7Z'C]IOX%R_M
M&P_LEVGQ&T#4?VA#\+M;^,]_\,M+G?4]>\/_  VT+7_"?AF?Q+XI^Q)/:^&(
M=2UGQIHEKX=LM=GL=2\21_VG>Z)9WMAHNJ7-JV/]IKX*S_M,?\,@VOC2WO/V
M@8O@M??M!:AX#L[#4[F71OA39^--#\ 0>(];UB&U?0])FU?Q/KL%IH6BWM_%
MK>L6MEJNJV5A)IFG3W5 'YY?\. ?^".'_2/OX ?^"GQ+_P#-/1_PX!_X(X?]
M(^_@!_X*?$O_ ,T]?L/10!^/'_#@'_@CA_TC[^ '_@I\2_\ S3T?\. ?^".'
M_2/OX ?^"GQ+_P#-/7[#T4 ?CQ_PX!_X(X?](^_@!_X*?$O_ ,T]'_#@'_@C
MA_TC[^ '_@I\2_\ S3U^P]% 'X\?\. ?^".'_2/OX ?^"GQ+_P#-/1_PX!_X
M(X?](^_@!_X*?$O_ ,T]?7_QY_;B^$?[/_Q3\*?!77O"WQX^(/Q-\7^!=6^)
M=AX3^!GP ^*OQOU&P\!Z)XETWPAJ/B?7Q\./#FN)H6FP^(M7T_34?46ADGFN
M%,$<BAB/:?@G\>/A9^T/X);Q_P#";Q*WB+0;;Q!XB\(:U:WNBZ_X7\4^$O&G
MA#4YM&\5^"?''@GQ9I>B>,/!'C/PWJ<#VNM>%?%6AZ3K=AOM[B6S^QWEG<W
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MNHM)\1^;;7=G.EQ;3Q%O$S 20S1I(A*D;E&01D']>\8Z>Y_,Y/ZT44 %%%%
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MX4\ :+HTGB3Q5X0\'VOQ0\)?%.T3P5H^J27?@;PQ=:]X;L=9L;&.TNOZ*Z3
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MQ\4:UXK^$4G@I)OZ02H)SSGCD$@G&< X(R!D\'(Y/%)M&0<8QV!('3'(! /
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M.1^0I-HSGGZ9..#D';G;G/.<9SWH 1!A0,8 X'KM!PN?<K@GT-.HHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)7Q,G!S]IF/L<(XM_P"BUN7U'YBC(]1^=?S^?\.PO^"F7_27?XK?^"/QU_\
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M9N&,X;N?NMGCKQC/?@=3R1D U_-O^S_^PY^V5X&\;_LNMX\\/^)K:;P'I7[
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M5/#B03RS^*O#,6K^XA@<?>YQU5AU&1G(X]\]#P<&OQ#^(_[//[6/C;XFZO\
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MCN_L+Q?^R!\??$&M>.]-A^"_Q"M_B;JWQ _;MUSXL?M/^$/CGX.^'FK?M _
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M4_V?/$?@"R_;"N=%U9_&5U:VMZ_@>/QGI'Q%NENXI/C7H9ET&:Y\86\]E;T
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MM HHHK,U"C ].G2BB@ P,8P,>G:BBB@ P/048'H*** # ]!SU]Z, ]1FBB@
MK+UG1-&\1:9=:+K^DZ;K>D7RQI>Z7J]A::GIMVD4T=Q$EU87T-Q:7"QSQ1S(
MLT+A)8TD4!T5AJ44 10006L$-M;0Q06\$4<$$$,:10PPQ((XHHHHU6..*.-5
M2.-%5$151%50 )<#KCGUHHH ,#T%&!Z>WX>E%% !@?E_GI1@>E%% !@>GO\
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MX)(?])%_V0O_  ]GA'_Y,H_X?:?\$D/^DB_[(7_A[/"/_P F4 ?J/17Y<?\
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MX)(?])%_V0O_  ]GA'_Y,H_X?:?\$D/^DB_[(7_A[/"/_P F4 ?J/17Y<?\
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MX)(?])%_V0O_  ]GA'_Y,H_X?:?\$D/^DB_[(7_A[/"/_P F4 ?J/17Y<?\
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<FN:3>QX2[TS5M,N[6_L+I $N+6XBE7AQ0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6877922320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 08, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Accelerate Diagnostics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000727207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,199,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6878212592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,585<span></span>
</td>
<td class="nump">$ 53,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">11,839<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">134,151<span></span>
</td>
<td class="nump">67,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,016<span></span>
</td>
<td class="nump">2,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intellectual property, net</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">139,324<span></span>
</td>
<td class="nump">69,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,623<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue and income</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligations</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,306<span></span>
</td>
<td class="nump">2,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">Long-term deferred income</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term capital lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">$ 3,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherValueOutstanding', window );">Common stock, $0.001 par value; 55,000,000 common shares authorized 51,191,184 (as of December 31, 2015) and 44,639,829 (as of December 31, 2014) shares issued and outstanding</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 preferred shares authorized and none outstanding as of December 31, 2015 and December 31, 2014</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Contributed capital</a></td>
<td class="nump">243,894<span></span>
</td>
<td class="nump">131,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(110,915)<span></span>
</td>
<td class="num">(65,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">133,018<span></span>
</td>
<td class="nump">65,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 139,324<span></span>
</td>
<td class="nump">$ 69,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of accumulated other comprehensive loss related to that portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized either as available-for-sale or held-to-maturity that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 7<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 25<br> -Article 5<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 17<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Subparagraph h<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section H<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6867958800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">51,199,017<span></span>
</td>
<td class="nump">44,639,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">51,199,017<span></span>
</td>
<td class="nump">44,639,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6878107056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesNetOfInterestExpenseAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing and royalty revenues</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Product sales</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,022<span></span>
</td>
<td class="nump">19,526<span></span>
</td>
<td class="nump">10,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">17,882<span></span>
</td>
<td class="nump">10,695<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Impairment of intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">45,696<span></span>
</td>
<td class="nump">31,112<span></span>
</td>
<td class="nump">15,359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(45,549)<span></span>
</td>
<td class="num">(30,990)<span></span>
</td>
<td class="num">(15,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Interest expense and other</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividend income</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Total other income</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes</a></td>
<td class="num">(45,498)<span></span>
</td>
<td class="num">(30,933)<span></span>
</td>
<td class="num">(15,282)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,498)<span></span>
</td>
<td class="num">$ (30,933)<span></span>
</td>
<td class="num">$ (15,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (dollars per share)</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (shares)</a></td>
<td class="nump">44,998<span></span>
</td>
<td class="nump">43,626<span></span>
</td>
<td class="nump">37,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">$ (45,498)<span></span>
</td>
<td class="num">$ (30,933)<span></span>
</td>
<td class="num">$ (15,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,498)<span></span>
</td>
<td class="num">(30,933)<span></span>
</td>
<td class="num">(15,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized (loss) gain on available-for-sale investments</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (45,517)<span></span>
</td>
<td class="num">$ (30,948)<span></span>
</td>
<td class="num">$ (15,260)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 7<br> -Subparagraph a, b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 3<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 7<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 7<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesNetOfInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesNetOfInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6880079600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Contributed Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, amount at Dec. 31, 2012</a></td>
<td class="nump">$ 12,068<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 31,245<span></span>
</td>
<td class="num">$ (19,202)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance (shares) at Dec. 31, 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td>
<td class="nump">19,912<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">19,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Exercise of options</a></td>
<td class="nump">20,969<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">20,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Exercise of options and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">3,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, amount at Dec. 31, 2013</a></td>
<td class="nump">41,517<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">75,937<span></span>
</td>
<td class="num">(34,484)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td>
<td class="nump">44,875<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">44,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Exercise of options</a></td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Exercise of options and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">9,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, amount at Dec. 31, 2014</a></td>
<td class="nump">65,991<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">131,356<span></span>
</td>
<td class="num">(65,417)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants</a></td>
<td class="nump">103,351<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">103,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Exercise of options</a></td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Exercise of options and warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">8,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, amount at Dec. 31, 2015</a></td>
<td class="nump">$ 133,018<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 243,894<span></span>
</td>
<td class="num">$ (110,915)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the pretax change in net unrealized holding gain (loss) on available-for-sale securities that has been included in accumulated other comprehensive income, a separate component of shareholders' equity, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6878316048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,498)<span></span>
</td>
<td class="num">$ (30,933)<span></span>
</td>
<td class="num">$ (15,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Amortization of investment discount</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">8,388<span></span>
</td>
<td class="nump">9,624<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expense and other</a></td>
<td class="num">(1,241)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract', window );"><strong>Increase (decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue and income</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(35,126)<span></span>
</td>
<td class="num">(18,785)<span></span>
</td>
<td class="num">(9,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of equipment</a></td>
<td class="num">(3,656)<span></span>
</td>
<td class="num">(1,933)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of available-for-sale securities</a></td>
<td class="num">(12,418)<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
<td class="num">(12,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales of available-for-sale securities</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of available-for-sale securities</a></td>
<td class="nump">13,258<span></span>
</td>
<td class="nump">5,357<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,675)<span></span>
</td>
<td class="num">(3,372)<span></span>
</td>
<td class="num">(13,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="nump">20,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock and warrants</a></td>
<td class="nump">104,165<span></span>
</td>
<td class="nump">44,875<span></span>
</td>
<td class="nump">19,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on capital lease obligations</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">104,823<span></span>
</td>
<td class="nump">45,691<span></span>
</td>
<td class="nump">40,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">67,022<span></span>
</td>
<td class="nump">23,534<span></span>
</td>
<td class="nump">17,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">53,563<span></span>
</td>
<td class="nump">30,029<span></span>
</td>
<td class="nump">12,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 120,585<span></span>
</td>
<td class="nump">$ 53,563<span></span>
</td>
<td class="nump">$ 30,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865828144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business; Basis of Presentation; Principles of Consolidation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Nature of Business; Basis of Presentation; Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1.  ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics, Inc. (&#8220;we&#8221; or &#8220;us&#8221; or &#8220;our&#8221; or &#8220;Accelerate&#8221; or &#8220;the Company&#8221;) is an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;"> diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.  Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention (&#8220;CDC&#8221;) calls one of the most serious healthcare threats of our time, antibiotic resistance.  A significant contributor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (&#8220;U.S. GAAP&#8221;), and applicable rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;), regarding annual financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (including the newly formed Accelerate Diagnostics S.L.) after elimination of intercompany transactions and balances. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6614177056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s main financial institution for banking operations held </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">83%</font><font style="font-family:Arial;font-size:10pt;"> of the Company&#8217;s cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company grants credit to domestic and international clients in various industries.  Exposure to losses on accounts receivable is principally dependent on each client's financial position.  At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">66%</font><font style="font-family:Arial;font-size:10pt;"> of the outstanding receivable balance was with Denver Health.  See </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;"> for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Estimated Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC Topic 820, Fair Value Measurements and Disclosures</font><font style="font-family:Arial;font-size:10pt;"> which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements.  The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 2:  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 3:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See </font><font style="font-family:Arial;font-size:10pt;">Note 3, Fair Value of Financial Instruments</font><font style="font-family:Arial;font-size:10pt;"> for further information and related disclosures regarding the Company&#8217;s fair value measurements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents.  Cash and cash equivalents include overnight repurchase agreement accounts.  As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank.  Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal.  We believe however, that the market risk arising from holding these financial instruments is minimal.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Investments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company invests excess funds in various short-term investments which are primarily held in the custody of a major financial institution.  Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper.  Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value.  Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity.  The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&#8217;s fair value remains less than its cost for more than twelve months.  This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs.  When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss.  The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost.  Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.  Gains and losses from retirement or replacement are included in costs and expenses.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years.  Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.  See </font><font style="font-family:Arial;font-size:10pt;">Note 5, Property and Equipment</font><font style="font-family:Arial;font-size:10pt;"> below.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Long-lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval.  We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance.  Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k) clearance, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted.  Inventory is reported as research and development costs, or if used in marketing evaluations reported to sales, general and administrative costs on the Statement of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue in accordance with ASC 605, &#8220;Revenue Recognition,&#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue represents amounts received but not yet earned under existing agreements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Accounts Receivable Allowances</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable.  Receivables are written off if reasonable collection efforts prove unsuccessful.  The Company provides for allowances on a specific account basis.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company accounts for leases in accordance with ASC 840, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases,</font><font style="font-family:Arial;font-size:10pt;"> which requires leases to be classified as either operating or capital leases.  In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception.  Other leases are classified as operating leases.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease rent is recorded as an operating expense monthly.  For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments.  The asset is included with property and equipment on the Balance Sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the Statements of Operations and Comprehensive Loss.  For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the Balance Sheet.  Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the Statements of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets.  The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period.  Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows the provisions of ASC 740, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Arial;font-size:10pt;">, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return.  This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return.  Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit.  Interest and penalties, if any, would be recorded as tax expense in general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC 260, Earnings Per Share</font><font style="font-family:Arial;font-size:10pt;">, which requires companies to present basic earnings per share and diluted earnings per share.  Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.  Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued.  Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred. See </font><font style="font-family:Arial;font-size:10pt;">Note 11, Earnings Per Share</font><font style="font-family:Arial;font-size:10pt;"> for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company awards stock options and other equity-based instruments to its employees, directors and consultants.  Compensation cost related to equity-based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method).  For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested.  The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model.  This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Volatility:  The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected term:  The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns.  For consultant awards, the estimated expected term is the same as the life of the award.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate:  The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield:  The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the future.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company estimates the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period.  The rate is calculated separately for awards to the board of directors/executives and all other awards. See </font><font style="font-family:Arial;font-size:10pt;">Note 12, Employee and Consultant Equity-Based Compensation</font><font style="font-family:Arial;font-size:10pt;"> for further information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows ASC 830 </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign Currency Matters</font><font style="font-family:Arial;font-size:10pt;">, which provides guidance on foreign currency transactions and translation of financial statements.  Adjustments resulting from translating foreign functional currency financial statements into U.S.  Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholder's equity.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency.  These balance sheet items are subject to re-measurement, the impact of which is recorded in interest expense and other, within the consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC 220, Reporting Comprehensive Income</font><font style="font-family:Arial;font-size:10pt;">, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements.  The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).  The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Arial;font-size:10pt;">.  This replaces the existing standards relating to leases for both lessees and lessors.  For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized  much like the existing standard.  For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases.  For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria.  The ASU is required for us on January 1, 2019 with early adoption permitted.  We are currently assessing the impact this will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January, 2016, the FASB issued ASU 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall</font><font style="font-family:Arial;font-size:10pt;">.  This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets.  The ASU is required for us on January 1, 2018.  We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes-Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position rather than separating these amounts between current and noncurrent amounts.  The deferred tax liabilities and assets continue to be offset and presented as a single amount.  The ASU is required for us on January 1, 2017 and we have elected to adopt this standard retrospectively for the period ended December 31, 2015.   There was no significant impact on our consolidated financial statements as a result of adopting this ASU.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires entities that measure inventory using first-in, first-out or average cost inventory to report inventory at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The ASU will become effective for us on January 1, 2016.  We do not expect the adoption of ASU 2015-11 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2015, the FASB issued ASU 2015-05, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other - Internal-Use Software; Customer&#8217;s Accounting for Fees Paid in a Cloud Computing Arrangement</font><font style="font-family:Arial;font-size:10pt;">.  Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&#8217;s accounting for fees paid in a cloud computing arrangement.  Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements.  This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses.  If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract.  The ASU does not change the accounting for service contracts.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2015, the FASB issued ASU 2015-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement - Extraordinary and Unusual Items</font><font style="font-family:Arial;font-size:10pt;">.  The new standard eliminates from U.S. GAAP the concept of extraordinary items.  Prior to the adoption of this standard, extraordinary items have been segregated from the results of ordinary operations and shown separately in the income statement, net of tax, after income from continuing operations.  The new standard eliminates such segregation as well as the requirements to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&#8217;s ability to continue as a going concern and, if so, disclose that fact.  Management will also be required to evaluate and disclose whether its plans alleviate that doubt.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2014-15 to have a significant impact on our consolidated financial statements</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.  We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements.  The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.  We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements.  In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers Deferral of the Effective Date</font><font style="font-family:Arial;font-size:10pt;">, which deferred the effective date resulting in a new effective date of January 1, 2018 for us.  We are permitted to adopt early but not before the original effective date of January 1, 2017.  The standard allows for either &#8220;full retrospective&#8221; adoption, meaning the standard is applied to all of the periods presented, or &#8220;modified retrospective&#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements.  We are currently evaluating the transition method and the adoption date that will be elected.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865832784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3.  FAIR VALUE OF FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (see </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;"> for further information):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Money market funds (cash equivalents)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1) &#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Money market funds (cash equivalents)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;Level 1 assets are priced using quoted prices in active markets for identical assets which include cash accounts and money market funds as these specific assets are liquid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data.  The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities.  The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.  There were no transfers between levels during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6751072976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4.  INVESTMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the Company&#8217;s available-for-sale investments at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;The following table summarizes the maturities of the Company&#8217;s available-for-sale securities at December 31, </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENT MATURITIES</font></div><div style="text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">At December 31, 2015</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">At December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 1-3 years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;For the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$141,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$861,000</font><font style="font-family:Arial;font-size:10pt;"> in proceeds from sales of marketable securities (including principle paydowns) were collected, respectively.  The Company determines gains and losses of marketable securities based on specific identification of the securities sold.  There were no gross realized gains and losses from sales of marketable securities for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">.  The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire  disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865817808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5.  PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost and consisted of the following at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (in thousands).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="68%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Technical equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Facilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital lease &#8211; leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital projects in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,904</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated amortization &#8211; capital lease</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated depreciation - other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,311</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;Depreciation expense (which includes amortization of capital lease assets) for the for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$1.8 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$817,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$286,000</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6757022880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements and Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract', window );"><strong>License Agreements and Grants - Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_LicenseAgreement', window );">License Agreements and Grants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6.  LICENSE AGREEMENTS AND GRANTS</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Defense Medical Research and Development Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (&#8220;DMRDP&#8221;) recommended </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;"> of funding for a proposed 35-month project.  The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections.  The project will apply the Accelerate ID/AST system to wound infections and other serious infections secondary to trauma.  The Company has invoiced a cumulative total of </font><font style="font-family:Arial;font-size:10pt;">$558,000</font><font style="font-family:Arial;font-size:10pt;"> under this grant which is recorded as an offset to research and development expenses.  The amount invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$179,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$221,000</font><font style="font-family:Arial;font-size:10pt;">,  </font><font style="font-family:Arial;font-size:10pt;">$143,000</font><font style="font-family:Arial;font-size:10pt;">, respectively.  The period of performance for the grant ended September 2015.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">National Institute of Health Grant</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2015, the National Institute of Health awarded Denver Health and the Company a five year, </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood.  In June 2015, the Company executed a subaward agreement with Denver Health for the services we will provide as part of this grant which covers the period of February 15, 2015 through January 31, 2016 and totals </font><font style="font-family:Arial;font-size:10pt;">$689,000</font><font style="font-family:Arial;font-size:10pt;">.  The amounts invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$483,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona Commerce Authority</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2012, the Company entered into a Grant Agreement (the &#8220;Grant Agreement&#8221;) with the Arizona Commerce Authority, an agency of the State of Arizona (the &#8220;Authority&#8221;), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the &#8220;Project&#8221;).  Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> (the &#8220;Grant&#8221;) for the use by the Company in the advancement of the Project.  The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 1 &#8211; Relocation of Company&#8217;s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 2 &#8211; Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 3 &#8211; Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 4 &#8211; Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For purposes of the Grant Agreement, a &#8220;Qualified Job&#8221; is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least </font><font style="font-family:Arial;font-size:10pt;">$63,000</font><font style="font-family:Arial;font-size:10pt;"> and offers health insurance benefits and pays at least </font><font style="font-family:Arial;font-size:10pt;">65%</font><font style="font-family:Arial;font-size:10pt;"> of the premiums associated with such benefits.  The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement.  The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company has collected all of the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestones.  The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are &#8220;claw-back&#8221; provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement.  Once the &#8220;claw-back&#8221; provisions expire in January 2018, we will recognize the grant as an offset to expense.  Further details are included in </font><font style="font-family:Arial;font-size:10pt;">Note 7, Deferred Revenue and Income</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&amp;D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has applied for and met the program requirements to receive a &#8220;Certificate of Qualification&#8221; from the Arizona Commerce Authority (&#8220;Authority&#8221;) which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&amp;D Refundable Tax Credit Program").  The amounts collected under this program are recorded as an offset to research and development expenses, and for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$647,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$527,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively.  If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_LicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_LicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreements and Grants - Research and Development [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_LicenseAgreementsandGrantsResearchandDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865839904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue and Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Deferred Revenue and Income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7.  DEFERRED REVENUE AND INCOME</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue consists of amounts received for products or services not yet delivered or earned.  Deferred income consists of amounts received for commitments not yet fulfilled.  If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income.  A summary of the balances as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research Use Only Accelerate ID/AST systems</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2014, we received </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the &#8220;claw-back&#8221; provisions under the Grant Agreement expire in January 2018.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred income includes </font><font style="font-family:Arial;font-size:10pt;">$114,000</font><font style="font-family:Arial;font-size:10pt;"> of payments received in December 2015, for Research Use Only Accelerate ID/AST systems.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865835072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract', window );"><strong>Securities Financing Transactions Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock', window );">Stock Purchase</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8.  STOCK PURCHASE</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2012, we entered into a Securities Purchase Agreement with Abeja Ventures, LLC (&#8220;Abeja&#8221;), pursuant to which the Company agreed to sell and issue to Abeja at a purchase price of </font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;"> per share for an aggregate purchase price of </font><font style="font-family:Arial;font-size:10pt;">$14.4 million</font><font style="font-family:Arial;font-size:10pt;">; (i) </font><font style="font-family:Arial;font-size:10pt;">14.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company&#8217;s common stock (&#8220;Common Stock&#8221;); (ii) a warrant to purchase </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;"> per share (the &#8220;</font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;"> " Warrant&#8221;); and (iii) another warrant to purchase </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$2.00</font><font style="font-family:Arial;font-size:10pt;"> per share (the &#8220;</font><font style="font-family:Arial;font-size:10pt;">$2.00</font><font style="font-family:Arial;font-size:10pt;">" Warrant&#8221;), with each warrant exercisable prior to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement (collectively, the &#8220;Investment&#8221;).  The purchase of Common Stock and warrants pursuant to the Investment, which was consummated in June, 2012, qualified for equity treatment under U.S. GAAP. The respective values of the warrants and Common Stock were calculated using their relative fair values and both are classified under Contributed Capital.  The value therefore recorded for the warrants was </font><font style="font-family:Arial;font-size:10pt;">$5.9 million</font><font style="font-family:Arial;font-size:10pt;"> and for the Common Stock was </font><font style="font-family:Arial;font-size:10pt;">$8.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Both warrants are exercisable until June 26, 2017, which was the fifth anniversary of the date on which the warrants were issued.  Other significant terms and conditions of the warrants are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the warrants provide for partial exercises, but they do not provide for a &#8220;cashless&#8221; exercise feature (i.e., they may only be exercised for cash);</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the warrants do not contain anti-dilution provisions that would trigger exercise price or other adjustments as a result of subsequent issuances of the Company&#8217;s equity securities, but they do contain customary provisions for equitable adjustments in connection with stock dividends, stock splits or reclassifications of Common Stock;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">following certain types of fundamental transactions involving the Company (e.g., a transaction resulting in a change in control of the Company), the holder of the warrants would continue to be entitled to exercise the warrants in exchange for the equity securities or alternate consideration receivable by a holder of Common Stock as a result of the fundamental transaction; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the holder of the warrants is entitled to certain demand and piggy-back registration rights, including for shelf registrations, with respect to the shares of Common Stock issuable upon its exercise of the warrants.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2013, Abeja exercised in full its warrant to purchase </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$1.03</font><font style="font-family:Arial;font-size:10pt;"> per share.  On the same date, Abeja also exercised the </font><font style="font-family:Arial;font-size:10pt;">92%</font><font style="font-family:Arial;font-size:10pt;"> of its warrant to purchase an additional </font><font style="font-family:Arial;font-size:10pt;">7.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock at an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$2.00</font><font style="font-family:Arial;font-size:10pt;"> per share (Abeja exercised such warrant for </font><font style="font-family:Arial;font-size:10pt;">6.4 million</font><font style="font-family:Arial;font-size:10pt;"> shares, leaving </font><font style="font-family:Arial;font-size:10pt;">571,160</font><font style="font-family:Arial;font-size:10pt;"> shares unexercised).  The Company received aggregate funds of </font><font style="font-family:Arial;font-size:10pt;">$20.1 million</font><font style="font-family:Arial;font-size:10pt;"> in connection with such exercises.  Shares issued by the Company in connection with the warrant exercises were issued directly to the members of Abeja on a pro rata basis in accordance with their membership interests and written exercise instructions provided to the Company by Abeja.  Immediately after giving effect to the warrant exercises, Abeja also distributed in kind to its members (on a pro rata basis in accordance with their membership interests) the remaining shares of Common Stock held by that entity.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionsDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a transferor's continuing involvement in financial assets that it has transferred in a securitization or asset-backed financing arrangement, the nature of any restrictions on assets reported by an entity in its statement of financial position that relate to a transferred financial asset (including the carrying amounts of such assets), how servicing assets and servicing liabilities are reported, and (for securitization or asset-backed financing arrangements accounted for as sales) when a transferor has continuing involvement with the transferred financial assets and transfers of financial assets accounted for as secured borrowings, how the transfer of financial assets affects an entity's financial position, financial performance, and cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=13989330&amp;loc=d3e107207-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7882072&amp;loc=d3e122596-111746<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=7882072&amp;loc=d3e122739-111746<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7882072&amp;loc=d3e122625-111746<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=7519067&amp;loc=SL6226446-111709<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=13989330&amp;loc=d3e107314-111719<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7519067&amp;loc=SL6226443-111709<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransfersAndServicingOfFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6752175264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=axdx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Public Offering</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9.  PUBLIC OFFERING</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 9, 2015, the Company published a prospectus supplement underwritten by J.P. Morgan and Piper Jaffray ("Underwriters") offering </font><font style="font-family:Arial;font-size:10pt;">5.6 million</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock with an option for the Underwriters to purchase up to </font><font style="font-family:Arial;font-size:10pt;">838,000</font><font style="font-family:Arial;font-size:10pt;"> additional shares of common stock for a total of </font><font style="font-family:Arial;font-size:10pt;">6.4 million</font><font style="font-family:Arial;font-size:10pt;"> shares.  The public offering price was </font><font style="font-family:Arial;font-size:10pt;">$17.00</font><font style="font-family:Arial;font-size:10pt;"> per share and underwriting discounts and commissions were </font><font style="font-family:Arial;font-size:10pt;">$1.19</font><font style="font-family:Arial;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Affiliates, including entities affiliated with one of Company's directors, Jack Schuler, and which together are our largest stockholders,  purchased </font><font style="font-family:Arial;font-size:10pt;">2.9 million</font><font style="font-family:Arial;font-size:10pt;"> of the offered shares at the public offering price of </font><font style="font-family:Arial;font-size:10pt;">$17.00</font><font style="font-family:Arial;font-size:10pt;"> per share.  These shares are subject to lock-up agreements for a period of 90 days starting December 9, 2015.  In general, the lock-up agreement, with limited exceptions, requires J.P. Morgan Securities LLC's prior written approval for the sale (directly or indirectly) of AXDX common stock.  This includes various types of sales or offers to sell.  The underwriters did not receive any underwriting discount or commissions on the sale of </font><font style="font-family:Arial;font-size:10pt;">2.4 million</font><font style="font-family:Arial;font-size:10pt;"> shares to such affiliates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The public offering was finalized and </font><font style="font-family:Arial;font-size:10pt;">6.4 million</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock were delivered to the purchasers on or around December 15, 2015.  Proceeds from the sale totaled </font><font style="font-family:Arial;font-size:10pt;">$109.3 million</font><font style="font-family:Arial;font-size:10pt;"> less underwriting and other expenses of </font><font style="font-family:Arial;font-size:10pt;">$5.9 million</font><font style="font-family:Arial;font-size:10pt;"> for net proceeds of </font><font style="font-family:Arial;font-size:10pt;">$103.4 million</font><font style="font-family:Arial;font-size:10pt;">.  The net proceeds will be used for general corporate purposes.  We may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so.  Accordingly, we will retain broad discretion over the use of these proceeds.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph d<br> -Article 4<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=axdx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=axdx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6753134816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Rights Offering<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=axdx_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Public Offering</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10.  RIGHTS OFFERING</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">April 2014 Offering</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 7, 2014, the Company commenced a rights offering to raise </font><font style="font-family:Arial;font-size:10pt;">$45.0 million</font><font style="font-family:Arial;font-size:10pt;"> to fund continued operations, clinical trials, and product commercialization efforts.  Under the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock as of March 14, 2014, which was established as the record date for the rights offering, </font><font style="font-family:Arial;font-size:10pt;">0.063921</font><font style="font-family:Arial;font-size:10pt;"> non-transferable subscription rights for each share of Common Stock owned on the record date.  Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of </font><font style="font-family:Arial;font-size:10pt;">$16.80</font><font style="font-family:Arial;font-size:10pt;"> per share which was lower than the market price of </font><font style="font-family:Arial;font-size:10pt;">$17.64</font><font style="font-family:Arial;font-size:10pt;"> per share on the date of the rights offering commencement and the </font><font style="font-family:Arial;font-size:10pt;">$17.54</font><font style="font-family:Arial;font-size:10pt;"> per share on the date the rights offering period expired.  In the aggregate, the Company intended to issue </font><font style="font-family:Arial;font-size:10pt;">2.7 million</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock in connection with the rights offering.  The purpose of the rights offering was to raise equity capital in a cost-effective manner that gives all of the Company&#8217;s existing stockholders the opportunity to participate on a pro rata basis.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the rights offering, the Company received standby commitments from the Jack W. Schuler Living Trust and the Schuler Family Foundation.  The standby purchasers agreed to purchase any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.  On May 1, 2014, the Company entered into an Assignment and Assumption Agreement with the standby purchasers, Oracle Institutional Partners, L.P. and Oracle Partners, L.P., pursuant to which each standby purchaser assigned and transferred its respective rights, responsibilities, liabilities and obligations under the Standby Purchase Agreement to purchase </font><font style="font-family:Arial;font-size:10pt;">297,619</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock not subscribed for by the Company&#8217;s stockholders in connection with the rights offering to (i) Oracle Institutional Partners, L.P., with respect to </font><font style="font-family:Arial;font-size:10pt;">119,047</font><font style="font-family:Arial;font-size:10pt;"> shares of such Common Stock, and (ii) Oracle Partners, L.P., with respect to the remaining </font><font style="font-family:Arial;font-size:10pt;">178,572</font><font style="font-family:Arial;font-size:10pt;"> shares of such Common Stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rights offering period expired on April 28, 2014, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company&#8217;s issuance of an aggregate of </font><font style="font-family:Arial;font-size:10pt;">2.7 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its Common Stock to the rights offering participants and standby purchasers) were completed on May 19, 2014.  The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$45.0 million</font><font style="font-family:Arial;font-size:10pt;"> before costs associated with the transactions which totaled </font><font style="font-family:Arial;font-size:10pt;">$125,000</font><font style="font-family:Arial;font-size:10pt;"> and are treated as a reduction of contributed capital in the Stockholders&#8217; Equity section of the Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because the exercise price of the rights offering of </font><font style="font-family:Arial;font-size:10pt;">$16.80</font><font style="font-family:Arial;font-size:10pt;"> was less than the fair value of the Company&#8217;s shares of Common Stock at the expiration of the offering, there is a bonus element that is treated similar to a stock dividend.  The weighted average shares outstanding, as well as the basic and diluted loss per share for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;"> have been revised for those effects.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">July 2013 Offering</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On July 12, 2013, the Company publicly announced the final terms of a rights offering.  Rights offering materials were subsequently distributed to the Company&#8217;s stockholders on July 18, 2013, at which time the rights offering period commenced.  Pursuant to the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock on July 8, 2013, which was established as the record date for the rights offering, </font><font style="font-family:Arial;font-size:10pt;">0.064038</font><font style="font-family:Arial;font-size:10pt;"> non-transferable subscription rights for each share of Common Stock owned on the record date.  Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of </font><font style="font-family:Arial;font-size:10pt;">$8.04</font><font style="font-family:Arial;font-size:10pt;"> per share.  In addition, any holder of subscription rights exercising his, her or its basic subscription privilege in full was eligible to subscribe to purchase additional shares of Common Stock at the same subscription price per share, subject to the conditions and limitations described further in the prospectus.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the rights offering, the Company received a standby commitment from Abeja to purchase, at </font><font style="font-family:Arial;font-size:10pt;">$8.04</font><font style="font-family:Arial;font-size:10pt;"> per share, any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rights offering period expired on August 7, 2013, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company&#8217;s issuance of an aggregate of </font><font style="font-family:Arial;font-size:10pt;">2.5 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its Common Stock to the rights offering participants and standby purchaser) were completed on August 8, 2013.  The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$20.0 million</font><font style="font-family:Arial;font-size:10pt;"> before costs associated with the transactions, which totaled </font><font style="font-family:Arial;font-size:10pt;">$88,000</font><font style="font-family:Arial;font-size:10pt;"> and are treated as a reduction of contributed capital in the Stockholders&#8217; Equity section of the Balance Sheets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph d<br> -Article 4<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=axdx_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=axdx_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6612902032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11.  EARNINGS PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The financial statements show basic earnings (loss) per share.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our Common Stock to be antidilutive.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, there were Common Stock options, restricted stocks and warrants exercisable for </font><font style="font-family:Arial;font-size:10pt;">6,778,580</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">6,174,886</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">5,731,246</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted average shares outstanding for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Arial;font-size:10pt;"> have been revised for the effects of the rights offering (See </font><font style="font-family:Arial;font-size:10pt;">Note 10, Rights Offering</font><font style="font-family:Arial;font-size:10pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6855293088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee and Consultant Equity-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12.  EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has </font><font style="font-family:Arial;font-size:10pt;">4</font><font style="font-family:Arial;font-size:10pt;"> equity-based compensation plans, which are discussed below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Qualified Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Qualified Stock Option Plan (the &#8220;Qualified Plan&#8221;) was a stockholder-approved plan that provided for stock option grants to employees, including executive officers.  The exercise price of each option, which has a maximum ten-year life, was established by the Company's Compensation Committee on the date of grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">527,500</font><font style="font-family:Arial;font-size:10pt;"> options exercised under the Qualified Plan and </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">ne that remain outstanding.  The Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> further options are available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Non-Qualified Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Non-Qualified Stock Option Plan (the &#8220;Non-Qualified Plan&#8221;) was a stockholder-approved plan that provided for stock option grants to independent contractors, technical advisors and directors of the Company.  The exercise price of each option, which has a maximum </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;"> year life, was established by the Company's Compensation Committee on the date of grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">270,000</font><font style="font-family:Arial;font-size:10pt;"> options exercised under the Non-Qualified Plan and </font><font style="font-family:Arial;font-size:10pt;">10,000</font><font style="font-family:Arial;font-size:10pt;"> that remain outstanding.  The Non-Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> further options are available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2004 Omnibus Stock Option Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2004, the Company&#8217;s stockholders approved the Omnibus Stock Option Plan and reserved </font><font style="font-family:Arial;font-size:10pt;">500,000</font><font style="font-family:Arial;font-size:10pt;"> shares of its authorized but unissued Common Stock for stock options to be granted to employees, independent contractors, technical advisors and directors of the Company.  The authorized shares in this plan were increased by </font><font style="font-family:Arial;font-size:10pt;">5,000,000</font><font style="font-family:Arial;font-size:10pt;"> shares to an aggregate amount of </font><font style="font-family:Arial;font-size:10pt;">5,500,000</font><font style="font-family:Arial;font-size:10pt;"> upon stockholder approval during the fiscal year ended July 31, 2012.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">403,474</font><font style="font-family:Arial;font-size:10pt;"> options exercised under the 2004 Omnibus Stock Option Plan and </font><font style="font-family:Arial;font-size:10pt;">3,536,526</font><font style="font-family:Arial;font-size:10pt;"> that remain outstanding.  The 2004 Omnibus Stock Option Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> further options are available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2012 Omnibus Equity Incentive Plan</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2012, the Company&#8217;s stockholders approved the Company&#8217;s 2012 Omnibus Equity Incentive Plan to replace the Qualified Stock Option Plan, Non-Qualified Stock Option Plan and 2004 Omnibus Stock Option Plan (&#8220;Prior Plans&#8221;).  The Prior Plans remain in effect until all awards granted under those plans have been exercised, forfeited, canceled, expired or otherwise terminated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the approval of such plan, all stock options, totaling </font><font style="font-family:Arial;font-size:10pt;">1,677,500</font><font style="font-family:Arial;font-size:10pt;"> formerly available for new awards under the Prior Plans were transferred to the 2012 Omnibus Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At the Company&#8217;s 2014 Annual Meeting of Stockholders held in May 2014, stockholders approved an amendment to the Company&#8217;s 2012 Omnibus Equity Incentive Plan increasing the number of stock options of Common Stock reserved and available for grant by </font><font style="font-family:Arial;font-size:10pt;">4,000,000</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">5,677,500</font><font style="font-family:Arial;font-size:10pt;"> shares.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options granted under this plan typically vest either (i) one year after grant date, (ii) monthly over a one year period, or (iii) </font><font style="font-family:Arial;font-size:10pt;">40%</font><font style="font-family:Arial;font-size:10pt;"> two years after grant date and the remaining </font><font style="font-family:Arial;font-size:10pt;">60%</font><font style="font-family:Arial;font-size:10pt;"> monthly over the next three years.  The maximum term is ten years.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">71,147</font><font style="font-family:Arial;font-size:10pt;"> options exercised under the 2012 Omnibus Equity Incentive Plan and </font><font style="font-family:Arial;font-size:10pt;">2,660,894</font><font style="font-family:Arial;font-size:10pt;"> that remain outstanding, leaving </font><font style="font-family:Arial;font-size:10pt;">2,945,459</font><font style="font-family:Arial;font-size:10pt;"> available for grant.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2015, the board of directors voted to restrict new grants under the 2012 Omnibus Equity Incentive Plan to 200,000 shares until such time as the Company&#8217;s total available shares are increased.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Combined Plans</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes option activity under all plans during the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;"> and shows the exercisable shares as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding January 1, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5,185,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">769,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(13,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(311,737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.96</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5,628,726</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5.20</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">717,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(54,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(124,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercisable December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,536,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The cash received from the exercise of options during the year ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$805,000</font><font style="font-family:Arial;font-size:10pt;"> and the tax benefit realized was </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;"> for the same period.  Upon exercise, shares are issued from shares authorized and held in reserve.  The intrinsic value of options exercised was </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$3.8 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$2.6 million</font><font style="font-family:Arial;font-size:10pt;"> for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">,  </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The total fair value of shares vesting during the period was </font><font style="font-family:Arial;font-size:10pt;">$7.3 million</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$3.8 million</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">$600,000</font><font style="font-family:Arial;font-size:10pt;"> for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">, the Company accounts for all option grants using the Black-Scholes option pricing model in accordance with ASC 718 for options granted or extended.  </font><font style="font-family:Arial;font-size:10pt;">Note 2</font><font style="font-family:Arial;font-size:10pt;"> also describes the significant assumptions utilized for estimating the various inputs required this pricing model.  The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Black-Scholes Assumptions for Option Granted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected dividends</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Estimated forfeitures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In general, option awards have a requisite service period and unvested options are forfeited upon employee or consultant termination.  The Company estimates a forfeiture rate which is applied to outstanding options to determine options expected to be forfeited with the remaining outstanding options being those expected to vest.  Further information regarding the forfeiture rate calculation is included in </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">.  The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Supplemental Information</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Exercisable</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Vested and Expected to Vest</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,536,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,088,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average remaining contractual term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Aggregate intrinsic value (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">86,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">85,804</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;The aggregate intrinsic value in the table above represents the total pretax intrinsic value that would have been received by the option holders had all option holders exercised their options on that date.  It is calculated as the difference between the Company&#8217;s closing stock price of </font><font style="font-family:Arial;font-size:10pt;">$21.49</font><font style="font-family:Arial;font-size:10pt;"> on the last trading day of </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> and the exercise price multiplied by the number of shares for options where the exercise price is below the closing stock price.  This amount changes based on the fair market value of the Company&#8217;s stock.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2015, in connection with the Company's public offering, we modified the stock options of three of our executive officers to restrict the ability to exercise until such time as additional available unissued shares have been authorized.&#160; Such authorization was obtained for a majority of our shareholders as of December 31, 2015 and was pending submission to the State of Delaware.&#160; There was an immaterial amount of incremental compensation associated with this modification.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes restricted stock activity during the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted Stock Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted stock outstanding December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">40,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested/released</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted stock outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expense and tax benefits recognized on Company&#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Equity-Based Compensation Expenses and Tax Benefit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Sales, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,828</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Recognized tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock was </font><font style="font-family:Arial;font-size:10pt;">$11.4 million</font><font style="font-family:Arial;font-size:10pt;">.  This is expected to be recognized over the years </font><font style="font-family:Arial;font-size:10pt;">2016</font><font style="font-family:Arial;font-size:10pt;"> through </font><font style="font-family:Arial;font-size:10pt;">2020</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865982384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 13.  INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The components of the pretax loss from operations for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Components of the Pretax Loss From Operations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S. Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(44,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,083</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pretax loss from operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company does not reflect income tax expense or benefit for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, as the Company has  a full valuation allowance.  The Company records the Arizona R&amp;D Refundable Tax Credit Program it has monetized as an offset to research and development expenses on the consolidated statement of operations and comprehensive loss as discussed in </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of the Company&#8217;s net deferred income taxes for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, are as are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.46875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="58%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Income Tax Components</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property &amp; equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible assets, definite-lived</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General business credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charitable contribution</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(37,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company has generated regular tax federal net operating losses of approximately </font><font style="font-family:Arial;font-size:10pt;">$85.0 million</font><font style="font-family:Arial;font-size:10pt;">.  The Company's ability to realize tax benefit from the net operating loss is subject to annual limitation under Internal Revenue Code Section 382.  Due to the change in control which occurred as a result of Abeja Ventures, LLC&#8217;s investment in the Company on June 26, 2012, the Company estimates that the annual Section 382 limitation on utilization of net operating losses will be </font><font style="font-family:Arial;font-size:10pt;">$420,000</font><font style="font-family:Arial;font-size:10pt;">.  As such, the Company will never get the benefit of </font><font style="font-family:Arial;font-size:10pt;">$4.2 million</font><font style="font-family:Arial;font-size:10pt;"> of the net operating losses generated prior to June 26, 2012.  The deferred tax asset has been adjusted to reflect the Section 382 limitation.  Section 382 also applies to built-in losses at the time of the transaction.  The amounts of any unrealized built-in losses or gains were not calculated at the date of the transaction.  The gross net operating losses available for future use are approximately </font><font style="font-family:Arial;font-size:10pt;">$80.8 million</font><font style="font-family:Arial;font-size:10pt;">.  For federal purposes, net operating losses can be carried forward for up to 20 years.  The Company&#8217;s net operating losses will begin to expire in 2023.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company relocated its headquarters to Arizona in January 2013.  As of December 31, 2015, the Company has generated Arizona net operating losses of approximately </font><font style="font-family:Arial;font-size:10pt;">$69.6 million</font><font style="font-family:Arial;font-size:10pt;">.  The Company's Arizona net operating losses will begin to expire in 2033.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company created a Spanish subsidiary in January of 2015 which generated a tax net operating loss of approximately </font><font style="font-family:Arial;font-size:10pt;">$403,000</font><font style="font-family:Arial;font-size:10pt;">.  The Spanish net operating losses carry over indefinitely.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The net deferred tax asset valuation allowance is </font><font style="font-family:Arial;font-size:10pt;">$37.8 million</font><font style="font-family:Arial;font-size:10pt;"> as of December 31, 2015 compared to </font><font style="font-family:Arial;font-size:10pt;">$21.5 million</font><font style="font-family:Arial;font-size:10pt;"> as of December 31, 2014.  The valuation allowance is based on management&#8217;s assessment that it is more likely than not that the Company will not have taxable income in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The difference between the U.S. federal statutory income tax rate and the Company&#8217;s effective tax rate for years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="52%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Effective Tax Rate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S. federal statutory income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">State taxes, net of federal tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rate differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nondeductible equity and other compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Limitation on net operating losses due to &#167;382 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Credit for increased research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company had uncertain tax positions of </font><font style="font-family:Arial;font-size:10pt;">$343,000</font><font style="font-family:Arial;font-size:10pt;">, determined as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="64%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increases for prior positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increases for current year positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Increases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Decreases due to settlements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expiration of the statute of limitations for the assessment of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Decreases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These uncertain positions are not expected to change within the next twelve months.  Of the </font><font style="font-family:Arial;font-size:10pt;">$343,000</font><font style="font-family:Arial;font-size:10pt;"> of uncertain tax positions, none would impact the effective tax rate, if reversed.  The Company accounts for interest on uncertain tax positions within tax expense.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has incurred federal net operating losses (NOLs) dating to the tax year ended July 31, 2004.  As such, all loss carryovers are subject to adjustment under IRS and state examination, depending on the jurisdiction in which they were incurred.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755430784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 14.  COMMITMENTS</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into lease agreements, lease amendments, and lease extensions ("Lease Agreements") for office, laboratory and manufacturing space located in Tucson, Arizona, the last of which expires in 2018.  In addition to rental payments and other standard provisions, one of the leases requires the Company to relocate to Tucson and comply with certain employment provisions through the term of the lease.  If such requirements are not met, the rental rate is increased.  We are in compliance with the lease terms as of fiscal years ending December 31, 2015, 2014 and 2013, thus no increased rental rates were paid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2013, as a condition of a Lease Agreement, the Company expanded its lease premises whereby the landlord provided tenant improvements.  These tenant improvements are treated as a capital lease whereby both an asset and a liability have been recorded and periodic interest based on an annual rate of </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> and depreciation are recorded to amortize the value of this asset and the liability over the remaining lease term.  The Company incurred interest cost of </font><font style="font-family:Arial;font-size:10pt;">$4,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$7,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;"> for and the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> , </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.  Further details regarding this capital lease are included in </font><font style="font-family:Arial;font-size:10pt;">Note 5, Property and Equipment</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The future minimum lease payments under the capital lease together with the present value of the net minimum lease payments as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.1796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Capital Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less amount representing interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Present value minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total rent expense for the Tucson facility, including common area charges was </font><font style="font-family:Arial;font-size:10pt;">$685,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$293,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$168,000</font><font style="font-family:Arial;font-size:10pt;"> for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">, respectively.  Future minimum lease payments under this agreement are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.7421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trial Agreements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed.  These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> we had a payable of </font><font style="font-family:Arial;font-size:10pt;">$512,000</font><font style="font-family:Arial;font-size:10pt;"> to the clinical trial sites and incurred expense of </font><font style="font-family:Arial;font-size:10pt;">$1.6 million</font><font style="font-family:Arial;font-size:10pt;">.  No amounts were incurred for these arrangements through December 31, 2014.  The expense incurred as part of the clinical trial is included in research and development on the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 19, 2015, a putative securities class action lawsuit was filed against Lawrence Mehren, and Steve Reichling, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504.  </font><font style="font-family:Arial;font-size:10pt;">The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System.  Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015.  On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class.  On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud.  Plaintiff seeks certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order.  Defendants moved to dismiss the amended complaint on July 21, 2015, which motion was pending before the Court as of December 31, 2015.  Subsequently, the Court granted the motion and dismissed the case with prejudice on January 28, 2016.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.  See </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 16, Subsequent Events</font><font style="font-family:Arial;font-size:10pt;"> for an update on this lawsuit.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Employment Agreement and Consulting Agreement</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2012, Thomas V. Geimer resigned as the Company&#8217;s Chief Executive Officer, Chief Financial Officer and Secretary.  In connection with his resignation, Mr. Geimer had an agreement with the Company to receive staggered payments due to him such that </font><font style="font-family:Arial;font-size:10pt;">$650,000</font><font style="font-family:Arial;font-size:10pt;"> was paid upon the closing of the July 2013 Offering as described </font><font style="font-family:Arial;font-size:10pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$700,000</font><font style="font-family:Arial;font-size:10pt;"> payable to him on July 1, 2013.  From January 1, 2013 through December 31, 2013, Mr. Geimer&#8217;s aggregate consulting fee was </font><font style="font-family:Arial;font-size:10pt;">$96,000</font><font style="font-family:Arial;font-size:10pt;">.  As of December&#160;31, 2014, no additional amounts were due under the Agreement and no further amounts were incurred during the year ending December&#160;31, 2015.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 7<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 25<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 17<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865828144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 15.  SEGMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company operates as </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> operating segment.  Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance.  The Company&#8217;s business operates in one operating segment because the Company&#8217;s chief operating decision maker evaluates the Company&#8217;s financial information and resources and assesses the performance of these resources on a consolidated basis.  Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865645568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 16.  SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&amp;D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2016, we were notified by the Arizona Commerce Authority (&#8220;Authority&#8221;) that we meet the program requirements to receive a &#8220;Certificate of Qualification&#8221; and, therefore, are eligible for a partial refund of research and development investments amounting to a maximum of </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;">.  The &#8220;Certificate of Qualification&#8221; does not obligate the Arizona Department of Revenue to issue the refund.  Furthermore, the calculation of the actual refund due will be based on actual qualifying expenses and income tax liability for the 2015 tax year and if qualifying expenses decrease or income tax liability increases, the refund amount may be less than the </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;">.  If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On January 28, 2016, the United States District Court for the District of Arizona granted Accelerate Diagnostics&#8217; Motion to Dismiss the class action lawsuit filed against it in March of 2015.  In granting the company&#8217;s motion, the court ordered that the action be dismissed with prejudice in its entirety.  On February 26, 2016, plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.  Plaintiff challenges the dismissal of the amended complaint.  Plaintiff&#8217;s opening brief, if she does not seek additional time, is due June 6, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6854970976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Data: Quarterly Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Supplemental Quarterly Financial Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 17.  SUPPLEMENTAL DATA QUARTERLY FINANCIAL INFORMATION (UNAUDITED)</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUARTERLY FINANCIAL INFORMATION</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unaudited</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the quarters ending:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">9/30/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6/30/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">9/30/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6/30/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12,252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,765</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic and diluted net loss per share (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:Arial;font-size:9pt;">(1)&#160;&#160;Loss per share has been adjusted for the effects of the rights offering (see </font><font style="font-family:Arial;font-size:9pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:9pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868010176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s main financial institution for banking operations held </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">83%</font><font style="font-family:Arial;font-size:10pt;"> of the Company&#8217;s cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company grants credit to domestic and international clients in various industries.  Exposure to losses on accounts receivable is principally dependent on each client's financial position.  At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">66%</font><font style="font-family:Arial;font-size:10pt;"> of the outstanding receivable balance was with Denver Health.  See </font><font style="font-family:Arial;font-size:10pt;">Note 6, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;"> for more information.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Estimated Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Estimated Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC Topic 820, Fair Value Measurements and Disclosures</font><font style="font-family:Arial;font-size:10pt;"> which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements.  The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 1:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 2:  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:Arial;font-size:10pt;">Level 3:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents.  Cash and cash equivalents include overnight repurchase agreement accounts.  As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank.  Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal.  We believe however, that the market risk arising from holding these financial instruments is minimal.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Investments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company invests excess funds in various short-term investments which are primarily held in the custody of a major financial institution.  Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper.  Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value.  Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity.  The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&#8217;s fair value remains less than its cost for more than twelve months.  This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs.  When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss.  The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost.  Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.  Gains and losses from retirement or replacement are included in costs and expenses.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years.  Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.  See </font><font style="font-family:Arial;font-size:10pt;">Note 5, Property and Equipment</font><font style="font-family:Arial;font-size:10pt;"> below.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Long-lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval.  We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance.  Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k) clearance, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted.  Inventory is reported as research and development costs, or if used in marketing evaluations reported to sales, general and administrative costs on the Statement of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue in accordance with ASC 605, &#8220;Revenue Recognition,&#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue represents amounts received but not yet earned under existing agreements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Accounts Receivable Allowances</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable.  Receivables are written off if reasonable collection efforts prove unsuccessful.  The Company provides for allowances on a specific account basis.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company accounts for leases in accordance with ASC 840, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases,</font><font style="font-family:Arial;font-size:10pt;"> which requires leases to be classified as either operating or capital leases.  In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception.  Other leases are classified as operating leases.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease rent is recorded as an operating expense monthly.  For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments.  The asset is included with property and equipment on the Balance Sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the Statements of Operations and Comprehensive Loss.  For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the Balance Sheet.  Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the Statements of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets.  The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period.  Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows the provisions of ASC 740, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Arial;font-size:10pt;">, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return.  This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return.  Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit.  Interest and penalties, if any, would be recorded as tax expense in general and administrative expenses.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC 260, Earnings Per Share</font><font style="font-family:Arial;font-size:10pt;">, which requires companies to present basic earnings per share and diluted earnings per share.  Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.  Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued.  Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Equity Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company awards stock options and other equity-based instruments to its employees, directors and consultants.  Compensation cost related to equity-based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method).  For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested.  The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model.  This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Volatility:  The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected term:  The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns.  For consultant awards, the estimated expected term is the same as the life of the award.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate:  The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield:  The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the future.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company estimates the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period.  The rate is calculated separately for awards to the board of directors/executives and all other awards.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">ASC 220, Reporting Comprehensive Income</font><font style="font-family:Arial;font-size:10pt;">, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements.  The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).  The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Arial;font-size:10pt;">.  This replaces the existing standards relating to leases for both lessees and lessors.  For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized  much like the existing standard.  For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases.  For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria.  The ASU is required for us on January 1, 2019 with early adoption permitted.  We are currently assessing the impact this will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January, 2016, the FASB issued ASU 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall</font><font style="font-family:Arial;font-size:10pt;">.  This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets.  The ASU is required for us on January 1, 2018.  We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes-Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position rather than separating these amounts between current and noncurrent amounts.  The deferred tax liabilities and assets continue to be offset and presented as a single amount.  The ASU is required for us on January 1, 2017 and we have elected to adopt this standard retrospectively for the period ended December 31, 2015.   There was no significant impact on our consolidated financial statements as a result of adopting this ASU.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires entities that measure inventory using first-in, first-out or average cost inventory to report inventory at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.  The ASU will become effective for us on January 1, 2016.  We do not expect the adoption of ASU 2015-11 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2015, the FASB issued ASU 2015-05, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other - Internal-Use Software; Customer&#8217;s Accounting for Fees Paid in a Cloud Computing Arrangement</font><font style="font-family:Arial;font-size:10pt;">.  Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&#8217;s accounting for fees paid in a cloud computing arrangement.  Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements.  This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses.  If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract.  The ASU does not change the accounting for service contracts.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2015, the FASB issued ASU 2015-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement - Extraordinary and Unusual Items</font><font style="font-family:Arial;font-size:10pt;">.  The new standard eliminates from U.S. GAAP the concept of extraordinary items.  Prior to the adoption of this standard, extraordinary items have been segregated from the results of ordinary operations and shown separately in the income statement, net of tax, after income from continuing operations.  The new standard eliminates such segregation as well as the requirements to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2015-01 to have a significant impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Arial;font-size:10pt;">.  The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&#8217;s ability to continue as a going concern and, if so, disclose that fact.  Management will also be required to evaluate and disclose whether its plans alleviate that doubt.  The new standard is effective for us on January 1, 2016 with early adoption permitted.  We do not expect the adoption of ASU 2014-15 to have a significant impact on our consolidated financial statements</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.  We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements.  The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.  We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements.  In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers Deferral of the Effective Date</font><font style="font-family:Arial;font-size:10pt;">, which deferred the effective date resulting in a new effective date of January 1, 2018 for us.  We are permitted to adopt early but not before the original effective date of January 1, 2017.  The standard allows for either &#8220;full retrospective&#8221; adoption, meaning the standard is applied to all of the periods presented, or &#8220;modified retrospective&#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements.  We are currently evaluating the transition method and the adoption date that will be elected.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for impaired assets to be disposed of by a method other than sale. Includes disclosure of the carrying value of the asset, the facts and circumstances leading to impairment, the amount of impairment loss, the income statement classification, the method for determining fair value and the segment in which the impaired long-lived assets being disposed of by a method other than sale is reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section M<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 2, 12<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6482485&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6870820192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (see </font><font style="font-family:Arial;font-size:10pt;">Note 2, Summary of Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;"> for further information):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Money market funds (cash equivalents)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1) &#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Money market funds (cash equivalents)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,242</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a,b,bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6752693488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock', window );">Available-for-sale investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the Company&#8217;s available-for-sale investments at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;The following table summarizes the maturities of the Company&#8217;s available-for-sale securities at December 31, </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENT MATURITIES</font></div><div style="text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">At December 31, 2015</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">At December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 1-3 years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865809008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost and consisted of the following at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;"> (in thousands).</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="68%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Technical equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Facilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital lease &#8211; leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital projects in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,904</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated amortization &#8211; capital lease</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated depreciation - other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,311</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6762142896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue and Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Deferred Revenue and Income Summary</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research Use Only Accelerate ID/AST systems</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6614177056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes option activity under all plans during the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;"> and shows the exercisable shares as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding January 1, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5,185,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">769,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(13,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(311,737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.96</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5,628,726</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5.20</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">717,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(54,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(124,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercisable December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,536,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Scholes Assumptions for Option Granted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Black-Scholes Assumptions for Option Granted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected dividends</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Estimated forfeitures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Stock Option Supplemental Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Supplemental Information</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Exercisable</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Vested and Expected to Vest</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,536,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,088,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average remaining contractual term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Aggregate intrinsic value (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">86,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">85,804</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted Stock Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes restricted stock activity during the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="74%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted Stock Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted stock outstanding December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">40,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested/released</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted stock outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Equity-Based Compensation Expense and Tax Benefit</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expense and tax benefits recognized on Company&#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Equity-Based Compensation Expenses and Tax Benefit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12 months</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Sales, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,828</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Recognized tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6867619648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Pretax Loss from Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The components of the pretax loss from operations for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Components of the Pretax Loss From Operations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S. Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(44,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,083</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pretax loss from operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(30,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15,282</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Income Tax Components</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant components of the Company&#8217;s net deferred income taxes for the years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, are as are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:55.46875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="58%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Income Tax Components</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property &amp; equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible assets, definite-lived</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General business credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Charitable contribution</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(37,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective Tax Rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The difference between the U.S. federal statutory income tax rate and the Company&#8217;s effective tax rate for years ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2014</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.03125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="52%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Effective Tax Rate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S. federal statutory income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">State taxes, net of federal tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rate differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nondeductible equity and other compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Limitation on net operating losses due to &#167;382 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Credit for increased research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Uncertain Tax Positions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, the Company had uncertain tax positions of </font><font style="font-family:Arial;font-size:10pt;">$343,000</font><font style="font-family:Arial;font-size:10pt;">, determined as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="64%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12/31/2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increases for prior positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Increases for current year positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Increases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Decreases due to settlements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expiration of the statute of limitations for the assessment of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Decreases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6751952256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock', window );">Capital Lease Obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The future minimum lease payments under the capital lease together with the present value of the net minimum lease payments as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.1796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Capital Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less amount representing interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Present value minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Operating Leases Obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Future minimum lease payments under this agreement are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.7421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for capital leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6870809296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Data: Quarterly Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Unaudited Quarterly Financial Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUARTERLY FINANCIAL INFORMATION</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unaudited</font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the quarters ending:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">12/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">9/30/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6/30/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3/31/2015</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">12/31/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">9/30/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6/30/2014</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3/31/2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12,252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,765</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic and diluted net loss per share (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:Arial;font-size:9pt;">(1)&#160;&#160;Loss per share has been adjusted for the effects of the rights offering (see </font><font style="font-family:Arial;font-size:9pt;">Item 8, Note 10, Rights Offering</font><font style="font-family:Arial;font-size:9pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6880147296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk concentration</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Accounts Receivable | Denver Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk concentration</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=axdx_DenverHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=axdx_DenverHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6878899104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 17,060<span></span>
</td>
<td class="nump">$ 26,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">5,221<span></span>
</td>
<td class="nump">13,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">11,839<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">5,221<span></span>
</td>
<td class="nump">13,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">5,221<span></span>
</td>
<td class="nump">13,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=axdx_CorporateBondsandNotesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">9,332<span></span>
</td>
<td class="nump">12,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=axdx_CorporateBondsandNotesMember', window );">Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=axdx_CorporateBondsandNotesMember', window );">Corporate notes and bonds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">9,332<span></span>
</td>
<td class="nump">12,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=axdx_CorporateBondsandNotesMember', window );">Corporate notes and bonds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=axdx_CorporateBondsandNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=axdx_CorporateBondsandNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868391776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from Sale and Maturity of Marketable Securities</a></td>
<td class="nump">$ 13,258<span></span>
</td>
<td class="nump">$ 5,357<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Corporate notes and bonds</a></td>
<td class="nump">17,060<span></span>
</td>
<td class="nump">26,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=axdx_FairValueMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetBackedSecuritiesAtCarryingValue', window );">Asset-backed securities</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Corporate notes and bonds</a></td>
<td class="nump">9,332<span></span>
</td>
<td class="nump">12,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Total</a></td>
<td class="nump">11,839<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsByCategoryAxis=axdx_UnrealizedLossesMember', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetBackedSecuritiesAtCarryingValue', window );">Asset-backed securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Corporate notes and bonds</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Total</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=axdx_UnrealizedGainsMember', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetBackedSecuritiesAtCarryingValue', window );">Asset-backed securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Corporate notes and bonds</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Total</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=axdx_CostMember', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetBackedSecuritiesAtCarryingValue', window );">Asset-backed securities</a></td>
<td class="nump">2,510<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Corporate notes and bonds</a></td>
<td class="nump">9,341<span></span>
</td>
<td class="nump">12,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Total</a></td>
<td class="nump">$ 11,851<span></span>
</td>
<td class="nump">$ 13,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetBackedSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in notes or bonds that are collateralized by a specific group of underlying assets owned by the issuer of the notes or bonds which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetBackedSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35711157&amp;loc=d3e42546-110969<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=axdx_FairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=axdx_FairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsByCategoryAxis=axdx_UnrealizedLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsByCategoryAxis=axdx_UnrealizedLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=axdx_UnrealizedGainsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=axdx_UnrealizedGainsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=axdx_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=axdx_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6867604160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Due in less than 1 year</a></td>
<td class="nump">$ 11,839<span></span>
</td>
<td class="nump">$ 10,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Due in 1-3 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Total</a></td>
<td class="nump">11,839<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Due in less than 1 year</a></td>
<td class="nump">11,851<span></span>
</td>
<td class="nump">10,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Due in 1-3 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Total</a></td>
<td class="nump">$ 11,851<span></span>
</td>
<td class="nump">$ 13,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35711157&amp;loc=d3e42546-110969<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6867602144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment (Details) (USD $) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract', window );"><strong>Property And Equipment - Property And Equipment Details Usd</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Computer equipment</a></td>
<td class="nump">$ 1,877<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Technical equipment</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Facilities</a></td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsGross', window );">Capital lease &#8211; leasehold improvements</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Capital projects in progress</a></td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,904<span></span>
</td>
<td class="nump">3,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization', window );">Accumulated amortization &#8211; capital lease</a></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation - other</a></td>
<td class="num">(2,622)<span></span>
</td>
<td class="num">(1,311)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">$ 5,016<span></span>
</td>
<td class="nump">$ 2,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_PropertyAndEquipmentPropertyAndEquipmentDetailsUsdAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 14<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45014-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization of deferred income and initial direct costs pertaining to direct financing leases, which resulted from producing constant periodic rates of return on the net investments in the leases over their respective lease terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 35<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=7662473&amp;loc=d3e43734-112732<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesNetInvestmentInDirectFinancingLeasesAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6865880096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_PropertyAndEquipmentDetailsNarrativeAbstract', window );"><strong>Property And Equipment Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">$ 1,782<span></span>
</td>
<td class="nump">$ 817<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_PropertyAndEquipmentDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_PropertyAndEquipmentDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6878928320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements and Grants - (Details Narrative 1)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">43 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2012 </div>
<div>USD ($) </div>
<div>job </div>
<div>milestone</div>
</th>
<th class="th">
<div>May. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Total grant funding</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689,000<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Offset to research and development project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,000<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Arizona Commerce Authority grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne', window );">Qualified jobs created, milestone one | job</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo', window );">Qualified jobs created, milestone two | job</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree', window );">Qualified jobs created, milestone three | job</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour', window );">Qualified jobs created, milestone four | job</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment', window );">Capital investment milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum', window );">Grant related minimum annual wages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums', window );">Percent of company paid premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=axdx_DefenseMedicalResearchandDevelopmentProgramMember', window );">Defense Medical Research and Development Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Total grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Offset to research and development project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="nump">$ 558,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Annual Wages, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodAnnualWagesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestone, Minimum Capital Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodMilestoneMinimumCapitalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodNumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Percent of Company Paid Premiums</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_RevenueRecognitionMilestoneMethodPercentofCompanyPaidPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=axdx_DefenseMedicalResearchandDevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=axdx_DefenseMedicalResearchandDevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6635273792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue and Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Fisher agreement</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_DeferredRevenueResearchUseOnly', window );">Research Use Only Accelerate ID/AST systems</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Research Use Only Accelerate ID/AST systems</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Arizona Commerce Authority grant</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Fisher agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsNoncurrent', window );">Total long-term deferred income</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_DeferredRevenueResearchUseOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Research Use Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_DeferredRevenueResearchUseOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph 5<br> -Article 9<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph a<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAndCreditsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.Q4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAndCreditsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6877994624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue and Income (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Arizona Commerce Authority grant</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868185120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase (Details Narrative)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / warrant </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2012 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / warrant </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2014 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 12, 2013 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2013 </div>
<div>$ / warrant </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionsAbstract', window );"><strong>Securities Financing Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.80<span></span>
</td>
<td class="nump">$ 8.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_CommonStockAndWarrantsIssuedValue', window );">Stock and warrants purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityIndexedShares', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3', window );">Price per warrant | $ / warrant</a></td>
<td class="nump">1.03<span></span>
</td>
<td class="nump">1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ExercisedWarrantPercentExercised', window );">Exercised warrants (percent)</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares', window );">Exercised warrant per purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares', window );">Additional warrant to purchase common stock</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2', window );">Price per warrant | $ / warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares', window );">Additional exercised warrant per purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ExercisedWarrantAmountUnexercised', window );">Unexercised warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Price per warrant | $ / warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Value of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the option contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the option contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_AdditionalOptionIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_CommonStockAndWarrantsIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock And Warrants Issued, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_CommonStockAndWarrantsIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ExercisedWarrantAmountUnexercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercised Warrant, Amount Unexercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ExercisedWarrantAmountUnexercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ExercisedWarrantPercentExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercised Warrant, Percent Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ExercisedWarrantPercentExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the option contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ExercisedlOptionIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6403732&amp;loc=d3e21300-112643<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the option contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868031872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Apr. 28, 2014</div></th>
<th class="th"><div>Apr. 07, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (dollars per share)</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="nump">$ 21.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.54<span></span>
</td>
<td class="nump">$ 17.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_UnderwritingDiscountandCommissionFeesPerShare', window );">Underwriting discount and commission fees (dollars per share)</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ProceedsFromSaleofCommonStockGross', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock issuance</a></td>
<td class="nump">$ 103.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">6,426,000<span></span>
</td>
<td class="nump">2,678,000<span></span>
</td>
<td class="nump">2,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=axdx_PublicOfferingMember', window );">Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="nump">838,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember', window );">Affiliated Entity [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember', window );">Affiliated Entity [Member] | Offering Exempt From Underwriter Commission [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants (shares)</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ProceedsFromSaleofCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Common Stock, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ProceedsFromSaleofCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_UnderwritingDiscountandCommissionFeesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting Discount and Commission Fees, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_UnderwritingDiscountandCommissionFeesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=axdx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=axdx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=axdx_OfferingExemptFromUnderwriterCommissionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=axdx_OfferingExemptFromUnderwriterCommissionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6869346160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Rights Offering (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May. 19, 2014</div></th>
<th class="th"><div>Aug. 08, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 09, 2015</div></th>
<th class="th"><div>Apr. 28, 2014</div></th>
<th class="th"><div>Apr. 07, 2014</div></th>
<th class="th"><div>Mar. 14, 2014</div></th>
<th class="th"><div>Jul. 12, 2013</div></th>
<th class="th"><div>Jul. 08, 2013</div></th>
<th class="th"><div>Apr. 30, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityShareSubscriptions', window );">Non-transferable subscription rights for each share of common stock owned on the record date (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.063921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.064038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Subscription right to purchase common stock (dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.80<span></span>
</td>
<td class="nump">$ 8.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.49<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="nump">$ 17.54<span></span>
</td>
<td class="nump">$ 17.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Standby purchase agreement issuance of unsubscribed shares to related party (shares)</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ProceedsfromIssuanceofWarrantsGross', window );">Gross proceeds from issuance of warrants</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedContractualRights', window );">Costs associated with rights offering</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=axdx_StandbyPurchasersMember', window );">Standby Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Standby purchase agreement issuance of unsubscribed shares to related party (shares)</a></td>
<td class="nump">297,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=axdx_OracleInstitutionalPartnersL.P.Member', window );">Oracle Institutional Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Standby purchase agreement issuance of unsubscribed shares to related party (shares)</a></td>
<td class="nump">119,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=axdx_OraclePartnersL.P.Member', window );">Oracle Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Standby purchase agreement issuance of unsubscribed shares to related party (shares)</a></td>
<td class="nump">178,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ProceedsfromIssuanceofWarrantsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Warrants, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ProceedsfromIssuanceofWarrantsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedContractualRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedContractualRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityShareSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityShareSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph i<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=axdx_StandbyPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=axdx_StandbyPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=axdx_OracleInstitutionalPartnersL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=axdx_OracleInstitutionalPartnersL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=axdx_OraclePartnersL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=axdx_OraclePartnersL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6855093632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock instruments outstanding (shares)</a></td>
<td class="nump">6,778,580<span></span>
</td>
<td class="nump">6,174,886<span></span>
</td>
<td class="nump">5,731,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6878939008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (shares)</a></td>
<td class="nump">5,628,726<span></span>
</td>
<td class="nump">5,185,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">717,833<span></span>
</td>
<td class="nump">769,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(54,505)<span></span>
</td>
<td class="num">(13,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(124,884)<span></span>
</td>
<td class="num">(311,737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (shares)</a></td>
<td class="nump">6,167,170<span></span>
</td>
<td class="nump">5,628,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, ending balance (shares)</a></td>
<td class="nump">1,536,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (dollars per share)</a></td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (dollars per share)</a></td>
<td class="nump">20.59<span></span>
</td>
<td class="nump">16.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (dollars per share)</a></td>
<td class="nump">11.71<span></span>
</td>
<td class="nump">13.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (dollars per share)</a></td>
<td class="nump">6.44<span></span>
</td>
<td class="nump">2.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (dollars per share)</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (dollars per share)</a></td>
<td class="nump">6.91<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, ending balance (dollars per share)</a></td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6880090192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2', window );">Expected term (in year) | yr</a></td>
<td class="nump">6.26<span></span>
</td>
<td class="nump">6.25<span></span>
</td>
<td class="nump">6.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility (percent)</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rates (percent)</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1', window );">Estimated forfeitures (percent)</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsPriceEarningsRatioMultiple', window );">Fair value per share (dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.69<span></span>
</td>
<td class="nump">$ 12.63<span></span>
</td>
<td class="nump">$ 6.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of shares under option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time an equity-based award is expected to be outstanding. An equity-based award's expected term is generally determined based on, among other factors, the instrument's contractual term and the effects of employees' expected exercise and post-vesting employment termination behavior.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsPriceEarningsRatioMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of an entity's stock price to its earnings per share. Price earnings (P/E) ratio is used as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsPriceEarningsRatioMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6873637024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value (in thousands) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsOutstandingMember', window );">Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options (shares) | shares</a></td>
<td class="nump">6,167,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a', window );">Weighted average remaining contractual term (in years) | yr</a></td>
<td class="nump">7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (dollars per share)</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value (dollars per share)</a></td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value (in thousands) | $</a></td>
<td class="nump">$ 86,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsExercisableMember', window );">Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options (shares) | shares</a></td>
<td class="nump">1,536,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a', window );">Weighted average remaining contractual term (in years) | yr</a></td>
<td class="nump">7.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (dollars per share)</a></td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value (dollars per share)</a></td>
<td class="nump">$ 5.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value (in thousands) | $</a></td>
<td class="nump">$ 21,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsVestedAndExpectedToVestMember', window );">Options Vested and Expected to Vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options (shares) | shares</a></td>
<td class="nump">6,088,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a', window );">Weighted average remaining contractual term (in years) | yr</a></td>
<td class="nump">7.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (dollars per share)</a></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value (dollars per share)</a></td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value (in thousands) | $</a></td>
<td class="nump">$ 85,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average period between the balance sheet date and expiration for all awards outstanding under the plan, which may be expressed in a decimal value for number of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1a</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsVestedAndExpectedToVestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=axdx_OptionsVestedAndExpectedToVestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6877920272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Restricted Stock Outstanding, beginning balance (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">40,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested/Released (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Restricted Stock Outstanding, ending balance (shares) | shares</a></td>
<td class="nump">40,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted Stock Outstanding, beginning balance (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1', window );">Granted (dollars per share) | $ / shares</a></td>
<td class="nump">20.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1', window );">Forfeited (dollars per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested/Released (dollars per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted Stock Outstanding, ending balance (dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of restricted stock outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6751208976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 8,388<span></span>
</td>
<td class="nump">$ 9,624<span></span>
</td>
<td class="nump">$ 3,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Recognized tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 5,909<span></span>
</td>
<td class="nump">$ 5,290<span></span>
</td>
<td class="nump">$ 2,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32672-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6867742256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - Stock Options Vesting (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member', window );">2012 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member', window );">2012 Omnibus Equity Incentive Plan | Vesting terms (i), cliff vesting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member', window );">2012 Omnibus Equity Incentive Plan | Vesting terms (ii), monthly vesting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member', window );">2012 Omnibus Equity Incentive Plan | Vesting terms (iii), cliff vesting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member', window );">2012 Omnibus Equity Incentive Plan | Vesting terms (iii), monthly vesting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axdx_NonQualifiedStockOptionPlanMember', window );">Non-Qualified Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axdx_OmnibusEquityIncentivePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=axdx_SharebasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=axdx_SharebasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axdx_NonQualifiedStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axdx_NonQualifiedStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868978080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee and Consultant Equity-Based Compensation - (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 09, 2015 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 28, 2014 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 07, 2014 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2004 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_EmployeeServiceSharebasedCompensationNumberofPlans', window );">Number of equity-based compensation plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract', window );"><strong>Qualified Stock Option Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber', window );">Options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5', window );">Options available (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract', window );"><strong>Non-Qualified Stock Option Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1', window );">Options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1', window );">Options outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2', window );">Options available (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>2004 Omnibus Stock Option Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2', window );">Options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2', window );">Options outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,536,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3', window );">Options available (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>2012 Omnibus Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares authorized (shares)</a></td>
<td class="nump">5,677,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,677,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3', window );">Options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3', window );">Options outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,660,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4', window );">Options available (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,945,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from the exercise of options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation', window );">Tax benefit from share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vesting | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="nump">$ 17.54<span></span>
</td>
<td class="nump">$ 17.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized equity-based compensation cos | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_EmployeeServiceSharebasedCompensationNumberofPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share-based Compensation, Number of Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_EmployeeServiceSharebasedCompensationNumberofPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisaedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date were converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedNumber3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Plan One [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanOneAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Plan Two [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPlanTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6747196640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income Taxes - Components of the Pretax Loss From Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Domestic</a></td>
<td class="num">$ (44,415)<span></span>
</td>
<td class="num">$ (30,933)<span></span>
</td>
<td class="num">$ (15,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes</a></td>
<td class="num">$ (45,498)<span></span>
</td>
<td class="num">$ (30,933)<span></span>
</td>
<td class="num">$ (15,282)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868402112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Income Taxes Components (Details) (USD $) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 28,584<span></span>
</td>
<td class="nump">$ 15,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property &amp; equipment</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">864<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">5,208<span></span>
</td>
<td class="nump">3,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets', window );">Intangible assets, definite-lived</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(37,820)<span></span>
</td>
<td class="num">(21,532)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Finite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_DeferredTaxAssetsFiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868086576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract', window );"><strong>Income Taxes - Effective Tax Rate Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="num">(2.93%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="nump">0.11%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Rate differential</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Unrecognized tax benefits</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible equity and other compensation</a></td>
<td class="nump">2.86%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Limitation on net operating losses due to &#167;382</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Credit for increased research activities</a></td>
<td class="num">(2.67%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation allowance</a></td>
<td class="nump">35.81%<span></span>
</td>
<td class="nump">33.80%<span></span>
</td>
<td class="nump">38.80%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Permanent Differences, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_IncomeTaxesEffectiveTaxRateDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6880072768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Uncertain Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract', window );"><strong>Income Taxes - Uncertain Tax Positions Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases for prior positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year positions</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_UnrecognizedTaxBenefitsOtherIncrease', window );">Other Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Decreases due to settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expiration of the statute of limitations for the assessment of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_UnrecognizedTaxBenefitsOtherDecrease', window );">Other Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_IncomeTaxesUncertainTaxPositionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_UnrecognizedTaxBenefitsOtherDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Other Decrease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_UnrecognizedTaxBenefitsOtherDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_UnrecognizedTaxBenefitsOtherIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Other Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_UnrecognizedTaxBenefitsOtherIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6868380896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) (USD $) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_IncomeTaxesDetailsNarrativeUsdAbstract', window );"><strong>Income Taxes Details Narrative Usd</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 37,820<span></span>
</td>
<td class="nump">$ 21,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_IncomeTaxesDetailsNarrativeUsdAbstract', window );"><strong>Income Taxes Details Narrative Usd</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_OperatingLossCarryforwardsGross', window );">Gross operating loss carryforwards</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount', window );">Operating loss carryforwards, Sec. 382 limitation</a></td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_OperatingLossCarryforwardLimitationsOnUseAmount', window );">Operating loss carryforwards, expected to be unrealized</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">80,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Arizona Department of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_IncomeTaxesDetailsNarrativeUsdAbstract', window );"><strong>Income Taxes Details Narrative Usd</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | Spanish Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_IncomeTaxesDetailsNarrativeUsdAbstract', window );"><strong>Income Taxes Details Narrative Usd</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_IncomeTaxesDetailsNarrativeUsdAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_IncomeTaxesDetailsNarrativeUsdAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_OperatingLossCarryforwardLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforward, Limitations On Use, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_OperatingLossCarryforwardLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforward, Limitations On Use, Annual Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_OperatingLossCarryforwardLimitationsOnUseAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_OperatingLossCarryforwardsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_OperatingLossCarryforwardsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=axdx_ArizonaDepartmentofRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=axdx_ArizonaDepartmentofRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_TaxAuthoritySpainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_TaxAuthoritySpainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6743352944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Capital Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">Year Ending December 31, 2016</a></td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">Year Ending December 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">Year Ending December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">Year Ending December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">Year Ending December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less amount representing interest</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value minimum lease payments</a></td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6750094432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Year Ending December 31, 2016</a></td>
<td class="nump">$ 954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Year Ending December 31, 2017</a></td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Year Ending December 31, 2018</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Year Ending December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total operating lease obligations</a></td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6869851456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease', window );">Capital lease interest expense</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense for Tuscan facility</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ClinicalTrialAgreementLiability', window );">Clinical Trial Agreement Liability</a></td>
<td class="nump">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_ClinicalTrialAgreementExpense', window );">Clinical Trial Agreement Expense</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Employment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliersAndEmployees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Capital Lease Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ClinicalTrialAgreementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Agreement Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ClinicalTrialAgreementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_ClinicalTrialAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_ClinicalTrialAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount, during the lease term, of each minimum [capital] lease payment allocated to interest expense so as to produce a constant periodic rate of interest on the remaining balance of the capital lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6916424&amp;loc=d3e43161-112731<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliersAndEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to suppliers for goods and services provided and to employees for services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliersAndEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6753391488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6758781680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_CertificateOfQualificationAbstract', window );"><strong>Certificate of Qualification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Operating Leases Obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Future minimum lease payments under this agreement are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.7421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axdx_CertificateOfQualificationAbstract', window );"><strong>Certificate of Qualification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RefundsDueUnderGovernmentContracts', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axdx_CertificateOfQualificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Certificate of Qualification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axdx_CertificateOfQualificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RefundsDueUnderGovernmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of renegotiation refunds which have been determined to be probable and reasonably estimated at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=21918128&amp;loc=d3e56153-109414<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RefundsDueUnderGovernmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6870131552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Data: Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,163)<span></span>
</td>
<td class="num">$ (11,186)<span></span>
</td>
<td class="num">$ (12,252)<span></span>
</td>
<td class="num">$ (8,897)<span></span>
</td>
<td class="num">$ (8,765)<span></span>
</td>
<td class="num">$ (8,814)<span></span>
</td>
<td class="num">$ (8,152)<span></span>
</td>
<td class="num">$ (5,202)<span></span>
</td>
<td class="num">$ (45,498)<span></span>
</td>
<td class="num">$ (30,933)<span></span>
</td>
<td class="num">$ (15,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per share (dollars per share)</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR*I19-4HLFH4636*K!I%5HTB:X,B:X,B:X,B:_-35C;_$>SZ!U!+ P04
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M"ANNM"[S2JF^'&_^1[Y,_1E2__59V/,G4$L#!!0    ( )J+:4A0)$8[F ,
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MB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB
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M*UX7@G7-L0") 1*_"L+>S#F $@ E/P$MG/\)C;1,K]AM(PR 4@"EKP(MG"X
ME $H>Q7H@ML-@'( Y<>@6[/FM?S>#4\W:C?<M48$T,?62@"= .CD&+1HJXJ;
MIZXI<EU+/^.Y%^%#4>C6BP"@4P"='H,^<6G8 U=M5XE/LO;#)KGR'EEGV@I
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MZ@0U!]V1,4E5 N$L\;VSN@H-G8H>I6YFJLWA<@ =R=K^KC-<N(K_4$L#!!0
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M'MIVL&,:\=&$P=$6^\M!90_#M)N,^QV^^^/!T)Z63QF7[RG;/U!+ P04
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MT5Z_:1Q#/"7<M54___5VK_W0UB;$]^KR%WR>F_GS"O^1(8;9 S@&\"6 )61
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MSO1NHB]Z$9Q,?I@O2G/LAJ^K_GMC3S/M15=?IL/9^81X\S]02P,$%     @
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MKE*X#Q48YUWY/S&E82"57XM53K$*L\T(M<@0"17JXZOV62HB'B]3ZE2:&A5
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M_ESC]G>(#GS[[.:6DL&_GC61T+D0?O&Q21<J)0['T_-8WVC]%U!+ P04
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MNUC'*Q43B\/R0-976OX#4$L#!!0    ( )J+:4C%&-)YHP$  +$#   9
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M<D+G3S8>0(OHP+?/[G:4]/[]K(F$UH7PBX]-NE(I<3@L#V1]I=4_4$L#!!0
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MH7$AO/.Q25<J)0[[^8$LK[3\!U!+ P04    " ":BVE(7H1(G*0!  "Q P
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MW3.DQ$'9.),ENUSOQS0,]1U>Y#UOX#O73:<,.:-U5R-,L$:TX,HG=SM*6O<
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MJ0D[VU,%IHU7QY(*!^W2EL[5^7;>Q4-D'_"RZ'D+C]RT0EMR0.=/-AY @^C
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M@KG_IPF[V%,%IHM7QY(:1^W2EJ[5]78^YO%,WN%5.? .?G#3"6W)"9T_V7@
M+:(#WSZ[VU'2^_>S)A):%\)//C;I2J7$X; \D/655G\!4$L#!!0    ( )J+
M:4B:S2BLIP$  +$#   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(53
MRV[;,!#\%8(?$,JRW#B&+"!.$;2' D$.[9F65A(1DJN0E)7^??F0%;LPD(NX
MNYJ9G>6CG-"\V1[ D0\EM=W3WKEAQYBM>U#<WN$ VO]IT2CN?&HZ9@<#O(DD
M)5F>9=^8XD+3JHRU%U.5.#HI-+P88D>EN/E[ (G3GJ[HN? JNMZ% JM*MO :
MH4!;@9H8:/?T<;4[% $1 ;\%3/8B)L'[$?$M)#^;/<V"!9!0NZ# _7*")Y R
M"/G&[[/F9\M O(S/ZL]Q6N_^R"T\H?PC&M=[LQDE#;1\E.X5IQ\PC[ )@C5*
M&[^D'JU#=:90HOA'6H6.ZY3^;(J9=IN0SX1\(6RS:#PUBC:_<\>KTN!$[,##
MV:UV'FZ"B%<FWIOU8T=-$P>ORE.UVMZ7[!2$KC")>)@Q"X)Y]9LM<GJ+GD=Z
M_C5]?4U?)X?KV>'V:X'B6J!( L4L\'!KQ(0YS)B'[+\F[&)/%9@N7AU+:ARU
M2UNZ5)?;^9C',_F$5^7 ._C%32>T)4=T_F3C ;2(#GS[[&Y#2>_?SY)(:%T(
M[WULTI5*B</A_$"65UK] U!+ P04    " ";BVE(?(^3^74"  "Z"0  &0
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M([;M^WO[WE>X]^F'9!L0W0,B#XBF%O=K+7K->=9$VR'Q:D@\ >)M0+(*2"9
M\J#*67/8#CFLAAPF0/H@9-9\V0Y)5T-2#XB#!R&SYO]#16[., =9NZNJ4"&&
M3OLCO.PNK\%SZ.[ ISS/>EK#3RKKME/H(K2Y2>[ 5T)H,/'!4XQ18]ZK9<&@
MTG9Z,'/IK[!?:-'/#]+R*N;_ %!+ P04    " ";BVE(L$Q%![(!   6!
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MY &ESY&:4H&EB_L4.:"1]\8\(;@6:IC(,3-'J9D(.DP7PWP[%?\ 4$L#!!0
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M)B"8W @\]?ZZM[\H>)%G+;TX[%3(;P)-!=[*("*R(UXY$Z.IB]EVXRG//O/
M3S+O4P;ZP>".>>J9=)QY[IG).+-4#!HG-A %^0/CB4JTY6!7ERJ&  :3><_@
M<6;1,X&AY)X)#25;,*N>B<:9=<_$AL[KF>1^YP4_.R]08R&  .G] .'/ *$*
M$$* FT'0=$RJWI!B(K_[&^>>%1>G$R.V5%B8!D9LI3 #L;XE1DN/M*5'JG2L
MM8A5KHJ)PV0D5X6M%!9A,[:.;!..M0G'D# :[Y.Y8M#==W67@PZPY%9Z;K3
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M3.;^J!F31(7X3[$'&O7 7!J4U%)74U7G]LZU#<F&Z06Y/&/%/U!+ P04
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M35XEA 93/GQ( ]28IVD.&%3:;E=F+_UM]8$6_?GMF1_ _#]02P,$%     @
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MVVZC,!1%?P7Q 8#-O2)(D_0R\S!2U8>99R=Q$E3 &>PTG;\?WZ#)Z)"Z?6B
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MIN?"M9D+%.]/C\;\<A7_ %!+ P04    " ";BVE(W@KYM/\"  "$"P  &0
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M3]Y+J_F2I5GBH:Y!A@AE^6T<YL1A@,,\. SBX#3//9^U!AU!B!%V&RAW N4
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MB\Y,#%,^)JI%J0G#@VFX4]<O_@%02P,$%     @ FXMI2/ZEK5:' @  .@H
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MUQ$()5NI';"ZG,B:4*J-U,)?SO.RI!9>WY_=?YAJ5?H-%F3-Z-]Z)RL5UO?
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MJDZ@$#]PIV#?*F420 'W"OY"LV"X6_ BI*H>5 8<"QAN&+P,J:H'E0&G!TG
M/,2W59D&4&"PJ@2'5Y7 '4.FCOGLK)U!'ZL:7]V /1-'>]%+M..G0;D+<-Z=
M'Q./]BT1O\/K:J1']HN*8SM(M.5*W\/VNCQPKIC.GSSD$6KT<V=>=.R@S+34
M<^$> &ZA^#B]9^9'5?T?4$L#!!0    ( )N+:4BJ\"8OQP,  ,T2   9
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MIYVTZ,#$L.!CHGHP-6'X9%I*V]=6_P%02P,$%     @ FXMI2)Q\P]MQ @
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M00D:L6(QD(R$6EK,2*#5+>)N&.P-@]W6X,<$Q+NW9/K>IEX'J2,86TZ+R3
M$X)F7IG,R:0C,A:3Q!-$9EZ1F1/)1D1F)Y$)*A!X9<RTUIF-Z#A0!K))2M"O
MY'J?3*'P-S_\0O=#?_M#-"6O!9$9F937W]O0-?=%4]ZGP/Z\^ MYB=\%&<OK
MWG<.E(#;UW)T<=YT=,]^T7Y?M2)8<ZF.+G/"[#B73)& )^6C5!\MYT'-=E+?
MIMJ@/<;M0/+N]%5R_C0J_@-02P,$%     @ FXMI2(?2LS+D 0  \P4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULC93;CILP%$5_Q>(#QMPO$4%J
MIAJU#Y5&\] ^.\$$-#9F;"=,_[Z^01,-(KS$%_;9:Q\13CDR_BY:C"7XI*07
M>Z^5<MA!*$XMID@\L0'WZDG#.$52'?D9BH%C5)LB2F#H^RFDJ.N]JC1WK[PJ
MV462KL>O'(@+I8C_/6#"QKT7>-/%6W=NI;Z 50GGNKJCN!<=ZP''S=[[%NP.
M@:\E1O&[PZ.XV0,=_LC8NS[\K/>>KS-@@D]26R"U7/$S)D0[*?*',_W/U(6W
M^\G]Q;2KXA^1P,^,_.EJV:JTO@=JW* +D6]L_(%=#XDV/#$BS"\X781D="KQ
M $6?=NUZLX[V23J5+1>$KB"<"T(;W(),S.](HJKD; 1B0/KE!3LEY]I$.0.5
M3:BVC2<WC5?EM4K2L(17;72GL84'JXF">-9 Y;\(">\AD86$QB#(BL<&T;U!
M; TBES*Z3]D;36Y36DT0/6;$BXS8,>(E1FH95N,_1B2+B,0ADA5$LA61+B)2
MATA7$.E61+:(R!PB6T%D6Q'Y(B)WB'P%D6]^W\4BHW",8H51;&TC\!<9YEI!
M,G_EC^M$7SJ!-]_S@,[X%^+GKA?@R*0:#>8+;AB36'GX3XD'6C6!YP/!C=3;
M3.VYG4GV(-DPC=AYSE?_ %!+ P04    " ";BVE(?==W_=,!   M!0  &0
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M+PRWI*#-K[$]4T9*)3&-,ON"8UXUQPO<B6PIZQ<@*4"MH.VG7^!*@=L)/*W
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M[D3,"A&D=B\5G44=-@G[H$"GR.(;NEX5*'LFQ2*(.2.C!@=P:Y@.YHSH:QK
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MAQ ;H+YJ*Q*;(G(8@W]J;CC.?M5<U43QZGR^N1\1PU/V%"OV!1AT;7.0_EH
M9BTO(^#3_#;C+)'P'8>["A)361 $ @NFAJ#D#30FA#%"6TZ')W)37-2$0<P9
M Q5?07][/KO'1CA<%CWP9?$M+7^8IPG6_Z;)5&TV6'[?!]<5MQB.KB:@MD5
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MW!/<]4-!9@^,,B..@)::#3$AF-&;P\-C.B"Z;HB20[GYS?PW05[C^%B*GNQ
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MY"[)]&5D]GI(;F/-5;]656-XZ,+'\*XD1Z $M<$0YEN7?38S'CASW_#>^*,
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M9-S%K7U<_# ^&1_&X\.3=BYZWDB?)9]*@1AP,"-_F3X4<C6K]D^'323.5TT
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M  !**MD[NU"LWVB@M8#L\;<4E\3PF7O?4?/&I/0=UW!E1QRTD]PBV"->>-@
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M,@YP(%NOQ\!& S^**P?()C!CZ;XP"& >\1F8%\8^8\6K0)G BHD():.W.^J
ME//YX.M'4+ \';+&XKBDF73>FO!BNENJRY#^J(]# N8(WB-CWF2L&]T9)H2
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M]IJ3H05.E(]'4/N+[(5:5*QD31A4,S[?:9!71+<"B3E"G'YH91BY9Q+8Z(R
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M6A,8L1T&FLX[EY2J%8T)6G#X.FVHX1K:=>;7PI@TTCQAZR\&C">/U4M'QWM
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M]:Q](?$D):XCQT@\J#49A-G2'D3/AF'J52V;B%>IR+>@%2D.)GVGIIGF\6(
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MR,(HA;["2\$42<Z</>F!(OHXO.B #%I.5J+MD;TPHKCZ$)8<BB5=B?YT6R#
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MX0RKX0P&O:.!'<Y@.(Z/C['FSJ0W'O^BX1Q&DW@P.8H'1WUHY,0U3QO:?'B
M/ NNTWYTU!L,ZI09)F9-32@CJE:R[S+?-JIF6B:4Q+I@Y"UIC2Q7@8;7:$F7
MB%$+?0E#%UUF(J982+24.1EJK&*/(XWH;?2:Z0&74@#R]D]M3-5]'(5Y4\22
MZ;#B3@/A3+ \$OQS;++$(MB\[R.@2OCG"/YQ+?C,&24,_#_5D6FF%<'0>OCV
MH'="_QYB2WX-38;,80^[ZO?&^-RXUX?__%3?FE OG/0F)&@->Q.\*B:]?D/*
M"CA$4/AK1Y&O5H9('*H2VX^MFXE[93.("XTD5I)P-08L;]OCO"'.56EYW;S%
M]E/),ZK!(#Q0_OS+&&37]%O/M7YGCZ]^]Z.D/*'@:L;R__9V=;MM[#CX5>8B
M!W !Q_5X_#/NQ0+9M#E(D;8^2;N+@V(OG,3I\2)QNG%\SLFB[[/OL4^VHJC?
M(:G1.,'>Y,>F-!J)(BGJ(PD?!\+7OHB7!WZS3Y7\K/N3Z8@NL<^?:B]. 'W0
MY-H9U.E2/VK\07KQ$7=:PA^@+#K04D;_IPRX-'=-!N,*?]7Z5Z4.(*ZTL6)Q
MM;4A1AW)&R;.05&KMQY":;01"'@P&I7.J(=$U9_[RAZX5GLJZ:!""$9..G7]
M7/7\IA#'F*%IM?3"^XW@5.85[GESW/=)56>%C16*XV%_-!F"BE.KZU6<)4-&
M??VP,@FQG*SJ\M1)])3\(/9W-O7R1D.3B[]BW@MN85<!:9#Z(XX/WT1']XYY
M@,)X8[LQUX$7Z]IHR>:IOO7UMLWWH^;^L_36N93A$\X[8UUN<-RO] Y3!T9E
M?5VTIO"<J&/<'#R_\R&<_6:5?4L,WKP*W]*N3-VOZKJ8*TMKK(Y_M5*4YWYI
MPFPML>='_4PF8!+M]JO?5M>[6VU9'$>%O1>0!?)/7%-]W>B7GN.LN"JX"3C2
M@''708")LI [)R@X,';AJI09GT%5&)2EC?YL,M$Q&43X%B?Q6^0=%P,.,4&&
MI@K:0=$;C_OC<J(=9;UJV)]7Z#3KE6K):SA6GYA@1G6\'M;PI94+B\3<0,>3
M_GA>RQWGKZ)G B<F>F;_R*?QH)'OC3PSN":@BQ]*$("T,;$0*X8-9'UA.<%
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MD > SIUF*/)IS7WJ=U:0TH3+C-'8D6(,?V>MDMFQL-]3.0"8)\D) -+$?!(
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MDL&C;N0OPVZ9/+D-)?IZNWW\R_\ 4$L! A0#%     @ FHMI2&:G;1D0 @
M$"8  !,              ( !     %M#;VYT96YT7U1Y<&5S72YX;6Q02P$"
M% ,4    " ":BVE(2'4%[L4    K @  "P              @ %! @  7W)E
M;',O+G)E;'-02P$"% ,4    " ":BVE(%\P0K"0"   J)@  &@
M    @ $O P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" ":BVE(4"1&.Y@#  !&#P  $               @ &+!0  9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( )J+:4CQJ80R/P$  &D#   1
M  "  5$)  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( )J+:4B97)PC
M$ 8  )PG   3              "  ;\*  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ FHMI2 DG_UMA @  * P   T              ( ! !$
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ":BVE(;1&0SQL%  #W$P  #P
M            @ &,$P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ FHMI
M2.9D#AR) @  ? D  !@              ( !U!@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( )J+:4C&W1'"I@,  %L1   8
M      "  9,;  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" ":BVE(=4?(\B@"  "%!P  &               @ %O'P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ FHMI2+=0F289!   WA,  !@
M             ( !S2$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( )J+:4B)34M3+@0  "T6   8              "  1PF  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ":BVE([3IB:XH$  #?
M%@  &               @ & *@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ FHMI2&"^KG^@ 0  L0,  !@              ( !0"\
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )J+:4A3OA-U
MH@$  +$#   8              "  18Q  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " ":BVE(6KN">J,!  "Q P  &
M@ 'N,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ FHMI
M2&D'_9RE 0  KP,  !D              ( !QS0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " ":BVE(J@MA**(!  "Q P  &0
M        @ &C-@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( )J+:4C%&-)YHP$  +$#   9              "  7PX  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ FHMI2)IG7_"D 0  L0,
M !D              ( !5CH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " ":BVE(7H1(G*0!  "Q P  &0              @ $Q/
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )J+:4@TP'@2
MJP$  /(#   9              "  0P^  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ FHMI2 IQNMVN 0  \@,  !D
M ( ![C\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ":
MBVE(T.0BC:0!  "Q P  &0              @ '300  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )J+:4CF//KGHP$  +$#   9
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M970R,BYX;6Q02P$"% ,4    " ":BVE(FLTHK*<!  "Q P  &0
M    @ 'R3   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M )N+:4A\CY/Y=0(  +H)   9              "  =!.  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ FXMI2$)$2+VD 0  L0,  !D
M             ( !?%$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " ";BVE(2"6E::4!  "Q P  &0              @ %74P  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )N+:4B)*GATI@$
M +$#   9              "  3-5  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ FXMI2-&?GBBG 0  L0,  !D              ( !
M$%<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ";BVE(
MBWMT?MP!  !%!0  &0              @ 'N6   >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )N+:4C _LYDV $  "$%   9
M      "  0%;  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ FXMI2+!,10>R 0  %@0  !D              ( !$%T  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " ";BVE((32-'*8!  "Q P
M&0              @ 'Y7@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( )N+:4CV2&CMZ0$  &D%   9              "  =9@  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ FXMI2-M^'Q=^
M P  NA,  !D              ( !]F(  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " ";BVE(S'-^)>X"  "<#   &0
M@ &K9@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )N+
M:4@A=F^Q#@(  *D&   9              "  =!I  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ FXMI2*&3=(!+ @  $ @  !D
M         ( !%6P  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " ";BVE(-[X17]P!  "Y!   &0              @ &7;@  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( )N+:4BCS".@( ,  -<-
M   9              "  :IP  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ FXMI2$!Z>8D- @  T@8  !D              ( ! 70
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " ";BVE(" M%
M]>,!   ,!0  &0              @ %%=@  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( )N+:4@*E/_F\0(  -<+   9
M  "  5]X  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MFXMI2 .W$B#. @  &0P  !D              ( !AWL  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " ";BVE(KB4WZ#(#  "2#0  &0
M            @ &,?@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( )N+:4A68<GTYP$  ,4$   9              "  ?6!  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ FXMI2-X*^;3_ @
MA L  !D              ( !$X0  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " ";BVE(GTO9:60"   !"   &0              @ %)
MAP  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( )N+:4C^
MI:U6AP(  #H*   9              "  >2)  !X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ FXMI2"R+8LDY @  C@<  !D
M     ( !HHP  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )N+:4BJMS(]=0(  !X)   9              "
M 6.:  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ FXMI
M2)F#WX^: @  XPH  !D              ( !#YT  'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " ";BVE(G'S#VW$"  !9"0  &0
M        @ '@GP  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( )N+:4B)R)R,80(  "8)   9              "  8BB  !X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ FXMI2(?2LS+D 0  \P4
M !D              ( !(*4  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " ";BVE(?==W_=,!   M!0  &0              @ $[IP
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( )N+:4@,72V[
M<@(  +$(   9              "  46I  !X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ FXMI2!&NFJBG 0  L0,  !D
M ( ![JL  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ";
MBVE(($9%)=L!  #M!   &0              @ ',K0  >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( )N+:4CL"#D4^ (  ! ,   9
M          "  =ZO  !X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#
M%     @ FXMI2.YM(E47@P  *>\! !0              ( !#;,  'AL+W-H
E87)E9%-T<FEN9W,N>&UL4$L%!@    !( $@ JA,  %8V 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>315</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidation</Role>
      <ShortName>Organization and Nature of Business; Basis of Presentation; Principles of Consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - License Agreements and Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants</Role>
      <ShortName>License Agreements and Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Deferred Revenue and Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/DeferredRevenueAndIncome</Role>
      <ShortName>Deferred Revenue and Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stock Purchase</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/StockPurchase</Role>
      <ShortName>Stock Purchase</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Public Offering (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://acceleratediagnostics.com/role/PublicOfferingNotes</Role>
      <ShortName>Public Offering (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Rights Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/RightsOffering</Role>
      <ShortName>Rights Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Employee and Consultant Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Supplemental Data: Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation</Role>
      <ShortName>Supplemental Data: Quarterly Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Deferred Revenue and Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables</Role>
      <ShortName>Deferred Revenue and Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/DeferredRevenueAndIncome</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Employee and Consultant Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/Commitments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Supplemental Data: Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables</Role>
      <ShortName>Supplemental Data: Quarterly Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/InvestmentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/InvestmentsDetails1</Role>
      <ShortName>Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/InvestmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Property and Equipment - Property and Equipment (Details) (USD $)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/PropertyAndEquipmentPropertyAndEquipmentDetailsUsd</Role>
      <ShortName>Property and Equipment - Property and Equipment (Details) (USD $)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - License Agreements and Grants - (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDetailsNarrative1</Role>
      <ShortName>License Agreements and Grants - (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Deferred Revenue and Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails</Role>
      <ShortName>Deferred Revenue and Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Deferred Revenue and Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetailsNarrative</Role>
      <ShortName>Deferred Revenue and Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Stock Purchase (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/StockPurchaseDetailsNarrative</Role>
      <ShortName>Stock Purchase (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/StockPurchase</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/PublicOfferingDetails</Role>
      <ShortName>Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/PublicOfferingNotes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Rights Offering (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/RightsOfferingDetailsNarrative</Role>
      <ShortName>Rights Offering (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/RightsOffering</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Earnings Per Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EarningsPerShareDetailsNarrative</Role>
      <ShortName>Earnings Per Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/EarningsPerShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Options Vesting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionsVestingDetails</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - Stock Options Vesting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Employee and Consultant Equity-Based Compensation - (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationDetailsNarrative</Role>
      <ShortName>Employee and Consultant Equity-Based Compensation - (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Income Taxes Income Taxes - Components of the Pretax Loss From Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxesIncomeTaxesComponentsOfPretaxLossFromOperationsDetails</Role>
      <ShortName>Income Taxes Income Taxes - Components of the Pretax Loss From Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Income Taxes - Deferred Income Taxes Components (Details) (USD $)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxesDeferredIncomeTaxesComponentsDetailsUsd</Role>
      <ShortName>Income Taxes - Deferred Income Taxes Components (Details) (USD $)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Income Taxes - Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxesEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxesUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Income Taxes (Details Narrative) (USD $)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/IncomeTaxesDetailsNarrativeUsd</Role>
      <ShortName>Income Taxes (Details Narrative) (USD $)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/IncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Commitments - Capital Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/CommitmentsCapitalLeaseObligationsDetails</Role>
      <ShortName>Commitments - Capital Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Commitments - Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails</Role>
      <ShortName>Commitments - Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Commitments - (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments - (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/CommitmentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Segments Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/SubsequentEvents</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="axdx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Supplemental Data: Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationDetails</Role>
      <ShortName>Supplemental Data: Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acceleratediagnostics.com/role/SupplementalDataQuarterlyFinancialInformationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>axdx-20151231.xml</File>
    <File>axdx-20151231.xsd</File>
    <File>axdx-20151231_cal.xml</File>
    <File>axdx-20151231_def.xml</File>
    <File>axdx-20151231_lab.xml</File>
    <File>axdx-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001628280-16-012510-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-16-012510-xbrl.zip
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M<E?P;?%LA?5 :%\.ZU)"+5B#4^/ _8P&=(65$$0PSE-F,7"([Y5:QQH?!FL
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M>LV^ 9@'P=THYD$*B94EP&I81I7V#L]O*YRPU;88*LG!X$ZEJ,/)*+_;T0T
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ML>(L. C@1)B/@P$5B+"HWGZH^JAM!R@_Y".@_^3NPZ SG*3$__],^[<WNWO
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M+<*9Y<QJC"$(S1DV42KPM+&UX)VDV='>2U.=-T;P>J';%B ='(.5;AEM C/
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M *[Y>%97M1O9(D<2Y"/U/FL-OZ\-=:4EP:K:_RRT0G@3F+7P/ SVQEWL:=V
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M*SD^Z$6^?%>*ZZ =.)26>Z'37GOJK2L="F96FHI*L%L GH&Q+["--+:&8$9
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MP7E8I; 'VXAI6BX69G@!_-^L+E0QP!G=H91V_O9=Q[2%81W=57S?=D)9,Y3
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M^GU+K4+HFC!CT_95)[3!625JH(#Q8"I@1#N&WCTJ5I9LA^T36IS^9)9OL0\
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M3HAO^3)6#UH.03X 3I#!QB =\!.CXWP?>^3GQ >^@3P@V[9* ML*@9Z&C7R
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M-<^R++/I+!EJL!VN:"9ZM%EO:V\7A)H&[EE@A)[**B?T1E-YEB)W+'7;6.J
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M"FT[N7*44-9"4W'=T MMQ?0PLE@#G[JROZ6SRHE3J$YFFF*'FH-Y"%O3&2"
M8:"HJN)JEEUC/0*%5+"Y5JDMU3"M_JBT8AHO3J5M?&1JBA\BCJ<5.AY6-CHD
M:"3-]?Q5(2Q=T^4^(OHO0Z7%+*Z=2WT7J4040]-]QW8]50G0K9&)T112:[Z]
M:@LT#5O6>R33BGF\.)FV9O,!-:Q  ZIX#GQ0'5_F6$:.8MBFO2KX9A+34M6S
M(=/FF$[(X^^;VJ1IQ/$"2W=):"$8ANO4H$FPR:ENL(I".GB&LM7'X>ZZ.;PP
M@38Z>YZE>Z9F.I[F@1%NR'(X"ZDK0+)56AO,*8PS7@Z!-O<F@QW-TP+5]75=
M"QQ0WTU+-<4P0V=5;S(#_#QB]KC]OQ2!]K/&U?76. */J> 8NR!CCHW-X76S
M(1K8!_(Z:UR]UGI4X3O.["2(N2&9V%8<U?8]< !--W0-HA'7;(KYB!RN=6WT
MZSX]PG,BY@8_$?1<Z%N*#$:\;V(O%M^>=0%15=-91TRCG_24UR,FS\=D#=IX
M-LRW'+]ZKGH,+0V\'S4,B1X0!UPDQ\-PO:;9F ,4!L?UBW:=U%Z$+'=S\N?F
M\^[,N3T5S;=4,S1\2W9=VS,T>]:;&84]]-1U_*GLEX_6ZQQ/B;J;\]*<$.AI
M>DR=ZH[E^H[JSNJBU>6F@&WIU[0+H6XGD- G]^JF$SA@&P:>KINFIR"&0Z-=
M-9FLI>^>2>D]S_*T*+R9@ST2:*'E>+X+?IPB.^#1*$T*C*V$Y U0>$4 HT\>
M=BW+LF73=64E &VL6Q[Q9L>#VC(<X9S"1+V6^U3!>T[SM$B\F8DM6[>PWY;J
MA8YEJH:J*DJ#6Z7J\EHCC)!K<Q\K[)1)O!@XZ9.!0]O5;==4E=! =>PK=C S
M(3Q=4=92U[A6]LD(ZF^&)T/8+6P;V+KJ^+YL6X'A$-MVZY:CMFIXKNJMM<WD
M:WV?-)^7)&Q]'CH[:&==<EJU\ZR+[\(SO^(PF^/4EJ6]LE5Q[3_,$J[X11_@
M)=_16,?6PK2H"^]GI?P\"ZYSHK8M \MV'=E5;!7SAW1P/WP3$7#5P J=$+&N
M#C\W[9U(Y[\NK1=L6Q<'[1(7#X%4GVBZ)FL,7A36Q=.(O3)18L<(FEB7SKJL
M\8BWK9%IVI9J&;;M![!</GCSQ*K7"!QZ?Q7,@B%;EFYLW3".OT;[!X%(:!)9
M\\S05VU#Q0,4#>O"P7LAFJG*^EI%3JZU946^6L]VQU1GR#B38K&[SZ)Q;P2Z
M:5FJ9]BJ;FBAHKFJ%A+?]SPOM(RU.[=YK2_[I_N/RUR+9J S+@B('WJA;[BF
M210<EJW[5D"T]>::>6T\9UBP@CZ-[;5!9D)LPU(-TS6\P/(5Q9,=L!XML"@5
M5R;K[1RSZPNM'M;M]LC4[?(>W09;^8H[<PEO1D09V)O/ =+F ,2OM1EROFG[
MH6*!+Q5XBFJ$K@MBIL G FSNM]EY7CVT[$+UO09BD0^'FUI[B C&K^.&L,B>
MJ;N!JIH&0WKS[!"!ILV5"[VL&4YRH>=QCLT)'T=8W$]Y]O=IE":CA Z7]LL.
MDI1.3 +:T'== J:3%1JPE:F.Y=BNKSF.)B.2E+P,)=4'/<Z=R+M(4)O.;HA(
MM-C(G#A&J(:6J2&CZX8A:Y82GC:=NR[5AZPJDJQ,8E9I25[2=UOLOVG*02"K
MKB$;AN4YMN8KI#8_P<NVNPT?B:FN@%8]"E'.DO0;W;-%J&6?J!:126 Z&OH
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MZU4"&HB.!E("3(@/S&G)VB0A1\[:0:&=FXS!1P,[=SBE7*2-&5UN*.UC#_B
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MV1EM)3+;&\9\5XM93W:NB!'I"':]*=,9,R]X-I!VB_:N_MQB)^^0.O=\K;/
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MM=9?:KM56-J*B?]?N1/N/CES^) 5^?D[N%J.+RN!;+J6XZJ&Z:NA9X2J1LS
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M0+:Z69!]$_1-((V]*$;Z"U"T9VX["3SU,Y12]5KK.NE"0-\B+OOS#/!?>*[
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M2^'N<W>OCR4=-U%*RX%T1S-:(!@/V'W1<)QD25GAZ>+#/LT[>JMMOHPVROK
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MYZWGSA^(AQ C"S,V0HPL+V(DNW0]<SSP2":A&AD!(Q:>!XX'C,CR,(0:UY]
M_PJL PCT[VC1+8'^%3/PV(^R%P$T1#Q(/$@\2#Q(/$@\2#Q8F+*$,\D]$^C?
M6==.G5$%5,TPJ]H:;<JB,(C%2\3BA(9&?$Y\3GQ.?%X./B>7I>0;"@3[]_X-
MA 36=4:IKO=L-*T:G=;6Q:;$(I?%(KLE/$G;$"N1MGEOG[!,KA]A Q;)_[L0
M%*8+YAJS?B1@&^*6$G(+Z1CB&M(Q1?4#+R(W2+B Y[$[<1%@-%KW-0B,A@22
M!/)@@30;[T\Q$D@22!+(4P2,))4DE225NT+U-XUJ7=^!31<OD%N!*.ZA//<9
M5HYD^^$S'A&.\;3S2;N<\Q.JM_7.*&O[26 ZTL0$#P2;((2-S>(0ALC^5+ V
M\KN0.1[C$D0FZ?"0D"W,20%2TJ>\CAQK!!=;;FP+)ML_N&6!($6J)FJ\V"3"
M0Q:-1"A8.!$68AOD1^0Z?\:.?7W&]"X=!R5X'HR_<,=%U7$%G' 5<E"?L]W/
ME>R4+'W"5<A#H0,OY,!+7A@%\1C;A!A\#:1Z@@G@K?/W1",>R<=;?A#X3[+J
MSF9/4Y9#PTCNL'G$KQE[' G6\\>@J:<P&,G,");!PAAX%=@/&#L&%HX"#CR+
M]QCL27C6")_"IHYP[1"^"?P_1/"3+6"B@9H-?(L\[4LLEG0:ZGXE!SA*_RGB
ML(8V&P;^>"D5#(8+-1%RM>1W..D7^.P'\"/0(GF#'P?R\LAGM@#%-X;GHNRP
MV(V<,18?SC**S!\F8I5*$XS4=?B3X\H%6D8628_T_3B/1#;Q.QCQ5-$-7S_F
M?PCFX%/AX6&H%@W?D(Z+1X[O*=GVYX>(HY._X@CQ$8[W(L)H+.?N!]'0=QU?
M/FL$=WM^!"^SA<%LX"P8EAP.F$4?-,<D@/F!!;!Q'5"KP+L=U$4VBH$:%+Q>
M3DLMN9HUK,HK_L?S<<V]<"B"$%8\>A7"8RZR=YA_W11$E^'JV&Q!:G<7GQ1$
M<::($S3%Q23 [@]?KRC3O__V4QQ>/7,^^7D _/([LLNM$UJNCYGI\!%4QXWK
M6W_\XW__YV\+%WX>#F!U/0M&<#<3V"^P:-84)-)#Q?-5#/_^P^ 6Y_1;_=^/
MMS^ G8 O0,RN!F:].ZCU;BN-VL"LFK=]L]_O#WI5LVM6!\UN_X=_O-%_^7EO
MP!M>YH,52GVJCVLKU>2+;6&A5@,9^1D-AGI;/U0"9#-<"_9[*N39<K#<>IRO
M=2F?O<RK65!N+L0/!^J113Y2A4@//?;H3\"!:E<K1IY-/JE-IYF:SHF[!JV3
M6#O4U[88*F,W,T3XO@![@ .AK$E*#%#-H/C!7COH)8)]Y&/QZH/)1:] [9.A
M"G[S*%L-?<[6C7/S2PS;[&ES[YZS/LLM(]B+I_\(2]JY%>](7!H.CPP$F&!'
MR!V]R23P.9I]SUYQ)U@98&UX+_BY>$=N/C:ZV,#NB>%.6$79('R)!;+_[ <P
MP/401866A;VD>R=\^B537&="V*I1+MO#5FCUK:W2(O/9B&-!=4?^9)>,Q )#
MO)G]7)9-+KV&1&JU>7B:$.8Y/[A:<\?<U,+4-X.+Y>7@2KWPT*C)_)FQ;Y[R
M3T'B-X786:@#,32XV0[* 7R#ZB&O5&SI^N?#<8/%'JB\"!Z,+T@4'5R1TW.'
MYXH.5S5S:RH%:X[HU3II'](^I'TT:9\J:)_?YE1./O^RPAM:T$K&HMI:T%<8
MMJN[9/XBR;=D/\\R-083CDQNV."B69$[59>GGPPUPO@)_$30;-R%"Z1S%+LN
MPTQ#ZBW)P><5W)34&ZDW4F^7I-YJH-X4"#\J@EFD%PEKY#E_QFGN. D(%[02
M</4(M.$,8#E)7:X(Y5!1QGD(Y@_.M;@&937!-*9*28,BBN 7F<Y.D[Y2+X*"
M^G%#LJX &JH(T5^AXUG,-%@\"*8R'3!6^UQ@DH994BZ_JY'N-ZAM,6"?M_!H
M1K('D6V9@1443F(H)X&8<,=FXOM$>*'<?$@OF_"IN@:^"6(Q9\#S>Q16' 3(
MNGG[+K,6WU5N'KD]$*[,,LZX'I/A(A6&< 3,?25-+]R2[O9DFPVYZ>Z=BUZ7
M8L[GI._&0(] V JX^=&_P2SV!%,IGX<WTT\B&OFVQ,E_'''O 2B<9;:W2%1W
M&MU!M=^Y:=^VS)O;>J=G5FLR4=VIU&\K[38EJE<EJC_ZJ$_ ];/9;F=4%(H$
M)558N<7)^?L6. 0<_'B5/Q@ZTIPY'OC<SYASD+MH3X*-A*MREG&HS%L^FXL6
M-! OCGA%Y8%>O!1/:2I?1\(#$QTP^$^RO6N!3#ZKZ,%R BL>HX>OP@G;L90R
M2E(=;Q2LS-QZB<<_YE,9;#SARRT\P O'_F9S$Z7=\6(_#B%\$,HQ2/+!V4TR
M9DBW)-T%*CUQG#(X$R+;AAG&H/Z2&H>AS.K+'5ZD#SXY=^'<IJPT @LO4%H:
M-/$+K$'XEGY.<EOL8;88B2#L_(OAZI6OY-+3">,A.#6.4%Y-,NM5U,6OWXYP
M5VV^OW*>4_&>Y8_%(_\^V[#828G?UGHW9N>VTFL.NOU:XV;0:BLEWJUW6NW!
M>RAQ+;*<%*4EU6HY=9T<]KJ#NK[__-AG9@U$YNZ^]_E3GSUV_U__0:>&(WV\
MP8$$-05325Q'56\A(OX=9#!,E(H_$4%24C%,A!VK$L(S*4LP=(QPZ8&3^XP%
M-:V>\=0T/$;E]\-L:WC^Y,-+V^L[N!9T"RT]%_.>_^G9S<ZU6:\TJPV-9VA7
M#CU#NW/J@Y0;YW+B,PUT*T::X\4M\Y;O<L#7H6'V DY9;\$=^*+<@8_H#@S0
M'?B<N0/;*E,ZJ[=T9T*?_]EXVD7'K/Y4,W]:ZK0200\BZ"YX>$30+0BZ&#H0
MKLJ.=N?;]<,UN_7'F/:R=N!/[1:F$-V"IV@T/?\^T@_UNE'7B+>PB2(SF3D;
MM/]W/:.)1.E\1*E6,3JUK>T8B1*)$HG2"E$R&T:UK0_>X))%Z4SR"OHH,_ #
MB#*\?0*T3:B>9X;:^<$T*FUM!ND2A*7$S$ GE=&JTZI3(FD+IOFRNMQ"FTMV
M4H"SPARX?>[H9\<@I/Z45L.H=]K%H>=.#M,9L*JV*)Z4 "F!,TG&D1(@)4!*
MX-R4@.8T(BD!#4G(<L&KGG>-\(G1OFQ?* 3#0 Q=1)1R9#L+PV SZ>+$UITG
MX8FA$U%E?\DJ^XT4/C/E!P1(0Z S!*^8M:=SK/O'WK<W76O8I!78Z@GPDO_Z
M'F=?Y2+B_V_95X'XN;+Z_!$8JA<(&YCH2^ _!WS,X$]\'>+M1C L6^*<(NK9
M$-OF9 ]8"'R6H)79V$#O3V2S6=I?C-UNLD',]Z0NEHUE803_R,O\8;XK1781
MPL #,8*;$2U$9E,0$<X)K3A,\,TT4/7>CP1K&NRC8TD!ZCX'(H=L]VO E^$?
M[OX>PAPNT(QNQ5 $@>2A5(.*,%.KR*4><C7JU>$0OE*ETV(\\0/$K;4=^#80
MLK\TQ7E=TOL8K@$%1.4\Z^H/!&(\X)V3.,"NQC#K^TP?)7MD91_G3.FG%X.D
M/^1P)A8;P!(=D&6S6[^$<H;V4CHL& X<6-$MAT9EK<EXJ#ZL^78LZK^B_JL-
M_5>-QG6]V6YI;+]J'=A]U6B?NE?HY.U>Q1[HQJ:FUH7U-&7V6S7T*X<ULWI[
M1-671E:5WZ%&JT(U6B%777(/B]XNJTNGYM8M5E3(L;O=P>A+17;K/?I].]E.
M2-URZ$XBW#$LM7F^ JR2>PCBJ[**WK-*(<H<S= /7GE@[\"!QRUJ//_-TO-I
MCJBVC49[E_[CBZCF)!8O$8N;6,&G;=^^+"Q^1#_WW.WDEP"M9#1EV7Z@A!&6
M&WC[N&F;N@"TNFGOV!Y0JW5T25DAVBN+TB52%OYHM8@]*%C9DEGN/$0S]H/I
M,23JS 2GW20/_7)6NUFMT&J3L[HEMSQ$B-;M3W9MJ+LX[Z-A5"OZ^KC*[H!<
M(H?4C&9=FZ$M/8>0BWJ7G>&1G3,A3VAV(J$.=R!GYI>:OK:YL@A.B5>[7C5I
MM<EUW9);?A6>"+C+GO# =X&[D;++@ER4-7L91N<$^)IED;U+Y)!VF_B#7-B=
M6W\"/#PN%N3#_%)KT5[Q!:UVFY*MY+%NRRWR3$7R/M;XIVW:XR7^."F"9.GY
MA+S4WH@#<54K*OP<.$\Q;G>1^P+ZEKR7RUEL2J63J[HML_R^"(%S%,=D0T]A
M61R7#[66T=97F',PV0@W_\+XKVH:C=J1T >)_S0[W&=N.Y8T]AZ'\30!M!:#
M:J>#6CV?WJMCQ/N;J%,6YY9$B42)1$EWG$B(P<69T EP^KH2]7%A_/OX1$<%
M^GV+9/LL:Z,BN3/_'+L\D+[84-BR8LI;0'(0"EYS,@G\[\X8;G2G.F;]EW;C
MNL+@(G=9OG7WY\VC\/Z?D"D,T*G"S 6N^*_"\LQ0F_' H!2!] UVA1.R,'[Z
MC\0H]1GWO!@HXSIC)U)Y#PA>1,#N4&8\^.6KJG" =]N"/<!=>$VM784AW<+7
M\ @)6CKBWK- -%V9:?9=]CIRK!'S+2N6+C&"6"*\;^Q*E-[ND_@/9[\#Y\;P
MI<$^?NS-X8HZWHL((XGIZWASJPQO_V?L"59M2C:JSO, 'KN-RX@(Q5R!L"8S
MS T]/UN<< 2T_&_R<;B<25YA*8&Z6GBC7JT88"7TL$475],:S5-!CM:#A0M
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M)?6/];G#VX5^._#NZ:AZ%H>SU^K72_*JQR)?Z8Y>_RMQ'G$><1YQ'G'>V0:
M1_5?'O!H>G4B=E*F,LS<F5S!GBYN/&'INOY.K>N.MD;=2VBW*C,OU*[U]8P2
M+YP[+^C#FKH$7J!\PKHSJD0PYGB^=VZO65^3YM&:IM]/_"K7IC9LXM)##ETB
M@Q T%?$)\4F!<'I*9K%QRSDSUA%<13XQ&.4Z@>U>SG(?0772JM.JG^^J4XB[
M;LO<"X3E/WNRNS278Z8P=[U%/?Z64%G$[Q(9A,(7XA/BDP*9\Y)9[7O?LX4=
M6Y$\%U'\&2.Z"_;8^'AV@NP(%%[(=\3O+JMO7+UN-\DIOICEKEVWZ+B9RUEN
M4^/N?UF6FT+>-0SS<0[/:RFH@ZVPRM*.G-8O".U$CBPYLA3P')HY:5#FA!AD
MG34_0;5U61B$0N'HEYX\SEKB<S@> E6%$LXU!)):(X90AR].Y.@KVSICV?I0
MO6YJ.SGP$HHCR\P+%2J4)5Z@ GHJFM9ND#-P[\-.1[LXU[?6N&Y3]31QR!H.
MT=G=0AQ21@YI$X>4+GXN'.C4>JXYQHE9YP 5\!YG1^WE;9\!;L",+?5!5Q!?
M$E\27Q)?$E^^=7[HN+[B3.@4Q_5%9X!>/G]BCLUBSP*1YPC/S[^SB1\ZF%G2
M=?#@7VIU78>&&,P6P))C6':;4,;W%^E5(\D]>,XRGC_*>*=ZW6H!([8TXHR;
ME0.!QIOU4\-W5T[]0AJHEA=N!$0W*ZL0@$$8CY%76>^"'1_>]UMFLQ ._4MJ
MLPY-3VU&F#][>JI]27D6CQ^'W+/#739J,P+5"@'!7ZS\'24]#T3:W\14EXQC
MOA?2/A%4,](^$?2]D/9/KR>/2+,;[LKC^'BD3FSUL$,"XFT\!TU7QFZOY.9Q
M]R4[^Y QN^DOVG*9F[:GC[\;?1@ES"95LY"8D)ALH 2U3I&XD+B0N!2ZSLD\
M=5VRYOW1NZ0U*)2-0I/ P?_NFH_;Y3"S@VL(SURFRB(ZI5WS5IN6^D*6FL1;
MKV7<KG"\7";3B@-$5):YG^-:SN.5Y9\T^='6AKE<>O?T\KBCK>WL*F*.TC$'
M1;@4X>YNKC]+Y,?,:)/32TXOK3FM.:WYY:XY&<5;D<:P":)C**+(%6.(9"EV
M)0>4PA3B$N(2XI*"<0G9[?[WB1,D$,U#V0H81CR*(X$?W0R_6:6F\6>.L,TA
MVG5Y _].$3!YQK3FM.:TYI>\YK2]NR%?G 7(Y,&2!TMQ#G$)<0EQ2;&XY$SZ
M\(YBJ>7'=7UY L_\T]N1=S9X9)H=(GTM%ML2\,SQVVIU?55,FTA6&/YY5\!B
MDDR2S&T(IK/SEB23)),D4Q?!W@/SM#!\=*(H@=!,BS.A$Z!3/HY$*'+PH#-H
M4!X(YOD0)'V?""L2-A8 6>ITFE<G&DET,;@"AL:B5^&^"#:&YX_":\8^JUW'
M!:KLH2+U(8MBI+<"!M5@N)3LU8]=FSGC";<B.0$Q' H\ D_(RP,>"8,Y0Q8(
MT"6AL&&FCSF<56Y9?NQ%87*:'K"B"",\)'<5^&I*1O@2B>R%XOI\&:F4HI'#
MT WQ@$1LX[+94(!%X.[RPX\_W'_^&/[(;/4ER PR$BZQ[/T2,%*;_3-VITSA
M_5;JP$7=D(6Q-3+PI"?Y'&;Q()@BB)N2PS!^^H] IO09MW'J<J\^AH<%[.[K
M ^.>+??X@66_P[0\N;^/4+K 5;;$'5+2^I\X<$+;L61M +#>Z\BQ1OC+E+T"
MNV937,^'Z=]_^RD.KYXYG_Q\YUG^6#SR[[=.:,$$XD \PL+<N+[UQS_^]W_^
MMG#=%S"CUC2[!DRGAROY50S__L/@%J'0?JO_^_'V!^;8\ 7(XU6W4>_6*K?]
M?K=6K=ST*LV;9KL_Z%7-3K7:-IN5'_[QAJ'RB[P!8W:9N2X4/ZJ/>/'/3@0O
MM!9S6_+%MK!\5?GQ,TI@UHH(1$<0S0T;546=?4GURZT8"JE/4#M@"0Z8#A1D
MU^%/CBN/797"'^"BHMI(RW7 K#ACCB9Y&$<@:LJ"2%LE$;TC,9X &P139COP
M;2# _H3L28"9%EZFCYYXZ,C+5[T:/O.QLFB!@ ?B"Q.KCZ9.*D;4+4])0C4<
M"7A.8A2M[!P[>XMIIC,#9>KX> #M!,^@Q3?CMW-/F 3^BQ/*VJ8 YN2)87)^
M[>Q^&$)_1@TU$E3?H'VY\F3@.2Y_#;<=GEJ%H:O\((X7Y/5P3LDO'5U"M&1R
M,"0Y#KR5['V!9I2W]PGLO%JW=$TE.W4?>JQ5KQ@'>K>+&GVSKMY]2H;T&)1?
M*H4$YY:YH]$46=-1KY15?](EQ?.?)XFWD0H[W(^B+A\!/LJ\'QOQ/T"O?(#?
M\K'"DU __(C.![YW]B)X ^@M3ZH*T$'/L6.K+9G)Q$5YPT'#6\"W2EQF*3E2
M7-.WYSV9<,Z5R=;00;WU9^P$:CQ#!Z)Z[BT=QC?I27V[?KAFOW:[7PQ\H(S[
M\4;4O\\>$!;OGO?E4PE/Q'_"IW#+&%@59S_V06VXSA\"G+T(E)",IH"#0O@=
M'B#=0V2OA(Z&5#OXS5AP]*"R>DSX*E,EZ!JZ5NSR1!/ACRX/GC'44-H:WR4O
ME.^7+VY4_IH-1"Y,((#E_@M/B">P.+#>OAOGZT63UP%E[M(X!@<'Z\%=U(@R
M# (:&TG,])2S4CBH642#E'R&IZ&_+"V*#>ZI$T;HI;R(]*IP;X?SC2,Y[VR^
M  7]8+J[L]GJ#ZKUFZK9,NN55O_V]K;5[BAGL]:LULP:.9NKG<V$Z.=K!\IM
MV1(H$E %DS@ WRA,7#VP<G9L23\I6<$$Z LTAE2, Q^<%[SR-HB?63<GQZ W
M/J2IV6KEE\%M-_MD_O(C>D*^+)<+Q#,J+GPT!YU@35'A@W'E+BB:?X&?YTL5
M^23 "+Q(N_LD#Q5)O%Q@-\\?.U:F#"U0;4^J>ETZI]EX486A@^J*5*DUS,J'
M/WY4:XJF!H-N"Q46K(L[G3\OQ_:!"C@0BT^D /P7QR*N7 [*?[2,/G@WZ#_A
M3*)E+S/ :K@B#)/K,B($XL4!+0'SM/!7S#' W\^@;D-ELC@8!R?5Z+Y, :#2
M5*HX"&/PX%&'OC@VNOCXZCR)$]JB*0CCX="QG&3=$[HJ@[,E<:4I2"?NY"("
MCG^',%,@#3[/AJ5S_8DT7I8?1F K,!TV9'&HXH<Q#_X0TIL0+^D1U[GG89LA
M=]'$K#$;\L%I4N,!$Q^IL?RL\C$R@0GWX9H&8@0V!F_[Z(<;+$VAQ;A4BND@
M*[.SM[#<$WCK+:AX;G=WX;93JU8J9K,"7D+WIGY3;S<'26ZJ9S;;;7(7UKD+
MBNJ4FBK0C/(.@R.7* 1775JI8>RI2.R%@_F+P;:,0'%?X9EMR:5R-9-X##,G
M8"9!Y\,+V4BX60K)@EGX]E0FH, F_ >,Q-#QP%PZ:+(\F&(D0Y+$\*2/!6$,
MG5"J>EL\P;0$.#0J2P,/EH[*,^;-/;S\*H3P)O0Q (1/CHI<@ LQ.Q:)A0>@
MP0"W82P".8@)!UL"K__$/7!7E$%SP1XZ0_FV*)R;+V:%7KCCHF6]@CCY"JW8
M_!6>G41)TA,(YW]-R))6)S[(9!H6*0ZY$S"TE$(&JEGH]@PQ9(BV-=EXD+'Y
MX@CR\U,9?C>VE26&P#X>)Z&D\M"L.7.91,K)*\!=D+\#>RM3"^MG_3$"^097
M)-N9;_W",.:.IF\VQ]93+L7'>^+H)"1VW>/2,TE"TK>4A.^<;,*8J)M*"L0J
MY$P?Z&?N -G] LUH;MM4-I]B[FDD)!."XRFY\0IS%U>S9#9NS#J!E$.Y1X;^
MLF\E>W()0@48&9RM%*>9X,Q"$.5\HA:QTTU8X':5%DKY*\?+8?XA@1A+D4M<
M>;Q'*J10I=9FZ9:WV^$RR97KL4UD$+[+#KO,NG53(LRS/'K<^=P:JA%0<DH-
MX]A0(O*WYO<MU:,B?(QTI1-I@<>@\+Y]$V;Z7)7W@[\L9R+50_+"Z>R-DO(X
MNW\M$!!'BR%)A/(N(X01?T&'?\N5-=BK2/+K22@71K/MBC?CM?U73Z;W\@L5
MQJZ,,%#)S9)=^.Q$+7G@;N4>ZR0!G]PJ4!LM8?P4@B;#5R23=Q;82NJA;!9)
M).5DR)_P%#N#4'ESYQM5O%K]DMXJQHQ.':\LC466!RQAU[-E0^*][R6&KRLW
MLG:)82KUYDWEMML;# :]VUZ[UNM6&BJ&N6UV^XWF>\0P6A8NZ>M)*O9RRY@<
M:;O#,MY_?NPS+-BXN_^]__#XJ7__^*"3F4GTUKL,:E=.;IR@DXMYK3&&%O\5
M>:,W9[\W^>3%/\Q;6AD-SUEZ'-X>PYD_5Y0.YMYU1EOHQKEZ]\*>S*V.W38K
M%8WG;=<./&^[WC[UZ= G/XZ:!GI9 ]U\,'@QSFE>+,2?Z8N]^[X7G#/YE.[O
MW;N/W9N/_:O!YZ]7#]V/_:T]LI(1]O :1.6YL)4."Q%/\PGKY]>1O\ESV</U
MHB/$]8(:=,<^4.*_PM[6>3WIZ'I^&-%":R'EKX$?;KU5>M*1S;:F"CF\7S%W
M3TQ(3/B>P_LHMVJ)"[40<X#;*;_C=LI172^MV%D%]LGDEL$5SE;8N:J!'9A5
MNP>[DO2%:<H_!;C# 6=.GP.H0]5HF(O]W;J)51B.*<W![H6A*,E@(8%5"L\W
M)(DDB863Q _'/]MTT0<M!YS6UAE8$DX2SGU=U4J+#*0. WE^NR":A:Z7M2%X
M?I0T'SSYGGV<LP2.D!TZ  ;\4-IUC%K]2!B=Y96X"^87XA7BE:T=<(W)J"TI
MLY,C7@SKM8NO?:F<!%:J5B7-4Y@SI\[<87ST(^X>AYUT06X7X3"5(L!M'Q('
M%R34-4VCW3@A#GX16*=\&/A%H"H)9)%C&))%DD62Q9UCQ!.>W:1U&Z<8S*9M
MIX8DE21UHQM;Z[P_Q<IB.K<Z*(8Z@*D#F#J +[5?E09*'<#4 7P.;17RKK<=
MP(L8(40\Z@#6V6VB/N+%*Y&T<D7)U"2\+XE7-PDS:LC51E3JA=R7<-202TSX
MWL.CAER-Q*2&7&K(?>^:=>IR.#QGKK&VNO#\0DV )(&%DT!JQR5))$DD221)
M)$DD222O]/T[+,K42$&=MP=(8=7H-/6UP%](4],E,\S)NBF)6<Z>632"WU#K
M[24S$IJIUM:5+*1Y#O ,B[D;0[VWA8MISKVCX2R"Y)IA5MKO3\[",-WEM!$6
MAN0DY^<;59&,DXR3C!=#QH\5#!^]Q_@,N/1,&Y#/@+(D_SI]^>W/XR,[3WW-
M[]W7?,P99;U 2\X!GQT#'LISP,<\2FIEF3_<Y63P69$M'@P^UQFW0+K=YT#G
M@1><Q]Y':E8-A=  " V !DH#W9;CSZGO^I1H .Q3]_';U[O'N_YZ7("U0S^B
MV:$>\CTHIS[BQ<?L(6\>09"*)#9O?-Q=SG^_;#(=#))!8DI0#QI)3.?!7^I"
M[]YS300ER:&%)K0"S6@%M[%@$,FX(L0D+/>8R::"!SLP*_6%45_8'MMD>@^J
M*#S+4',F"6$AA5 CS';A68:$D(2P>$)8,1KM)@DA"2$)X?L*H;ZJK<*S3.'Z
MT<K4=I;$U.953<;2!%#P/H ]%]+^25Q#7$-<LTL%I=&HT@'/Q"\[\$N-X% (
ME(! "8I!P//H52I*8$L'@I>XLY@$\BP%DHXV)8$D@2R*0!8$?(<$D@22!/*Y
M.!WT91'(K9KD]TB^[C,LZB1^I_[[@1_(EGJY(<4$O$U+-WK:83-[T<J.I-T?
M7K"6>2UH G\QZZ8!:J= Y/E+NZEM2([')H$/^M,.V3#PQPP!&B2>PY@'?X@$
M]V&&U_#!\2PW1B&!^^!O9P*_3_C4]E^]\$?V*@*!FM<55B1L@P4BG,"?SHMP
MI]>,/<XP(I@M(A&,00)#]HQ'5$KJN/*<P-6O?^(AR('O,7RL,W0LYJ 8XE\\
M<N#[!(@B=TOHN[9Z-0Q-CL_SV3,>Y,C2(Q,7![ -*88GEE M*!+Z)%2'PK@^
M8TU=.MMS[S,?^#FXPK:"JTB,\?2&8,H<D%<G&,,;041 ? )AH8MF,QZB*#G>
MBP@C]?.(P[=LB!T?+]CQ@1T*$=PP!OF"&V9-"PY<;/EA)(5H[ ="?1V]"O=%
MP!=>- KQ^2!\9/1V$ZDW6M87N$H1+%,$*HI%/J@PUYU;-9R  U>$:B5<YP_0
MUFI!\$ZYAJ^@.QVX#[]X0A[X,W8"L?QY3V+H)WP"+KZ$#X(1\>Q4;%SX]9*?
M_OVWG^+PZIGSR<]WL^=W/?LS\NF][X$N#N K>8)G^ BB<>/ZUA__^-__^5MZ
MWT<!%N.+[SK6-/L=!N"A''T5P[__,+A%/OBM_N_'VQ_ F, 7W(JN6H/N3=5L
MU2NU7J?3&'2JK4&]/^A5S4Z]6VWT!C_\XXTXYQ=G W[+LG"D4-I ?<2+5W83
MRQ?;J BDV?T9]9]ZFR3XUF<D%VK>)=7K>77 +0L"YT@Y+ZY<*G0!\>O YIZ%
M4AZ-6/>AQ]KURJ$.]"(CY5C$T*%[7T>.-4JU49C.")02Z"C+Y6$(GJ&R5,)!
MG<'\B4"6!9T$!+#X!,>5W ::\\YCS\*#*UPCCV<V>U3V"GCB_-TP%($ (^A@
M.MGK.(L"[H5#?/.0@8\L@G#D3!#V#)^/&CGQ6.53&+K$1NXS:BKEFX+K&Z";
MRB9Q8(WP-W^"HF>\N1M?'HH7X*/IU1#\;@83QB9/EAK:Y'V@39TQ!R>=@11[
M_AA<:=<9BKGAV!@;P/W1E"6^+OCKSC@>)^\#OW_F%GC ^'#ABM?E? *8N[H=
MP@<AYP"4EQH](V[P=O5FRY:LU?F*8_D4S.?YQ6%HDI$-\XXB^!*S-13?)\(+
M$S]/!H:#!6DT&,QGA/=QM.XJ.'/XD^,ZP&7S?J@2IHR=YD4J"QGQJPEH"1R=
MXD2X;IZ1$^=)O=%!U8C!KK"55LR$ <>"*F<REIRN'GW#7:E 'T8B&6[B\:C
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M.;9*3 /9@C.<$=B">_]%@05C^+K2%C2NS-:1;,&=%$;VR+^#6S>?_NO->X7
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M(U[\,RI;QU+?; =>-X>:UM\J<"XJ'4IJ@G? M;MF[!-W0%@\[EE"WA"("7?
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M!-U)0*C%H"8!H6KI8R8@U,)5"90>A)& 4 O<55=\BI(,:I!! D*E'GAM[$1
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M.3CM6P$Z.Q!V\LLVIT)T!F:].>BT&H/;FWJW"KJL)S59M]HTVP.33H5(3H7
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M1H5  R (B&UH06 IN]A%DA22%)*4LKC=QP3K#X%TUHA]"P7[[+E3UH4E=D6
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M*FB?W^94#BJ-T(&;>;#*&UK02L:BVEK05YX?)7<9J'624ZFRG_VG4 1))E]
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MLRR6$#?#)DGT4J_R,<,\P"]*N (RC+1XK+'ZM__C<L=*Y#R8(N>4)(+@3E@
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MR7N"=/9EDVW00IOPF%%I8B7^ M^/C]PZPTY2RF1#Z<A3/E(;*R3<BI5F[4]
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M#>1WKM1^#G \#1A?<!'U B+DR#>M51+N7F.;?!G >SE_RL0!8X^\)R//A*M
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M?E[)FL-O[3R5M"N@,EI(QJA'5@MH=S[H#I[ 4HE%)(QPH\T/LJSL1Y>AT"I
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MWE+N"3*0EE @VBSZWN?1;=- 8K<X#4AEWH9YUIK6/ R6:.\=,1PJ8+"EAG"
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MT[ KM/KUQ6J6X7F6OIDB"$B%8H LOAE"M*&.8F)(?$!'^*ILU^?AFQ'%H1(
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MNDK5R#+LKU&P C,R8C_P$/:(YX?8=WME#B+;DU)%"3N:-?#?=P7;V-\<:Z]
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M3$TOR^(FJYM,-/397D,2!E%DD!C;Q(R&3-0G8D5$!1ZK60=?C9::B:[MKA'
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MU8C@IO!(GJB^&9:1-6KPJ]#] HNIX<4#.Z5".WI3BKN*=S4U^FN69_>[^[Z
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MBH6B6B'?-,+(]TPK)K8;6V8([1Z%:3NAR#!5M6W-(U9V!7V6@VU:5:"^2W(
MP5.:O'\7_31\"^9S,U"M,+T[ PSNLP\ZQ#/E>WQT\J1_BAMF&:JIS;OWDD,M
M+*K6TL^4O Y($,>1%;H0&R$B=FBYA@E[($&,?!UR*F!^&D6EW:M14L%E3QUT
MJU5334SK%=0]Z&5JZAZ? EF5:*$?2UEE')045VDNN<?B[9W#R79_U6EU\2U/
M-[@>,NA5A"PSPM@)B>.[9DQB-^@G,4EL.615%W6RY1R)JS HI*$#-N[N?<7^
M1' (KH1'SB'XU!0*#L%[>.  WQEH$)Z!I 8<TQQZ1N <O!T;@:ND?1F*I]:E
MER-P]7SQJMJ_[Y*2YD[;IP,,-%+?-YN.25:MMP6;$QCN5@^8H,:&XT.* @96
M&)((V2A"/HHLG]B<'5.U67U]=$ *#GOK@!7LP8+?>[@3SY<)DGFDX^IJEF7T
M86W>%=.\W(*GS&BR5'U)']-\EWY.ZQ6Q/=^"5$4B$T5A[,511%HK%@RQ#<66
M"42?KGU%H,,R\>&=YRP<Z5FR?"VCYTBC?WFV910+W/LGT_H\7Q?WZ:>BJE9^
MZ ?(@2@V<!QXF%T_[0TV7$=P>4SLV=K?>@H'4#69>*OQ,Q*.;?F3(FL9K[PD
M]I?;_$8PP+_!KS? ]BB'15YG^2[+;R\>TK().=5E6@9)E:UQOB'9=E=WI:96
M7N1%#D(1,=F-9]"B8/;=S_6%YO_TH= \#=A@ DF^ 9L6%<B[3G50C.##IMAN
MD_+@(\[;RR9H)+Z,>QGM(Y9[MYC!!X;ZI_:0Q1XXV"-O;NL"^X;LX+<G@:?>
M62A)\]'MAKJ;;AF2.X&?KS8F3L,LKY3O!P<7-X>G?[^DVZ1.VZV3KP[_5L-
M(B:&[U'CKF^YV#4H#@/1>&.0R#.\&+N<4J$9A3Z].!B+%S?/:P1TV-L]R&=O
MU0BH9AN_C^/[B'!,U)#+4(^IG"UFZ2R"8__U7;K9;2FDQG3PLII <^BVJQ>
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MRRK9]/$V,F,'$=.)3,=U JLUZ&'##GDW2XZPH*]W[4&!'M5LVR+?)^A(GU+
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MM*+"Z_7N?K=-:'\FZ4VVSNH5C&(SA-B.71)X;AC8$0P&);5LH4&O G.:!>T
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MOZ;U7;'I2Y0.'U<KUXT,PP\BXIIV$$(<!Z$UP' =KFK9VHQK%KM]!>/[ 9/
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MSEO&"/OX.D>)A;WF>D?+7[WF2_::&ZN:] ^FGZ"<,D#*$KWFLC%;M-<<K,+
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M487Z4&SS/9_S[O;WG]ATN&%BR&>\Z/[T3^"/LEFY.(@C-XW]S(4!BC($23(
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M+_)SIM";SJD=]9T&/VK=HTVBFANT+OM1W-ZU)WW;BQJ^[TKV4>/Z]K9LFB,
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MIWB$G(A=A!+":H[8A2#"64HC,#B! A_/G*?U@C>>I4\.N2V>I37'?:8<O5S
M%\S0SQRT^]GRLU1<369G,P/L)\G-ALC1G9E-QG#&O"RU_[VBD>OZ8>:AC+B
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MPB16A]L6(;FD)+IJ<^7D>Z=WPAF]>/P?73GO"V:G>KE7TTR;]/00G&N@GC'
M=A3#LWK\N.EZ=K9UIH;V\#7?2& 1W)XDLY6'04"1'V? 3T'B\F<OR0#)P[&G
M.R<H S'=*<-Q<='G%[M6Q9Y/\8?<H-SK;38R^M+ +$$QI?]=Y-I]5P[_Y.=Y
M**W5_9<XGRCXDT/Y>I1^NJL*$J^)7Z'%"A$\;4<^&^2W.>_^("7[3W8%H[CI
M!_Z*87)IBA*"81PAE'C I0.N*,)"9[[G0V-8Y4=HSN:(36)98YZ(""PL61<,
M4^K>G1\ZQNW$C<OBOE0 )5:LK NDTEK67 $56R33P>E+RV>SQLN"A;5Y_:V7
M^C+TS[CZDQ(/?F( N"_S[0H1$+K0A6G,*@6^_Y]1OX?F^\33OAHW&9#AW-RJ
MQ>8$D/ZYUO28Z)MSS1H.4]EY.(#V^.=.';%X#G8I!A/G8MI"_'KF9/I<5IB;
M:>9;9S9@_Q+7[?-\+#V5;+H(*(DH\*+4I0!@+_92' ]0(@"DKN(R L!X3]1)
M4\S) IMD5Y09[O6IO%':3:EZ=Z!D0'UOL8 _IG>B8"M'Z_4(M+J+"H(\D4^=
M OQ[76V*S8']V/5VN$+L^4MS^ , *PA@!B+/97\-"*9IYJ=P !J"2.IQJ@7@
M&1;O!VB=HKT,K%V!K]O)_5KY594E(JE/[!<,HJE4\##2O4]7+]Y"UC[98G&^
MD(O0Q&QB:#B\GEQCB@"%3&0T%J;SU KA.$X]&B8TQ5D<>PD.@@%.&L31'-GH
M(@C#.>=M>5MVB](.^U^[0]_=5%1]<;9UPR^.W1P*9U\[__*_O"C^]R#QY\D]
MEZ-C-L-H#<S,>>15)0H#Z4 X=J];],7=U"3MDKSJ%'#28:FKIMV<6/F>%\8@
M@%X2THQZ_(6P,97X$$:KJOC"?LGFDUX)EX4A)!)I)Q)/$ L+!MX5FW+?GI@J
MJ_6N: O(W?B  G>J/>2N7[FEPZ)/M(V$PK!>CYC[#5N+I?H1O1-56C58KT>@
ME3U4T.9I;.J4Y>$@VI/;-?@SZ5WS[G9;?\\9S2L70$0S-TPC2BDD !(X)H\X
MCJ0NCYL;F^$J_'BJ=<3FY ,X_:JM-6KZ%'VI@)E2^V-4G[O2Z!CIT2N+TX%$
M;":F"A.CX/6D$2/>*Z08<U&8EGZZC8\#?T5^O%%YA2 "%'DI=HD; 8IQE(4#
M $BQN]K7^WP[);,HF95*&B/"Z4*D(V&H\3PE%QBGV)3,6Z39SW$H+<>3 F&S
MTDYS3$A$-7 G?!O1L^OL<+?CPLU;C=']D_?6X?=\M^E>&7I3-?M=VY+<32(^
M,<%_=]<"_KVNOA7-OMA\J+=;6N_X?[1*89I2E-(4A021*/4)3<, 8!!D?@9Q
M(G4UD5W036_K'OB+6OSD6^N4[ 5%=G$E>EN17:C-I8D7MVQ/?'6N[Q]L[?;^
M.JW#5T[GLG/B<]_-OV=>.[W;[5I_YSC[VT<CROG,R7!Z-N:^UFC64)_)9I:.
M.3LRHJWD/+[]R%*8XJ<+E3WH<;X[[)M]7FU8"=%]YMXJ A%**(9)$J>\>HA#
M%P\HO<0#*U9JE/7FXS[?[<\GX*40RNCO8V?$3SJP\.[*-0NQ\W%?K_]T3H!>
M.=?%E[*J^+;V=;[ETU;GEZ853\%W&18+[OF$^QHBJI!1M3IC>8 ECC5:'FBU
M0X[':F9W_(*;]@NN3[_@LEIO#YOV"Z[W7YU.S=O^R*JN?NW_L>X<_=O$LX[Z
MB7ZF<%DZI!:<@US2^]J.#\N66?_?V:_8-V^J]VW^7:&$>"@)6!D$,N"&)$J(
M.\!G7DF=H[0&M.&9?HN&B9!<96$=2XO/\0U&U=;9?><RWROLG/Y9YO /0[G(
M[%UQ-/WL\W956F:;L4^*V_+YE-:[FZ)DZ6#T( Q(F)#$RS $ 8JS+ 1D7&T
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M%3HSLW*BWX-S&#KGP.$Y1WS."'#N:^(N$7:F1-7(MAW%JDZ'GES4IIFKR:\
M/==P@5/D^5Z 41;'O([V21!T#1<PR9)$:M- JV'#>F?T)2 EHL7T;C&.Y93O
M[(M =K1WR3!Y1A*-!,0.<33CFNC+0-/Y$UYQ7'\M-H<M*T';VUG:6T%.;RN
MNQT;V]W1 W1__)GW^3W_=_![OMMTC28T"#!(88AARF82'LE\F@0P\9G*AR'"
M4KW_\Z$RO:;9.\(G9RW,7Z^?W+OBG'K#7[4Y_<'>(Z=U2;&-;;X0"ZZ>6AE=
MR>76>0-K9IU65QS.+>S.'FL[\L<"?C]>.EZ(>>%2G7U/O^>W7;\0\6+V"XE/
M,C?Q80"!'X6#"=^3._0K]8M-E]KLGQP.1JE!4(XBP2+:%#N21;(H,6;JWQ,2
MSM6W*ES9H3]JT!_7I^K^RZI WZT# DJ"A&8N]%(:94$: G T$DD=DI+\U?,I
M@5+#GBQ1<FI@@"-E/5BD'>\A$0*:(,F87:H@"_X%75#B0&@O^MUM55X?FNZN
MRC<5OX&H_%9PNRQ^?M^#0RB."<BB$ $W\R@B 9.AWBZ@R!/>C=9BS;!^<"1.
M#]3I[_ <H;8K31);J7KH%=B7GIU9.=4YR^>5TW)^L6_/%+T2>]6STZRV6ZV%
M;K'=:Q%&7MJ_ULJF!3O8>OVI38T[B?3P>UWU.^;%YN.^7O_Y[JY]4XX9[HTF
MB1?%%,1A%*9N%@,<!"XSF@59YOE K!5;DRG#B8$!_'5$Z+00G0YC^UFIZ)<&
M>@5RP[S,RB4&.TF5R CSDJN6#B:3+)8*+E+Q4A[0QZ$%24"C,[61<2:W;M M
M3P['#9,D 7X2$R\*79J!F*; '5(,@;Y07ZK:;S8L[MWN@/()8TF6Q-8,S!$D
MI]'BW!A9,7A PYD% S6Z[%@O4,1>ZQ@PDOO8RGL<1W35YM'"1D9PBE$0)A'Q
M$A>E88K&C0^<IJG4EO82  VK4S^/Z[<PU<XA+Q(WP7UJVT,FIY=RT3*SXVR
MT7.;STL&T X%7Y:"QUO2R\=#^/F[V[MM?5\4)S5M7\^B+,0X %&<(D H3%*
MQN4,]C^II*!NQ73?TLED3/*Q.W7BQ%1Y'LXDI;7']' 2N\R)[Q?Y.2.4TSFU
M0^TT^/'X^3I-S(CJSC^*AM]@VE;*.$CBD-"$ DI=D,4NP...>Y3Z4OWI,K_7
ML+;T4)0FM%+TB.F)*6;D%$20%".*<<+ &8U0X<D.55!"7D\?)4I??E_5^#1(
M"0TS&$,$$D1#'X^SY"0+I%X<DOO-<WW]2M-%29*D%,  /XH:L,C<[ $+EW5
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MV:?:Y%B54[LG]MZQ0B[GA?G;NFEPOMO=W]0[+K_-RG/9B(E\/W1!G&44@23
M/0((TT#JMGZ==@TKW^_%WJD'=,Z6P7/6)_CD1% KWV)2N!35<H+XC 1>.2-2
MAT-U'F"=5Q4E2#RCC29"88="&O&L-C^0)ZKEBT]YK8B;8#_V(78]&@99"((P
M&N3:\T V22S5S1K6RO&-P7_);^_^W2G47AG42;.B1L[#L :)//OLX,(:^2*)
M,A(Y/1*6*J0&QRX)I"[NE/7Q3?6-6:MW]ZL@BT*"*(8D8+^?DIB2P2 $$*'5
MMV)W72LKHK@AF>_S%)/P9SI"F2AZ$MPIBIP9TC2(VF4*YQ&P$8>,8,FS:JE
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M67!'O[N]&3ZA7^8T+&]O_@%02P,$%     @ FXMI2& Z+EN)<0  XI,% !4
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M1Y\$$6.DVW2<T<S%JX])"$V2H05HF^/$[GGA<*/@E&%0*&09A] #J8W>S'F
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MQ0X0=CHS?Z:'2<=-+S.-8=H!<?QH,IH7KT=?4MFQ^6#R>13MJQ4@^ZFSOV'
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M/24!$-#>^PW=H[F4QXX>G3CL@AVG@=J6'[J:X=X7=^4T74F;3@,L]I-C>Y/
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M,?:\.NF \+^7D^+;[X/IG\7<+R97LX-9T]L;!"V,8I18)@0$$AE$@8V"H:0
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M7R>L]4I.YZ5F Z!WO(>\]0ZBM]?OIA&GKRDGQT=H[X6YK"UF:H7$0!K,(82
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MSV3M!5T .5ZS^[F2!6C_//G0((/HKB8A?@4W4FEGF,',(N" W9AAIYR\H#V
M#B>A7#BSPE/359"[<=1#<77WO\O19/U#PG_W<KQARR"(\0A:BR 1F$57B%N*
M"8CCR1"OZ.642CA>@=,ND>TE4GYS _Y#,9H7\ZN[#\5\7AQ8LJGY2X+C7AN+
M%</4"@RP-(1CPJ$@4@+BSK]J0NM,>!,CWQ'6/9#M4W&W+&_G=EG\5D:]_77Z
MO9B5F[MM*U3VS5WUC8-5&#,#14K>0!3%REM;86H%.O\,V%V3JW6,^]DC>W@8
MS9ZN[CZ/[\L5%N5"W=RDZ(TJ#\^X.,F6]MM>--@KV]TH4)42QB'/L$7,(<:9
M)NO]2:$ /=6=]GVH-]KC;O2"8*31&L2IV,?5/(4L)4^KA$=6Y1[!#V=PMTF
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M !$              ( !     &%X9'@M,C Q-3$R,S$N>&UL4$L! A0#%
M  @ FXMI2,-F*X$[$0  UL\  !$              ( ![DH! &%X9'@M,C Q
M-3$R,S$N>'-D4$L! A0#%     @ FXMI2 <T;,R]'@  9SX! !4
M     ( !6%P! &%X9'@M,C Q-3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( )N+
M:4B\%1PBS"X  *LE @ 5              "  4A[ 0!A>&1X+3(P,34Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " ";BVE(9A.P6W[&  !%HPH %0
M    @ %'J@$ 87AD>"TR,#$U,3(S,5]L86(N>&UL4$L! A0#%     @ FXMI
M2& Z+EN)<0  XI,% !4              ( !^' " &%X9'@M,C Q-3$R,S%?
=<')E+GAM;%!+!08     !@ & (H!  "TX@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
